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A bstract
Enhancement of the cytotoxicity of MRP substrates by indomethacin
and related compounds.
Sam antha Touhey
C ertain  non-stero idal an ti-inflam m atory  drugs (N SA ID s), including 
indom ethacin  and sulindac, at non-toxic concentrations, w ere found to  enhance 
the tox icity  o f  a  range o f  chem otherapeutic  drugs, such as doxorubicin, 
epirubicin , v incristine  and V P -16. This effec t appeared to  be m ost significant 
in  M R P-expressing  cell lines such as D L K P and A 549, and w as n o t evident in  
Pgp-overexpressing  cell lines such as D L K PA . A nalogues o f  indom ethacin  
w ere subsequen tly  generated to investigate the structure-activ ity  relationship 
(SA R ) o f  indom ethacin-m ediated  tox icity  enhancem ent. A n  im portan t goal o f  
th is research  w as to identify  an analogue o f  indom ethacin , capable o f  
po ten tia ting  the  tox icity  o f  anticancer drugs to  the  sam e degree as 
indom ethacin  b u t w ithout the toxic side effects observed  after p ro longed  use o f  
indom ethacin . It is believed tha t these side effects are m edia ted  through 
inh ib ition  o f  the  constitu tively  expressed form  o f  the C yclooxygenase enzym e, 
C yclooxygenase-1  (COX -1). A  num ber the  positive  indom ethacin  analogues 
(B R I 138/1, B R I 153/1 and BR I 60/1) w ere found to have  the ability  to 
po ten tia te  the  tox ic ity  o f  a  num ber o f  an ticancer drugs w hile hav ing  little  or no 
COX-1 inh ib ito ry  activity  rendering these  com pounds less likely  to  cause 
gastro in testinal toxicity . BRI 60/1 w as also found to be a  good  CO X -2 
inhibitor. T hese resu lts for BRI 60/1 suggest a  potential clin ical application  due 
to  reduced  to x ic  side effects and in  addition, increased ability  as a tum our 
suppresser due to  inh ib ition  o f  CO X-2.
M ost o f  the active indom ethacin  analogues w ere found to  have very  little 
G lu tath ione S-transferase inhibitory  activ ity  and hence their m ode o f  action 
w as n o t by  inh ib iting  the conjugation o f  glu tath ione to the  an ticancer drug. 
Inside-ou t M em brane V esicles (IO V s) w ere u tilised  to  dem onstrate the ability 
o f  the  analogues to  directly  inhibit the M R P pum p by m easuring the  uptake o f
the M R P substrate, L T C4 in  to the vesicle. Surprisingly, B R I 138/1, w h ich  w as 
quite active in  the  com bination  tox icity  assay, w as a  w eak  inhibitor o f  L T C4 
transport as com pared  to  indom ethacin  and  o ther positive  indom ethacin  
analogues suggesting, due to  structural varia tions, reduced  ability o f  B R I 138/1 
to  b ind  to  the  active site on  the M R P m olecu le  and  com pete w ith  L T C4.
R esults from  drug  efflux  studies suggested  tha t the active N S A ID s are 
com petitive substrates for M R P1. Several o f  these analogues are as effective as 
indom ethacin  a t po ten tia ting  the tox icity  o f  certain  anticancer drugs b u t som e 
are less po ten t (on a  m olar basis) th an  indom ethacin . A n  analogue o f  
indom ethacin  (e.g. BR I 138/1, B R I 153/1, B R I 60/1) w ith  sim ilar po ten tia tion  
ability, bu t w ithou t the  side effects caused  by  the  inh ib ition  o f  CO X -1, m ay  be 
a  prom ising  candidate fo r fu ture cancer therapy .
The ability  o f  indom ethacin , indom ethacin  analogues and  sulindac to  po ten tia te  
the tox icity  o f  chem otherapeutic  drugs in  cell lines expressing  M R P2-6 has no t 
prev iously  been  investigated . The results from  the  com bination  tox icity  assays 
in  the  ovarian  carcinom a cell line, 2008, transfected  w ith  M R P2 or M R P3, 
suggest tha t indom ethacin  m ay have the  ability  to potentiate  adriam ycin  
tox ic ity  in  b o th  2008 M R P2 and M RP3. H ow ever, a  basal level o f  M R P 1 w as 
found in  all the  2008 cell lines w hich  m akes it d ifficu lt to  d istinguish  i f  the 
poten tia tion  w as sim ply as a  resu lt o f  the expression  o f  M R P 1 in  the cells. The 
tox icity  o f  m ethotrexate  w as not po ten tia ted  in  the 2008 M R P2-transfected  cell 
line (w hich is M T X -resistan t in  short-term  tox ic ity  assays) suggesting that 
indom ethacin  is no t active in  M R P2-overexpressing  cell lines. In  contrast, 
sulindac had  a  sm all, b u t significant, po ten tia tion  effect on m ethotrexate in  the 
2008 M R P2 cells.
The tox ic ity  o f  taxol and  taxotere w as po ten tia ted  by  indom ethacin  and 
sulindac in  a num ber o f  cell lines and the  effect appears to be M R P-related. 
H ow ever, the  synergy betw een  p iroxicam  (w hich  w as unab le  to enhance the 
tox icity  o f  o ther M RP1 substrate chem otherapeutic  drugs) and taxol suggests 
an  alternative o r additional m echanism  o f  taxane tox ic ity  enhancem ent m ay 
also be  present. E nhancem ent o f  taxol and taxotere  tox icity  w as no t observed  
in  A 549 cells w h ich  overexpress M RP1 b u t w ere also found to  h ighly  
overexpress M R P4.
In  contrast, the  tox ic ity  o f  c isp latin  w as decreased in  the presence o f  
indom ethacin  in  a  num ber o f  cell lines including D L K P, D L K PC  14, H epG 2 
and the 2008 cell lines. B R I 138/1 did no t po ten tiate  the toxicity  o f  cisplatin  
bu t the effect w as additive  no t antagonistic. Therefore, it is possib le that the  
antagonistic effect on  cisp latin  tox icity  is indom ethacin  specific. Perhaps 
indom ethacin  actually  enhances the  efflux (o r inh ib its efflux) o f  certain  
an ticancer drugs, includ ing  cisplatin , from  particular cancer cell lines.
Pulse selecting  D L K P cells w ith  300(.ig/ml indom ethacin  increased the 
resistance o f  the  cells to  adriam ycin, vincristine, V P -16, cisplatin , 
indom ethacin  and, in  particular, 5-FU. R T -PC R  analysis dem onstrated an 
increase in  M R P1, 2 and 4 m R N A  expression  in the pulsed cells relative to  the  
parental D L K P cell line.
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1.0 Introduction
1.1 Multidrug resistance in cancer
M ultidrug  resistance (M D R ) is a m ajor im pedim ent to  the success o f  cancer 
chem otherapy. M D R  m ay be observed in  prim ary therapy  (inherent resistance) or 
be acquired  during  o r after treatm ent (acquired resistance) (Y u et al., 1999). In 
vitro, M D R  can  appear after exposure o f  cells to  a  single drug, w hich  is alm ost 
alw ays a  na tu ra l product, and is characterised  b y  resistance to  structurally  
unrelated  com pounds w ith  different subcellu lar targets (L autier et al., 1996). 
T here are num erous m echanism s o f  drug resistance observed  in clinical settings 
and  the spectrum  o f  drugs to  w hich  resistance m ay  be conferred  is very b road  and 
encom passes a ll c lasses o f  chem otherapeutic agents including alkylating agents, 
antim etabolites, horm ones, p latinum  containing drugs and natural products (G rant 
et al., 1994).
O ne m ajor m echan ism  o f  such resistance is linked  to  decreased cellu lar 
accum ulation  o f  an ticancer drugs through  enhanced cellu lar efflux o f  the an ti­
tum our com pounds. Such m ultidrug resistance can  be conferred  in vivo and  in 
vitro, by  a  num ber o f  p ro te ins including the M r 170,000 P-g lycopro tein  (encoded 
by  the MDRl gene) (G ottesm an et al., 1993), and the m ore recently  identified  
190kD a M R P (C ole et al., 1992 and G rant et al., 1994). B oth  o f  these proteins are 
m em bers o f  the A B C  (A T P-binding cassette) transporter fam ily and function  as 
A T P-dependen t active transporters (Sarkadi et al., 1997).
B o th  pro teins have  been  dem onstrated  to con ta in  tw o functional nucleo tide 
b ind ing  dom ains connected  to  large m em brane-bound regions (H iggins, 1992; 
H ipfner et al., 1997 and 1999). It has been  established tha t bo th  proteins can 
transport a  w ide  varie ty  o f  chem ically  unrelated, large, am phiphilic, uncharged  or 
sligh tly  positively  charged  m olecules in  an A T P-dependent fashion (Sarkadi et 
al., 1997), w h ile  M R P also transports som e negatively  charged com pounds, 
especially  g lu tath ione conjugates (Loe et al., 1996b). T he com pounds m ost 
frequently  applied  in  cancer chem otherapy bu t effectively  ex truded  by  M D R l and 
M R P from  the  tum our cells are o f  natural and sem i-synthetic  origin. These 
include the an thracyclines (e.g. adriam ycin, daunorub icin  and idarubicin), 
m itoxantrone, vinca alkaloids (vincristine, vinblastine), epipodophyllo toxins (e.g. 
V P-16), the taxanes (e.g ., taxo l and taxotere) and actinom ycin  D  (H ipfner et al, 
1999).
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Pgp is localised  m ainly  in  the p lasm a m em brane and confers drug resistance by 
functioning  as an  A T P-dependent drug efflux  pum p w hich  is ab le  to  transport 
an ticancer drugs against a  substrate concentration  gradient, causing both 
decreased  drug  uptake and increased drug efflux (G erm ann et ah, 1997). The 
basis fo r M R P-m ediated  drug resistance is less w ell defined. In  addition  to  drug 
accum ulation  defects, differences in  subcellu lar drug distribu tion  have been 
observed  in  a  num ber o f  drug-selected  M R P-expressing  cell lines o r M R P cD N A - 
transfected  cells (C ole et ah, 1992; Z am an  et al., 1993; Loe et ah, 1996 and 
V arsenvoort et ah, 1995). Therefore, M R P m ay  also function  by sequestering 
som e o f  its substrates in  in tracellu lar m em brane com partm ents.
It is generally  believed  tha t the preferential developm ent o f  m ultidrug  resistance 
is dependen t upon  the types o f  tum our and drugs used (C hoi et ah, 1999). The 
authors have also suggested that the overexpression  o f  M R P or Pgp is dependent 
upon  drug  concentrations and  reported  tha t in  experim ents w ith  adriam ycin  in 
acute m yelogenous leukaem ia, M R P w as first expressed  w ith  exposure to  low  
concentrations o f  adriam ycin  fo llow ed by an  overexpression  o f  Pgp by increasing 
the  drug concentration.
O ther b iochem ical m echanism s associated  w ith  acquired  resistance to  broad 
groups o f  cy to tox ic  drugs in  laboratory  system s include overexpression  o f  the 
hum an  m ajor vau lt protein , LR P (Izquierdo et ah, 1996a), cytosolic  detoxification 
due to  overexpression  o f  glutathione S-transferase and/or rela ted  enzym es 
(resu lting  in  resistance to anthracyclines and  alkylating agents including cisplatin) 
and nuclear changes including m odified  activ ity  o f  topoisom erase II (resulting  in 
resistance to  an thracyclines and ep ipodophyllo toxins) (T w entym an et ah, 1997). 
In  add ition  o ther b iochem ical determ inants, including m utations o f  the p53 gene 
o r overexpression  o f  the bcl-2  gene p roduct have been  associated  w ith  protecting 
the  cell against p rogram m ed cell death  or apoptosis (T w entym an et ah, 1997).
The u ltim ate  goal o f  M D R  research is to  im prove treatm ent outcom e in  patients 
w ith  cancer by  devising  strategies tha t are able to  prevent the em ergence o f  M D R  
or to  c ircum vent existing resistance. It appears tha t drug resistance in  m any 
cancers is m ultifactoral (Larsen et ah, 2000 and Lehnert, 1996), and m odulating  a 
single resistance  m echanism , such as M R P, m ay no t sufficient in  several cancer 
types. H ow ever, in  a  num ber o f  cancers, w here a  particu lar m echanism  is the 
dom inan t fac to r fo r clinical M D R , and has been  show n to be  o f  prognostic
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significance, m odula tion  o f  a  single resistance m echan ism  could prove to  have a 
sign ificant im pact on  treatm ent outcom e.
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1.1.1 M ultidrug transporters from  bacteria to man.
Toxic com pounds have alw ays been  part o f  the  natural environm ent in  w h ich  all 
o rganism s dw ell. T he developm ent o f  strategies for life in  this habitat has been 
crucial for survival o f  the cell. A s a  resu lt organism s, from  bacteria to  m am m alian  
cells, have developed  versatile  m echanism s to  resist the effects o f  xenobiotics, 
including an tib io tics and  o ther cytotoxic drugs. Exam ples o f  such  m echanism s 
include the enzym atic  degradation  or inactivation  o f  drugs and the a lteration  o f  
drug targets. In  addition, m any cells have been  show n to  possess m em brane 
p ro teins w hich  can  actively  efflux  drugs, and hence, are able to overcom e cell 
tox icity  by low ering  the cytoplasm ic drug concentration.
Som e o f  these drug  transporters are specific for a  g iven drug or class o f  drugs, but 
the m ultidrug  transporters have specificity  fo r com pounds w ith  very  different 
chem ical structures and cellu lar targets (van V een  et al, 1997). These transport 
system s can be d iv ided  into tw o m ain  groups on  the basis o f  b ioenergetic  and 
structural criteria: 1. Secondary transporters, w hich  m ediate  the extrusion o f  drugs 
from  the cell in  a  coupled exchange w ith  ions (Paulsen  et al., 1996), and 2. A TP- 
b ind ing  cassette [ABC] transporters, w hich  u tilise  the  release o f  phosphate  bond- 
energy by A TP hydro lysis to  pum p drugs out o f  the cell (H iggins, 1992).
1.2 Secondary m ultidrug transporters
The study o f  m ultid rug  transporters is rapidly  developing. Secondary m ultidrug  
transporters belong  to  one o f  th ree d istinct fam ilies o f  transport p roteins: The 
M ajor F acilita to r Superfam ily  (M FS), The R esistance-N oduiation-C ell d iv ision  
(R N D ) fam ily , and the  Sm all M ultidrug R esistance (SM R) fam ily  (M a et al, 
1994; Saier et al, 1998; W illiam s, 1996) as described  in  Table 1.2.1.
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Table 1.2.1: Properties o f transport protein families that include multidrug 
resistance (MDR) efflux pumps.
A. The ATP binding cassette (ABC) superfamily
1. 28 fam ilies specific  for sugars, am ino acids, ions, drugs, antibiotics, 
vitam ins, iron  com plexes, peptides, proteins, com plex  carbohydrates etc.
2. D riven  by  A T P hydrolysis.
3. M ulticom ponent, m ultidom ain  system s; total size, >  1000 residues; 
U sually  12 (6+6) m em brane spanning dom ains.
4. Found in  bacteria , archaea, and eukaryotes.
5. > 500 sequenced  m em bers.
6. W ell characterised  m em bers: M alEFG K , M D R 1, M R P1, and CFTR.
7. D rug efflux  pum ps are found in a  few  (3 - 4) o f  the  m any  (about 3 dozen) 
recognised  fam ilies.
B. The major facilitator superfamily (MFS)
1. 17 fam ilies specific  for sugars, drugs, m etabolites, anions etc.
2. C onsists o f  sym porters, antiporters and uniporters.
3. Size, ~400 residues or larger; 12 or 14 m em brane spanning dom ains.
4. Found in  bacteria , archaea and eukaryotes.
5. A pprox. 500 sequenced  m em bers.
6. W ell characterised  m em bers: LacY , G lu tl and TetB.
7. M D R  pum ps are found in  3 o f  the 17 recognised fam ilies.
C. The small multidrug resistance (SMR) family
1. Tw o subfam ilies specific for drugs and unknow n substrates, respectively
2. C atalyze d rug :H + antiport.
3. P robably  hom ooligom eric; subunit size ~ 100 residues w ith  4 spanners.
4. Found on ly  in  prokaryotes.
5. 16 sequenced  m em bers.
6. W ell characterised  m em bers: Sm r and Em rE.
7. M D R  p um ps are found in  one o f  the tw o subfam ilies.
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D. The resistance/nodulation/division (RND) fam ily
1. Three subfam ilies specific for drugs, m etal ions and lipopolysaccharides 
respectively.
2. C atalyze drug:H + antiport.
3. Subunit size ~1000 residues; 12 spanners.
4. F ound  only  in  prokaryotes.
5. 16 sequenced  m em bers.
6. W ell characterised  m em bers: A crB  and M exB.
7. M D R  pum ps are found in  one o f  three subfam ilies.
(Table taken  from  Saier et al, (1998))
Secondary m ultid rug  transporters have been  detected  in  ra t k idney cells (OCT1) 
(G rundem an et al., 1994), and synaptic vesicles o f  p resynap tic  neurons (VM A T) 
(Schuld iner et al., 1995), in  pathogenic yeasts such  as Candida albicans 
(caM D R lp ) (B en-Y aacov et al., 1994; W alsh el al., 1997), and pathogenic 
bacteria , such  as m eth icillin  resistant Staphylococcus aureus (Q a c Q  (W illiam s,
1996), Mycobacterium smegmatis (LfrA ), Neisseria gonorrhoeae (M trD ) (van 
V een  et al., 1997), L. lactis (Lm rP) and Pseudomonas aeruginosa (M exB) 
(N ikaido et al., 1994). Som e o f  the m ost com m on secondary m ultidrug 
transporters are  listed  in  Table 1.2.2.
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Table 1.2.2: Examples of most common secondary multidrug transporters.
Transporter Organism Gene location Substrate
Major facilitator in Gram Positive Bacteria
OtrB Streptomyces rimosus Chromosome Oxytetracycline
Tel(L) Various cocci, Bacillus subtilis Plasmid Tetracycline
Mmr Streptomyces coelicolor 
A ctll Streptomyces coelicolor 
TcmA Streptomyces glaucescens 
Nor A Staphylococcus aureus
QacA* Staphylococcus aureus
Bmr Bacillus subtilis
Chromosome Methylenomycin 
Chromosome Actinorhodin 
Chromosome Tetracinomycin 
Chromosomal Fluoroquinolones,
Basic dyes, 
puromycin 
chloramphenicol, 
tetraphenylphosphonium. 
Plasmid Quarternary ammonium
compounds 
Chromosome Basic dyes,
chloramphenicol
puromycin,
fluoroquinolones.
Major facilitator in Gram Neeative Bacteria
TetA Eschericia coli 
CmlA Pseudomonas aeruginosa 
Bcr Eschericia coli 
EmrB Eschericia coli
EmrD Eschericia coli
Plasmid Tetracycline
Plasmid Chloramphenicol
Chromosome Bicyclomycin  
Chromosome CCCP**, nalidixic acid, 
tetrachlorosalicyanilide, 
phenylm ercury  acetate. 
Chromosome CCCP**, phenylmercury 
acetate.
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Transporter Organism Gene location Substrate
RND family
A crE (A crB )| Eschericia coli
EnvD Eschericia coli
M exB P.areuginosa
Smr family 
Sm r(Q acC )| S.aureus
Chromosome Basic dyes, S D S ,|
erythromycin, novobiocin, 
fusidic acid, tetracycline, 
mitomycin C.
Chromosome Basic dyes, SDS,f
erythromycin, fusidic acid, 
tetracycline, mitomycin C 
and others.
Chromosome Tetracycline,
chloramphenicol,, 
fluoroquinolones 
ß-lactams, pyoverdine.
Plasmid
QacE Klebsiella aerogenes Plasmid
Quartemary ammonium 
compounds, basic dyes. 
Quarternary ammonium 
compounds, basic dyes. 
M vrC (E m rE )| E.coli Chromosome basic dyes.
Methyltriphenyl-
-phosphonium
* QacB is very similar to QacA; ** CCCP, carbonyl cyanide m-chlorophenyl-hydrazone; 
j  SDS, sodium dodecylsulfate;
J  alternative nam es are show n in parentheses;
(T able taken  from  N ikaido  el al., (1994).)
M em bers o f  the  M FS and SM R  fam ilies tend  to  have specificity  for an 
exceptionally  w ide range o f  am phiphilic, cationic drugs including several types o f  
antib io tics, quaternary  am m onium  com pounds, arom atic dyes, and phosphonium  
ions. T ransporters in  the  R N D  fam ily tend  to  confer resistance to am phiphilic
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anionic com pounds such as antibiotics, basic  dyes and detergents. In  G ram  
negative bacteria , transport o f  drugs from  the  in terior o f  the cell to  the  external 
m edium  requires the  translocation  o f  solutes across the  cytoplasm ic outer 
m em brane. T herefore, there  are a  num ber o f  d rug  transporters (e.g., M exB ) in  
such organism s, w h ich  are found in  association w ith  an accessory protein , w hich  
spans the perip lasm ic  sphere and interacts w ith  a  po rin  in  the outer m em brane. 
These auxiliary p ro te ins belong  to  the M em brane F usion  P ro tein  fam ily and O uter 
M em brane F acto r fam ily  (van V een  et al, 1997).
1.3 ABC T ransporters
T he A T P-binding  cassette  (A BC ) transporters, p resen t in  organism s ranging from  
bacteria  to m an, are involved in  the  A T P-dependent transport o f  a w ide variety  o f  
com pounds, rang ing  from  inorganic ions to  large polypeptides (Tusnady et al.,
1997), and are invo lved  in  the to lerance to  a  w ide diversity  o f  cytotoxic agents in  
both  prokaryotes and  eukaryotes (H iggins, 1992).
In  m ost cases these  p ro teins have been  dem onstrated  to  function as transport 
A T Pases, tha t is, hydro lysing  A TP in conjunction  w ith  transporting substrate 
m olecules th rough  cellu lar or in tracellu lar m em branes. Included in  th is transport 
fam ily  are the  h um an  m ultidrug resistance P-glycoprotein , M DR1 (Pgp) 
(G ottesm an et al., 1993), and hum an m ultidrug  resistance associated pro tein  
M RP1 (M RP) (C ole  et al., 1992). B oth  are p lasm a m em brane transporters w hich  
catalyse the ex tru sion  o f  anti-tum our drugs from  drug-exposed  cancer cells. O ther 
characteristic eukaryo tic  A B C  transporters include the yeast pherom one 
transporter, STE 6, L tPgpA  (a Leishmania tarentolae protein) and the  hum an  
cystic  fibrosis transm em brane conductance regulator (C FTR ), the  m utations o f  
w h ich  are causative o f  cystic fibrosis.
The A B C transporters, form  one o f  the largest know n  pro tein  fam ilies. They are 
bu ilt from  com binations o f  conserved dom ains, that is, A TP- (nucleotide-) 
b inding A B C  un its and characteristic m em brane bound regions (V aradi et al,
1998). The A B C  un its contain  the h ighly  conserved  ‘W alker A ’ and ‘W alker B ’
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sequences, m ost p robably  d irectly  responsible for the in terac tion  w ith  A TP or 
o ther nucleotides. T hese W alker sequences are separated  by  a  stretch o f  about 
120-170 am ino acids, includ ing  a  short peptide m otif, 12-13 am ino acids in 
length , called  the A B C  transporter ‘signatu re’ reg ion , w hich  is in  fact 
characteristic  fo r these p ro teins. The m em brane bound dom ains o f  the ABC 
transporters in  m ost cases are predicted  to  contain  six  transm em brane (TM ) 
helices. In  som e bacteria l and  in  all eukaryotic A B C  transporters a t least one A B C  
un it and one transm em brane dom ain  are encoded by  a single gene (Tusnady et al, 
1997). T hey m ay  exist as a  single unit or be fused, as in  the  case o f  Pgp, so that 
they  contain  2 non-identical sets o f  transm em brane dom ains and nucleotide 
b ind ing  sites (H iggins et al., 1997).
1.4 Pgp, L R P and M R P  in M ultidrug R esistance
R em arkab le  advances in  cancer treatm ent have been  m ade since the  in troduction 
by Farber and associates, in  1948, o f  the folate antagonists for the  treatm ent o f  
leukem ia  (Farber et al., 1948).
D uring  the  last few  decades, n ew  cytotoxic agents have been  developed tha t have 
im proved  the  outcom e o f  m any  cancers, including solid  tum ours. A m ong these 
drugs, the  natural p roduct iso lates and their derivatives - including  anthracyclines, 
v inca  alkaloids, epipodophyllo toxins, and taxanes - have proved  to  be effective in 
inducing  rem issions and cures in  m any m alignancies (B eck  et al., 1997).
T he developm ent o f  resistance to  m ultiple drugs used  in  cancer chem otherapy is a 
serious lim ita tion  to  th is fo rm  o f  treatm ent and is considered to  be one o f  the m ost 
sign ifican t obstacle  to  curing  cancer (H ipfner et al., 1999 and deVita, 1989). In 
vitro, b road  resistance to  m ultip le  structurally  and functionally  unrelated  drugs is 
observed  in trinsically  or after in term ittent or pro longed  exposure o f  tum our cells 
to  only  a  single agent. This “classical” m ultidrug  resistance is typically  
characterised  by  cross-resistance to four classes o f  com m only  used  natural 
p roduct drugs, the an thracyclines, Vinca alkaloids, taxanes and 
ep ipdophyllo toxins (H ipfner et al, 1999). E lucidation  o f  the m echanism s 
determ ining  inherent or chem otherapy - induced  resistance in  hum an  tum ours to
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m any cancer agents, is o f  great in terest to  researchers and o f  great im portance to 
patients.
The nature o f  drug resistance is com plex. To date, m ultidrug  resistance in  m odel 
system s is know n  to  be conferred  by  tw o different in tegral m em brane proteins, 
the  170kD a P-g lycopro tein  (Pgp) (R iordan et al, 1985), and the 190-kD a 
m ultidrug  resistance-associated  pro tein  (M R P) (Cole et al, 1992). T hese proteins 
belong  to the  A TP binding  cassette  (A BC ) (H iggins, 1992), or traffic  A TPase 
superfam ily  o f  transport p roteins (A m es, 1992).
In  1993, Scheper et al, identified  a  llO k D a A T P-dependent cytoplasm ic 
transporter pro te in  in  a num ber o f  non-P-g lycopro tein-m ediated  M D R  tum our cell 
lines, norm al cells and  tissues by the use o f  a  p i  10-specific m onoclonal antibody 
LR P-56. T his protein , know n  as the Lung R esistance P ro tein  (LRP), w as 
identified  by  Scheper et al., (1995), as the m ajor vau lt protein. Isquierdo et al, 
(1996a), describes these  vaults as cellu lar organelles in  search  o f  a  function. They 
are com plex ribonucleopro tein  particles containing at least th ree m inor proteins 
and a sm all R N A  m olecule  in  addition  to  the 110-kD a m ajor vau lt protein. V aults 
are  m ain ly  located in  the cytoplasm  and current specu lation  sees vaults as part o f  
the  b idirectional transport system  betw een nucleus and cytoplasm  (Borst et al,
1997). Izquierdo  et al., (1996), have also suggested th a t vau lts  m ight som ehow  be 
invo lved  in  the transport o f  drugs into cytoplasm ic vesic les or directly  out o f  the 
cell, but, a t present, there is no evidence to back  th is  suggestion.
1.5 P-glycoprotein  (Pgp)
O ver-expression  o f  the transm em brane transport p rotein , P-glycoprotein , (P-gp), 
has been  detected  in  m any m ultidrug  - resistan t tum our cell lines and in  a variety  
o f  tum ours from  patien ts w ith  both  acquired  and inheren t drug resistance. This 
protein , encoded by  the hum an  M DR1 gene, is a 170 kD a m em brane pro tein  and 
from  its structure, appears to  be a m em ber o f  the  A B C  fam ily  o f  transporters 
(G ottesm an et al, 1993). It w as originally  found on  the  surface o f  m ultidrug 
resistan t tum our cells. In vitro studies have show n that it confers resistance to  a 
range o f  natu ral p roduct xenobiotics that are used  as chem otherapeutic  drugs
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(V inca alkaloids, anthracyclines, etoposide, taxol), calcium  channel blockers 
(verapam il, diltiazem , azidopine), im m uno- m odulators (cyclosporin  A , FK -506), 
cardiac g lycoside (d igoxin), fluorescen t dyes (rhodam ine 123, fluo-3), and 
steroids (cortisol, a ldosterone) (N aito  M  et al., 1998; C lynes et al., 1993 and 
Sharom  etal., 1999).
The basis o f  th is M D R  appears to  be a  decrease in  drug  accum ulation  in  the cells 
due to  increased expulsion  o f  drug from  the  cytosol by  th is  transm em brane 
transport protein. It is believed  tha t Pgp  is a transm em brane pore  form ing protein 
w ith  an  energy dependent drug effluxing ability. It has also been  suggested that 
Pgp  can low er in tracellu lar drug concentrations by  regu la ting  the plasm a 
m em brane pH  gradient and electrical m em brane po ten tia l (R oepe et al., 1994). 
T hree classes o f  Pgp gene products exist; the class I and  II isoform s are m ultidrug 
transporters, w hereas the class III isoform  appears to  be a  lip id  flippase, m oving 
phosphatidylcholine (PC) from  the  inner to  the outer leaflet o f  the b ile  canalicular 
p lasm a m em brane (Sharom  et al., 1999). Photoaffm ity  labelling  experim ents 
w ith  a  photoactive analogue o f  v inblastine have dem onstrated  the ability  o f  Pgp to 
b ind  cytotoxic drugs directly. M utations in  critical transm em brane regions can 
in terfere  w ith  th is b ind ing  (C ornw ell et al., 1986). P lasm a m em brane vesicles 
from  Pgp- overexpressing cells have the ability  to transport [3H ]-labelled  drug in  
an  A T P-dependent m anner (H orio et al., 1988).
P gp  has been  identified no t only in  tum our cells in vitro, b u t also in  a num ber o f  
d ifferen t types o f  cancers w here, in  a  num ber o f  cases, it has been  show n to be 
associated  w ith  the clin ical m anifestations o f  resistance (B arrand et al, 1997). In 
m any cases, P gp-expression  in  tum ours has been  show n to  be associated  w ith  a 
poor therapeutic  prognosis (F isher and Sikic, 1995).
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The Pgp pro tein  in  hum ans is encoded  by  the M D R  gene, w hich is present on the 
long  arm  o f  chrom osom e 7, band  q21.1 (C hen et al., 1986). This gene possesses 
27 exons in  the  pro tein  cod ing  reg ion  o f  the  gene w ith  14 o f  these exons coding 
fo r the  le ft and 13 fo r th e  righ t h a lf  o f  the  Pgp m olecule (R oninson, 1991). Tw o 
p rom oter regions for th is gene have b een  identified, one o f  w hich is upstream  and 
the  o ther is dow nstream  (U eda el al., 1987a, b). The m ajority  o f  resistant cells in 
vitro preferentially  use  the  dow nstream  prom oter (U eda el al., 1997).
1.5.2 Structure of the gene encoding P-glycoprotein
1.5.3 P-glycoprotein protein structure
The m dr 1 gene p roduct is a  170kD a m em brane-associated  protein o f  1280 am ino 
acids con tain ing  12 transm em brane dom ains w ith  6 extracellu lar loops and two 
cytoplasm ic A T P dom ains (G ros et a l, 1986). Pgp  is expressed  at the apical 
surface o f  in testinal ep ithelium , w here it is responsible for the low  b ioavailability  
o f  m any drugs in  the gut, and  in  the endothelial cells o f  capillaries in the brain, 
w here it  is a m ajor con tribu to r to  the  b lood-brain  barrier (Sharom  et al., 1999). 
T he Pgp pro te in  is p redom inately  localised  in  the p lasm a m em brane o f  M D R  cells 
(Isquierdo, 1996a), b u t low  levels o f  expression have b een  show n to  be present in  
association  w ith  the  endoplasm ic reticu lum  and G olgi apparatus (G erm ann, 
1996).
P-glycoprotein  is a  phosphory lated  glycoprotein. Increased  phosphorylation o f  P- 
g lycopro tein  has been  show n to  cause an  increase in Pgp-m ediated  drug efflux 
activ ity  w hilst inh ib ition  o f  phophorylation  decreases th is activity (Cham bers et 
al., 1990). It is now  be lieved  tha t phophorylation m ay  have an indirect role in 
certain  aspects o f  P gp  ac tiv ity  including  th e  kinetics o f  d rug  transport, Pgp pro tein  
stability  and  d rug  resistance pattern  o f  Pgp-overexpressing cells (Elliott, 1998).
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1.6 Multidrug Resistance Protein -  MRP
A  num ber o f  hum an  tu m our cell lines show  decreased cellu lar accum ulation and 
increased  resistance to  drugs associated  w ith the  M D R  phenotype, bu t do not 
possess P gp  (T w entym an  et al., 1996). A  novel 96-kD a m em brane protein  has 
been  characterised  in  the  hum an  breast cancer M C F-7/A drV p subline, w hich  does 
no t over-express Pgp. This p ro te in  has been  correlated  w ith  drug  resistance to 
doxorubicin  (C hen  et a l, 1990). S im ilarly, a 42-kD a and  85-kD a m em brane 
bound  pro tein  have  been  iden tified  by  a  polyclonal antibody against the putative 
A T P b inding  dom ain  o f  P gp  in  M C F/M X  cells selected  by m itoxantrone. These 
cells are cross resistan t to  doxorubicin  and etoposide bu t w ithout Pgp-over 
expression. (N akagaw a et al., 1992).
It w as know n th a t m em bers o f  the A T P-dependent fam ily o f  transporters shared 
certa in  structural and  sequence hom ologues and that, particularly  in  the region o f  
the  nucleo tide b ind ing  dom ains, there  w ere h ighly  conserved am ino-acid 
sequences. M arquard t el al, (1990), raised  antibodies to  a  num ber o f  different 
sequences a long  th e  leng th  o f  the  Pgp m olecule and  found tha t one particular 
antibody, (A SP 14), raised  against one o f  these h ighly conserved  dom ains was 
ab le  to  recognise a  protein , over-expressed  in  certain o f  these non-Pgp cell lines 
(B arrand et al, 1997).
W hile searching  fo r such  alternative m olecules, m any investigators analysed the 
H L 60 hum an  leukaem ia  cell line and its drug-selected  resistant variants. It was 
d iscovered th a t H L 60 cells se lected  fo r resistance to  doxorubicin  exhibited M D R  
bu t d id  n o t con ta in  detectab le  levels o f  P-g lycopro tein  (M cG rath, 1987). 
C om parison  o f  m em brane proteins from  the H L60 and  H L 60/A D R  cell lines, 
using  antibodies ra ised  against synthetic peptides derived  from  P-glycoprotein, 
revealed  the presence o f  a  190-kD a A T P-binding pro tein  tha t w as prim arily  
localised  in the  endoplasm ic reticu lum  o f  the H L60/A D R  cells. This pro tein  was 
no t detectable in  the m em branes o f  parental cells and could  easily b ind 8- 
azido[alpha-32P] A T P (M arquard t el al, 1990).
Investigators p roceeded  to  study gene expression in  various cell system s to  further 
characterise th is  unique 190kD a protein. O ne o f  the m ost extensively
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characterised non-Pgp multidrug resistant cell line is H69AR, a small cell lung 
cancer cell line which was derived from the drug-sensitive parental H69 line by 
stepwise selection in doxorubicin (Mirski et ah, 1987). H69AR displayed a drug 
resistance pattern typical of that associated with increased amounts of Pgp. The 
cells displayed moderately high levels of resistance (10-100-fold) to the Vinca 
alkaloids, epipdophyllotoxins, doxorubicin and mitoxantrone. In addition, these 
cells were highly resistant to daunorubicin, epirubicin and colchicine (Mirski et 
al., 1987 and Cole et ah, 1992). A number of biochemical alterations occurred 
during selection, including reduced levels of DNA topoisomerase II a  and P 
(Giaccone et ah, 1992), increased expression of annexin II, a decrease in reduced 
glutathione (GSH), and altered levels of GSH-associated drug detoxification 
enzymes. However, as with most clinical specimens of SCLC, H69AR does not 
over-express Pgp protein or its cognate mRNA. Consistent with this observation, 
major differences in net drug accumulation or efflux did not appear to be part of 
the resistant phenotype of the H69AR cell line (Cleary, 1995). Another feature 
that distinguishes H69AR from cell lines that over-express Pgp is the inability of 
cyclosporin A and several other chemosensitising agents to reverse doxorubicin 
(Cole et ah, 1992).
As a result of these findings, a search was undertaken for evidence of other 
alterations in gene expression using a differential hybridisation approach to 
identify mRNA species that are over-expressed in H69AR relative to those 
present in parental H69 cells. Using this technique a 7.8 - 8.2kb mRNA was 
identified, which was expressed in the resistant cell lines at levels approximately 
100 - 200 fold higher rate than the sensitive parental cell line. Sequencing of 
cDNA clones derived from this mRNA revealed that it had the potential to encode 
a 1531 amino acid protein that was predicted to be a member of the ABC 
transporter superfamily and was subsequently named the multidrug resistance 
protein, or MRP ( Loe el al., 1996). This protein is now recognised as MRP1 
(Hipfner et al., 1999).
Though MRP1 and Pgp both belong to the ABC transporter family, they share 
only 15% amino acid homogeneity (Cole et al., 1992). Nevertheless, both proteins 
confer resistance to a broad range of cytotoxic xenobiotics including doxorubicin, 
vincristine and VP-16 (etoposide), drugs that are widely used in the treatment of
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many human cancers. However, growing evidence suggests that the mechanisms 
by which MRP1 and Pgp reduce cellular drug accumulation are not the same, 
indicating that there are major differences in the drug protein interactions of these 
two molecules (Loe et al., 1996).
1.6.1 Homologues of MRP
When the sequence of MRP was first analysed in 1992, the most closely related 
members of the ABC superfamily were the CFTR chloride channel (19% identity) 
and LtPgpA (30% identity) (Cole et al., 1992). The first transport protein to be 
recognised as a member o f the MRP family was cMOAT (Taniguchi et al., 1996). 
The authors specifically targeted the ATP-binding domain conserved in MDR1, 
MRP, and CFTR genes and compared the difference in mRNA from both 
cisplatin resistant and sensitive cells. They isolated a full length human cMOAT 
cDNA which was highly homologous to rat cMOAT and found that human 
cMOAT was a homologue of MRP. Sequencing of cMOAT revealed an open 
reading frame coding for 1545 amino acids that showed 46% similarity to that of 
human MRP. Taniguchi et al.,(1996), estimated the size of cMOAT to be approx. 
4.5kb, similar to that of MRP mRNA but larger than the human MDR 1 mRNA. 
Since this time many proteins more closely related to MRP1 have been identified 
in a wide variety o f eukaryotic organisms, ranging from plants and yeast to 
mammals (Klein et al., 1999). The Yeast family contains one well characterised 
MRP homologue, the Yeast Cadmium Resistance Factor, YCFI, shown by Li et 
al, (1996), to be a vacuolar GS-X pump. YCFI mutants can be complemented by 
MRP1 (Borst et al., 1997). At least 4 MRP homologues are expressed in 
Caenorhabditis elegans (Kool et al., 1997), and it was therefore possible that the 
human MRP gene family would have more than two members. To date five 
human MRPl-related proteins, designated MRP2, MRP3, MRP4, MRP5 and 
MRP6  have been discribed (Kool et al., 1997; Taniguchi et al., 1996; Paulusma et 
al, 1996; Konig et a l, 1999; Kool et a l, 1999a and 1999b and Kiuchi et al,
1998). A search of the human Expressed Sequence Tag (EST) database by 
Allikmets et a l, (1996), yielded 21 new ABC genes, including genes for 
transporters related to MRP1. In an independent search, Kool et al., (1997), found
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four transporters related to MRP1 and cMOAT and analysed the expression of 
these genes, called MRP3-6, in normal tissues and tumour cell lines. A fifth 
homologue of MRP1 was also identified as the human SUR (sulfonyl urea 
receptor) gene. The percentages o f homology for the COOH-terminal 124 amino 
acids are shown in Table 1.6.1. The highest homology is found between MRP1 
and MRP3 (83% similarity) and the lowest between SUR and any of the MRPs (< 
59% similarity).
MRP1 cMOAT MRP3 MRP4 MRP5 M RP6 HSUR
MRP1 100 ■
I .  > J r A &
cMOAT 73 100
. . .  _ ________________ '
MRP3 83 73 100
. ' ■' . - ■ ■ . •
-
•
MRP4 69 65 64 100
MRP5 66 65 62 66 100 ■
MRP6 69 64 67 62 57 100
HSUR 59 57 57 58 57 46 100
Table 1.6.1: Homology between the COOH terminal 124 amino acids of the six 
human MRP homologues and human SUR. Percentages of identity were 
determined using the GAP program of GCG (Kool el al., 1997).
The existence of a seventh family member, MRP7, has only been inferred from a 
database search and so far there is no other information available (Borst et al.,
1999). Some of the MRPs are known by other names as summarised in table 
1.6 .2 .
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The Mammalian MRP family
MRP1 = ABCC1 = MRP
MRP2 = ABCC2 = cMOAT = cMRP = EBCR (rabbit)
MRP3 = ABCC3 = MOAT-D = cMOAT-2 = MLP-2
MRP4 = ABCC4 = MOAT-B
MRP5 = MOAT-C = MOAT- C = pABC 11 = sMRP*
MRP6 = ABCC6  = MLP-1 = ARA*
MRP7 = ABCC10
*only 3’end.
Table 1.6.2: Overview of the MRP family and the alternative names used in the 
literature for the individual members (Borst et al., 1999).
The sMRP has been reported by Suzuki et a l, (2000), to be a spliced variant of 
the MRP5 gene, expressed in various human tissues. ARA represents the 3’end of 
the MRP6  gene that is incidentally co-amplified with MRP1 in cells selected for 
adriamycin resistance (Kool et al., 1999). Within the group of mammalian ABC 
transporters the MRPs form a cluster that is clearly demarcated from the other 
known groups, such as Pgp, CFTR and the sulphonylurea receptors.
1.6.2 Chromosome location of MRP and homologues
The newly identified MRP homolgues MRP3-5 are all located on other 
chromosomes other than those containing MRP1 or cMOAT genes (Kool et al, 
1997; Cole et al. 1999). This confirms that MRP3, MRP4, and MRP5 are indeed 
new genes and not alternative splice products of MRP 1 or cMOAT. The MRP1 
gene has been mapped to chromosome 16 at band p i3.13-13.12, the cMOAT gene 
was mapped to chromosome 10, band q24, MRP3, MRP4 and MRP5 were found 
on chromosomes 17, 13 and 3 respectively (Kool et al., 1997). MRP6  is located 
on chromosome 16, band 16pl3.11, next to MRP1 (Kool et al., 1999).
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1.6.3 Cellular location of MRP
Although MRP was initially believed to be predominantly located in the 
endoplasmic reticulum of resistant cells (Krishnamachary and Centre, 1993), 
significant levels are now known to be predominantly localized to the plasma 
membrane (Flens et ah, 1994; Muller et ah, 1994 and Zaman et ah, 1994), with 
detectable levels present in intracellular membrane compartments of some cell 
types (Almiquist et ah, 1995 and Hipfner et ah, 1999). Immunohistochemical 
studies show that MRP1 in normal tissue is predominantly cytoplasmic, whereas, 
in malignant tissue, it is mainly plasma membrane located with some granular 
cytoplasmic staining observed (Flens et ah, 1996). However, Flens et ah, (1996), 
and Zaman et ah, (1994), have reported that resistant cell lines show 
predominantly plasma-membrane staining.
MRP2 is localised to the canalicular membrane of rat and human hepatocytes 
(Paulusma et ah, 1997 and Keppler et ah, 1996), as well as to the apical 
membrane of rat hepatoma cells (Konig et ah, 1999a). MRP3 was found in the 
basolateral membrane of hepatocytes but was not detectable in the canalicular 
membrane domain of hepatocytes. In polarised monolayers of kidney cells, MRP 
1, 3 and 5 are routed to the basolateral membrane and MRP2 is the apical MRP 
isoform (Borst et ah, 1999). The subcellular locations of MRP4 and MRP6  have 
not yet been analysed (Borst et ah, 1999). Using specific monoclonal antibodies, 
MRP2 has been located in apical and MRP1 and MRP3 in basolateral membranes 
of tissues (Kool et ah, 1999, Flens et al., 1996 and Konig et ah, 1999b).
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MDRÍ MRP1 MRP2 MRP3
*
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BASOLATERAL
Figure 1.6.1: Schematic presentation of the localisation of MDR1 Pgp, MRP1, 
MRP2, MRP3 and MRP5 in transfected polarized epithelial cells. The physical 
barrier between the apical and basolateral plasma membrane is formed by tight 
junctions.
1.6.4 MRP expression in cell lines
Since the discovery of MRP1 in the small cell lung cancer cell line, H69AR, 
MRP1 has been identified in non-Pgp multidrug resistant cell lines from a variety 
o f tumour types, including leukemias, fibrosarcoma, non-small cell lung, human 
small cell lung, breast, cervix, prostate, and bladder carcinomas (Table 1.6.3) 
(Izquierdo et al., 1996). Although many of these cell lines have been selected in 
doxorubicin or other anthracyclines, others have been selected in etoposide (VP- 
16) or vincristine. (Loe, 1996). Recently cell lines have been identified which co­
express both MRP1 and Pgp but the relative contribution of each protein to the 
overall multidrug resistance phenotype has yet to be determined. (Brock et al.,
1995).
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Tumour Tyne Cell line Selecting drug
Human small cell lung H69AR Doxorubicin
GLC4/ADR Doxorubicin
POGB/DX Doxorubicin
H69/VP VP-16
UNCC-VP VP-16
Non-small cell lung MOR/R Doxorubicin
CORL23/R Doxorubicin
Cervical HelaJ2 Doxorubicin
KB/C-A Doxorubicin*
KB/7d VP-16
Fibrosarcoma HT1080/DR4 Doxorubicin
Leukaemia HL60/ADR Doxorubicin
U-937/A Doxorubicin
CEM/E Doxorubicin
Breast MCF7/VP VP-16
MCF7/GL Geldanamycin
Bladder T24/ADM Doxorubicin
KK47/ADM Doxorubicin
5637/DR5.5 Doxorubicin
Prostate P/VP20 VP-16
Mouse Erythroleukemia PC-V Vincristine
WEH1-3B/NOVO Novobiocin
*With cepharanthine and mezerine. (Taken from: Loe et al., 1996a) 
Table 1.6.3 MRP1 expressing tumour cell lines.
1.6.5 MRP expression in tissues
MRP1 has been detected either at the protein or mRNA level in normal human 
tissues including lung, stomach, colon, peripheral blood macrophages, thyroid, 
testis, nerve, bladder, adrenal, ovary, pancreas, gall-bladder, duodenum, heart, 
muscle, placenta, brain, kidney, liver and spleen (Sugawara et al, 1997; Loe et 
al, 1996a; Zaman et a l, 1993; Cole et al, 1992 and Kool et al., 1997).
MRP2 (cMOAT) is found predominantly in the liver, duodenum and, in low 
levels, in the kidney (Kool et al, 1997; Schaub et al, 1997). Kool et al, (1997) 
and Kiuchi et al., (1998), reported that MRP3 mRNA is mainly expressed in the 
liver, colon, intestine and adrenal gland, and to a lesser extent in several other 
tissues.
MRP3, like MRP2, is found predominantly in the liver. High levels of MRP3 
mRNA in human liver have also been reported by other authors including Kiuchi 
et al, (1993); Belinsky et al, (1998) and Fromm et al, (1999). However, results 
with new MRP3 antibodies show that there is little MRP3 protein in normal 
human liver (Kool et al, 1999a). Hirohashi et al, (1998), reported that MRP3 
mRNA levels are low or undetectable in normal rat liver but that the level is 
increased in rats made cholestatic by bile duct ligation. Therefore, it appears that a 
high level of MRP3 is detected in diseased liver cells and only a very low 
expression is detected in normal liver cells.
Kool et al., (1997), reported that MRP4 was found only in a small number of 
tissues at very low levels. However, Lee et al., (1998), demonstrated, using RNA 
blot analysis, the expression of MRP4 in a wide range of tissues, with particularly 
high levels in prostate, but almost undetectable levels in the liver. MRP5, like 
MRP1, is readily detected in several tissues with highest levels in skeletal muscle, 
intermediate levels in kidney, testis, heart and brain and low levels in most other 
tissues, including lung, liver, spleen, thymus, prostate, ovary and placenta 
(Belinsky et al., 1998).
Recent investigations have shown that MRP6  is predominantly expressed in liver 
and kidney cells and to a lesser extent in other tissues (Kool et a l, 1999b). Table
1.6.4 shows the levels of RNA transcripts of MRP1, cMOAT, MRP3, MRP4, 
MRP5 and MRP6 .
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MRP11 cMOAT1 MRP3' MRP41 MRP51 MRP62
Lung •  • • • O • • • • •  •
Kidney • • • • • • •  • •  • • •
Bladder •  • • • o • • •  • 0
Spleen • • • • o • O •  • 0
Mammary gland ND o o ND ND ND
Salivary gland ND o o O • • • •
Thyroid • • • • o o O • •
Testis • • • • o o o • • O
Nerve • o o • • 0
Stomach • • • o • o • • 0
Liver • •  •  • • • • • o • • • • •
Gall bladder • • • ND ND • •  • 0
Duodenum •  • •  • •  • • ND ND • •
Colon • • • o •  • • o • • • •
Adrenal gland • • • • o •  • • o • D
Skeletal muscle • • o o o • • • • 0
Heart o o o • • O
Brain o o o • • • 0
Placenta • • o o o • 0
Ovary • • o o o • 0
Pancreas o • o • o
Tonsil ND o • • • • o
1 Kool et al., (1997); 2Kool et a l, (1999b). ND, not determined; O, no expression; 
•  - • • • • ,  low to high expression.
Tablel.6.4: Levels o f mRNA transcripts of MRP1, cMOAT (MRP2), MRP3, 
MRP4, MRP5 and MRP6  in human tissues.
1.6.6 MRP Protein structure
Both of the known human multidrug resistance transporters, P-glycoprotein and 
MRP, together with several other bacterial and eukaryotic transporters, are 
members of the ABC transporter protein family. In most cases these proteins have 
been shown to function as transport ATPases, hydrolysing ATP in conjunction 
with transporting their substrate molecules through cellular or intracellular
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membranes. These proteins share a common molecular architecture - they are 
built from combinations of conserved domains, that is ATP- (nucleotide-) binding 
ABC units, and characteristic membrane- embedded regions (Varadi et al, 1998).
Most ABC transporters are comprised of two polytopic MSDs (Membrane 
Spanning Domain) and two NBDs (Nucleotide Binding Domain) (Higgins, 1992). 
In proteins such as Pgp, CFTR, and STE6, all four domains are contained within a 
single polypeptide but others, such as bacterial transporters and the maltose and 
histidine permeases, consist of four polypeptides each encoding a single domain. 
Mammalian TAPI and TAP2, which are involved in antigen presentation, each 
contain one MSD and one NBD, and heterodimerise to form a functional 
complex. It is thought that ABC transporters such as Pgp, CFTR, and STE6 
evolved by duplication or fusion of genes encoding half-transporters with domain 
organisations similar to those of TAPI and TAP2 (Gao et a l, 1998). The 
predicted topology of MRP1 is inconsistent with the typical four-domain 
structure. It was the first example of a subgroup of the ATP-binding cassette 
superfamily whose members have three membrane spanning domains and two 
nucleotide binding domains (Hipfner et al., 1997 and 1999). Mutagenesis of 
potential N-glycosylation sites has recently shown that the NH2 terminus of 
MRP1 is extracellular so it appears most likely that MSD1 spans the membrane 
five times (Varadi et al., 1998). This additional hydrophobic domain is not 
present in ABC transporters such as Pgp and CFTR. Thus, it is a characteristic 
feature of members of the MRP branch of the ABC transporter superfamily 
(Hipfner el al., 1997).
More recently identified ABC transporters with a third NH2 terminal MSD 
include cMOAT (MRP2), MRP3 and MRP6 the yeast cadmium resistance factor 
(YCF1), and the sulfonylurea receptors (SUR), as well as several less well 
characterised MRP-related proteins (Lautier et al, 1996; Hipfner et al, 1999; 
Tusnady et al, 1997 and Bakos et al., 1996). Comparisons of protein primary 
structure and gene organisation suggest that the MRP-related proteins share a 
common, four-domain ancestor with the CFTR. It is also apparent from such 
comparisons that the NH2 terminal MSDs of the MRP-related proteins are poorly 
conserved relative to the other four domains in these proteins. Gao et al., (1998), 
investigated the possible role of the third MSD of MRP1 and its related
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transporters and their results demonstrated that two truncated molecules (MRP229- 
1531 and MRP2 8 I-1531) lacking MSD1 can be expressed in Sf21 cells as efficiently 
as the full length protein. They then examined the ability of various MRP1 
fragments, expressed individually and in combination, to transport the MRP 
substrate, Leukotriene C4 (LTC4). It was found that elimination of the entire NH2 
terminal MSD, or just the first putative transmembrane helix, or substitution of 
the MSD with the comparable region of the functionally and structurally related 
transporter, the canalicular multispecific organic anion transporter 
(cMOAT/MRP2), had little effect on protein accumulation in the membrane. 
However, all three modifications decreased LTC4 transport activity by at least 
90%. Transport activity could be reconstituted by co-expression of the NH2- 
terminal MSD with a fragment corresponding to the remainder of the MRP 
molecule, but this required both the region encoding the transmembrane helices of 
the NH2 terminal MSD and the cytoplasmic region (Lo) linking it to the next 
MSD. In contrast, a major part of the cytoplasmic region linking the N H r 
proximal nucleotide binding domain of the protein to the COOH-proximal MSD 
was not required for active transport of LTC4.
In most ABC transporters, the binding and the subsequent hydrolysis of ATP by 
the NBDs is believed to be coupled to, and provide the energy for substrate 
transport (Hipfner et al, 1999). These domains are highly conserved, typically 
showing 30-40% identity among different superfamily members in a core region 
of about 200 amino acids. The NBDs of ABC superfamily members share two 
sequence motifs, designated “Walker A” and “Walker B”, with many other 
nucleotide binding proteins (Walker et al, 1982). Mutational analysis of a 
number o f ABC proteins indicates that these two regions are critical for ATPase 
function (Hipfner et al, 1999). Another feature that distinguishes MRP 1-like 
transporters from other ABC superfamily members is a difference in the structure 
of the NH2-proximal NBD (NBD1). Alignment of the primary sequences of 
MRP1, LtPgpA, and CFTR with the human Pgp encoded by the MDR1 gene 
revealed that, in comparison to P-glycoprotein, these transporters all contain a 
“deletion” of 13 amino acids located between the Walker A and B motifs of 
NBD1.
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Figure 1.6.2: Proposed membrane topology of MRP 1. Models of the membrane 
topology o f MRP 1 are shown with amino acids experimentally determined to be 
localised to the cytosolic or extracytosolic side of the membrane indicated. Six 
amino acids have been localised to the extracytoplasmic side of the membrane by 
N-glycosylation site utilization analysis (N19, N23 and N1006$) or HA epitope 
insertion (amino acid positions 4, 574, 1001 and 1222^). Additional amino acids 
or regions have been localised to the cytosolic side of the membrane by epitope 
mapping of MRPl-specific mAbs MRPrl, QCRL-1 and MRPr6 ( 0  ) or by HA 
epitope insertion (at amino acid positions 163, 271, 653, 938A ). A glycoylation 
site that is not utilised but predicted to be extracytosolic is indicated ^  ) (Hipfner 
etal., 1999).
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Within the MRP family, homolgy is highest between MRP1, 2, 3 and 6. MRP 2, 
MRP3 and MRP6 have a similar structure to MRP1 and are characterised by the 
presence of MSD1 connected to a Pgp-like core by cytoplasmic linker, Lo. 
However, both the MRP4 and the MRP5 cDNA sequences predict a structure 
more similar to CFTR and MDR1 than MRP1 because of the lack of the NH2- 
terminal membrane-bound extension of about 280 amino acids. Although this 
segment is absent in these MRP homologues, it is reported that they still have the 
basic structure that seems to be required for GS-X pump activity in MRP1 (Bakos 
et a l, 1998), i.e. the P-glycoprotein-like core structure and the Lo loop.
The amino acid sequence of MRP 1 contains various sites known to be relevant 
for ATP binding and post-translational modification (Loe el a l, 1996a). MRP1 
has been detected immunologically as a 190 kDa N-glycosylated phosphoprotein 
which binds ATP. Various studies have shown that the unmodified MRP 
polypeptide has an apparent mass of 170 kDa and is processed into a mature 190 
kDa form by addition of N-linked oligosaccharides (Almiquist et al, 1995). Only 
three o f the twelve potential sites for N-linked glycosylation, contained in the 
human MRP1 gene, are external to the plasma membrane and glycosylated 
(Almiquist el al, 1995). The effect of glycosylation on MRP1 activity is not fully 
known but it has been demonstrated that tunicamycin-induced inhibition of 
glycosylation has little effect on the cellular drug accumulation characteristics of 
MRP1 expressing cells (Almiquist et al, 1995). Hipfner et a l, (1997), also report 
that although MRP1 expressed in Sf21 cells is underglycosylated, it displays 
transport kinetics similar to those of fully glycosylated MRP1.
MRP1 is highly phosphorylated with phosphate groups contained in at least 9 
tryptic peptides (Ma el al., 1995). All phosphate groups are present at serine 
residues and it has also been observed that certain protein kinase inhibitors such 
as chelerythrine and staurosporine are capable of reducing P I90 phosphorylation 
and reversing drug resistance (Ma et al, 1995).
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It is believed that phosphorylation of MRP 1 occurs mainly in the linker region of 
the protein but the precise location and functional role of these phosphorylated 
residues on MRP 1 are unclear.
1.6.7 Function /Transport by MRP1
Lutzky et a l, (1989), demonstrated that inhibition of Glutathione (GSH) 
synthesis by buthionine sulfoximide (BSO), an inhibitor of y-glutamylcysteine 
synthetase, resulted in significant sensitization to daunorubicin and suggested that 
changes in the intracellular distribution of GSH/Glutathione-S transferase (GST) 
and/or increased drug retention may have been involved in mediating this effect. 
Increased intracellular GSH levels were shown to correlate with intrinsic 
anthracycline resistance (Russo et al., 1985). Increased activity of GSH- 
dependent enzymes was associated with acquired resistance (Lutzky et al., 1989). 
In 1994 two groups independently demonstrated that MRP1 is able to transport 
glutathione (GSH) conjugates of drugs (Leier et al, 1994 and Jedlitschly et al, 
1994). Leier et a l, (1994), demonstrated, using isolated plasma membrane 
vesicles with an inside out orientation prepared from HeLa cells transfected with 
MRP1 expression vectors, that the MRP1 gene encodes a primary-active ATP 
dependent export pump that can transport the cysteinyl leukotriene, LTC4 and 
glutathione conjugates such as glutathione disulphate (GSSG). Elevated levels of 
ATP-dependent transport of LTC4 and certain other GSH conjugates were 
demonstrated by Jedlitschly et al, (1994), in membrane vesicles prepared from 
drug selected HL60/ADR cells. The findings that MRP1 can transport cysteinyl 
leukotrienes (e.g. LTC4) as well as other GSH conjugates suggest that this protein 
may be a GSH conjugate/organic anion transporter, a GSH-X pump. Therefore, it 
appears that MRP1 is a transporter of multivalent organic anions, preferably 
glutathione S-conjugates (Loe et al, 1996b; Jedlitsky et al, 1996; Muller et al., 
1994), but also of sulphate conjugates (Jedlitsky et al., 1996; Renes et al, 1999). 
MRP1 confers resistance to heavy metals that interact with GSH and transports 
oxidised GSH (GSSG), steroid glucuronides and bile salt derivatives (Loe et al, 
1996; Cole et al. 1994), and complexes of reduced glutathione (GSH) with 
arsenite (Zaman el al., 1995). Moreover, because of the MRP-mediated export of
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glutathione disulfide from cells (Leier et al, 1996), MRP family members are 
reported to play a role in the defence against oxidative stress (Keppler el al, 
1999a).
The mechanism of MRP-mediated transport of chemotherapeutic drugs is 
presently unclear. Although MRP1 has been shown to reduce cellular 
accumulation of at least some of the drugs to which it confers resistance, such as 
adriamycin, daunorubicin, vincristine and VP-16, it has previously not been 
possible to demonstrate direct transport of these compounds or other unmodified 
chemotherapeutic drugs by MRP 1-enriched membrane vesicles (Cole et al., 1998; 
Jedlitschky et al, 1996; Loe et al., 1996 and Muller et al., 1994), and contrary 
reports claiming to have shown direct transport of these compounds have recently 
been retracted (Cole et al., 1998). However, Vezmar et al., (1998), reported the 
direct binding of the antimalarial drug, chloroquine, to MRP1 and the transport of 
this compound in an ATP-dependent manner.
Because MRP1 has the ability to transport glutathione conjugates, it was 
postulated that the transporter confers multidrug resistance by pumping the 
glutathione conjugates of anionic metabolites of lipophilic cytotoxic drugs (Paul 
et al., 1996). However, glutathione conjugates of the natural drug products for 
which MRP1 confers resistance have not been isolated (Tew, 1994), and MRP 
transfectants do not exhibit increased resistance to alkylating agents, a class of 
drugs for which glutathione conjugation is known to occur (Grant et al., 1994; 
Paul et al. 1996; Loe et al, 1996 and Renes et al., 1999). There are also other 
reasons why the ability to transport drug conjugates is unlikely to provide a 
general explanation of the ability of MRP 1 to confer resistance to a structurally 
diverse spectrum of anti-neoplastic agents in such a wide variety of cell types. 
Most interesting is the observation that Phase II conjugation plays a relatively 
minor role in the in vivo and in vitro metabolism of these compounds (Loe et al.,
1998). In addition, Phase I and Phase II biotransformation reactions are known to 
occur primarily in the liver (and to a lesser extent in other tissues), and it is 
highly unlikely that all of the cell types in which MRP1 overexpression causes 
resistance are competent to carry out these reactions with the required efficiency 
and completeness (Cole et al., 1998; Hipfner at al., 1999).
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A number of authors have also reported the ability of the MRP protein to mediate 
the active transport of neutral (etoposide (VP-16)) and cationic (adriamycin, 
vincristine, daunorubicin and rhodamine 123) lipophilic drugs as well as anions 
(e.g. dinitrophenyl-S-glutathione and calcein) (Broxterman et al, 1996; Renes el 
al, 1999). Therefore, the need for extensive conjugation in tumour cells of such a 
variety of compounds makes this hypothesis even more unlikely.
However, a number o f authors have reported that depletion of cellular GSH 
(reduced glutathione) levels by treatment with BSO (buthionine sulfoximine), 
improved the efficacy of some natural product drugs both in cultured cells and in 
mice bearing tumours that express elevated levels of MRP1 (Loe et al., (1998); 
Lautier el al., 1996 and Schneider et a l, 1995). Recently Benderra et al., (2000), 
have reported that BSO was able to increase nuclear accumulation of 
daunorubicin in cells overexpressing MRP1 (MCF7/VP) but had no effect in cells 
that overexpressed Pgp.
These findings together with the observation that MRP1 increased drug efflux 
from intact cells but was apparently unable to transport the same compounds in 
isolated plasma membrane vesicles, suggested that either the efflux of certain 
drugs might require the activation of MRP1 by GSH or that some form of co­
transport mechanism might be involved (Cole et al., 1998). Loe et al, (1996), 
reported that physiological concentrations of GSH significantly enhanced the 
ability of vinblastine and vincristine to inhibit MRP 1-mediated ATP-transport of 
LTC4 although GSH or vincristine alone are very poor inhibitors of MRP- 
mediated ATP-transport of LTC4. They also demonstrated the direct uptake of 
unmodified VCR by MRP 1-enriched vesicles in an ATP and GSH-dependent 
manner and that the tripeptide structure of GSH is a requirement for stimulation 
o f VCR transport to occur. Renes et al., (1999), demonstrated, using membrane 
vesicles isolated from in vitro selected multidrug resistant cell lines 
overexpressing MRP1 (GLC4/ADR) (which did not express MRP2, MRP3, 
MRP4 or MRP5 (Kool et al., 1997)) and a MRP 1-transfected cell line (SI (MRP)), 
that MRP1 transports vincristine and daunorubicin in an ATP-and GSH- 
dependent manner. This transport can be inhibited by the MRP1 inhibitor, 
MK571, and the MRP 1-specific monoclonal antibody, QCRL-3. Previously, Leier 
et al, (1996), reported that GSH was not transported by MRP1. But Loe et al,
(1998), reported that VCR stimulates the ATP-dependent transport of GSH in a
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concentration-dependent manner although in the absence of VCR, they detected 
no ATP-dependent GSH transport. Therefore, the information provided by Loe et 
al, (1996) and (1998), and Cole et al, (1998), indicates that MRP1 can actively 
cotransport GSH and unmodified vincristine and that these compounds probably 
interact, either with LTC4 binding site(s) on the protein or with a mutually 
exclusive site.
Additional evidence favouring a drug/GSH co-transport mechanism has been 
obtained from studies using murine MRP double-knockout (MRP7 ) cell lines. 
The export of GSH from murine wild type (MRP+/H ) embryonic stem cells, but 
not from the knockout (MRP_/ ) cell lines, has been reported to be increased in the 
presence of VP-16 (Cole et al., 1998; Rappa et a l, 1997; Wijnholds et al, 1997 
and Loe et al., 1998). In addition expression of MRP1 in some cell lines, but not 
all, is associated with a significant (2- to 6 -fold) decrease in intracellular GSH 
levels (Loe et al, 1998). Recently, Rappa et al., (1999), reported in studies of 
murine MRP knockout models that MRP, besides being capable of exporting 
certain glutathione conjugates, may also catalyse the co-transport of GSH and 
drugs or endogenous metabolites. A recent publication by Poirson -Bichat et al., 
(2 0 0 0 ), reported that most, if  not all, human tumours are dependent on methionine 
for growth and that depletion of methionine resulted in a reduction of the ATP 
pool and glutathione content, resulting in increased efficiency of a number of 
chemotherapeutic drugs including adriamycin, cisplatin and carmustine. This 
further indicates the involvement of GSH and ATP in chemoresistance and drug 
efflux mechanisms.
However, this co-transport mechanism still can not fully explain all MRP- 
mediated resistance mechanisms, in particular, with respect to the anthracycline 
antibiotics, since GSH displays little or no ability to enhance either their transport 
directly or their ability to inhibit ATP-dependent, MRP1 mediated LTC 4 transport 
(Loe et al, 1996b). These authors also found that treatment of either drug- 
selected or transfected cells with BSO restored sensitivity to vincristine far more 
effectively than to adriamycin. It appears that GSH is of far greater importance to 
MRP1-mediated transport of Vinca alkaloids compared to anthracyclines. 
However, recently several GSH-independent interactions of MRP 1 have have also 
been reported. The MRP 1-mediated transport of antifolates and the induction of 
MRP1 ATPase activity by the (iso)flavonoids, both in the absence of GSH,
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showed that the presence of GSH was not absolutely required for MRP1 function 
(Hooijberg et a l, 1999 and 2000).
A number of cell lines, which over-express MRP1, have been developed through 
a process of drug selection. Because these cell lines are obtained by a stepwise 
selection in drug it is difficult to obtain information on the potential drug 
transporting abilities of MRP1 as it is more than likely that a variety of drug 
resistance mechanisms are co-expressed in the cell lines. MRP- transfected cell 
lines may be more useful models for defining the profile of drugs transported by 
MRP as the use of cell systems such as these should avoid the interference from 
multiple resistance mechanisms found in drug selected cell lines. However, as 
most cells contain endogenous (organic anion) transporters, resulting in 
background transport activity (Borst et al., 1999), it has been difficult to generate 
cell lines which express one transport protein only. Therefore, MRP-transfected 
cell lines may only be useful when the problem of endogenous transporters is 
resolved.
Cole et al, (1994), found that MRP 1-transfected cell populations were 6.9-fold, 
6.3-fold, 8.6-fold, 11.6-fold, 10.3-fold more resistant to adriamycin, daunorubicin, 
epirubicin, vincristine and VP-16, respectively, than negative control transfectant. 
These transfectants were only slightly resistant to taxol, vinblastine, and 
colchicine (1.7-fold, 3-fold, 2.1-fold respectively). In addition, antifolates, such as 
the anticancer agent methotrexate, have recently been described as MRP1 
substrates (Hooijberg et al, 1999 and Kool et al, 1999a). In addition to 
methotrexate, several additional amphiphilic organic anions which are not 
conjugated have been shown to be transported by MRP1 directly in a GSH- 
dependent manner (Keppler et al, 1999 and Konig et a l, 1999). Although the 
resistance profiles of drug-selected MRP or Pgp-overexpressing cell lines were 
similar, considerable differences existed particularly with regard to taxol, 
mitoxantrone and colchine resistance (Cole et al, 1994). These three highly 
lipophilic drugs are normally included as members of the resistance spectrum of 
Pgp. However, a number of authors have reported low level resistance to taxol in 
MRP-overexpressmg cell lines (Zaman et al, 1994; Breuninger et al, 1995 and 
Vanhoefer et al., 1996 and 1997). The MRP transfected cells were also resistant 
to a number of heavy metal anions including arsenite, arsenate and trivalent and
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pentavalent antimonials but were not resistant to cadmium chloride. MRP1 
transfected cells were not resistant to 9-alkyl anthracyclines, or cisplatin (Loe et 
ah, (1996a). It appears that MRP1 has a preference for more hydrophilic 
xenobiotics.
The drug accumulation characteristics of MDR cell lines with high levels of 
MRP, vary significantly. Cell lines which over-express MRP following drug 
selection, can accumulate less drug and/or have higher rates of efflux than the 
sensitive cells from which they were derived. A number of MRP expressing cell 
lines also appear to sequester drug into cytoplasmic vesicles (Marquardt et ah 
1992) which may lead to the diversion of the drug from the relevant cellular target 
without affecting total cellular accumulation levels.
It is unclear why a cell develops MRP over Pgp-mediated resistance during drug 
exposure but it is believed that overexpression of MRP 1 may confer initial levels 
of resistance, while Pgp overexpression develops as higher levels of resistance are 
required for survival (Elliott, 1997 and Choi et ah, 1999). Brock et ah, (1995) 
showed that in the small cell cancer cell line, H69, MRP1 was over-expressed 
during selection in low concentrations of VP-16. Following further selection in 
higher concentrations of drug, MRP1 expression remained relatively constant, but 
Pgp expression developed.
1.6.8 MRP1 and clinical multidrug resistance
There is considerable interest in determining the potential involvement of MRP1 
in clinical multidrug resistance and a number of different MRP 1-specific 
monoclonal antibodies (mAbs) including mAbs QCRL-1, QCRL-3, MRPrl and 
MRPm6 have been used in a wide variety of immunoassays for the analysis of 
MRP1 expression and localization in both normal and malignant tissues (Flens et 
al., 1994). The expression of MRP 1 protein and/or mRNA has been detected in 
almost every tumour type examined, including both solid tumours (lung, 
gastrointestinal and urothelial carcinomas, neuroblastoma, glioma, 
retinoblastoma, melanoma, cancers of the breast, endometrium, ovary, prostate 
and thyroid) (Ito et ah, 1998; Canitrot et ah, 1998; Chan et ah, 1997; Nanashima 
et ah, 1999; Hipfner et ah, 1999; Oshika et ah, 1998; Loe et ah, 1996), and
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hematological malignancies (Filipits et al, 1997; Abbaszadegan et al., 1994; Loe 
et al, 1996). Among the common tumour types, expression of high levels of 
MRP1 is particularly frequent in the major histologic forms of non-small cell lung 
cancer (Nooter et al., 1996; Giaconne et al., 1996; Hipfner et al., 1999). There are 
difficulties in establishing a causative role for MRP1 (and other resistance- 
associated proteins such as Pgp) in clinical multidrug resistance. There are a 
number of reasons for this. The broad spectrum of drugs encompassed by clinical 
multidrug resistance indicates that multiple resistance mechanisms are likely 
involved. Due to differences in the methods used to quantify MRP in clinical 
samples discrepant results have been reported by different investigators. The 
design and execution of more informative studies to address the role of resistance 
proteins in chemotherapy failure has been hindered by difficulties in obtaining 
suitable patient samples (e.g. pre-and post-chemotherapy samples from the same 
patient) (Hipfner et al, 1999).
However, a number of authors have reported that the expression levels of MRP 1 
are of prognostic si gnificance. Chan et al., (1997), reported that MRP1 expression 
in retinoblastoma (RB) was associated with the rare failures of chemotherapy in 
RB. Canitrot et al., (1998), and Campling et al., (1997), reported that the 
expression of MRP 1 mRNA was a negative determinant of the chemotherapeutic 
response of untreated Small Cell Lung Cancer (SCLC). MRP1 was also reported 
by Ito et al., (1999), to have prognostic value in primary breast cancer and might 
be used as one of the markers for poor prognosis in patients with this disease 
(Huang et a l, 1998). Oda et a l, (1996), also suggested a link between MRP1 
expression and poor prognosis in Ewings sarcoma and malignant peripheral 
neuroectodermal tumour of bone (MPNT).
Norris et al., (1997), and Bordow et a l, (1994), have reported that amplification 
of the N-myc oncogene is a powerful indicator of poor response to chemotherapy 
and poor outcome in neuroblastoma and is central to the malignant phenotype of 
this disease. Expression of the MRP1 gene is common in both primary 
neuroblastoma tumours and cultured cell lines and was found to correlate with 
amplification and overexpression of the N-myc oncogene (Bordow et al, 1994). 
Norris et a l, (1997), have hypothesised that the N-wyc oncogene influences 
neuroblastoma outcome by regulating MRP1 gene expression.
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It has also been reported that mutant p53 gene significantly correlated with MRP 
overexpression in a number of cell lines derived from different tumour types 
including NSCLC (Oshika et al, 1998 and Wang et al., 1998), colorectal cancer 
(Fukishima et al, 1999), acute myeloblastic leukemia (Turzanski et al., 2000), 
leukaemia and ovarian carcinoma (Wang et al., 1998). Wang et al., (1998), have 
suggested that it may be feasible to overcome drug resistance due to MRP1 
overexpression by restoring the wild type p53 status of those cells bearing mutant 
p53.
1.6.9 Function/Transport properties of the MRP analogues
1.6.9.1a MRP2 (cMOAT)
The discovery that MRP1 is a GS-X pump also raised the question as to whether 
other GS-X pumps, known to exist in human tissues might be involved in some 
forms of drug resistance. The first of these pumps to be recognised as a member 
of the MRP family was the canalicular multispecific organic anion transporter 
gene, cMOAT (MRP2) (Taniguchi et al., 1996).
The liver converts many endogenous and xenobiotic lipophilic compounds into 
anionic conjugates with glutathione, glucuronate or sulfate. These conjugates are 
transported across the canalicular (apical) membrane into bile by the 190kDa 
membrane glycoprotein, MRP2 (Jansen et al., 1985; Taniguchi et al., 1996). 
Defects in MRP2 are known to cause Dubin-Johnson syndrome (DJS) (Mayer et 
al, 1995; Paulusma et al., 1996). Koike et al., (1997), reported that MRP2 
activity mediates the ATP-dependent transport of various hydrophobic anionic 
compounds in liver canalicular membranes and other tissues. Studies with mutant 
rats (TR/GY or EHBR), which lack the MRP2 protein in the canalicular 
membrane of hepatocytes, have shown that the substrate specificity of MRP2 is 
very similar to that of MRP 1 (Oude Elferink et al., 1995; Keppler et al., 1997; 
Roelofsen et al., 1999). Paulusma et al, (1999), demonstrated a role for cMOAT 
in the excretion of GSH both in vivo and in vitro. In several independent cMOAT 
transfectants, the level o f GSH excretion correlated with the expression level of
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the protein (Paulusma et al., (1999). The authors further demonstrated, using 
membrane vesicles isolated from cMOAT-expressing MDCKI1 cells, that GSH is 
a low-affmity substrate for the transporter and that its excretion is reduced upon 
ATP depletion.
Like MRP1, MRP2 transports bilirubin glucuronides in an ATP dependent 
manner. Bilirubin is secreted from the liver into bile mainly as glucuronosyl and 
bisglucoronsyl conjugates. Jedlitschy et al., (1997), demonstrated that bilirubin 
glucuronides were better substrates for MRP2 than MRP!. Keppler et al., 
(1998,1999a and 1999b), and Konig et al., (1999), have also reported that the KIn 
value (the Michaelis Menton constant (the dissociation constant for the complex)) 
of human MRP2 for LTC 4 was 10-fold higher than that for MRP1. Moreover, the 
Km of human MRP2 for 17p-glucuronosyl estradiol was 4.8-fold higher than for 
MRP1. MRP2 is also reported to be the predominant export pump responsible for 
hepatobiliary excretion of the amphiphilic anion Fluo-3 (Keppler et al., 1999 and 
Konig et al., 1999). In addition, the quinoline-based LTD4 analog, MK571, more 
potently inhibits MRPl-mediated transport than the rat MRP2-mediated transport 
(Keppler et a l, 1998).
1.6.9.1 b: Proposed working model for MRP1 and MRP2
Borst et al., (1999), proposed a working model for MRP1 and MRP2 with two 
drug binding sites: one with a relatively high affinity for GSH (G-site) and a low 
affinity for drug, and one with a relatively high affinity for drug and a low affinity 
for GSH (D-site). The authors propose that in the absence of drugs, both binding 
sites are occupied by GSH resulting in a slow export of GSH. At low drug 
concentrations, the G-site remains occupied by GSH and the D-site becomes 
occupied by drug, resulting in co-transport of both compounds. The authors infer 
that both sites show positive cooperativity i.e. the activity of MRP requires 
substrate binding to both binding sites and the binding of a substrate to to the G or 
D-site can affect the transport of the substrate on the other binding site (for 
example, GSH and vincristine). Borst et al, (1999), also suggest that at high drug 
concentrations some (negatively charged) drugs appear to be able to occupy both
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the G- and the D- site resulting in transport of drug alone. Evers et a l, (1998), and 
Jedlitschky et al., (1996) and (1997), reported that MRP1 and MRP2 do not 
require free GSH for the transport of compounds that are conjugated to 
glutathione, glucuronide or sulfate. Therefore, Borst et al., (1999), suggest that 
these substrates have a relatively high affinity for both the G- and the D-site and 
are therefore transported efficiently without requiring GSH or stimulating GSH 
export.
1.6.9.1c MRP2 and drug resistance in cancer
Cancer cells that overexpress Pgp or MRP1 do not show cross-resistance to 
platinum-containing compounds, alkylating agents and anti-metabolites 
(Taniguchi et al., 1996; Koike el al., 1997). MRP 1-transfected cells show 
resistance to anthracyclines, vinca alkaloids, epipodophyllotoxins and heavy 
metal anions but are sensitive to platinum-containing compounds. It was first 
suggested by Tanaguchi et al, (1996), that human cMOAT may function as a 
cellular cisplatin transporter, as expression of human cMOAT was enhanced in 
cisplatin resistant human cell lines with decreased cellular cisplatin accumulation, 
but was not enhanced in cell lines with normal levels of drug accumulation. 
Human cMOAT was overexpressed 4.0-6.0 fold in the three cell lines analysed by 
Tanaguchi et al, (1996), as compared to their parental drug-sensitive counterparts 
but did not overexpress MRP1. The cell lines analysed were the cisplatin resistant 
human (CRH) head and neck cancer KB cell line KB/KCP4, the CRH prostatic 
cancer PC-3 cell line P/CDP5 and the CRH bladder cancer T24 cell line T24 
DDP10.
HepG2, a human hepatic cancer cell line, was found to express high levels of 
cMOAT mRNA (Narasaki et a l, 1997), and protein (Koike et al, 1997). Koike 
et al., (1997), transfected an expression vector containing cMOAT antisense 
cDNA into the HepG2 cell line and observed a reduction in the cMOAT protein 
as well as an enhanced level of glutathione in the antisense transfectants but 
increased expression of MRP and MDR1 was not observed. The transfectants 
displayed an increased sensitivity to cisplatin, vincristine, doxorubicin and the
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camptothecin derivatives but not to etoposide (VP-16), mitomycin C and 5-FU 
(5’Fluorouracil). The results suggested that cMOAT levels are inversely 
correlated with those of glutathione and that cMOAT and it’s related genes may 
be involved in the sensitivity of cells to certain anticancer agents. Kool et al.,
(1996), examined a large number of cisplatin and doxorubicin resistant cell lines 
and showed a correlation between cMOAT transcript levels and sensitivity to 
cisplatin but not to doxorubicin. Increased resistance to vincristine and etoposide 
was observed in MDCKII cells transfected with MRP2. HEK292, transfected with 
MRP2, showed increased resistance to etoposide, cisplatin, epirubicin and 
doxorubicin (Konig et al., 1999). MRP2 was also shown to confer resistance to 
the antifolate drug, methotrexate (Hooijberg et al., 1999).
Thus there is indirect evidence to suggest that an organic anion pump, notably 
cMOAT, could contribute to cisplatin resistance by exporting the cisplatin -  GSH 
complex. Elevated GSH levels and synthesis may be required to drive formation 
of the complex if  contact with cisplatin is extended, as is usually the case with 
cell lines selected for resistance in vitro. However, even in the limited set of cell 
lines analysed by Kool et al., (1996), all chosen for lowered cisplatin 
accumulation, there was no simple quantitative correlation between cisplatin 
resistance and the combination of raised GSH and cMOAT (Borst et al., 1997). 
Kauffmann et al., (1997), demonstrated the inducibility o f cMOAT gene 
expression in rat hepatocytes treated with 2-AAF (acetyl aminofluorene), cisplatin 
or cyclohexamide. This group of researchers put forward the theory that 
expression of the cMOAT transporter may be part of an adaptive response 
mechanism aimed at preventing further cell damage. They also postulated that the 
stress-activated kinases, a subgroup of the mitogen-activated protein kinase 
family, are involved in the regulation of cMOAT. Additional candidates that may 
participate in cMOAT regulation include other protein kinases or factors 
inducible by cDNA damage such as gadd45 and p53.
It would seem, from the evidence to date that cMOAT may be induced by a 
variety of cytotoxic, carcinogenic and chemotherapeutic agents which is likely to 
be of relevance for the acquisition of multidrug resistance during chemotherapy. 
Matsunga et al. (1998), reported that the enhanced expression of MRP or cMOAT 
in childhood liver tumours was more common and higher, especially in advanced 
cases, with poor outcome, than that observed in normal liver or in 9 hepatocellular
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carcinomas from adult patients. The author suggests that the enhanced expression 
of these genes might be characteristic of childhood malignant tumours and related 
to their clinical chemoresistance. However, there is no direct evidence to date for 
the involvement of cMOAT in clinical drug resistance, particularly the cisplatin 
resistance of MDR (Borst et al, 1997).
1.6.9.2 MRP3
MRP3, like MRP1 and MRP2 has also been established as an organic anion 
transporter and is a GS-X pump (Kool et a l, 1999a). Among the current members 
of the MRP family, MRP3 has the highest sequence homology to MRP1. The 
most striking difference between MRP1 and MRP3 is that 2008 or MDCKII 
MRP3-transfected cells, overexpressing MRP3, do not detectably excrete more 
GSH than the parental cells, in contrast to cells transduced with either MRP1 or 
MRP2 constructs (Paulusma et al, 1999; Kool et al, 1999a). Kool et a l, (1999a), 
also suggested that cells with high levels of MRP3 did not secrete GSH. If the 
MRP model, proposed in section 1.6.8.1b, is correct, then it appears that the G- 
site in this transporter may have a very low affinity for GSH. Zeng et al, (1999), 
reported that MRP3 did not appear to transport natural product agents in a GSH- 
dependent manner in human embryonic kidney 293 cells transfected with MRP3. 
The authors also reported that the transport of glutathione conjugates such as 
LTC4, which is an excellent substrate for MRP1, was not detected. Hirohashi et 
al, (1999), reported that cloning of rat MRP3 and determination of its substrate 
specificity in inside-out membrane vesicles from transfected cells indicated that, 
unlike MRP1 and MRP2, it preferentially transported glucuronosides, such as 17 
(3-glucuronosyl estradiol, but that glutathione S-conjugates were relatively poor 
substrates. Konig et a l, (1999a), observed a particularly strong expression of the 
MRP3 protein in the basolateral hepatocyte membrane of two patients with 
Dubin-Johnson syndrome who are deficient in MRP2. They concluded that MRP3 
might be upregulated when the canalicular secretion of anionic compounds is 
impaired.
Early studies of MRP3 did not find any correlation between expression of this 
transporter and drug resistance (Kool et al, 1997). A more recent survey of a
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panel of lung cancer cell lines showed, however, a strong correlation between 
MRP3 and doxorubicin resistance and a weaker, but still highly significant 
correlation with resistance to vincristine, etoposide and cisplatin (Young et al,
1999). MRP3 was also found to transport methotrexate (Hirohashi el al, 1999 and 
Kool et al., 1999a), and was also reported by Kool et al, (1999a), to confer low 
levels of resistance on etoposide and teniposide. Uchiumi et al., (1998), analysed 
cisplatin resistant human head and neck cancer and human prostatic cancer cell 
lines over their parental counterparts for the overexpression of MRP3. They did 
not observe any specific change in cellular levels of the MRP3 mRNA in cisplatin 
resistant cancer cell lines with decreasing drug accumulation.
As it is difficult to generate transfected cells with high concentrations of MRP3 in 
the plasma membrane (Kool et al., 1999a and Borst et al., 1999), it remains 
possible that higher levels of MRP3 will also result in resistance to adriamycin 
and other drugs as suggested by the correlation study by Young et al., (1999). 
mRNA levels of MRP3 have been reported to be higher in NSCLC (non-small 
cell lung cancer) cell lines than in SCLC cell lines (Young et al., 1999), hence, 
this MRP-transporter may contribute to the multifactoral multidrug resistance 
phenotype of lung cancer cells, particularly NSCLC.
1.6.9.3 MRP4
Although MRP4 is expressed in a wide range of tissues (Lee et al., 1998), and the 
similarity between MRP1 and MRP4 suggested that it may share a similar 
substrate specificity, characterisation of MRP4 substrates remains to be 
elucidated. Borst et al, (1999), reported that the structure of MRP4 differed from 
that of MRP1, MRP2, MRP3 and MRP6 in that the NH2 terminal MSD was 
absent from MRP4. However, Bakos et a l, (1998), reported that MRP4 still had 
the basic structure required for GS-X pump activity in MRP1. Kool et al., (1997), 
screened a large number o f human cell lines derived from various tissues and their 
resistant sublines selected with either adriamycin, cisplatin, tetraplatin or CdCl2. 
They reported that MRP4 was expressed only at low or very low levels in the 
cells lines they analysed and no overexpression of MRP4 was detected in resistant
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sublines. Schuetz et al, (1999), carried out a study of alternative or additional 
mechanisms of resistance operating during antiviral therapy and discovered that 
the overexpression and amplification of the MRP4 gene correlated with the ATP- 
dependent efflux of PMEA (9-(2-phosphonylmethoxyethyl)adenine) and 
azidothymidine mono-phosphate from cells and, thus, with resistance to these 
drugs. Overexpression of MRP4 mRNA and MRP4 protein severely impaired the 
antiviral efficiency of PMEA, azidothymidine and other nucleoside analogues in 
the human T-lymphoid cell line, CEM-rl. The authors reported that increased 
resistance to PMEA and amplification of the MRP4 gene correlated with 
enhanced drug efflux; transfer of chromosome 13 containing the amplified MRP4 
gene also conferred resistance to PMEA. Therefore, these results appear to link 
expression of MRP4 with the efflux of nucleoside monophosphate analogs from 
mammalian cells.
1.6.9.4 MRP5
Little is known as yet about MRP5 (Borst et al, 1995). Suzuki et al, (2000), 
reported that MRP5 mRNA was detected in a large number of human tissues but 
also that the spliced variant of MRP5, sMRP, was preferentially expressed in the 
liver and placenta and that this sMRP may also have a physiological role.
Kool et a l, (1997), reported that MRP5 was expressed in all of the cell lines 
analysed with the highest levels in MOR/P and 2008, but MRP5 was not highly 
overexpressed in any of the resistant cell lines. The authors reported that MRP5 
was only slightly overexpressed in three cell lines selected for cisplatin resistance 
(T24/DDP10, HCT8/DDP and KCP-4(-)), but many other cisplatin-selected cell 
lines showed no overexpression. Therefore, it is questionable whether this low 
level of MRP5 overexpression has anything to do with cisplatin resistance. 
Recently, Wijnholds et al., (1999), reported a possible connection between MRP5 
and resistance to thio-purines although this remains to be substantiated by drug 
accumulation and vesicular transport studies (Borst et al, 1999).
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1.6.9.5 MRP6
Within the MRP family, homology is highest between MRP 1,-2,-3, and -6. Using 
3’ and 5’ derived MRP6 probes, Kool et al., (1999b), determined that MRP6 was 
highly expressed in liver and kidney cells and to a low or very low extent in a few 
other tissues including the colon, gall bladder and ovary. The authors reported 
that their analysis o f a number of MDR and cisplatin resistant cell lines provided 
no evidence for the involvement o f MRP6 in drug resistance. They found 
overexpression of MRP6 only in those cell lines with high expression or 
amplification of the MRP1 gene. It seems that MRP6 does not play a role in the 
resistance of the cells analysed and that MRP6 is only co-amplified with MRP1 
because of it's location, immediately next to it, on the same chromosome. 
However, Belinsky el al, (1999), suggested that MRP6 might participate in 
hepatobiliary and renal excretion of organic anions. While cMOAT (MRP2) is a 
major pump for organic anions in liver, the hepatobiliary excretion of organic 
anions is not completely abolished in cMOAT-deficient rat strains, suggesting the 
existence of other organic anion transporters. MRP1 is expressed in hepatocytes 
at low levels, but it is localised at the lateral membrane which does not 
communicate with bile canaliculi (Mayer et al, 1995). Belinsky et al, (1999), 
suggested that MRP6 may function as an alternative system to cMOAT for the 
hepatobiliary excretion of organic anions. The authors also suggest that MRP6 
may also serve a different function in the liver and suggests also that due to the 
abundant expression of MRP6 in the kidney, it may function as an ATP- 
dependent transporter of organic anions into urine.
1.6.10 Circumvention of chemotherapeutic drug resistance
In attempting to find modulators of multiple drug resistance, where membrane 
changes were clearly involved, a range of membrane active compounds were 
investigated by Tsuruo et a l, (1981). This investigation led to the development of 
the calcium channel blocker, verapamil, and the calmodulin inhibitor, 
trifluoperazine as specific modulators of Pgp in a mouse leukaemia cell line. A
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large number of other calcium antagonists were subsequently examined and 
compared with verapamil for effectiveness as Pgp modulators. However, it was 
not possible to achieve sufficient plasma levels of these early compounds, which 
could be predicted from in vitro studies to produce adequate reversal of Pgp 
(Twentyman et al, 1996). Subsequently, research began on the 
immunosuppressive cyclic peptide, cyclosporin A (Twentyman et a l, 1987). 
Because of its potent immunosuppression and also because adequate plasma 
levels could not be achieved in patients, cyclosporin A still left much to be 
desired as a clinical modifier (Twentyman et a l, 1996). Gaveriaux et al, (1991), 
reported a modifier of MDR, SDZ-PSC-833, which was non-suppressive and 10- 
20 fold more potent than cyclosporin A. Other compounds that have also been 
extensively studied as modifiers of Pgp-mediated multidrug resistance include 
quinine and quinidine, the anti-oestrogen, tamoxifen, dexniguldipine, and the 
acridone carbocamide derivative, GF120918 (Ford, 1995). These compounds 
have generally been shown to restore the defective drug accumulation seen in 
Pgp-mediated MDR cells and to displace binding of the photoactive calcium 
antagonist, azidopine, from a 170kD band on protein gels prepared from 
membranes of MDR cells. It is, therefore, assumed that their primary mode of 
action is competition for drug-binding sites on the Pgp molecule. Photoactive 
analogues of verapamil and cyclosporin A have been shown to bind directly to the 
170kD band (Safa 1988). In 1997, Germann et a l, evaluated the ability of VX- 
710 (Biricodar), a novel non-macrocyclic ligand of the FK506-binding protein, 
FKBP12, to reverse Pgp-mediated MDR in vitro. The authors demonstrated a 
direct, high affinity interaction of VX-710 with Pgp, preventing efflux of cytotoxic 
drugs by the MDR1 gene product in multidrug resistant tumour cells. Safa et al.,
(1999), reported that VX-710, modulated both Pgp as well as MRP mediated 
resistance. VX-710 reversed Pgp-mediated MDR at concentrations of 0.5-2.5jani 
by direct interaction with P-glycoprotein and inhibition of its efflux activity. 
Moreover, at 0.5-5.0p.m, it restored the sensitivity of IIL60/ADR cells, known to 
express MRP1, to the cytotoxic action of adriamycin, VP-16 and vincristine. VX- 
710 was about two-fold more effective than verapamil and cyclosporin A in 
circumventing MRP-mediated MDR.
In 1989, studies of two cell lines, H69AR and HT1080/DR4, now known to over­
express MRP1, demonstrated that both verapamil and cyclosporin A had only a
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modest effect as modulators of resistance and that verapamil was the most 
effective of the two (Cole et al, 1989). Twentyman et al, (1996), reached the 
same conclusions using the MRP-overexpressing cell lines, CORL23 (R) and 
MOR(R). However, studies performed with MRP-transfected HeLa-T5 cells 
showed that the cytotoxic effects o f vincristine and adriamycin could be enhanced 
in a dose-dependent fashion by co-administration of verapamil (Cole et al, 1994). 
In addition, it was found that cyclosporin A also increased vincristine toxicity but 
that it had less of an effect on adriamycin toxicity. A further study by Brueninger 
et al, (1995), showed that verapamil increased the sensitivity of MRP-transfected 
HeLa-pSRa-MRP16 cells relative to control transfectants, to adriamycin and VP-
Barrand et a l, (1993), and Aszalos et al, (1999), reported that clinically optimal 
plasma levels of the Pgp blockers, verapamil, SDZ-PSC-833 and cremophor, 
which are capable o f completely blocking the functioning of Pgp in Pgp- 
overexpressing cell lines, only partially blocked the function of MRP. 
Combinations of these optimal concentrations acted antagonistically in MRP- 
overexpressing cells whereas these combinations resulted in synergistic effects in 
Pgp-overexpressing cells. The reasons for this antagonism were difficult to 
explain but Aszalos et a l, (1999), reported that verapamil, SDZ-PSC-833 and 
cremophor reduced membrane “fluidity” in the MRP-expressing MCF-7 cells 
than in the Pgp-expressing 3T3 cells and this reduction might effect the uptake of 
the chemotherapeutic drug in to the cell. Membrane fluidity is determined by the 
degree of unsaturation of the fatty acid residues in the component phospholipids 
and by the cholesterol content (Davies et al, 1999).
Nakamura et a l, (1999), demonstrated, by measuring [3H] leukotriene C4 uptake 
into membrane of cells and intracellular calcein and [3H]vincristine accumulation, 
that MS-209, a novel quinoline derivative capable of reversing P-glycoprotein- 
mediated multidrug resistance (MDR) is also effective at reversing intrinsic and 
acquired MRP-mediated MDR of gastric cancer cells by interacting directly with 
MRP, MK571 is also reported in the literature as an anionic quinoline LTD 4 
receptor antagonist MRP inhibitor which does not significantly inhibit Pgp 
(Gekeler et al., 1995 and Renes et al., 1999). A complete reversal of vincristine 
resistance was achieved by co-incubation with a non-toxic level (40jjM) of 
MK571 in an MRP-expressing cell line (HL60/AR). This compound was found to
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have no effect in a Pgp-overexpressing multidrug resistant HL60 subline. MK571 
has been shown to completely inhibit LTC4 transport by MRP in membrane 
vesicles prepared from MRP-overexpressing cells and has also been shown to 
totally inhibit photoaffinity labelling of MRP by [3H]-LTC4 (Jedlitschky et al,
1994). Gekeler et a l, (1995b), showed that the specific bisindolylmaleimide 
protein Kinase C inhibitor GF 109203X totally reversed vincristine resistance in 
one MRP-overexpressing cell line, but only partially reversed adriamycin and 
vincristine resistance in a second MRP-overexpressing cell line.
Nakano et al., (1998), demonstrated that ONO-1078, a new class of peptide 
leukotriene receptor antagonist, modulated multidrug resistance and inhibited 
LTC4 efflux in lung cancer cells (NCI-H520) by inhibition of MRP function. This 
resulted in the enhanced sensitivity of these cells to vincristine, doxorubicin and 
etoposide. Marbeuf-Gueye et al., (2000), reported that 2-[4-(diphenylmethyl)-l- 
piperazinyl]ethyl-5-(trans-4,6-dimethyl-l,3,2-dioxaphos-phorinan-2-yl)-2,6- 
dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate P oxide (PAK-104P) was a 
non-competitive inhibitor of the of both Pgp and MRP 1-mediated efflux of 
anthracycline derivatives and calcein acetoxymethyl ester, at low concentrations. 
The authors suggested the existence of two very different mechanisms for the 
inhibition by PAK-104P of the MRP 1-mediated efflux of molecules: the first 
mechanism, involving a low-affinity site for PAK-104P, and which affects 
molecules such as calcein, LTC4 etc. whose efflux does not seem to depend on 
glutathione. The second mechanism involves a high-affinity site for PAK-104P 
and which interacts with molecules such as the anthracyclines and calcein 
acetoxymethyl ester whose efflux depends on the presence of glutathione.
Curtin et al., (1999), reported that the nucleoside transport inhibitor, dipyridamole 
(DP), caused chemosensitisation to VP-16, methotrexate and adriamycin in 
MRP 1-overexpressing cell lines, CORL23(R). However, this effect appears to 
have been caused by a depletion of cellular GSH rather than a direct effect of DP 
on MRP-mediated drug accumulation and efflux.
Hipfner et al., (1999), reported that MRP-specific monoclonal antibodies, QCRL- 
2, -3, -4 and - 6  can inhibit the transport of several MRP substrates by interfering 
with substrate binding or by trapping MRP in a conformation that does not allow 
transport to occur.
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In addition, a number of authors (Bennet et ah, 1982; Hall et ah, 1989; Maca et 
ah, 1991; Hollo et ah, 1996; Draper et ah, 1997; Kobayashi et ah, 1997; Duffy et 
ah, 1998 and Roller et ah, 1999), have described the ability of a number of Non- 
Steroidal Anti-Inflammatory Drugs (NSAIDS), at non-toxic concentrations, to 
enhance the toxicity of chemotherapeutic drugs, including adriamycin, 
daunorubicin, epirubicin, vincristine, methotrexate and VP-16. The spectrum of 
drugs, on which the NSAIDs exerted their potentiation effect, were recognised as 
being MRP substrates (Duffy et ah, 1998), and the enhancement effect was 
observed in cell lines which overexpressed MRP (Duffy et ah, 1998 and Hollo et 
ah, 1996). These authors also reported that the enhancement effect was 
independent of Pgp expression and Duffy et ah, (1998) and Roller et ah, (1999), 
demonstrated the effect to be independent of COX-1 and COX-2 inhibition. The 
potentiation of cytotoxic drug toxicity by the NSAIDs is discussed in detail in 
section 1.9. It appears that these NSAIDs are specific modulators of MRP- 
mediated resistance and may be of clinical significance as the potentiation effects 
were evident when these compounds were used at concentrations readily 
achievable in the blood.
These results suggest that the identification of the specific mechanism of drug 
resistance is important for the selection of chemotherapeutic strategies to block 
the efflux pump on the cancer cell. In addition, MRP and Pgp are reported to have 
protective functions in normal tissues (Twentyman et ah, 1997). Therefore, 
effective clinical application of resistance reversal strategies will depend on 
optimisation of therapeutic benefit versus increased toxicity.
1.6.11 Influence o f  D rug influx and accum ulation on m ultidrug  
resistance
Before the chemotherapeutic drug reaches its intracellular target, it has to be taken 
up in to the cell by some mechanism of drug uptake. In addition to increased drug 
efflux, it is possible that decreased drug uptake may also contribute to the drug 
resistance mechanism of a particular cell line. A reduction in drug influx has been 
identified in some MDR cell sublines as the only factor involved in drug 
resistance (Pallares-Trujillo et ah, 2000). Both the plasma membrane lipid
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composition (Pallares-Trujillo et al., 1993), and the pH of the extracellular 
medium (Gerweck et al., 1999, Larsen et al., 1998 and Larsen et al., 2000), have 
been reported to affect drug influx.
Many anticancer agents, such as the anthracyclines, adriamycin and daunorubicin, 
vincristine, vinblastine and mitoxantrone, are weak lipophilic bases with pATs 
between 7 and 9 (Larsen et al., 2000). A substantial fraction of these molecules 
are uncharged (non-ionized) at normal intracellular pH and in their non-ionized 
forms the lipophilicity of these drugs is increased, thereby enhancing their 
diffusion through the cell membrane to an intracellular site of action (Gerweck et 
al, 1999). Although the intracellular pH of tumour and normal tissues are similar, 
the extracellular pH of human tumours is more acidic than normal tissues, giving 
rise to substantially different cellular pH gradients in these tissues (Gerweck et 
al., 1999). Adriamycin accumulation and toxicity in Chinese Hamster ovary cells 
was reported by Gerweck et al., (1999), to increase with increasing medium pH 
and that the pH gradient across the cell membrane was the major determinant of 
adriamycin uptake. It appears that passive diffusion of the non-ionized form of the 
drug is the most likely explanation for the pH-dependent modification of cellular 
drug uptake (and by implication, cytotoxicity).
Several studies suggest that vesicular trafficking may be involved in the uptake, 
distribution and efflux of many cancer agents (Hindenburg et al., 1989; Coley et 
al, 1993). Larsen et al., (2000), reported that when the drug encounters an acidic 
environment, such as the interior of acidic vesicles, it is converted to a charged 
form that is unable to cross internal membranes. This results in the sequestering 
and accumulation of such anticancer agents in cytoplasmic organelles, followed 
by transport to the cell surface and extrusion in to the extracellular environment. 
Since the equilibrium between the charged and the uncharged forms of the drug is 
pH-dependent, drug accumulation in acidic vesicles is favoured by a large pH 
gradient between the cytoplasm and the acidic compartments, whereas 
acidification of the cytoplasm and/or alkalization of the acidic vesicles decreases 
drug accumulation in these organelles.
MRP is thought to cause multidrug resistance by decreasing the intracellular 
concentration of the cytotoxic drugs, and although most MRP-expressing cell 
lines show a defect in accumulation (Gaj et al., 1998; Zaman et al., 1993; 
Krishnamachary et al., 1993; Zaman et al., 1994), others do not (Gaj et al., 1998).
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There is no clear evidence in the literature to date to suggest a correlation between 
the MDR -transporters, Pgp and MRP, and drug uptake. However, Colin et al,
(1997), suggested that a reduced influx of drugs could be a major defect in MDR 
cells. Pgp modulators such as verapamil, sodium orthovanadate, chlorpromazine 
or triperazine induced an enhanced influx in CEM/VLB100 and also suggested a 
possible role for Pgp-membrane lipids in drug influx.
Protein Kinase C (PKC) may also be involved in the reduction of drug influx 
(Palleres-Trujillo et al, 2000). Sachs et a l, (1995), reported that the PKC-p I 
isoenzyme, which could reduce drug influx, was also shown to inhibit the Pgp 
ATPase and drug binding activity through phosphorylation which seemed to 
suggest an involvement between Pgp and drug uptake. However, Drew et al, 
(1996), Bergman et a l, (1997) and Sedlak el al., (1997), have reported the 
induction of drug uptake by PKC inhibitors by a mechanism that does not involve 
Pgp or MRP. This mechanism of drug uptake has yet to be fully elucidated. 
Decreased intracellular accumulation of cisplatin and carboplatin has been 
associated with resistance to these chemotherapeutic drugs (Shen el al., 2000). 
The mechanism(s) by which cisplatin enters the cell, and by which decreased 
accumulation occurs in resistant cells have yet to be determined. It has generally 
been believed that cisplatin enters cells largely through passive diffusion, 
however, evidence provided by Shen et al, (2000), suggest the involvement of a 
novel active transport process in the uptake of cisplatin and carboplatin in to the 
human liver carcinoma cell line, BEL-7404. This uptake was significantly 
reduced in the cisplatin resistant derivative 7404-CP20. Shen et al, (2000), 
demonstrated decreased MRP1 and MRP2 protein expression in this cisplatin 
resistant cell line making it highly unlikely that MRP1 or cMOAT is involved in 
reducing cisplatin or carboplatin influx or efflux in this particular cell line. 
Nucleoside transporters are involved in the uptake of nucleosides and provide the 
route of entry in to cells for many cytotoxic nucleoside analogues used in cancer 
and viral chemotherapy (Baldwin et al, 1999). Nucleoside transport into cells is 
divided into two categories. In equilibrative transport, the flux of nucleoside 
molecules across the membrane is driven solely by the concentration gradient, 
whereas in concentrative transport, the flux is coupled to that of sodium ions such 
that the electrochemical ion gradient can drive cellular uptake of nucleosides 
against their concentration gradient (Baldwin et al, 1999). It is possible that this
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mechanism is involved in the cellular uptake of chemotherapeutic agents such as 
5-FU, Gemcitabine and AZT.
1.7 N onsteroidal anti-inflam m atory drugs (NSA ID s)
The history of aspirin can be traced to ancient Egypt, where an extract of willow 
bark was used to treat inflammation. Willow bark contains the glucoside of salicyl 
alcohol, which can be converted to the actual anti-inflammatory agent salicylic 
acid through stepwise hydrolysis and oxidation (Vaino et al., 1997). The 
development of aspirin in 1897 was a significant landmark in the history of 
medicine because it stimulated the development of a family of medicines that are 
collectively called NSAIDs, which are amongst the most prescribed therapeutic 
drug class.
NSAIDs such as sulindac, indomethacin and piroxicam are effective in alleviating 
pain, inflammation and fever, and they are commonly prescribed for the treatment of 
rheumatoid arthritis (Vaino et al., 1997). In the USA the estimated number of 
NSAID prescriptions rose from 27.5 million in 1973 to 100 million in 1983., In 
1984 it was estimated that nearly one in seven Americans were treated with an 
NSAID, although since then the prescription trends have levelled off (Pace et al., 
1995 and Brooks et al, 1991). Over 20% of Australians over the age of 65 years are 
exposed to these drugs and in the UK over 20 million prescriptions for NSAIDs are 
issued each year (Pace et al., 1995). NSAIDs are the principle therapy for the 
majority of arthritis patients. It has been estimated that more than 15 million people 
with arthritis take these drugs daily. This use is predicted to increase greatly, not 
only as a result of an aging population, with the consequent increase in the 
prevalence of arthritis, but also because NSAIDs may prove to have a role in 
decreasing colonic neoplasma and in reducing the likelihood of conditions such as 
Alzheimers disease (Silverman, 1998).
NSAIDs come from a variety o f chemical classes (Table 1.7.1). Their 
physiochemical properties determine their distribution in the body, and thus
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differences in these properties may lead to variable therapeutic performance. 
NSAlDs are planar, anionic molecules that partition into lipid environments, such as 
the lipid bilayers of plasma membranes, and the more acidic the pH, as at 
inflammatory sites, the greater the lipophilicity (Abramson et ah, 1989). The more 
lipid soluble NSAIDs penetrate the central nervous system more effectively and may 
have greater central effects. The central effects of NSAIDs include mild changes of 
mood and cognition which are more common with the more lipid soluble NSAIDs. 
The vast majority of these drugs are weakly acidic, with ionizing constants (pKa) 
ranging from 3 to 5 (Verbeeck et ah, 1990). The proportion of an NSA1D that is not 
ionised at a particular pH is of importance as it influences the distribution of these 
drugs in tissue (Brooks et ah, 1991). More acidic NSAIDs become sequestered 
preferentially in the synovial tissue of inflammed joints, which may be of potential 
advantage during episodes of arthritis. Some NSAIDs are pro-drugs (such as 
sulindac), with the active drug being produced in vivo by the normal processes of 
metabolism.
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Table 1.7.1: Chemical Classification of NSAIDs 
Garbo- and heterocyclic acetic acids;
Etodolac
Indomethacin
Sulindac
Phenylacetic acids:
Diclofenac
Fenamates:
Niflumic acid 
Mefenamic acid 
Cfadcams:
Isoxicam
Tenoxicam
Propionic acid derivatives:
Benoxaprofen
Fenbufen
Flurbiprofen
Ketoprofen
Oxaprozin
Suprofen
Infoprofen
Pyrazoles:
Azapropazone 
Oxyphen butazone 
Salicylates:
Aspirin (ASA)
Diflunisal
Acetamidophenol
Salicylamide
Non-Acidic compounds:
Nabumetone
Bufecamic
Zomepirac
Acemetacin
Tolmetin
Aclofenac
Flufenamic acid 
Tolfenamic acid
Piroxicam
Sudoxicam
Carprofen
Fenoprofen
Ibuprofen
Naproxen
Pirprofen
Tiaprofenic acid
Acetaminophen (paracetamol)
Phenylbutazone
Fendosal 
Salicylic acid 
Acetaphenetidin
Proquazone
Compiled from Brooks etal., (1991); Lu et al., (1995) and Verbeeck et al., 1990.
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The increase in NSAID use has been accompanied by an increase in adverse effects 
reports. Brooks et al, (1988), reported that the adverse reactions due to treatment 
with NSAIDs could be produced by a number of different mechanisms:
i. consequences o f inhibition of prostaglandin synthesis,
ii. idiosyncratic reactions, dose-related effects
iii. production of reactive intermediate metabolites.
The most common toxic effects of NSAIDs are gastrointestinal pathology 
(gastrophy), renal dysfunction, liver function abnormalities and hypersensitivity 
reactions (Alhava, 1994).
It is generally believed that NSAIDs function pharmacologically primarily by 
reducing the synthesis of prostaglandins (Vane et al, 1991; Vainio et al, 1997; 
Vane et al, 1996; Levy et al, 1997 and Abramson et al, 1989). At sites of 
inflammation, prostaglandins are produced in excess amounts and exert pro- 
inflammatory effects. It is postulated that NSAIDs reduce the production of 
prostaglandins by inhibiting the enzyme prostaglandin endoperoxide synthase, 
which exists in two isoforms 1, and 2, and which transforms arachidonic acid, 
liberated by phospholipase A2, to prostaglandins. Vane et al, (1998), reported that 
the NSAIDs inhibit the binding of the prostaglandin substrate, arachidonic acid, to 
the active site of the enzymes. This enzyme is commonly referred to as 
cyclooxygenase (COX-1 and COX-2). COX is a dual function enzyme, 
incorporating both a cyclooxygenase and a peroxidase activity (Vane et al, 1996). 
PGE2 is the predominant eicosanoid detected in man in inflammatoiy conditions 
ranging from experimental acute oedemas and sunburn through to chronic arthritis. 
It is a potent dilator of vascular smooth muscle which causes the characteristic 
vasodilation and erythema (redness) seen in acute inflammation. PGE2 also acts 
synergistically with other mediators to produce inflammatory pain. Additionally, 
PGE2 is a potent pyretic agent and its production, stimulated by the release of IL-1, 
in bacterial and viral infections contributes to the associated fever. Other COX 
products have been found in inflammatory lesions including PGF20C, PGD2, 
prostacyclin (PGI2 as 6-oxo-PGFia) and thromboxane A2 (TXA2) (Vane et al,
1996), but usually they are present at less than a quarter of the concentrations of 
PGE2.
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The inhibition by aspirin is due to the irreversible acetylation of the cyclooxygenase 
component of COX, leaving the peroxidase activity of the enzyme unaffected. In 
contrast to the irreversible action of aspirin, other NSAIDs such as indomethacin or 
ibuprofen produce reversible COX inhibition by competing with the substrate, 
arachidonic acid, for the active site of the enzyme (Vane et ah, 1996; 1998). The 
inhibition of prostaglandin synthesis by NSAIDs has been demonstrated in a wide 
variety of cell types and tissues, ranging from whole animals and man to microsomal 
enzyme preparations.
Therefore NSAIDs prevent the pathological over-production of prostaglandins 
which contribute to the inflammatory process (therapeutic effects) and the 
physiological formation of prostanoids (which results in the characteristic side 
effects). Several of the NSAIDs inhibit the production of prostacyclin, an important 
cytoprotective product of the gastric mucosa, potentialy leading to the formation of 
ulcers (Fosslien et ah, 1996). NSAIDs also damage the gastrointestinal tract via 
other mechanisms including effects on neutrophil function, altering gastric mucosal 
blood flow in a non-prostaglandin dependent manner, direct irritant effects including 
ion trapping and interference with growth factors and ulcer healing mechanisms 
(Donnelly et al, 1997).
1.7.1 COX-1 and COX-2
It is now known that the cyclooxygenase enzyme exists as two distinct isoforms, 
Cyclooxygenase 1 (COX-1) and Cyclooxygenase 2 (COX-2). COX-1 is 
constitutively produced and is believed to be involved in regulating normal cellular 
processes, such as gastro intestinal (GI) cytoprotection, vascular homeostasis, and 
renal function. The concentration of the enzyme remains largely stable, but small 
increases of expression of two-to four-fold can occur in response to stimulation with 
hormones or growth factors (DeWitt et ah, 1991). In contrast, COX-2, identified by 
Fu et ah, (1990), as an inducible synthase and a distinct isoform of cyclooxygenase 
encoded by a different gene from COX-1, is undetectable in most normal tissue. 
However, the expression of COX-2 can be increased dramatically after exposure of
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fibroblasts, vascular smooth muscle or endothelial cells to growth factors, hypoxia, 
phorbol esters or cytokines and by lipopolysaccharides (LPS) in 
monocytes/macrophages (Bolten 1998 and Vane el al, 1996). In chronic 
inflammation, levels of COX-2 protein also increase in parallel with the over­
elaboration of prostaglandins in many cells and tissues. The family of primary 
response genes, of which COX-2 is a member, also includes the gene for inducible 
nitric oxide synthase which is induced during inflammation and cell growth. 
Conversely, COX-2 seems to play a physiological role in some situations. It is 
believed to be involved in uterine contraction and appears to be present in the renal 
medulla. Recently, H in z  et al, (1999), reported that COX-2 is expressed 
constitutively in the brain, spinal cord and kidney as well as numerous other organs. 
Hence COX-2 inhibition may lead to adverse effects in these tissues (Donnelly et 
al, 1997).
Human COX-1, a 22kb gene, is a membrane bound hemo-and glyco-protein with a 
molecular weight of 71kD. It is found in greatest amounts in the endoplasmic 
reticulum of prostanoid forming cells. It functions by cyclizing arachidonic acid and 
then adding the 15-hydroperoxy group to form PGG2. The hydroperoxy group of 
PGG2 is reduced to the hydroxy group of PGH2 by a peroxidase (in the same 
enzyme protein). PGH2 is then coverted to PGE2, PGF2a. PGD2a> PGI2 and 
thromboxane A2. The three-dimentional structure, determined by Picot et al, (1994), 
shows that COX-1 comprises three independent folding units: an epidermal growth 
factor like domain, a membrane binding motif and an enzymatic domain. The sites 
for peroxidase and COX activity are adjacent but spatially distinct. Three of the 
helices of the structure form an entrance channel to the active site and it is postulated 
that their insertion into the membrane could allow arachidonic acid to gain access 
from the interior of the lipid bilayer. The COX active site is a long hydrophobic 
channel. Tyrosine at position 385 and serine 530 are at the apex of this active site. 
Aspirin irreversibly inhibits COX-1 by acétylation of serine 530 and as a result 
excludes access by arachidonic acid. Other subsites for drug binding may exist in the 
channel to explain the interactions of reversible COX inhibitors such as 
indomethacin and ibuprofen (Vane et al., 1996).
The human COX-2 gene is 8.3kb in size, smaller than COX-1 but with a similar 
molecular weight. The amino acid sequence of its cDNA shows only a 60%
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homology with COX-1. COX-2 and COX-1 also have similar active sites for the 
attachment of arachidonic acid or NSAIDs, although the active site of COX-2 is 
larger than that of COX-1 and can accept a wider range of structures as substrates 
(Meade et al, 1993). Both enzymes have similar Km and Vmax values for the 
metabolism of arachidonic acid. (Meade etal., 1993).
1.7.2 NSAIDs and inhibition of COX-1 and COX-2.
NSAID inhibit the synthesis of cytoprotective prostaglandins by COX-1 in the 
gastrointestinal tract leading to the accumulation of surplus arachidonic acids. The 
surplus enhances the generation of leukotrienes via the lipoxygenase pathway 
inducing neutrophil adhesion to endothelium and vasoconstriction. The NSAIDs 
containing a carboxyl group also inhibit oxidative phosphorylation (OXPHOS) 
lowering adenosine-triphosphate (ATP) generation, leading to loss of mucosal cell 
tight junctions and increased mucosal permeability (Fosslien, 1998). Inhibition of 
COX-2 by NSAIDs reduces synthesis of pro-inflammatory prostaglandins and 
produces analgesia (Fosslien, 1998). Evidence, therefore, suggests that much of the 
G1 toxicity associated with NSAID use is primarily the result of inhibition of COX-1 
and anti-inflammatory effects are largely due to the inhibition of COX-2. An 
NSAID, which selectively inhibits COX-2, and has little effect on COX-1, would be 
ideal. However, on the basis of data obtained in several laboratories by means of the 
"human whole blood assay", there is now convincing evidence that none of the 
currently available NSAIDs is a selective COX-2 inhibitor (Hinz B et al, 1999). A 
number of COX-2 specific inhibitors are presently being tested world wide in phase 
III clinical trials on patients with rheumatoid arthritis and osteoarthrits (Hinz B et al, 
1999; Lefkowith et al., 1999).
Aspirin, indomethacin, piroxicam, tolmetin and sulindac are slightly more potent 
against COX-1 than COX-2 but are generally considered as non-selective NSAIDs 
(Riendeau et al, 1997). These drugs are also known for their propensity to cause 
gastric damage. Meloxicam has been shown by Engelhardt et al, (1996), to possess 
a high preference in intact cells for inhibition of the COX-2 rather than COX-1 
isoenzyme. Two case control studies carried out in 1994 and data obtained from the 
UK Committee on the Safety of Medicines showed that ibuprofen and diclofenac
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were associated with the least number of adverse effects, while piroxicam was 
associated with the most (Bateman, 1994).
1.7.3 Non-prostaglandin-dependent properties of NSAIDs
NSAIDs exert biological effects other than the inhibition of PG synthesis. It is 
suggested that this broad spectrum of effects results from their physiochemical 
properties, which may disrupt protein-protein interactions of many kinds within 
biological membranes (Abramson et al, 1989).
NSAIDs have been found to inhibit a variety of membrane-associated processes, 
including that of superoxide anion generation by a cell-free NADPH oxidase system 
of neutrophils, mononuclear cell phospholipase C activity, and the 12- 
hydroperoxyeicosatetraenoic acid peroxidase of the lipoxygenase pathway in 
platelets. Aspirin-like drugs uncouple oxidative phosphorylation via effects with in 
the mytochondrial membrane. Aspirin also alters the uptake of precursor 
arachidonate and its insertion into the membrane of cultured human monocytes and 
macrophages. Salicylates inhibit anion transport across a variety of cell membranes 
including human erythrocyte and renal tubular epithelium. (Abramson et al, 1989). 
Acetaminophen, an anti-pyretic and analgesic, has little anti-inflammatory activity. 
Salicylate is an order of magnitude less active than aspirin on the crude COX- 
enzyme prepared from lung tissue, yet it is reported that salicylate is as potent as 
aspirin in suppressing arthritis (Vane et al., 1996 and Mitchell et al, 1994).
1.7.4 Initiation of carcinogenesis by Prostaglandin H synthases
Prostaglandin H synthases (PHS) (COX-1 and COX-2) may be involved in the 
initiation of carcinogenesis by activation of carcinogens to DNA-binding forms. The 
peroxidase activity of PHS has a broad specificity. Other hydroperoxides, other than 
the primary substrate PGG, can be reduced by PGH peroxidase. Among the classes 
of carcinogens that can be used as electron donors for "co-oxidation", and thereby 
activated by PHS, are polycyclic aromatic hydrocarbons, aflatoxins, halogenated 
pesticides, aromatic amines and phenols (Levy et al, 1997). PHS may be also
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involved in initiation of carcinogenesis by the generation of malondialdehyde 
(MDA), a direct acting mutagen in bacterial and mammalian test systems and also 
carcinogenic in rats. MDA is produced by non-enzymatic as well as enzymatic 
breakdown of PGH. The enzyme Thromboxane Synthase is particularly active in 
MDA production. MDA formation from PGH may be inhibited by NSAIDs 
(Mamett, 1992). A third suggested mechanism for the involvement of PHS in 
tumour initiation involves peroxyl radicals as reactive intermediates (Levy et al.,
1997). Peroxyl radicals may be formed by PHS and can epoxidize double bonds of 
pro-carcinogens such as benzopyrene-7,8-diol or dihydroxydihydrobenzo- 
anthracene to produce the carcinogens of these compounds (Levy et al, 1997).
1.7.5 NSAIDs and Cancer
Chemoprevention is defined as the use o f natural or pharmacological agents to 
disrupt the process o f  carcinogenesis (  Garay et al., 1999).
The origin of the hypothesis that NSAIDs have chemopreventative properties, dates 
back to 1975 when Bennet and Del Tacca (1975), observed that certain human 
cancers, including breast cancer and colorectal cancers contain more prostaglandin 
E2 than surrounding normal mucosa. They hypothesized that tumours that 
overproduce prostaglandin E2 might promote their own growth and /or spread 
(Bennet et al, 1975; Hwang et al, 1998; Vaimo et al, 1997).
Because NSAIDs reduce the synthesis of prostaglandins, a series of experimental 
studies in rodents were carried out to assess whether NSAIDs would inhibit or 
prevent the growth of coloretal cancer and various other forms of cancer. Most of 
the NSAIDs tested (aspirin, sulindac, piroxicam and indomethacin) effectively 
inhibited colorectal tumours in rats and mice. Oesophageal tumours in mice treated 
with N-nitrododiethylamine were reduced by indomethacin administered either with 
the carcinogen or 4 months after exposure (Rubio et al, 1984). Pancreatic tumours 
induced by N-nitrosobis(2-oxopropyl)amine were reduced in hamsters receiving 
indomethacin, aspirin or phenylbutazone beginning five weeks after initiation of 
carcinogenesis (Takahashi et al, 1990). Narisawa et al., (1981), demonstrated that 
rats exposed to methylnitrosourea developed colonic tumours but that their
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incidence could be significantly lowered by indomethacin. However, in rats given 
the carcinogen and then indomethacin, cessation of treatment led to rapid 
development of tumours. Thus, indomethacin treatment inhibited the development 
of tumours but did not kill the initiated cells. Piroxicam was shown by Reddy et al, 
(1987), to inhibit azoxymethane-induced colon cancer in rats in a dose-dependent 
manner. Sulindac was shown by Moorghen et al, (1988), to have a protective effect 
against dimethylhydrazine-induced colonic tumours in mice. Sulindac administered 
with the carcinogen caused a significant reduction in tumour incidence and tumour 
burden but sulindac administered 17 weeks after the carcinogen, had no inhibitory 
effect, thus demonstrating protection against initiation of tumours but no effect on 
regression of established tumours in this model. The incidence of adenocarcinomas 
was reduced 69% in rats with dimethylhydrazine-induced colonic carcinogensis, by 
aspirin received one week before and after the carcinogen (Craven et al, 1992). 
Aspirin also had no effect on tumour incidence when started 4 weeks after 
carcinogen exposure.
1.7.6 NSAIDs in Human Cancer.
Colorectal cancer is a major cause of death in the United States where it accounts for 
approximately 57,000 deaths per year (Garay et al, 1999). Differences in dietary 
habits and lifestyles among populations in different geographic locations have been 
associated with an altered risk for developing colorectal cancer (Smalley et al,
1997).
In 1988, Kune et al, reported an observational study in which a negative association 
was found between the incidence of colon cancer and the use of aspirin. This 
Australian study demonstrated that people who used aspirin had a 40-50% reduction 
in colon cancer incidence than those who reported no aspirin use and the reductions 
in colon cancer were of similar magnitude in men and women. Reduction of a lesser 
magnitude was noted with the use of other NSAIDs. No reduction of risk was 
observed with the use of steroids, oral contraceptives, tranquilizers or sedatives. 
Thun et al, (1991), reported that in a study of over one million persons, men who 
used aspirin more than 16 times a month had a relative risk of developing colorectal 
cancer of 0.48 (0.30-0.76) and women a relative risk of 0.53 (0.32-0.87) compared
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to those who didn't regularly use aspirin. Giovannucci et al., (1994), reported similar 
results from a study involving persons between the ages of 40 -70 who regularly and 
consistently took aspirin. Analysis of the duration of aspirin use showed that the 
protective effect of aspirin did not become statistically apparent unless intake had 
been for ten years or greater. This was attributed to the idea that adenomas take 
approximately 10 years to evolve into invasive carcinomas. (Giovannucci et al,
1995). In contrast to the results for aspirin use, no association of change in fatal 
colon cancer risk with acetominophen use was found (Levy et al., 1997).
1.7.7 NSAIDs and Familial Adenomatous Polyposis
Further evidence for the anti-carcinogenic effect of NSAIDs is provided by studies 
of familial adenomatous polyposis (FAP), an autosomal dominant disorder 
characterised by the formation of hundreds to thousands of colorectal 
adenomas/polyps in adults, usually below the age of thirty, and subsequent elevated 
risks of development of colorectal cancer (Levy et al, 1997 and Owen et al., 1998). 
Clinical trials using the NSAID sulindac have shown dramatic regression of colonic 
adenomas in patients with FAP (Wadell et al., 1983; Tonelli et al., 1994; Piazza et 
al, 1997 and Ahnen, 1998). D'Alteroche et al., (1998), reported the complete 
remission of a mesenteric fibromatosis in a male patient, after taking sulindac for 
periods of 1 to 8 months for 6 years, 11 years after having familial adenomatous 
polyposis coli treated by total colectomy. Hirata et al., (1994), demonstrated the 
regression of rectal polyps by indomethacin suppositories in FAP although it had 
previously been reported that oral indomethacin failed to reduce the number of rectal 
adenomas (Hirota et al., 1996).
Boolbal et al, (1996), used a mouse model of FAP in which a strain containing a 
dominant mutation in the APC (adenomatous polyposis coli) tumour suppressor 
gene was developed. This strain, known as MIN mice, developed gastrointestinal 
adenomas by 110 days of age. It was found that the MIN mice produced increased 
levels of COX-2 and PgE2 compared to wild type mice. Treatment with sulindac 
inhibited tumour formation and decreased PGHS2 and PgE2 levels to baseline as 
well as restoring normal levels of apoptosis (normally at a level of 27-47% of the
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levels of wild-type mice) (Giardiallo et al., 1998; and Vainio et al., 1997). In a study 
using piroxicam in the MIN mouse, Jacoby et al., (1996), showed a dose-dependent 
decrease in the intestinal adenomas and aberrant crypt foci as well as a parallel 
decrease in serum levels of thromboxane B2. Watson (1998), reported that mutation 
of APC caused the up-regulation of COX-2 whose products cause further tumour 
progression. Treatment of APC-mutated mice, with an NSAID selective for COX-2 
reduced tumour formation significantly.
However, Watson (1998), also raised the possibility that inhibition of submucosal 
COX-1 by NSAIDs could reduce the mutation frequency in colonic epithelium and 
prevent polyp initiation and this could explain how NSAIDs, such as aspirin and 
sulindac, which have greater potency against COX-1 than COX-2, can inhibit polyp 
formation.
Koki el al., (1999), characterised the expression of COX-1/-2 in biopsies of human 
lung, colorectal, oesophageal, breast, pancreatic and prostate cancers to assess the 
importance of COX enzymes in tumourigenesis. In human cancers, COX-2 was 
consistently detected in the angiogenic vessels, neoplastic epithelium and in 
in flam m atory cells. COX-2 was either not expressed, or detected at very low levels 
in normal, compared to hyperplastic or neoplastic regions. In contrast COX-1 was 
ubiquitously expressed throughout the malignant and non-malignant areas. 
(Langman et al., 1998; Koki et al., 1999 and Gilhooly et al., 1999).
A recent study found a statistically significant elevation of PGE2 in 21 surgically 
excised colorectal cancers compared to the accompanying normal colorectal 
mucosa. (Shenge/ al, 1998).
1.7.8 NSAIDs and Apoptosis.
Another common property of NSAIDs and related drugs that may explain their anti­
neoplastic effect on colorectal cancer is their ability to induce apoptosis of 
colonocytes (Levy et al., 1997).
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This explanation for the antineoplastic properties of NSAIDs was first suggested by 
Aldolphie et al., (1972), who reported that certain NSAIDs were capable of 
inhibiting the proliferation of cultured HeLa cells by causing cell cycle arrest. 
Programmed cell death (Apoptosis) is an intrinsic part of organismal development 
and aging (Lu et ah, 1995). It is an orderly process of internal cellular disintegration 
which is associated with membrane blebbing, structural condensation and the 
maintenance of some organelle integrity (Samaha et ah, 1997).
Until recently, reports in the literature attributed the anti-neoplastic activity of 
sulindac and other NSAIDs to their ability to inhibit protaglandin synthesis. This 
rationale was based on studies showing that the levels of PGE2 and mRNA for 
COX-2 are elevated in a number o f human cancers (Hubbard et ah, 1988). 
Prostaglandins stimulate the proliferation of cancers (Qiao et ah, 1995), and PGE2 
may interfere with host anti-tumour immunologic functions (Sheng et ah, 1998).
1.7.9 COX-2 and apoptosis.
Colonic neoplasms are believed to develop through a series of sequential steps 
over 15-20 years that reflect the progressive accumulation of mutations. Early in 
the transition from normal colonic epithelium to adenoma, mutations of key genes 
occur, which have been implicated in the transformation process. One such gene 
is the APC gene. Inactivating mutations of this gene are known to cause 
colorectal cancer in patients with familial adenomatous polyposis syndrome, and 
truncation mutations in the APC gene occur somatically in a large percentage of 
colorectal cancers that form spontaneously (Sheng et al 1998). Recently, it has 
been shown that disruption of the APC gene in mice leads to increased levels of 
COX-2 in intestinal tumours (Oshima et ah, 1996). Therefore, the increased levels 
of COX-2 in intestinal tumours could represent an event downstream of an early 
mutation in a key regulatory gene, such as APC (Oshima et ah, 1996). COX-2 
levels are increased in human colorectal adenocarcinomas (Kargman et ah, 1995; 
Kutchera et ah, 1996). Forced expression of COX-2 in intestinal epithelial cells 
leads to inhibition of apoptosis and induction of Bcl-2 expression (Sheng et ah, 
1998). These authors determined the effect of COX-2-derived eicosanoids, such 
as PGE2 on the biology of human colon cancer cells. In addition to observing an
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increase in the number of HCA-7 human colon cancer cells, in response to PGE2 
treatment, there was also a reduction in the percentage of cells undergoing 
apoptosis. They also determined that PGE2 treatment led to a significant induction 
of Bcl-2 (the anti-apoptotic oncogene) expression but not Bax or Bcl-x. PGE2 
treatment also led to a marked activation of MAPK, which preceded induction of 
Bcl-2 and which may indicate a putative signal transduction pathway by which 
Bcl-2 expression and other genes could be induced. In the HCA-7 cell line 
apoptosis was found to be regulated by treatment with a highly selective COX-2 
inhibitor (SC-58125), and that this is reversible upon treatment with PGE2 .
Watson et al., (1998), reported that once polyp initiation had occurred, COX-2 was 
expressed in epithelial cells and acted to inhibit apoptosis and drive the growth of 
the tumour through interactions with growth factors such as TGF~p. TGF-|3 inhibits 
proliferation in normal intestinal epithelium but this anti-proliferative effect is 
frequently lost after malignant transformation. This change in the action of TGF-P 
from anti-proliferative to pro-proliferative is thought to be due to COX-2 
overexpression. COX-2 also enhanced angiogenesis and cell migration and thereby 
aided metastasis (Watson et al., 1998). This indicates that COX-derived eicosanoids 
are likely to play an important role in colorectal carcinogenesis. Many tumour types 
over-produce prostanoids and these prostanoids have been shown to increase the 
proliferation rate of tumour cells and related cells in vivo (Qiao et al., 1995). 
NSAIDs such as indomethacin can cause a subsequent reduction in tumour cell 
growth by inhibition of this growth stimulatory activity (Tripathy et al., 1996 and 
Tanaka et al., 1989).
1.8 The anti-tum our activities o f  N SA ID s
It is widely assumed that the inhibition of PGHS activity is the main mode of action 
by which the NSAIDs assert their anti-neoplastic effect (Bennet and Del Tacca, 
1975 and Mamett et al., 1992). However, the mechanism by which NSAIDs 
influence tumour growth is presently unclear.
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A number of recent reports indicate that there are several other possible explanations 
for the anti-tumour activity of NSAlDs. Suggested mechanisms include induction of 
apoptosis in the cancer cell by the NSAID, independent of COX inhibition, and 
interference with the tumour cell cycle (Shiff et al., 1995; 1996 and Qiao et al,
1998). It is known that the influence of NSAIDs on tumour cell growth is not 
entirely dependent on PGHS inhibition because of a number of factors:
i. DeMello et al., (1980), demonstrated that there was no correlation between 
the ability of an NSAID to inhibit tumour cell growth and the potency of that 
NSAID as an inhibitor of PGHS.
ii. When indomethacin was used to inhibit cell growth, the inhibition could not 
be overcome by the addition of prostaglandins or arachidonic acid. If 
inhibition of PG synthesis was the mechanism of NSAID cytostasis, addition 
of PG would be expected to overcome this inhibition. This was not the case; 
in fact higher concentrations of PG enhanced the cytostatic effect of 
indomethacin (DeMello et al, 1980). This was also demonstrated by 
Planchón et al., (1995), with the breast cancer cell line MCF-7.
iii. Sulindac is a pro-drug that is metabolised to a pharmacologically active 
sulfide derivative that potently inhibits prostaglandin synthesis. Sulindac can 
also be reversibly oxidised to sulindac sulfone, which is devoid of any PGHS 
inhibitory activity. Sulindac sulfone has been shown to inhibit HT-29 colon 
carcinoma cell growth to an extent comparable to that achieved with sulindac 
sulfide (Piazza et al, 1995). This inhibition was not due to inhibition of 
prostanoids due to the lack of any PGHS-inhibitory activity. Therefore, the 
mechanism of the anti-neoplastic affect of NSAIDs does not necessarily 
include anti-prostaglandin activity. (Piazza el al., 1995; 1997a; 1997b; Levy 
eta l, 1997).
iv Haniff et al., (1996), demonstrated that sulindac sulfide and piroxicam had
comparable growth inhibitory effects on two cell lines: HT-29, which 
produces PGE2,. PGF2tx and PGI2 and HCT-15, a cell line which does not 
possess PGHS and hence is devoid of prostanoid synthesising ability. 
Therefore, both NSAIDs exerted their growth inhibitory effects independent 
of any inhibition of PGHS.
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In 1995, Lu et al. used chicken embryo fibroblasts (CEFs) transformed with a 
temperature sensitive mutant of the Rous sarcoma virus (RSV) to demonstrate the 
ability of a large number of NSAIDs to induce programmed cell death. Of the 
effective drugs, indomethacin, diclofenac, carprofen, niflumic acid, mefanamic acid, 
flufenamic acid, diflunisal and acemetacin were the most potent in inducing 
apoptosis in the cells. Treatment of the CEFs with any of the above eight NSAIDs 
induced transglutaminase (Tgase), a molecular indicator of apoptosis. This induction 
was not proportional to the ability of these NSAIDs to inhibit COX-1 and/or COX-2. 
Piazza et al., (1995), concluded that increased apoptosis was the mechanism for 
growth inhibition of cells by sulindac sulfide and sulfone rather than inhibition of 
cell proliferation, altered differentiation or necrotic cell death.
The pro-apoptotic ability of sulindac and its metabolites was further defined by Han 
et al., (1998), who demonstrated that sulindac and its metabolites were capable of 
inducing apoptosis in MCF-10F and MCF-7, a normal human mammary epithelial 
cell line and a human mammary carcinoma cell line respectively (Han et al., 1998). 
Treatment of MCF-10F and MCF-7 cells with sulindac sulfide, the most potent 
inhibitor of cell growth of the three compounds tested by Han et al, (1998), resulted 
in accumulation of the cells in the GO/ Gl phase of the cell cycle, decreases in the 
percent of cells in the S and G2/M phases of the cell cycle, and induction of 
apoptosis. Chan et al., (1998), demonstrated the ability of sulindac sulfide to induce 
apoptosis in two colon cancer cell lines, HCT116 and SW480.
It was recently reported by Thompson et a l, (1997), that sulindac sulfone inhibited 
the occurrence of mammary carcinomas which were classified as having either the 
wild type or mutant Ha-ra.v gene, but was significantly more potent in the the case of 
carcinomas with the mutant Ha-rav gene. This group suggested that the effect of 
sulindac sulfone on mammary carcinogenesis involved interference in the signal 
transduction cascade involving Ha-ras.
Schiff et al., (1996), evaluated the effect of four structurally unrelated NSAIDs: 
aspirin, indomethacin, naproxen and piroxicam, on cell proliferation, cell cycle 
phase distribution and the development of apoptosis in the HT-29 colon 
adenocarcinoma cells in vitro. All of the NSAIDs examined reduced the 
proliferation and altered the morphology of these cells in a time- and concentration-
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dependent manner. In addition, they increased the proportion of the cells in the 
G0/G1 phase and reduced the proportion in the S phase of the cell cycle. Aspirin and 
indomethacin also reduced the percentage of cells in the GO/M phase but naproxen 
and piroxicam did not. Han et al, (1998), reported that sulindac sulfide treatment of 
the breast cancer cell lines resulted in:
i. An increase in the cyclin dependent kinase (CDK) inhibitor protein p21WAF1, 
which is often induced during differentiation or apoptosis, within 24 hours after 
treatment, and may be mediated by wild type p53 gene;
ii. A decrease in the cyclin D1 expression. Cyclin D1/CDK4 complex regulates 
progression through the G1 phase of the cell cycle. However, sulindac sulfide had no 
effect on the expression of CDK4 or the immediate early response gene c-jun.
Parallel to their effect on the cell cycle, aspirin and indomethacin also reduced the 
levels of p34odc2 and p33cdk2, two cyclin-dependent kinases that are important for cell 
cycle progression (Shiff et al, 1996).
Schiff et al, (1996), and Qiao et al, (1998), reported that indomethacin, naproxen, 
aspirin and piroxicam induced apoptosis inHT-29 colon adenocarcinoma cells.
Chan et al, (1998), hypothesised that the tumour suppressive effects of NSAIDs are 
not likely to be due to the reduction in prostaglandins but rather are due to the 
elevation of the prostaglandin precursor arachidonic acid (AA). NSAID treatment of 
colon tumour cells results in a dramatic increase in AA that in turn stimulates the 
conversion of sphingomyel into ceramide, a known mediator of apoptosis.
1.9 N SA ID s and enhancem ent o f  cytotoxicity o f  chem otherapeutic  
drugs
In 1982, Bennet et al., demonstrated that indomethacin and flurbiprofen 
decreased cancer development and spread in mice bearing a transplanted 
mammary adenocarcinoma when treated in combination with methotrexate and 
melphalan. Indomethacin increased cytotoxicity of methotrexate to the human 
breast cell lines DU4475 and T47D (though the mechanism of this enhancement 
was unknown). Hall et al., (1989), demonstrated that indomethacin enhanced the 
toxicity of chlorambucil (5.5-fold) in a resistant Chinese Hamster Ovary cell line.
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Non-toxic concentrations of indomethacin were reported by Maca, (1991), to 
have the ability to potentiate the toxicity of VP-16 and methotrexate in a number 
o f cell lines including cultured Lewis lung carcinoma (LLC) cells, mouse 
lymphoma cells, a human acute lymphoblasic leukemia cell line and human 
chronic myelogenous leukemia cells. These cell lines are relatively insensitive to 
VP-16 alone but indomethacin was found to enhance VP-16 toxicity in all cases 
and this enhancement occured by increasing the cellular concentration of VP-16. 
In 1995, Jimbo et a l, reported that the antitumour effect of a synthetic lipid A 
derivative, DT-5461a, which markedly inhibited the growth of various syngenic 
tumours in mice, was enhanced by indomethacin.
Hollo et a l,  (1996), reported the ability o f the NSAID indomethacin to inhibit 
MRP-mediated calcein acetoxymethylester (calcein AM) extrusion from SI MRP 
cells (MRP-transfected SI cells re-selected and cloned in ADR-containing media) 
at IC50 concentrations of 10-20(o,M. In contrast, indomethacin was unable to 
inhibit MDR1 (Pgp)-mediated calcein AM extrusion by 50% at concentrations 
less than 800jaM. This suggests that indomethacin is selectively an MRP 
inhibitor. Draper et al., (1997), reported that indomethacin increased multi drug 
susceptibility o f both murine and human cell lines overexpressing MRP, but not 
those displaying Pgp-associated resistance. Indomethacin increased the 
accumulation of vincristine in MRP-overexpressing cell lines and sensitised these 
cell lines to vincristine and adriamycin. Indomethacin had little effect on the 
function of P-gp as it failed to modulate the P-gp-mediated altered accumulation 
of vincristine and failed to alter the drug resistance of both human and murine P- 
gp- overexpressing cell lines. This report suggested that indomethacin acts as a 
specific inhibitor of MRP and so modulated drug resistance as a result of this 
activity (Draper et al., 1997). Kobayashi et a l,  (1997), reported that 
indomethacin, mefenamic acid, sulindac and tolmetin enhanced the toxicity of 
both adriamycin and vincristine in two pulmonary adenocarcinoma cell lines. 
Indomethacin was shown to enhance the toxicity of methotrexate, adriamycin, 
VP-16 and vincristine but not cyclophosphamide, mitomycin C, 5-fluorouracil, 
cisplatin, vindestine or cytarabine. Djordjevic et al, (1998), reported that there 
was no synergistic interactions between 5-FU and indomethacin in a human colon 
adenocarcinoma cell line, and, in fact, this combination appeared to result in an
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alleviation of the 5-FU toxicity. In 1999, Roller et al, reported that indomethacin 
and ibuprofen specifically enhanced the cytotoxic effects of adriamycin and 
vincristine in T98G, human malignant glioma cells. In contrast, these NSAIDs did 
not alter the cytotoxic effects of cytarabine, camptothecin or cisplatin. The 
authors concluded that the effects of indomethacin and ibuprofen were not related 
to alterations in the formation or detoxicification of reactive oxygen species and 
was also independent of COX-1 and COX-2 expression.
A number of NSAIDs have been demonstrated by our group to have the ability to 
enhance the cytotoxicity of a number of anti-cancer drugs in vitro when co­
administered to a multi-drug resistant cell line which overexpresses MRP.
The NSAIDs, indomethacin, sulindac, tolmetin, acemetacin, zomepirac 
(heteroarylacetic acids) and mefenamic acid, all at non-toxic levels, significantly 
increased the cytotoxicity of the anthracyclines (doxorubicin, daunorubicin and 
epirubicin), as well as teniposide, VP-16 and vincristine. The other vinca 
alkaloids, vinblastine and vinorelbine and other anticancer drugs including 
methotrexate, 5-fluorouracil, cytarabine, hydroxyurea, chlorambucil, 
cyclophosphamide, cisplatin, carboplatin, mitoxantrone, actinomycin D, 
bleomycin, paclitaxel and camptothecin displayed no synergy in combination 
with the NSAIDs (Duffy et al, 1998). In addition, two sulindac derivatives, 
sulindac sulfide and sulindac sulfone were found to be active in the combination 
toxicity assay (Duffy et al, 1998 and Elliot, 1997). As described previously, 
sulindac sulfone is, by definition, not an NSAID due to the fact that it is not a 
COX inhibitor.
This paper presents the first clear evidence that enhancement, by a range of 
NSAIDs, of the cytoxicity of several anti-cancer drugs was MRP related. The 
authors reported that the enhancement o f cytotoxicity was not found in p-170- 
overexpressing multidrug resistant cell lines, DLKP-A (a 300-fold resistant 
variant of DLKP, which overexpresses P-170) and DLKP pHaMDRl/A #2 (a 
MDR1 transfectant of DLKP, which is 15-fold resistant to doxorubicin) but was 
found in HL60/ADR, CORL23R, A549 and DLKP cell lines which express MRP.
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1.10 Aims of thesis.
The initial aim of the thesis was to investigate the structural requirements and aspects 
of the mechanism of chemotherapeutic drug enhancement by NSAIDs in MRP- 
overexpressing cell lines. It had been previously reported by our laboratory that 
indomethacin was capable of potentiating the toxicity of chemotherapeutic drugs, 
which were MRP substrates, in MRP-overexpressing cell lines (Duffy et al, 1998). 
Structural analogues of indomethacin were generated in a collaboration with a 
synthetic organic chemistry laboratory (Dr. Anita Maguire and Dr. Steven Plunkett, 
Chemistry Dept., University College, Cork) and in the work described here the SAR 
(Structure Activity Relationship) in a series o f indomethacin analogues was 
investigated in order to elucidate which substituents were required for the 
enhancement effect to occur. These analogues were analysed in a number of assays 
to determine if:
i. The indomethacin analogues were capable of enhancing the toxicity of 
chemotherapeutic drugs and if this enhancement effect was restricted to those 
drugs known to be MRP substrates.
ii. The mechanism of drug enhancement by the positive analogues was through 
an interaction with MRP and occurred only in MRP- expressing cell lines.
Most of the undesirable side-effects of NSAIDs are caused by inhibition of 
cyclooxygenase 1 (COX-1) but not of COX-2 (section 1.7). Furthermore inhibition 
of COX-2 appears to have anti-tumour effects (section 1.7.9, Sheng et al, 1998). 
Another aim of this thesis was, therefore, to find an analogue of indomethacin which 
had reduced COX-1 activity (but, preferably, while retaining COX-2 activity) and to 
determine the SAR, in the series of indomethacin analogues, for inhibition of these 
activities. It would also, of course, be beneficial if  this work could find an analogue 
of indomethacin, which had greater ability to enhance to toxicity of 
chemotherapeutic drugs, at lower concentrations, with less toxicity and reduced toxic 
side effects than indomethacin.
It has been reported that taxol is a relatively poor MRP1 substrate (Cole et al, 1994). 
There is evidence however, that resistance to taxol (paclitaxel) and taxotere 
(docetaxel) can, in part, be attributed to MRP1 (Vanhoefer et a l, 1996 and 1997). In
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previous work in our laboratory some of the positive NSAIDs were not capable of 
enhancing the toxicity of taxol in an MRP 1-overexpressing lung carcinoma cell line, 
A549 (Duffy et al, 1998). However, no analysis had previously been carried out on 
the ability of the NSAIDs to potentiate the toxicity of taxotere, another member of 
the taxane family of chemotherapeutic drugs. Further experimental work on the 
taxanes was therefore undertaken in order to assess the effects of selected NSAIDs 
on toxicities of these drugs in a number of cell lines and to investigate mechanisms 
by which NSAIDs might enhance the toxicity of taxol and taxotere.
A substantial body of work has been carried out in our laboratory (Duffy et al,
1998), and elsewhere (Hollo et al, 1996; Draper et al, 1997; Koboyashi et al, 1997 
and Roller et al., 1999), on enhancement of toxicity of cancer chemotherapeutic 
drugs in MRP 1-overexpressing cell lines. However, in contrast, there have been no 
corresponding reports in cell lines which overexpress other (more recently 
discovered) MRP homologues (MRP2-6). A human hepatic cancer cell line, HepG2, 
which overexpresses cMOAT (MRP2), and ovarian carcinoma cell line (2008) 
variants, transfected with cDNA for MRP1, MRP2 or MRP3, were investigated to 
determine if indomethacin, indomethacin analogues or another MRP-positive 
NSAID, sulindac, were capable of enhancing the toxicity of a range of 
chemotherapeutic drugs, including taxol and taxotere, in cell lines overexpressing 
MRP2 or MRP3.
It has yet to be determined if indomethacin is a substrate for MRP homologues other 
than MRP1. To investigate this DLKP cells were pulse-selected for a period of six 
weeks with concentrations of indomethacin which resulted in 80-90% cell kill. The 
resulting proliferating cell population were assessed to determine if  resistance to 
indomethacin cytotoxicity is associated with increased expression of specific MRP 
homologues.
The mechanism(s) of cisplatin resistance in cancer cells has not as yet been fully 
elucidated and, in particular, the relationship between cisplatin resistance and MRP 
overexpression remains unclear. The enhancement of the toxicity of cisplatin by 
NSAIDs was investigated in a number of cell lines. The aims of this were two-fold:
i. To investigate the possibility that cisplatin may be a substrate of a homologue 
of MRP other than MRP 1.
ii. To determine if  non-MRP 1 substrates, such as cisplatin, were potentiated by 
positive NSAIDs in cell lines which overexpress MRP2 or MRP3.
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2.0 Materials and Methods
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2.1 Ultrapure W ater
Ultrapure water, (UHP) was used for the preparation of all media and 
solutions. This water was purified to a standard of 12-18 MQ/cm resistance by 
a reverse osmosis system (Millipore Milli-RO 10 Plus, Elgastat UHP). A 
conductivity meter in the system continuously monitored the quality of the 
UHP.
2.2 G lassw are
The solutions utilised in the various stages of cell culture were stored in sterile 
glass bottles. These sterile bottles and other glassware required for cell culture- 
related applications were prepared as follows: glassware and lids were soaked 
in a 2% solution of RBS-25 (AGB Scientific) for 1 hour. After this time they 
were cleaned and rinsed in tap water. The glassware were then washed in an 
industrial dishwasher, using Neodisher detergent and rinsed twice with UHP. 
The materials were finally sterilised by autoclaving as described in Section 
2.3.
2.3 Sterilisation Procedures.
All thermostable solutions, water and glassware were sterilised by autoclaving 
at 121°C for 20 min at 15 p.s.i.. Thermolabile solutions were filtered through
0.22(j,m sterile filters (Millipore, Millex-GV SLGV025BS). Large volumes, 
(up to 10 litres) of thermolabile solutions were filter sterilised through a micro­
culture bell filter. (Gelman, 12158).
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2.4 Preparation o f cell culture media
The basal media used during cell culture were prepared as follows: 10X media 
was added to sterile UHP water, buffered with HEPES (N-(2-Hydroxyethyl) 
piperazine-N-(2-ethanesulfonic acid)) and NaHCC>3 as required and adjusted to 
pH 7.5 using sterile 1.5 N NaOH or 1.5 N HCL. The media was then filtered 
through sterile 0.22jam bell filters (Gelman, 12158) and stored in sterile 500ml 
bottles at 4°C. Sterility checks were performed on each bottle of media by 
inoculating samples of the media on to Colombia blood agar plates (Oxoid, 
CM217), Thioglycollate broths (Oxoid, CM 173) and Sabauraud dextrose 
(Oxoid, CM217) and incubating the plates at 37°C and 25°C. These tests 
facilitated the detection of bacteria, fungus and yeast contamination.
Basal media were stored at 4°C for up to three months. The HEPES buffer was 
prepared by dissolving 23.8g HEPES in 80ml UHP water and this solution was 
then sterilised by autoclaving. Then 5ml sterile 5N NaOH was added to give a 
final volume of 100ml. NaHC0 3  was prepared by dissolving 7.5g in 100ml 
UHP water followed by autoclaving. Complete media was then prepared as 
follows: supplements of 2mM L-glutamine (Gibco, 11140-0350) and 5% 
foetal calf serum (Sigma, F-7524) were, in the majority of cases, added to 
volumes of 100ml basal media. 1ml of 100X non-essential amino acids 
(Gibco, 11140-035) and 1ml of lOOmM sodium pyruvate (Gibco, 11360-035) 
were also added to MEM. Complete media were maintained at 4°C for up to a 
maximum of 1 week.
2.5 Cells and C ell C ulture
All cell culture work was carried out in a class II laminar air-flow cabinet
(Nuaire Biological Laminar Air-Flow Cabinet). All experiments involving
cytotoxic compounds were conducted in a cytogard laminar air-flow cabinet
(Gelman Sciences, CG series). Before and after use the laminar air-flow
cabinet was cleaned with 70% industrial methylated spirits (IMS). Any items
brought into the cabinet were also cleaned with IMS. At any time, only one
cell line was used in the laminar air-flow cabinet and upon completion of work
with the cell line the laminar air-flow cabinet was allowed to clear for at least
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15 minutes so as to eliminate any possibility of cross- contamination between 
the various cell lines. The cabinet was cleaned weekly with an industrial 
disinfectant (Virkon or TEGO) and these disinfectants were alternated every 
month. Details pertaining to the cell lines used for the experiments detailed in 
this thesis are provided in table 2.5.1. All cells were incubated at 37°C and 
where required, in an atmosphere of 5% CO2 . Cells were fed with fresh media 
or subcultured (see section 2.5.1) every 2-3 days in order to maintain active 
cell growth. All of the cell lines listed in table 2.5.1, except for HL60ADR, are 
anchorage dependent cell lines. HL60ADR cells were grown in suspension in 
vented 75cm2 flasks (Costar, 3276) at 37°C in an atmosphere of 5% C 0 2 in 
RPMI media (Gibco, 52400-025) containing 10 % serum.
2.5.1 Subculturing of cell lines
1. The waste cell culture medium was removed from the tissue culture 
flask and discarded into a sterile bottle.
The flask was then rinsed out with 1ml of trypsin/EDTA solution 
(0.25% trypsin (Gibco, 043-05090), 0.01% EDTA (Sigma, E9884) 
solution in PBS (Oxoid, BRI4a)) to ensure the removal of any residual 
media.
2. 5mls of trypsin was then added to the flask, which was then incubated 
at 37°C, for approximately 5 minutes, until all of the cells detached 
from the inside surface of the flask.
3. The trypsin was deactivated by adding an equal volume of complete 
media to the flask.
4. The cell suspension was removed from the flask and placed in a sterile 
universal container (Sterilin, 128a) and centrifuged at lOOOrpm for 5 
minutes.
5. The supernatant was then discarded from the universal and the pellet 
suspended in complete medium. A cell count was performed and an 
aliquot of cells was used to reseed a flask at the required density.
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Cell line Basal
Medium*
Cell type Source**
A549 ATCC Human lung 
adenocarcinoma
ATCC
DLKP ATCC Human lung squamous 
carcinoma
NCTCC
DLKPSQ ATCC Clonal subpopulation o f  
DLKP
NCTCC
DLKPC14 ATCC Carboplatin-selected 
variant o f  DLKPSQ
NCTCC
HL60ADR RPMI 1640 Adriamycin-resistant 
variant o f  HL60 human 
leukaemia cell line
Dr. M. Centre1
2008 RPMI 1640 Ovarian carcinoma Dr. M. Kool“
CORL23(P) RPMI 1640 Large cell lung cancer cell 
line
Dr.P.TwentymanJ
CORL23(R) RPMI 1640 Adr-resistant variant o f  
CORL23(P)
Dr.P.Twentyman3
HepG2 MEM Human hepatocellular 
carcinoma
ATCC
Table 2.5.1 Source description and media requirements of cell lines used in 
experiments described in this thesis 
University of Kansas, USA.
2Division of Molecular Biology and Centre of Biomedical Genetics, The 
Netherlands Cancer Institute, Amsterdam.
3MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge 
CB2 2QH, U.K.
* ATCC basal media consists of a 1:1 mixture of DMEM and Hams F 12. 
**ATCC — American Tissue Culture Collection.
NCTCC = National Cell and Tissue Culture Centre.
R PM I1640 media supplied as a IX  stock (Gibco, 52400-025)
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2.5.2 Assessment of cell number and viability
1. Cells were trypsinised, pelleted and resuspended in media. An aliquot 
of the cell suspension was then added to trypan blue (Gibco, 525) at a 
ratio of 5:1.
2. The mixture was incubated for 3 minutes at room temperature. A 10)4,1 
aliquot of the mixture was then applied to the chamber of a glass 
coverslip-enclosed haemocytometer.
3. Cells in the 16 squares o f the four grids of the chamber were counted. 
The average cell numbers per 16 squares were multiplied by a factor of 
104 and the relevant dilution factor to determine the number of cells per 
ml in the original cell suspension.
4. Non-viable cells stained blue, while viable cells excluded the trypan 
blue dye as their membrane remained intact, and remained unstained. 
On this basis, % viability could be calculated.
2.5.3 Cryopreservation of cells
1. Cells for cryopreservation were harvested in the log phase of growth 
and counted as described in Section 2.5.2.
2. Cell pellets were resuspended in a suitable volume of serum. An equal 
volume of a 10 % DMSO/serum solution was added dropwise to the 
cell suspension.
3. A total volume of 1ml of this suspension (which should contain 
approximately 7x106 cells) was then placed in cryovials (Greiner, 
122278).
These vials were then placed in the vapour phase of a liquid nitrogen 
container, which was equivalent to a temperature of-80°C.
4. After a period of three hours, vials were removed from the vapour 
phase and transferred to the liquid phase for storage (- 196°C).
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2.5.4 Thawing of cryopreserved cells
1. A volume of 9ml of fresh growth medium was added to a sterile 
universal. The cryopreserved cells were removed from the liquid 
nitrogen and thawed rapidly at 37°C. The cells were removed from tire 
vials and transferred to the aliquoted media.
2. The resulting cell suspension was centrifuged at 1,000 r.p.m. for 5 
minutes. The supernatant was removed and the pellet resuspended in 
fresh culture medium.
3. An assessment of cell viability on thawing was then carried out 
(Section 2.5.2).
4. Thawed cells were then added to an appropriately sized tissue culture 
flask with a suitable volume of growth medium and allowed to attach 
overnight.
2.5.5 Monitoring of sterility of cell culture solutions
Sterility testing was performed in the case of all cell culture media and cell 
culture-related solutions. Samples of prepared basal media were inoculated on 
to Colombia blood agar plates (Oxoid, CM331), Thioglycollate broths (Oxoid, 
CM173) and Sabauraud dextrose (Oxoid, CM217) and incubating the plates at 
37°C and 25°C. These tests facilitated the detection of bacteria, fungus and 
yeast contamination. Complete cell culture media were sterility tested at least 
four days prior to use, using Columbia blood agar.
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2.6 Mycoplasma analysis of cell lines
C e l l  l in e s  w e r e  te s te d  fo r  p o s s ib le  M y c o p la s m a  c o n ta m in a tio n  b y  D r. M a r y  
H e e n a n  at th e  N a t io n a l C e l l  an d  T is s u e  C u ltu re  C e n tre , G la s n e v in , D u b lin  9. 
T h e  p ro to c o l u s e d  is  d e ta ile d  in  th e  fo llo w in g  S e c t io n s  2 .6 . 1  an d  2 .6 .2 .
2.6.1 Indirect staining procedure for Mycoplasma analysis
M ycoplasm a-n e g a t iv e  N R K  (N o rm a l ra t k id n e y  f ib r o b la s t)  c e l ls  w e r e  u s e d  as 
an  in d ic a to r  c e l ls  fo r  th is  a n a ly s is . T h e  c e l ls  w e r e  in c u b a te d  w ith  a  sa m p le  
v o lu m e  o f  su p e rn a ta n t f ro m  th e  c e l l  lin e s  in  q u e stio n  an d  th en  e x a m in e d  fo r  
M ycoplasm a  c o n ta m in a tio n . A  f lu o re sc e n t  H o e c h s t  s ta in  w a s  u se d  in  th is  
a n a ly s is .  T h e  s ta in  b in d s  s p e c i f ic a l ly  to  D N A  an d  so  s ta in s  th e n u c le u s  o f  th e  
c e l l  in  a d d it io n  to  a n y  M ycoplasm a  p re sen t. M ycoplasm a  in fe c t io n  w a s  
in d ic a te d  b y  f lu o re sc e n t  b o d ie s  in  the c y to p la sm  o f  th e  N R K  c e lls .
2.6.2 Direct culture procedure for Mycoplasma analysis
D ir e c t  s ta in in g  fo r  M ycoplasm a  a n a ly s is  in v o lv e d  in o c u la t in g  sa m p le s  o n  to  a  
M ycoplasm a  c u ltu re  b ro th  (O x o id , C M 4 0 3 ) .  T h is  w a s  su p p le m e n te d  w ith  1 6 %  
se ru m , 0 .0 0 2 %  D N A  ( B D H , 4 2 0 2 6 ) , 2|ag/m l fu n g iz o n e  ( G ib c o , 0 4 2  0 5 9 2 0 ) , 
2 x l 0 3 u n its  p e n ic i l l in  ( S ig m a , P e n -3 )  an d  10 m l o f  a  2 5 %  y e a s t  e x tra c t  so lu tio n . 
In c u b a tio n  w a s  c a rr ie d  o u t at 3 7 ° C  fo r  a  p e r io d  o f  4 8  h o u rs . S a m p le s  o f  th is  
b ro th  w e re  th e n  s tre a k e d  on to  p la te s  o f  M ycoplasm a  a g a r  b a s e  (O x o id , 
C M 4 0 1 )  w h ic h  h a d  b e e n  su p p le m e n te d  a s  d e sc r ib e d  a b o v e . T h e  p la te s  w e r e  
in c u b a te d  fo r  th re e  w e e k s  at 3 7 ° C  w h ile  e x p o s e d  to  C 0 2 . T h e  p la te s  w e re  
e x a m in e d  m ic r o s c o p ic a l ly  e v e r y  7  d a y s . T h e  a p p e a ra n c e  o f  sm a ll o v a l  sh a p e d  
c o lo n ie s  in d ic a te d  th e  p re se n c e  o f  M ycoplasm a  in fe c t io n .
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2.7 Miniaturised in vitro toxicity assays
2.7.1a “Long-term” in-vitro toxicity assay experimental procedure
1 .  C e l ls  in  th e  e x p o n e n t ia l p h a se  o f  g ro w th  w e r e  h a rv e s te d  b y
tr y p s in is a t io n  a s  d e sc r ib e d  in  se c t io n  2 . 5 . 1 .
2 .  C e l l  su sp e n s io n s  c o n ta in in g  l x l  0 4 c e lls / m l w e r e  p re p a re d  in  c e ll
cu ltu re  m e d iu m . V o lu m e s  o f  1 0 0 (il/w e ll o f  th e se  c e l l  su sp e n s io n s  w e r e  
a d d e d  to  9 6 - w e ll  p la te s  (C o sta r , 3 5 9 9 )  u s in g  a  m u ltic h a n n e l p ip e tte . 
P la te s  w e r e  a g ita te d  g e n t ly  in  o rd er to  e n su re  e v e n  d isp e rs io n  o f  c e lls  
o v e r  a  g iv e n  w e l l .  C e l ls  w e re  th en  in c u b a te d  o v e r n ig h t  a t 3 7 ° C  in  an  
a tm o sp h e re  c o n ta in in g  5 %  C O 2.
3 .  C y to to x ic  d r u g / N S A ID  d ilu tio n s  w e r e  p re p a re d  at 2 X  th e ir  f in a l 
c o n c e n tra tio n  in  c e l l  c u ltu re  m e d iu m . V o lu m e s  o f  th e  d ru g  d ilu tio n s  
( 10 0 j.i l)  w e r e  a d d e d  to  e a c h  w e l l  u s in g  a  m u ltic h a n n e l p ip e tte . P la te s  
w e r e  th e n  m ix e d  g e n t ly  a s  a b o v e .
4 . C e l ls  w e r e  in c u b a te d  fo r  a  fu rth e r 6 d a y s  a t 3 7 ° C  a n d  5 %  C O 2. A t  th is  
p o in t  th e  c o n tro l w e l ls  w o u ld  h a v e  re a c h e d  a p p ro x im a te ly  8 0 -9 0 %  
c o n flu e n c y .
5 . A s s e s s m e n t  o f  c e l l  s u r v iv a l  in  th e p re s e n c e  o f  d ru g  w a s  d e te rm in e d  b y  
th e  a c id  p h o sp h a ta se  a s s a y  (se c t io n  2 .7 .2 ) .  T h e  c o n c e n tra tio n  o f  d ru g  
w h ic h  c a u s e d  5 0 %  c e l l  k i l l  ( IC 50 o f  th e  d ru g )  w a s  d e te rm in e d  fro m  a  
p lo t  o f  th e  %  s u r v iv a l  ( re la t iv e  to  th e  c o n tro l c e l ls )  v e r s u s  c y to to x ic  
d ru g  c o n c e n tra tio n .
2.7.1b “Short-term” in-vitro toxicity assay experimental procedure
1 .  C e l l s  in  th e  e x p o n e n tia l p h a se  o f  g ro w th  w e r e  h a rv e s te d  b y  
t r y p s in is a t io n  a s  d e sc r ib e d  in  se c t io n  2 . 5 . 1 .
2 . C e l l  s u sp e n s io n s  c o n ta in in g  2 x 1 04 c e lls / m l w e r e  p re p a re d  in  c e ll  
cu ltu re  m e d iu m  a n d  th e  9 6 -w e ll  p la te s  w e r e  se t  u p  an d  in c u b a te d  
o v e r n ig h t  a s  d e s c r ib e d  in  2 .7 . 1 a .
3 . C y t o t o x ic  d ru g  d ilu t io n s  w e re  p re p a re d  at 2 X  th e ir  f in a l  co n c e n tra tio n  
in  c e l l  c u ltu re  m e d iu m . V o lu m e s  o f  th e  d ru g  d ilu tio n s  ( 10 0 |j,l)  w e re
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th e n  a d d e d  to  e a c h  w e l l  u s in g  a  m u ltic h a n n e l p ip e tte . P la te s  w e re  th en  
m ix e d  g e n t ly  a s  a b o v e  a n d  a llo w e d  to  in c u b a te  a t 3 7 ° C  a n d  5 %  C O 2 fo r  
4  h o u rs .
5 . A f t e r  th is  in c u b a tio n  p e r io d  th e p la te s  w e r e  r e m o v e d  fro m  the 
in c u b a to r , th e  d r u g / N S A ID  w a s  re m o v e d  fro m  th e  w e lls  a n d  the p la te s  
w e r e  w a s h e d  ou t 4  t im e s  w ith  fre sh  m e d ia . A f t e r  w a s h in g , th e w e lls  
w e r e  re - fe d  w ith  fr e s h  m e d ia .
6 . C e l ls  w e r e  in c u b a te d  fo r  a  fu rth e r 4  d a y s  at 3 7 ° C  an d  5 %  C O 2. A t  th is  
p o in t  th e  c o n tro l w e l ls  w o u ld  h a v e  re a c h e d  a p p ro x im a te ly  8 0 -9 0 %  
c o n flu e n c y .
5 . A s s e s s m e n t  o f  c e l l  s u r v iv a l  in  the p re s e n c e  o f  d ru g  w a s  d e te rm in e d  b y
th e  a c id  p h o sp h a ta se  a s s a y  (se c t io n  2 .7 .2 ) .  T h e  c o n c e n tra tio n  o f  d ru g  
w h ic h  c a u s e d  5 0 %  c e l l  k i l l  ( I C 50 o f  th e  d ru g ) w a s  d e te rm in e d  fro m  a  
p lo t  o f  th e  %  s u r v iv a l  ( re la t iv e  to  th e  c o n tro l c e lls )  v e r s u s  c y to to x ic  
d ru g  c o n c e n tra tio n .
2.7.2 Assessment of cell number - Acid Phosphatase assay
1 .  F o l lo w in g  th e  in c u b a tio n  p e r io d  o f  6 d a y s , m e d ia  w a s  re m o v e d  fro m
th e  p la te s .
2 . E a c h  w e l l  o n  th e p la te  w a s  w a s h e d  w ith  10 0 |J.l P B S .  T h is  w a s  th en
re m o v e d  a n d  lOOjxl o f  f r e s h ly  p re p a re d  p h o sp h a ta se  su b stra te  ( lO m M  
p -n itro p h e n o l p h o sp h a te  ( S ig m a  10 4 - 0 )  in  0 . 1 M  so d iu m  a ceta te  
( S ig m a , S 8 6 2 5 ) ,  0 . 1 %  tr ito n  X - 1 0 0  ( B D H , 3 0 6 3 2 ) ,  p H  5 .5 )  w a s  a d d e d  
to  e a c h  w e l l .
3 . T h e  p la te s  w e r e  th en  in c u b a te d  in  th e  d a rk  at 3 7 ° C  fo r  2  h o u rs.
4 . T h e  e n z y m a tic  re a c t io n  w a s  sto p p ed  b y  th e a d d it io n  o f  50fj.l o f  I N
N a O H .
5 . T h e  p la te  w a s  re a d  in  a  d u a l b e a m  p la te  re a d e r  at 4 0 5 n m  w ith  a
re fe re n c e  w a v e le n g th  o f  6 2 0 n m .
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2.7.3a NSAID-raediated drug toxicity enhancement assays 
(Long-term assays)
1 .  C e l ls  w e r e  t ry p s in is e d  fro m  th e f la s k  in  th e  e x p o n e n tia l p h a se  o f  
g ro w th  a s  d e s c r ib e d  in  se c t io n  2 . 5 . 1 .
2 . C e l l  su sp e n s io n s  c o n ta in in g  l x l  0 4 c e lls / m l w e r e  p re p a re d  in  c e l l  
c u ltu re  m e d iu m . V o lu m e s  o f  1 0 0 |4,l/w e ll o f  th is  c e l l  su sp e n s io n  w e re  
a d d e d  in to  9 6 - w e ll  p la te s  (C o s ta r , 3 5 9 9 )  u s in g  a  m u ltich a n n e l p ip e tte . 
P la te s  w e r e  a g ita te d  g e n tly  in  o rd e r  to  en su re  e v e n  d isp e rs io n  o f  c e lls  
o v e r  a  g iv e n  w e l l .  C e l ls  w e re  th en  in c u b a te d  o v e r n ig h t  at 3 7 ° C  in  a n  
a tm o sp h e re  c o n ta in in g  5 %  C O 2.
3 .  C y to to x ic  d ru g  d ilu tio n s  an d  N S A I D  d ilu tio n s  w e r e  p re p a re d  at 4 X  
th e ir  f in a l  c o n c e n tra tio n  in  m e d ia . V o lu m e s  o f  5 0 ja l o f  th e  d ru g  d ilu tio n  
a n d  50(j,l o f  th e  N S A I D  d ilu tio n  w e r e  th en  a d d e d  to e a c h  re le v a n t  w e l l  
so  th at a  to ta l f in a l  v o lu m e  o f  200(j,l w a s  p re se n t in  e a c h  w e ll .  A l l  
p o te n tia l to x ic ity -e n h a n c in g  a g e n ts  w e r e  d is s o lv e d  in  D M S O , eth a n o l 
o r  m e d ia . S t o c k  so lu tio n s  w e re  p re p a re d  at a p p ro x im a te ly  1 5  m g / 10 m l 
m e d ia , f i lte r  s te r i lis e d  w ith  a  0 .22 (j.m  f i lte r  ( M i l le x - G V , S L G V 0 2 5 B S )  
a n d  th en  u s e d  to  p re p a re  a l l  su b se q u e n t d ilu tio n s . S o lv e n t  co n tro l 
e x p e r im e n ts  s h o w e d  th at n o  t o x ic it y  e n h a n c e m e n t e f fe c ts  w e r e  d u e  to  
th e  p re s e n c e  o f  D M S O  o r  eth an o l.
4 . C e l ls  w e r e  in c u b a te d  fo r  a  fu rth e r  6 d a y s  a t 3 7 ° C  in  an  a tm o sp h e re  
c o n ta in in g  5 %  C O 2. A t  th is  p o in t th e  c o n tro l w e l ls  w o u ld  h a v e  re a c h e d  
a p p ro x im a te ly  8 0 -9 0 %  c o n flu e n c y .
5 . C e l l  n u m b e r  w a s  a s s e ss e d  u s in g  th e  a c id  p h o sp h a ta se  a s s a y  (se c tio n  
2 .7 .2 ) .
6 . S ta t is t ic a l  a n a ly s is  o f  th e  d a ta  w a s  p e r fo rm e d  as d e ta ile d  in  S e c t io n
2 . 1 6 .
2.7.3b NSAID-mediated drug toxicity enhancement assays 
(Short-term assays)
1. Cells were set up in 96-well plates as described in section 2.7.1b.
2 . C y t o t o x ic  d ru g  d ilu tio n s  an d  N S A I D  d ilu t io n s  w e r e  p re p a re d  an d  
a d d e d  to  th e  9 6 -w e ll  p la te s  a s  d e sc r ib e d  in  se c t io n  2 .7 .3 a .
3 .  P la te s  w e r e  th en  m ix e d  g e n t ly  an d  a llo w e d  to in c u b a te  at 3 7 ° C  an d  5 %  
C O 2 f o r  4  h o u rs.
4 . A f t e r  th is  in c u b a tio n  p e r io d  th e  p la te s  w e r e  re m o v e d  fro m  th e 
in c u b a to r , th e  d r u g / N S A ID  w a s  re m o v e d  fro m  th e  w e l ls  a n d  the p la te s  
w e r e  w a s h e d  o u t 4  t im e s  w ith  fre s h  m e d ia . A ft e r  w a s h in g , th e  w e lls  
w e r e  r e - fe d  w ith  f r e s h  m e d ia  o r  fre s h  m e d ia  c o n ta in in g  th e  re q u ire d  
d ilu t io n  o f  N S A I D .
5 . C e l l s  w e r e  in c u b a te d  fo r  a  fu r th e r  4  d a y s  at 3 7 ° C  a n d  5 %  C O 2. A t  th is  
p o in t  th e  c o n tro l w e l ls  w o u ld  h a v e  re a c h e d  a p p r o x im a te ly  8 0 -9 0 %  
c o n flu e n c y .
6 . A s s e s s m e n t  o f  c e l l  s u r v iv a l  in  th e  p re se n c e  o f  d ru g  w a s  d e te rm in e d  b y  
a c id  p h o sp h a ta se  a s s a y  (se c t io n  2 .7 .2 ) .
7 .  S ta t is t ic a l  a n a ly s is  o f  th e  d a ta  w a s  p e r fo rm e d  a s  d e ta i le d  in  S e c t io n
2 . 1 6 .
2.8 Procedure for determination o f COX-1 and COX-2 activity
2.8.1 E LISA  for assessm ent of COX-2 production
T h e  c o n c e n tra t io n  o f  P g E 2 in  c e l l  cu ltu re  su p ern atan ts  w a s  a n a ly s e d  as
fo llo w s :
1 .  C e l l s  w e r e  se e d e d  a t  h ig h  d e n s ity  (2 .5  x  1 0 5 c e l ls  p e r  w e ll)  in  6 w e ll  
p la te s  ( F a lc o n , 3 0 4 6 ) .
2 . P la te s  w e r e  th en  in c u b a te d  o v e rn ig h t  in  se ru m -c o n ta in in g  m e d ia .
3 . T h e  m e d ia  w a s  th e n  re m o v e d  and c e l ls  w a s h e d  tw ic e  w ith  D M E . T h e  
c o m p o u n d s  o f  in te re st  (su c h  a s  N S A I D s  o r  I L - 1 P )  w e r e  th e n  a d d ed  to 
th e  c e l ls  at a  c o n c e n tra tio n  a p p ro p ria te  fo r  th e  c e ll  d e n s ity  p re sen t. 
C o n tro l w e l ls  w e r e  tre a te d  w ith  m e d ia  o n ly .
4 . A f t e r  2 4  h o u rs  th e  m e d ia  w a s  re m o v e d  fr o m  th e w e l ls ,  p la c e d  in  to 
a p p ro p r ia te ly  la b e lle d  e p p e n d o r fs  an d  s to re d  a t - 8 0 °C .
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5 .  S a m p le s  w e re  a n a ly s e d  u s in g  a  P g E 2 e n z y m e  im m u n o a s s a y  k it  
(C a y m a n  C h e m ic a l, 5 1 4 0 1 0 ) .  C o n c e n tra tio n s  o f  P g E 2 p re se n t in  the 
sa m p le s  w e r e  d e te rm in e d  fro m  a  stan d ard  c u rv e  o f  a b so rb a n c e  at 4 0 5  
n m  v e r s u s  P g E 2 co n c en tra tio n .
T h e  P g E 2 a s s a y  k it  w a s  b a s e d  o n  th e  c o m p e tit io n  b e tw e e n  P g E 2 an d  a  P g E 2 - 
a c e ty lc h o lin e s te r a s e  c o n ju g a te  fo r  a  lim ite d  a m o u n t o f  P g E 2 m o n o c lo n a l 
a n tib o d y . B e c a u s e  th e  co n c e n tra tio n  o f  th e  P g E 2 tra c e r  w a s  h e ld  co n sta n t w h ile  
th e  c o n c e n tra t io n  o f  th e P g E 2 v a r ie d , th e a m o u n t o f  th e d e te c ta b le  P g E 2 tra ce r 
th at w a s  a b le  to  b in d  to  th e  P g E 2 m o n o c lo n a l a n t ib o d y  w a s  in v e r s e ly  
p ro p o rt io n a l to  th e  co n c e n tra tio n  o f  th e P g E 2 p resen t.
2.8.2 Procedure for detection of COX-1 activity
T h e  e x p e r im e n t u se d  to  te st  fo r  th e  a b ility  o f  th e N S A I D s  a n d  th e  U C C  
c o m p o u n d s  to  in h ib it  C O X - 1  is  a  sp e c tro p h o to m e tric  a s s a y  in  w h ic h  
a ra c h id o n ic  a c id  is  u se d  a s  th e  su b stra te  fo r  th e  C O X - 1  e n z y m e .
T h e  C O X  - 1  a s s a y  w a s  b a s e d  o n  th at u sed  b y  B o o p a th y  et a l ,  ( 19 8 4 )  an d  
P ia z z a  et al., ( 1 9 9 7 ) :
1 .  10 0 m l o f  lO O m M  T R I S - H C L  ( S ig m a  T - 1 3 7 8 )  (p H  7 .4  -  8) w a s  
p re p a re d  ( 1 . 2 1 1  g  in  1 OOmls U H P ).
2 .  T h e  fo l lo w in g  c o m p o u n d s  w e r e  w e ig h e d  o u t a n d  a d d e d  to  10 0 m l  o f  
lO O m M  T R I S - H C L :
0 .0 5 m M  G lu ta th io n e  ( S ig m a  G - 9 0 2 7 )  1 5 . 3 7 m g
0 .6 2 5 JJ .M  H a e m o g lo b in  ( S ig m a  H - 2 5 0 0 )  4 .0 3 m g
0 .5 m M  H y d ro q u in o n e  ( S ig m a  H -9 0 0 3 )  5 . 5 1  m g
1 . 2 5 m M C a C l 2  1 8 .3 m g
3 .  T h e  re a c t io n  m ix tu re  fo r  the C O X - 1  a s s a y  w a s  p re p a re d  a s  fo llo w s :
•  2 5 0  u n its  o f  P ro s ta g la n d in  H  sy n th e s is  1 ( C O X - 1 )  (C a y m a n  
C h e m ic a ls )
•  lO O jaM  a ra c h id o n ic  a c id  (C a y m a n  C h e m ic a ls , 9 0 0 10 )
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T R I S  -H C 1  +  co m p o n en ts  (a s  p re p a re d  a b o v e )  - a d d e d  to  m a k e  a  fin a l 
v o lu m e  o f  1 m l in  th e  re a c t io n  m ix tu re .
(N o te : 2 5 0  u n its  o f  C O X - 1  e n z y m e  w a s  u s e d  in  th e  a s s a y  a s  it  w a s  
a s s e s s e d  in  p r io r  tr ia ls  th at th is  a m o u n t o f  e n z y m e  g a v e  th e  o p tim u m  
le v e l  o f  a c t iv ity  w h e n  in c u b a te d  w ith  a ra c h id o n ic  a c id .)
T h e  re a c t io n  m ix tu re  w a s  in c u b a te d  @  3 7 ° C  fo r  2 0  m in u te s .
T h e  re a c t io n  w a s  te rm in a te d  b y  th e  a d d it io n  o f  0 .2 m l o f  1 0 0 %  (w /v )  
t r ic h lo ro a c e t ic  a c id  in  1 M  H C 1  ( 9 1 .7 m l  H 2O  +  8 .3 m l c o n c . H C 1 ).
A f t e r  th o ro u g h  m ix in g , 0 .2 m l o f  1 %  (w /v )  th io b a rb itu ric  a c id  so lu tio n  
( in  1 M  N a O H )  w a s  a d d e d  a n d  th e  m ix tu re  w a s  h e a te d  in  a  b o ilin g  
w a te r  b a th  fo r  2 0  m in .
A ft e r  c o o lin g  to  ro o m  te m p e ra tu re  a n d  b r ie f  c e n tr ifu g a t io n , th e  e n z y m e  
a c t iv ity  w a s  m e a su re d  b y  th e  th io b a rb itu r ic  a c id  c o lo u r  re a c t io n  o f  
m a lo n a ld e h y d e  fo rm e d  in  th e  re a c t io n  an d  d e te rm in e d  b y  a  
sp e c tro p h o to m e te r  at 5 3 0 n m .
T o  a s s e s s  th e  a b ility  o f  th e  N S A I D s  an d  B R I  c o m p o u n d s  to  in h ib it  
C O X - 1 ,  12 | ig / m l o f  th e  c o m p o u n d s  w e r e  a d d e d  to  th e  re a c t io n  m ix tu re , 
th e  v o lu m e  b ro u g h t u p  to  1  m l w ith  T R I S - H C L  +  co m p o n e n ts  an d  the 
C O X - 1  a s s a y  c a rr ie d  o u t a s  p e r  s te p s  4 - 9 .
1 2 ( ig /m l o f  co m p o u n d  w a s  u se d  in  th e  a s s a y  a s  th is  w a s  fo u n d  to  b e  the 
c o n c e n tra tio n  at w h ic h  in d o m e th a c in  in h ib ite d  C O X - 1  b y  a p p ro x . 5 0  
% . T h e  e n z y m a tic  a b ility  o f  C O X - 1  w a s  a s s e s s e d  b y  its  a b il i t y  to  a c t o n  
th e  su b stra te  a ra c h id o n ic  a c id  to  fo r m  m a lo n a ld e h y d e . T h e  g re a te r  th e 
o p t ic a l d e n s ity  re a d in g  th e  g re a te r  th e  a c t iv ity  o f  C O X - 1  in  th e  re a c tio n  
m ix tu re . In d o m e th a c in  w a s  u s e d  a s  th e  p o s it iv e  c o n tro l. T h e  B R I  
c o m p o u n d s  w e re  a d d e d  to  th e  re a c t io n  m ix tu re  at th e  sa m e  
c o n c e n tra tio n  as in d o m e th a c in  a n d  th e ir  a b ilit ie s  to  in h ib it  C O X - 1  w e re  
c o m p a re d .
T h e  c o n tro ls  u se d  in  th e  e x p e r im e n t w e re :
i. A ra c h id o n ic -n e g a t iv e  co n tro l.
i i . In d o m e th a c in -n e g a tiv e  c o n tro l
i i i .  D M S O  co n tro l.
In  th e  c o n tro l re a c tio n  m ix tu re  a ra c h id o n ic  a c id  o r  e n z y m e  w a s  a d d ed  
to  th e  re a c t io n  m ix tu re  a fte r  th e  a d d it io n  o f  th e  t r ic h lo ro a c e t ic  a c id .
2.9.1 Sample preparation
1 .  C e l ls  w e r e  s e e d e d  a t  a  d e n s ity  o f  3 x 1 0 6 c e l ls  p e r  1 7 5 c m 2 f la s k  tw o  d a y s  
b e fo re  th e  e x p e rim e n t.
2 . M e d ia  w a s  re m o v e d  an d  r e p la c e d  w ith  m e d ia  c o n ta in in g  th e  a g e n ts  o f  
in te rest ( su c h  a s  a  c y to to x ic  d ru g ).
3 . A f t e r  a n  a p p ro p ria te  t im e  p e r io d , m e d ia  w a s  re m o v e d  a n d  c e l ls  w e re  
try p s in is e d  a s  d e sc r ib e d  in  se c t io n  2 . 5 . 1 .
4 . C e l ls  w e r e  w a s h e d  t w ic e  w it h  ic e  c o ld  P B S .  A l l  p ro c e d u re s  f ro m  th is
p o in t  fo r w a r d  w e r e  p e r fo rm e d  o n  ic e .
5 . C e l ls  w e r e  re su sp e n d e d  in  1 m l  o f  N P - 4 0  ly s i s  b u ffe r . T a b le  2 .9 . 1  b e lo w
p r o v id e s  th e  d e ta ils  o f  th e  l y s i s  b u ffe r . Im m e d ia te ly  b e fo r e  u se , 1 Ofal o f  
th e  1 0 0 X  s to c k s  l is te d  in  ta b le  2 .9 .2  w e r e  a d d e d  to 1 m l  o f  l y s i s  b u ffe r .
2.9 Western blotting
Addition required per 500ml stock Final concentration
425ml U H P  w a te r -
2 5 m l 1 M  T R I S - H C L  (p H  7 .5 ) 5 0 m M  T R I S - H C L  (p H  7 .5 )
1 5 m l 5 M  N a C I 1 5 0  m M  N a C I
2 .5 m l  N P - 4 0 0 .5 %  N P -4 0
Table 2.9.1: N P - 4 0  ly s i s  b u f fe r
100X stock Preparation instructions
lO O m M  N a 3 V O 4 1 .8 3 g N a 3 V O 4 in 10 0m l UH P
lO O m M  D T T 15 4 m g  in 10m l U H P
lO O m M  P M S F I74 m g  in 10m l 10 0 %  ethanol
1 0 0 X  P ro te a s e  in h ib ito rs 2 .5  m g/m l leupeptin, 2 .5  m g/m l aprotinin, 1 5  m g/m l 
benzam idine and 1 m g/m l trypsin  inhibitor in U H P 
w ater
Table 2.9.2: N P - 4 0  ly s i s  b u f fe r  1 0 0 X  s to c k s
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6 . C e l l s  w e r e  so n ic a te d  im m e d ia te ly  w ith  9 p u lse s  la s t in g  0 .9  s e c o n d s  a t 
5 0 %  p o w e r .
7 . L y s e d  c e l ls  w e r e  t ra n s fe rre d  to  a n  e p p e n d o r f  and p e lle te d  a t 1 3 ,0 0 0  
r .p .m  fo r  1 0  m in u te s
8 . S u p e rn a ta n t w a s  re m o v e d  a n d  p ro te in  co n c e n tra tio n  q u a n tifie d  a s  
d e ta ile d  in  se c t io n  2 .9 .2 .  S a m p le s  w e r e  th en  sto re d  in  a liq u o ts  at -8 0 °C .
2.9.2 Protein Quantification
P ro te in  le v e ls  w e r e  d e te rm in e d  u s in g  th e  B io - R a d  p ro te in  a s s a y  k it  ( B io - R a d ,
5 0 0 0 0 0 6 )  a s  fo llo w s .
1 .  A  2 m g / m l b o v in e  se ru m  a lb u m in  ( B S A )  so lu tio n  ( S ig m a , A 9 5 4 3 )  w a s  
p re p a re d  f r e s h ly  in  ly s is  b u ffe r .
2 . A  p ro te in  stan d ard  c u rv e  w a s  p re p a re d  fro m  th e  B S A  s to c k  w ith  
d ilu t io n s  m a d e  in  ly s i s  b u ffe r .
3 . T h e  B io - R a d  re a g e n t w a s  d ilu te d  1 : 5  in  U H P  w a te r  an d  f i lte re d  
th ro u g h  W h a tm a n  p a p e r  b e fo r e  u se .
4 . A  2 0 (j.l v o lu m e  o f  p ro te in  stan d ard  d ilu tio n  o r  sa m p le  w a s  a d d e d  to
0 .9 8 m l o f  d ilu te d  d y e  re a g e n t  an d  th e m ix tu re  v o rte x e d .
5 . A f t e r  5 m in u te s  in c u b a tio n , a b so rb a n c e  w a s  a s s e ss e d  a t 5 7 0 n m .
6 . T h e  c o n c e n tra tio n  o f  th e  p ro te in  sa m p le s  w a s  d e te rm in e d  fro m  th e p lo t  
o f  th e  a b so rb a n c e  at 5 7 0 n m  v e r s u s  c o n c e n tra tio n  o f  th e  p ro te in  
stan d ard .
2.9.3 Gel electrophoresis
P ro te in s  fo r  a n a ly s is  b y  W e ste rn  b lo tt in g  w e re  r e s o lv e d  u s in g  S D S -  
p o ly a c r y la m id e  g e l  e le c tro p h o re s is  ( S D S - P A G E ) .  T h e  s ta c k in g  an d  r e s o lv in g  
g e ls  w e r e  p re p a r e d  a s  illu s tra te d  in  ta b le  2 .9 .3 .  T h e  g e ls  w e r e  se t  in  c le a n  1 0 c m  
x  8c m  g e l  c a s s e tte s , w h ic h  c o n s is te d  o f  a  g la s s  p la te  an d  an  a lu m in iu m  p la te . 
T h e s e  p la te s  w e r e  se p a ra te d  b y  0 .7 5 c m  p la s t ic  sp a c e rs . T h e  r e s o lv in g  g e l  w a s  
a d d e d  to th e  g e l  c a s se tte  a n d  a llo w e d  to  se t w h ile  c o v e re d  w ith  0 . 1 %  S D S .
86
O n c e  set, th e  0 . 1 %  S D S  w a s  re m o v e d  an d  th e  s ta c k in g  g e l  w a s  th e n  ad d ed . A  
c o m b  w a s  p la c e d  in to  th e  s ta c k in g  g e l  a fte r  p o u r in g , in  o rd e r  to  c re a te  w e l ls  
fo r  s a m p le  lo a d in g  (m a x im u m  sa m p le  lo a d in g  v o lu m e  o f  15 -2 0 ( x l)
7.5% Resolving  
Gel
15% Resolving 
Gel
5% Stacking
Gel
A cry lam id e  stock 3 .8 m l 5 .0 m l 0 .8m l
U H P  w ater 8 .0 m l 6 .8m l 3 .6 m l
1.8 7 5  M  T R IS -H C L  
pH  8.8
3 .0 m l 3 .0 m l
1 .2 5  M T R IS -H C L  
pH  6.8
0 .5 m l
10 %  S D S 1 5 0 jj.L 15 0 j.iL 5 0 p L
10 %  N H 4- persulfate 6 0|xL 5 0 j iL 17 j. iL
T E M E D 9j.iL 10 j.iL 8 j.iL
Table 2.9.3: P re p a ra t io n  p ro to c o l fo r  S D S - P A G E  g e ls  (2  x  0 .7 5 m m  g e ls ) .
T h e  a c r y la m id e  s to c k  in  T a b le  2 .9 .3 . 1  w a s  c o m p o se d  o f  2 9 . l g  a c ry la m id e  
( S ig m a , A 8 8 8 7 )  a n d  0 .9 g  N N -m e th y le n e  b is -a c ry la m id e  ( S ig m a , N 7 2 5 6 )  m a d e  
u p  to  1 0 0 m l  w ith  U H P  w a te r . In  a d v a n c e  o f  sa m p le s  b e in g  lo a d e d  in  to  th e 
r e le v a n t  sa m p le  w e l ls ,  1 5 j j ,g  o f  p ro te in  w a s  d ilu te d  in  5 X  lo a d in g  b u ffe r  ( 2 .5 m l 
1 . 2 5  M  T R I S - H C L ,  l.O g  S D S ,  2 .5 m l  m e rca p to e th a n o l ( S ig m a , B 6 2 5 0 )  5 .8 m l 
g ly c e r o l  ( B D H , 4 4 3 0 5 )  a n d  0 . 1 %  b ro m o p h e n o l b lu e  ( S ig m a , B 8 0 2 6 )  m a d e  u p  
to  10 m l  w ith  d is t i l le d  w a te r ) . T h e  m o le c u la r  w e ig h t  m a rk e rs  ( S ig m a , P I 6 7 7 )  
a n d  p ro te in  s a m p le s  ( fo r  P G H S - 2  a n a ly s is )  w e r e  h e a te d  to  9 5 ° C  fo r  2  m in u te s. 
A f t e r  h e a t in g , e q u a l a m o u n ts  ( 15 j j .g  in  5 X  lo a d in g  b u f fe r  in  a  to ta l v o lu m e  o f  
I O pl) o f  p ro te in  w e r e  a d d e d  in  to  e a c h  w e ll .  T h e  g e ls  w e r e  ru n  a t 2 5 0 V  an d  
4 5 m A  u n til th e  b ro m o p h e n o l b lu e  d y e  fro n t  w a s  fo u n d  to  h a v e  re a c h e d  th e en d  
o f  th e  g e l,  at w h ic h  t im e  s u ff ic ie n t  re so lu t io n  o f  th e  m o le c u la r  w e ig h t  m a rk e rs  
w a s  a c h ie v e d .
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'.4 Western Blotting - Transfer of protein to nitrocellulose
O n c e  e le c tro p h o re s is  h a d  b e e n  c o m p le te d , th e  S D S - P A G E  g e l w a s  
e q u ilib ra te d  in  tra n s fe r  b u f fe r  ( 2 5 m M  T R I S  ( S ig m a , T 8 4 0 4 ) , 19 2 m M  
g ly c in e  ( S ig m a , G 7 1 2 6 ) ,  p H  8 .3 - 8 .5 )  fo r  a p p ro x im a te ly  3 0  m in u te s.
P ro te in  w a s  tra n s fe rre d  fro m  th e g e l to  H y b o n d  E C L  n itro c e llu lo s e  
m e m b ra n e s  (A m e rs h a m , R P N  2 0 2 0 D )  b y  s e m i-d ry  e le c tro b lo tt in g . F iv e  
sh e e ts  o f  W h a tm a n  3 m m  f i lte r  p a p e r  w e r e  s o a k e d  in  f r e s h ly  p re p a re d  
tra n s fe r  b u f fe r . T h e s e  w e re  th en  p la c e d  o n  th e c a th o d e  p la te  o f  a  s e m i­
d ry  b lo tt in g  a p p a ra tu s  (B io -ra d ) . A i r  p o c k e ts  w e r e  th en  re m o v e d  fro m  
fro m  b e tw e e n  th e  f i lte r  p a p e r . N it r o c e llu lo s e  w a s  a lso  so a k e d  in  the 
tra n s fe r  b u f fe r  a n d  p la c e d  o v e r  th e  f ilte r  p a p e r  o n  th e  ca th o d e  p la te . A i r  
p o c k e ts  w e r e  o n c e  a g a in  re m o v e d . T h e  a c r y la m id e  g e l  w a s  la y e re d  
g e n t ly  o n  to p  o f  th e  n itro c e llu lo se . F iv e  a d d it io n a l sh e e ts  o f  tra n s fe r  
b u f fe r - s o a k e d  f i lte r  p a p e r  w e r e  p la c e d  o n  to p  o f  th e  g e l  an d  a ll  a ir  
p o c k e ts  re m o v e d . T h e  p ro te in s  w e re  t ra n s fe rre d  fro m  th e  g e l  to  th e 
n itro c e llu lo s e  a t  a  cu rre n t o f  3 4 m A  at 1 5 V  fo r  3 5  m in u te s.
T h e  p ro to c o l u s e d  fo r  M R P  p ro te in  a n a ly s is  is  su m m a rise d  in  se c t io n  
2 .9 .6 .
F o r  a n a ly s is  o f  P G H S - 1  an d  P G H S - 2 ,  th e  m e m b ra n e s  w e re  b lo c k e d  
o v e r n ig h t  u s in g  5 %  m ilk  p o w d e r  (C a d b u ry s ; M a r v e l  sk im m e d  m ilk )  in  T B S  
( 1 2 5 m M  N a C l ,  2 0 m M  T R I S  p H  7 .5 )  at 4 ° C .
M e m b ra n e s  w e r e  tre a te d  w ith  p r im a ry  a n tib o d y  o v e rn ig h t  a t 4 ° C  (w ith  
p ro s ta g la n d in  H  sy n th a se  I  m o n o c lo n a l a n t ib o d y  (C a y m a n  C h e m ic a ls  
1 6 0 1 1 0 )  o r  p ro s ta g la n d in  H  sy n th a se  2  (h u m an ) p o ly c lo n a l a n tib o d y  
( C a y m a n  C h e m ic a ls , 1 6 0 1 0 7 )  d ilu te d  at 1 in  1 ,0 0 0 )  a  n e g a t iv e  co n tro l 
w h e re  th e  g e l  w a s  e x p o s e d  to  a n tib o d y  d ilu e n t o r  a n im a l p re -b le e d  w a s  
a ls o  p e r fo rm e d .
P r im a r y  a n tib o d y  w a s  re m o v e d  a fte r  th is  p e r io d  an d  th e m e m b ra n e s  
r in se d  5  t im e s  w ith  T B S  fo r  a  to ta l o f  3 0  m in u te s .
S e c o n d a r y  a n tib o d y  ( 1  in  1 ,0 0 0  d ilu tio n  o f  a n t i-m o u se  I g G  p e ro x id a s e  
c o n ju g a te  ( S ig m a , A 4 9 1 4 )  in  T B S  o r a  1  in  1 ,0 0 0  d ilu t io n  o f  a n ti­
ra b b it  I g G  ( S ig m a , A 4 9 1 4 )  in  T B S )  w a s  a d d e d  fo r  1 h o u r  at ro o m  
te m p e ra tu re .
7 . T h e  m e m b ra n e s  w e r e  w a s h e d  th o r o u g h ly  in  th e  w a s h  b u ffe r  ( T B S  
c o n ta in in g  0 .5 %  T w e e n  ( S ig m a , P 7 9 4 9 ) )  fo r  1 5  m in u te s.
2.9.5 Enhanced chemiluminescence (ECL) detection
Im m u n o b lo ts  w e r e  d e v e lo p e d  u s in g  an  E n h a n c e d  C h e m ilu m in e sc e n c e  k it
(A m e rsh a m , R P N 2 1 0 9 )  w h ic h  fa c ilita te d  th e  d etectio n  o f  b o u n d  p e ro x id a se -
co n ju g a te d  se c o n d a ry  an tib o d y .
1 .  F o llo w in g  th e f in a l w a sh in g , n itro c e llu lo se  f ilte rs  w e re  su b je c te d  to  E C L .
2 .  A  la y e r  o f  p a ra film  w a s  fla tten ed  o v e r  a  g la s s  p la te  an d  the n itro c e llu lo se  
p la c e d  g e n tly  u p o n  the p late .
3 . A  v o lu m e  o f  3 m l o f  a  5 0 :5 0  m ix tu re  o f  E C L  re ag en ts w a s  u se d  to  c o v e r  
th e  n itro c e llu lo se .
4 . T h e  E C L  re a g e n t  m ix tu re  w a s  c o m p le te ly  re m o v e d  a fte r  a  p e r io d  o f  
o n e  m in u te  an d  th e m e m b ra n e  w r a p p e d  in  c l in g fi lm . A l l  e x c e s s  a ir  
b u b b le s  w e r e  re m o v e d .
5 . T h e  n itro c e llu lo se  w a s  th en  e x p o s e d  to  a u to ra d io g ra p h ic  f i lm  (K o d a k , X -
O M A T S )  fo r  v a r io u s  tim es ( fro m  1 to  1 5  m in u te s d e p en d in g  o n  th e 
s ig n a l) .
6 . T h e  e x p o s e d  a u to ra d io g ra p h ic  f i lm  w a s  d e v e lo p e d  fo r  3  m in u tes in
d e v e lo p e r  (K o d a k , L X - 2 4 )  fo r  2  m in u tes.
7 . T h e  f i lm  w a s  th en  w a sh e d  in  w a te r  fo r  1 5  seco n d s an d  tra n sfe rred  to  a
f ix a t iv e  (K o d a k , F X -4 0 )  fo r  2  m in u tes.
8 . T h e  f i lm  w a s  th en  w a sh e d  w ith  w a te r  fo r  5 - 1 0  m in u tes an d  le ft  to  d ry  at
ro o m  tem p eratu re .
2.9.6 Western blot analysis of MRP in inside-out vesicles.
W e ste rn  b lo ttin g  fo r  M R P  p ro te in  d etectio n  in  1 0 V s  w a s  p e r fo rm e d  as d e scr ib e d
in  S e c t io n s  2 .9 . 1  to  2 .9 .5  w ith  the fo llo w in g  m o d ifica tio n s:
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1 .  A  tota l o f  20(j,g  p ro te in  w a s  d ilu ted  in  5 X  lo a d in g  b u ffe r  and lo a d e d  onto 
the 5 %  sta c k in g  g e l an d  7 .5 %  r e so lv in g  g e l.
2 .  M o le c u la r  w e ig h t  m a rk e rs  ( N e w  E n g la n d  B io la b s , 7 7 0 8 S )  w e re  h eated  to 
9 5 - 1 0 0 ° C  fo r  3 -5  m in u te s o r  h eated  a t 4 0 ° C  fo r  1  m in u te .
3 . M e m b ra n e s  w e re  b lo c k e d  u sin g  5 %  m ilk  (C a d b u ry s : M a r v e l sk im m e d  
m ilk )  in  T B S  ( 1 2 5 m M  N a C l,  2 0 m M  T R I S  p H  7 .5 )  fo r  4  h ou rs at ro o m  
tem p eratu re .
4 . A n ti-h u m a n  M R P  m o n o c lo n a l p r im a ry  a n tib o d y  (T C S  B io lo g ic a ls ,  
Z U M C - 2 0 1 )  w a s  ad d ed  ( 1 :5 0  d ilu tio n  in  T B S )  to  m e m b ran e s o v ern ig h t 
at 4 ° C .
5 . R a b b it  an ti-rat se c o n d a ry  a n tib o d y  (D a k o , P 0 4 0 5 0 )  w a s  a d d ed  a t a  
1 : 1 2 , 0 0 0  d ilu tio n  in  T B S  fo r  2  h o u rs  at ro o m  tem perature. M e m b ra n e s  
w e re  th en  w a sh e d  5 t im e s  in  T B S  co n ta in in g  0 .5 %  T w e e n -2 0  
(C a lb io c h e m , 6 5 5 2 0 5 ) .
6 . A  S u p e rS ig n a l U L T R A  C h e m ilu m in e sc e n c e  k it (P ie rc e , 3 4 0 7 5 )  w a s  u se d  
fo r  the d e v e lo p m e n t o f  im m u n o b lo ts. T h is  in v o lv e d  m ix in g  1 .5 m l  S u p e r 
S ig n a l R e a g e n t  1  w ith  S u p e r  S ig n a l  re a g e n t 2  an d  a d d itio n  o f  th is m ix tu re  
to  the m e m b ra n e s  as  d e sc r ib e d  in  2 .9 .5 . A ft e r  5  m in u te s the re ag en ts  w e re  
re m o v e d  an d  th e m e m b ran e  w rap p e d  in  c lin g  film . T h is  w a s  th en  e x p o se d  
to  a u to ra d io g ra p h ic  f i lm  fo r  3 0  seco n d s. A u to ra d io g ra p h e d  f i lm  w a s  
p ro c e sse d  a s  d e sc r ib e d  in  S e c tio n  2 .9 .5 .
2.10 Inside-out vesicle preparation
2.10.1 Spinner flask preparation
S p in n e r  f la s k s  w e re  so ak e d  in  a  so lu tio n  o f  2 %  R B S  fo r  o n e  h ou r an d  scru b b ed  
v ig o r o u s ly  w ith  a  sc ru b b in g  bru sh . T h e y  w e re  r in se d  th ree  tim e s w ith  tap  w a te r  
an d  th ree  t im e s  in  U H P  w a ter . S p in n e r  f la s k s  w e re  a llo w e d  to c o m p le te ly  d ry  at 
3 7 ° C ,  an d  a fte r  th is  p o in t w e re  treated  w ith  10 m l o f  d im eth y lc h lo ro silan e  
(S ig m a , D 6 2 5 8 ) . T h e  v e s s e l  w a s  rotated  to  en su re  e x p o su re  o f  a ll  g la s s  su rfa ce s  
to  th e s il ic o n is in g  agen t. S u rp lu s  flu id  w a s  th en  re m o v e d  an d  th e v e s s e l  le ft  in  the
9 0
fu m e  h o o d  to d ry . O n c e  c o m p le te ly  d ry , the f la s k  w a s  rin se d  th ree tim e s in  U H P
w a ter . T h e  sp in n er f la s k s  w e re  th en  a u to c la v e d  ( 1 2 1 ° C  fo r  2 0  m in u tes).
2.10.2 Large Scale culture of cells.
— 4 -y a c
1 .  C e l ls  w e r e  su b cu ltu re d  in to  7 5 c m  f la s k s  at a  d e n s ity  o f  2 x 1 0  c e lls  p e r 
fla sk .
2 .  O n ce c e l ls  re a c h e d  7 0 %  to 8 0 %  c o n flu e n c y , th e y  w e re  try p s in ise d  an d  
u sed  to  se e d  a  1 7 5 c m 2 fla sk .
3 .  C e lls  w e r e  cu ltu red  fo r  4 -5  d a y s  un til th ey  re a c h e d  7 0 %  to  8 0 %  
c o n flu e n c y . T h e  c e lls  w e re  th en  try p sin ise d , an d  u se d  to see d  a  la rg e  
5 0 0 m l sp in n e r  f la s k  (T e c h n e , T R 1 7 4 -3 0 )  co n ta in in g  2 5 0 m l m ed ia .
4 . S p in n e r  f la s k s  w e re  in c u b a ted  at 3 7 ° C  an d  p la c e d  o n  a  sp in n er ap p aratu s 
set at a  ro ta tio n a l sp eed  o f  2 5  r.p .m .
5 . A fte r  a  p e r io d  o f  2 4  h o u rs, th e ag ita tio n  rate  w a s  in c re a se d  to  3 5  r.p .m .
6 . C e lls  w e re  fe d  w ith  10 0 m l o f  m e d ia  a fte r  three d a y s  o f  g ro w th  in  the 
sp in n er f la s k s .
7 . C e lls  w e re  h a rv e ste d  a fte r  7  d a y s  a t w h ic h  tim e  c e ll n u m b er w a s
o
a p p ro x im a te ly  1 . 5 x 1 0  c e lls  p e r f la sk .
8 . W h en  I O V s  w e re  iso la te d  fro m  H L 6 0 - A D R , c e lls  ( in  R P M I  m e d ia
su p p lem e n ted  w ith  1 0 %  seru m ) w e re  cu ltu red  in  5  v e n te d  7 5  cm 2 f la s k s  
(C o sta r , 3 2 7 6 )  un til 7 0 -8 0 %  co n flu en t. T h e  m e d ia  co n ta in in g  the 
an ch o rag e -in d ep e n d en t H L 6 0 - A D R  c e ll lin e  w a s  re m o v e d  fro m  the 
f la s k s  an d  ce n tr ifu g e d  at lOOOr.p.m. fo r  5  m in u tes. T h e  p e lle ts  w e re  th en  
re su sp e n d e d  in  5 m l m e d ia  an d  u se d  to  see d  th e ro lle r  bottle (F a lc o n , 
3 0 2 7 )  co n ta in in g  5 0 0 m l o f  m e d ia . C e l ls  w e re  cu ltu red  in  the ro lle r  b o ttle  
until 6 0 %  co n flu e n t. O n ce  th is h ad  b e e n  a ch ie v e d , c e lls  w e re  sp lit  e q u a lly  
in  to  a n  a d d itio n al fo u r  ro lle r  b o ttles  an d  th e f in a l v o lu m e  in  e a c h  o f  th e 
f iv e  ro lle r  b o ttle s  m a d e  u p  to  5 0 0 m l w ith  co m p le te  m ed ia . C e lls  w e re  
h a rv e ste d  u p o n  re a c h in g  7 0 %  c o n flu e n c y .
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2.10.3 Isolation of IOVs
T h e  iso la t io n  o f  IO V s  fro m  v a r io u s  c e ll  lin e s  w a s  p e r fo rm e d  a s  d e sc r ib e d  b y
I s h ik a w a  et a t ,  ( 19 9 4 ) ,  an d  a s  d e ta ile d  b e lo w :
1 .  A p p r o x im a te ly  7 x 1 0 s c e l ls  w e re  p e lle te d  a t  5 ,0 0 0 r .p .m . ( l ,2 0 0 g )  fo r  1 0  
m in u te s  at 4 ° C  in  a  S o r v a l l  re fr ig e ra te d  ce n trifu g e .
2 . T h e  su p ern atan t w a s  d e ca n ted  an d  th e p e lle ts  re su sp e n d e d  in  5 0 m l ic e  
c o ld  P B S .  T h e  co m b in e d  p e lle ts  w e re  th en  tra n sfe rred  to  a  5 0 m l tu b e  and 
sp u n  a t 4 ,0 0 0  r.p .m . fo r  5  m in u tes.
3 .  T h e  re su lt in g  c e ll  p e lle t  w a s  re su sp e n d ed  in  2 3 0 m l  h y p o to n ic  b u ffe r , 
(T a b le  2 . 1 0 . 1 ) .  T h e  P M S F  w a s  ad d ed  to  th e b u ffe r  im m e d ia te ly  b e fo re  
u se .
Buffer constituent Preparation instructions
0 .5 m M  S o d iu m  p h o sp h a te  (p H  
7 .0 )
3 0  m g  N a P  in  5 0 0 m l U H P
0 .1  m M  E G T A 19 .2  m g  E G T A  ad d ed  to  N a P  
so lu tion
0 . 1  m M  P M S F lO O m M  sto c k  p re p a re d  in  E tO H
Table 2.10.1: H y p o to n ic  b u ffe r  fo r  I O V  iso latio n
4 . C e l ls  w e re  ly se d  b y  g e n tle  a g ita tio n  a t 4  ° C  fo r  1 . 5  h ou rs.
5 . T h e  c e ll  ly sa te  w a s  ce n tr ifu g e d  a t 2 8 ,0 0 0  r.p .m . ( 10 0 ,0 0 0 g )  fo r  3 5  
m in u te s  a t 4 °  C  w ith  a  b e c k m a n  S W 2 8  ro to r in  a  B e c k m a n  X L - 8 0  
u ltrac en trifu g e .
6 . T h e  re su lt in g  p e lle ts  w e re  th en  re su sp e n d ed  in  10 m l o f  h y p o to n ic  b u ffe r  
a n d  th en  h o m o g e n ise d  fo r  1 5  m in u tes a t 4 ° C  w ith  a  B r a u n  P o tter S 886 
h o m o g e n ise r .
7 .  T h e  h o m o g e n ise d  c e ll  ex tra c t  w a s  d ilu ted  to  a  f in a l v o lu m e  o f  2 0 m l w ith  
in c u b a tio n  b u ffe r  w h ic h  w a s  p re p ared  as  sh o w n  in  ta b le  2 . 1 0 .2 .
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Buffer constituent Preparation instruction
1 O m M  T R I S - H C L  (pH  7 .4 ) 1 . 2 1  l g  T R I S  in 1 L U H P  w a te r
2 5 0 m M  S u c ro se 4 2 .7 9 g  S u c ro se  in  5 0 0 in l 10  m M  T R IS -  
H C L  (p H  7 .4 )
Table 2.10.2: In cu b a tio n  b u ffe r  fo r  I O Y  iso la tio n .
8 . A  100|_tl a liq u o t o f  th is cru d e  m e m b ran e  frac tio n  w a s  then retained  fo r  
m a rk e r  e n z y m e  a ss a y s
9 . T h e  cru d e  m e m b ran e  fra c tio n  w a s  la y e re d  o v e r  3 8 %  su cro se/ lO m M  
T R I S - H C L  p H  7 .4 , ( 3 8 g  su cro se  in 10 0 m l lO m M  T R JS - H C L  pH  7 .4 )  
and c e n tr ifiig e d  at 2 8 ,0 0 0  r .p .m  ( 10 0 ,0 0 0 g )  fo r  3 5  m in u tes at 4 ° C  w ith  a 
S W 2 8  rotor. A  v o lu m e  o f  10 m l crud e m e m b ra n e  fractio n  w a s  layered  
o v e r  2 8 .5 m l 3 8 %  su cro se/1 OmM T R I S - H C L , p H  7 .4 . T h e  in terface  w a s  
m a rk ed  to s p e c ify  the lo catio n  o f  the p la sm a  m e m b ran e  band w h ic h  
d e v e lo p e d  a fte r  the su c ro se  ce n trifu g atio n  step.
1 0 .  A  thin w h ite  b and  b e c am e  lo ca lise d  at the in te rfa ce  a fte r cen trifu gatio n  
an d  th is w a s  re m o v e d  w ith  a  p asteu r p ipette an d  d ilu ted  to a  fin a l v o lu m e  
o f  2 0 m l w ith  in cu b atio n  b u ffer.
1 1 .  T h e  su sp e n sio n  w a s  ce n trifu g ed  at 3 8 ,2 0 0  rpm  ( 10 0 ,0 0 0 g )  fo r  3 5  m in u tes 
at 4 ° C  u s in g  a  B e c k m a n  7 0 .1  rotor.
1 2 .  T h e  p e lle ts  w e re  resu sp en d ed  in  0 .2 m l in cu b atio n  b u ffe r . V e s ic le s  w e re  
fo rm ed  b y  p a ss in g  resu sp en d ed  p e lle ts  th ro u g h  a  2 7 -g a u g e  n ee d le  2 0  
tim e s u s in g  a  I m l sy r in g e .
1 3 .  A  p ro te in  a ssa y  w a s  then p erfo rm ed  (S e c tio n  2 . 1 0 .4 )  and the IO V  
p re p aratio n  w a s  th en  d ilu ted  to a  co n cen tra tio n  o f  5 m g  protein  /m l w ith  
in cu b atio n  b u ffe r . V o lu m e s  o f  50|.il IO V s  w e re  then fro ze n  at -8 0 °  C .
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2.10.4 Protein assay
T h is  a s s a y  w a s  p e r fo rm e d  in  th e  sa m e  m a n n er a s  d e sc r ib e d  in  se c tio n  2 .9 .2 . F o r  
th e  1 0 V s  a n d  th e c ru d e  m e m b ra n e  p rep aratio n s, sa m p le s  w e re  d ilu ted  1  in  5 
b e fo re  a n a ly s is .
2.11 Transport assays with IOVs.
T ra n sp o rt a ss a y  w ith  IO V s  w e re  p e rfo rm ed  as d e sc r ib e d  b y  Ish ik a w a  et a l,  
( 19 9 4 ) .  T h e  p ro to co l u sed  in th ese  a s s a y s  is  a s fo llo w s :
1 .  A  n u m b er o f  so lu tio n s  w e re  prep ared  in a d v a n c e  o f  the a ssa y . T h e  
p ro to co l used  fo r  the p rep aratio n  o f  the in cu b atio n  b u ffe r  h as a lre a d y  
b een  p ro v id e d  in  T a b le  2 . 1 0 .2 .
A n  A T P /c re a t in e  p h o sp h a tc / M g C l2/ 1 O m M  T R I S - H C L  (p H  7 .4 )  
s o lu tio n  is  p re p a re d  a s  d e ta ile d  in  T a b le  2 . 1 1 . 1 .  V o lu m e s  o f2 0 0 f .i l  w e re  
then  fro z e n  at - 8 0 °C .
Buffer constituent Preparation instructions
M g C I2 6 H 20 2 0 3 .3 m g  in 3 0 m l In cu b atio n  b u ffe r
A T P  (D iso d iu m  salt) 6 .0 5  m g  A T P  in 3 m l M g C l26 H 20 
so lu tio n
C re a tin e  p h o sp h ate 3 2 .7  m g  in  3 m l A T P  so lu tion
Table 2.11.1: A T P / C re a t in e  p h o sp h a te /M g C l2/ l  O m M  T R I S - H C L  (p H  7 .4 )  
p re p aratio n  p ro to c o l.
2 . F o r  th e  A M P  so lu tio n , 4 .9 9 m g  A M P  (S ig m a , A 1 7 5 2 )  w a s  su bstitu ted  fo r  
th e  A T P  ( S ig m a  A 7 6 9 9 ) . O n ce  p re p ared  a s  in  T a b le  2 . 1 1 . 1  a b o v e , 1 OOjj.1 
v o lu m e s  w e r e  fro z e n  at -8 0 °  C .
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A  crea tin e  k in a se  so lu tio n  (2m g /m l), (S ig m a , C 5 7 5 5 )  w a s  p rep ared  in  
in c u b a tio n  b u ffe r  an d  50|xl a liq u o ts  fro z e n  at -8 0  °C .
P r io r  to  p e r fo rm in g  the a ssa y , filte rs  (M illip o re , G S W P -0 2 5 0 0 )  w e re  
so a k e d  in  th e in cu b atio n  b u ffe r  fo r  1  h o u r at 4 ° C .  O n ce  so ak e d , the filte rs  
w e re  a p p lie d  to  th e f ilte r  ap p aratu s (M illip o re , 1 2 - 2 5  S a m p lin g  M a n ifo ld )  
a n d  a  v a c u u m  w a s  a p p lie d  to  th e syste m .
A n  E p p e n d o r f  th e rm o m ix e r  (E p p e n d o rf, 5 4 3 6 )  w a s  a llo w e d  to  eq u ilib rate  
at 3 7 ° C  an d  o n c e  at tem p eratu re , th e  A T P , A M P , c rea tin e  k in a se  and IO V  
so lu tio n s  w e re  th a w e d  ra p id ly  a t 3 7 ° C .  A fte r  th a w in g , so lu tio n s w e re  
im m e d ia te ly  p la c e d  o n  ic e .
A n  e p p e n d o r f w a s  p la c e d  in  the th e rm o m ix e r  an d  th e fo llo w in g  ad d ed  
se q u e n tia lly : 6 0 jj.L  in cu b a tio n  b u ffe r , 3 0 ^ 1  A T P , 5p.l creatin e  k in a se , 5 u l 
[3H ] - L T C 4 (D u P o n t N E N , N E T - 1 0 1 8 ,  0 .0 1  m C i/m l)  and 10(j.l IO V s . 
A fte r  e v e r y  seq u e n tia l ad d itio n  th e  th e rm o m ix e r  w a s  a d ju sted  to  h a l f  
sp e e d  m ix in g  to  a l lo w  a g ita tio n  o f  th e  v a r io u s  co m p o n en ts o f  the m ixtu re . 
A liq u o ts  o f  20|xl w e re  re m o v e d  at ap p ro p ria te  tim e -p o in ts  an d  ad d ed  in  to 
l m l  o f  ic e  c o ld  in cu b a tio n  b u ffe r .
T h e se  w e re  th en  w a s h e d  th ro u g h  th e  filte r  ap p aratu s. T h e  e p p e n d o r f w a s  
w a s h e d  ou t w ith  lm l  o f  ic e  c o ld  in cu b atio n  b u ffe r . T h e  f ilte r  w a s  f in a lly  
w a sh e d  w ith  2  m l o f  ic e  c o ld  in cu b a tio n  b u ffe r .
F ilte rs  w e re  re m o v e d  and p la c e d  in  8m l sc in tilla tio n  co c k ta il ( IC N , 
8 8 2 4 7 5 )  in  a  sc in tilla tio n  v ia l. A fte r  a llo w in g  1 2  h o u rs  fo r  the filte rs  to  
fu l ly  d is s o lv e , th e  v ia ls  w e re  co u n ted  fo r  [3H ] co n ten t u s in g  a  B e c k m a n  
L S - 6 5 0 0  sc in tila tio n  co u n ter u s in g  a  1 m in u te  co u n t tim e.
F o r  an  A M P  n e g a tiv e  con tro l, th e a b o v e  p ro c e d u re  w a s  rep eated  w ith  
A T P  re p la c e d  b y  A M P . F o r  a  to ta l n e g a t iv e  co n tro l, n eith er A T P  n o r 
A M P  w e re  in c lu d e d  b ut w e re  in stead  re p la c e d  w ith  3 0 ja L  in cu b ation  
b u ffe r .
F o r  a sse ssm e n t o f  a  co m p o u n d s a b ility  to  in h ib it L T C 4 transport, the 
co m p o u n d  o f  in terest w a s  d isso lv e d  in  in cu b a tio n  b u ffe r  at the d e sired  
c o n cen tra tio n . 5p.l o f  th is  w a s  a d d ed  to  an  e p p e n d o r f  in  the th erm o m ixe r. 
5 5 jj.1 o f  in c u b a tio n  b u ffe r  w a s  th en  add ed . T h e  stan d ard  v o lu m e s  o f  A T P , 
A M P , cre a tin e  k in a se , L T C 4 and IO V  w e re  th en  ad d ed  to  a tota l f in a l 
v o lu m e  o f  1 1 0 p.l.
2.12 Glutathione-S-Transferase assay.
2.12.1 Preparation of cell extract
1 .  D L K P  c e lls  w e re  g ro w n  in a  7 5 c m 2 f la s k  un til a p p ro x im a te ly  8 0 -9 0 %  
co n flu en t. T h e  c e lls  w e re  then tiy p s in ise d  and p e lle te d  as d escrib ed  in 
sec tio n  2 . 5 . 1 .
2 . T h e  p e lle t  w a s  w a sh e d  w ith  5 m l P B S  and th e c e lls  re su sp e n d ed  in  2 m l 
P B S  +  2 m l lOO m M  P M S F  (p rep ared  a s  in T a b ic  2 .9 .2 ) .
3 .  T h e  c e l ls  w e re  so n ica ted  un til th ey  burst (~  2 0  p u lse s  at 0 .9 m sec) and the 
supernatant w a s  then sp u n  at 3 8 ,0 0 0  rp m  ( 10 0 ,0 0 0 g )  fo r  1 h our at 4 ° C  
u s in g  a  B e c k m a n  7 0 .1  rotor.
4 . A  protein  a ss a y  (d e sc rib ed  in  sectio n  2 .9 .2 )  w a s  then  carried  out on  the 
supernatant, w h ic h  co n ta in ed  the c e ll extract.
5 . T h e  c e ll ex tra c t w a s  fro z e n  at -8 0 °C  until req u ired .
2.12.2 GST assay
1 .  A  n u m b er o f  so lu tio n s  w e re  p rep ared  in a d v a n ce  o f  th e G S T  a ssa y . T h e se
are  d e sc r ib e d  in  ta b le  2 . 1 2 . 1 .
Buffer constituent Preparation instructions
3 0 m M  G lu tath io n e 18 4 .2 0  m g  in 2 0 m l U H P
3 0 m M  l-C h lo r o -2 ,4 -  
d in itro b en zen e
1 2 1 . 2  m g  in 2 0 m l E th an o l
lO O m M  P o ta ss iu m  P h o sp h ate  
b u ffe r
13 6 m g  P o ta ss iu m  d ih y d ro g e n  +  17 4 m g  
P o ta ss iu m  h y d ro g e n  in  2 0 m l U H P
Table 2.12.1: B u f fe r  co n stitu en ts fo r  G S T  a ssa y .
2 . T h e  re a c tio n  m ix tu re , co n s is t in g  o f  th e  fo llo w in g  co m p o n en ts w a s  
p re p ared :
•  0 . 1 m l  G lu ta th io n e  sto ck
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•  0 . 1m l  l-C h lo ro -2 ,4 -d in itro b e n z e n e
•  2 .2 m l  P o ta ss iu m  b u ffe r
•  0 .6  m l C e l l  ex tra c t  (p rep are d  as in  sectio n  2 . 1 2 . 1 )
T h e  f in a l v o lu m e  o f  the re a c tio n  m ix tu re  w a s  3 m l.
3 . T h e  in c re a se  in  a b so rb a n c e  w a s  m o n ito red  at 3 4 0 n m  fo r  3  m in u tes b y  a  
sp ectro p h oto m eter. T h e  a b o v e  re ac tio n  m ix tu re  w a s  th e  n e g a t iv e  con tro l 
(no te st  co m p o u n d  ad d ed ) fo r  th e  a ssa y . T h e  re fe re n c e  c e ll  m ix tu re  
co n s is te d  o f  th e  sa m e  co m p o n en ts  a s  th e re ac tio n  m ix tu re  a b o v e  e x c e p t
0 .6 m ls  c e ll  ex tra c t w a s  re p la c e d  w ith  0 .6 m l P B S .
4 . F o r  a sse ssm e n t o f  the a b ility  o f  a  co m p o u n d  to  in h ib it G S T  a c tiv ity , the 
co m p o u n d  o f  in terest w a s  d is so lv e d  in  D M S O  a t th e  re q u ired  
c o n cen tra tio n  ( 5 - 1 0  m g /m l). A n  a liq u o t o f  the c o m p o u n d  to b e  tested  
w a s  ad d ed  to 0 . 1 m l g lu tath io n e  s to ck , 0 . 1 m l l-c h lo r o -2 ,4 -d in itro b en zen e  
an d  2 .2 m l p o ta ss iu m  b u ffe r . A  f in a l v o lu m e  o f  3 m l w a s  o b ta in e d  b y  th e 
a d d itio n  o f  c e ll e x tra c t to  th e  re a c tio n  m ix tu re  an d  th e  a d d itio n  o f  P B S  to  
th e re fe re n c e  c e ll  m ixtu re .
5 . T h e  in c re a se  in  a b so rb a n c e  is  m o n ito re d  at 3 4 0 n m  fo r  th ree  m in u tes in  
th e  sp ectro p h oto m eter.
6 . In d o m e th a c in  w a s  u se d  as  th e p o s it iv e  con tro l in  th e  G S T  a ss a y  a s  it is  a  
k n o w n  G S T  in h ib itor.
2.13 Quantification o f adriamycin efflux in DLKP cells
1 .  D L K P  c e lls  w e re  se e d e d  into  7 5 c m 2 f la sk s  (C o sta r, 3 3 7 5 )  at 0 .5 x l0 6 c e lls  
p e r  f la sk . C e lls  w e r e  in cu b ated  fo r  48  h ou rs, a fte r w h ic h  tim e  m ed iu m  
w a s  re m o v e d  a n d  fre sh  m e d iu m  co n ta in in g  a d r ia m y c in  ( 10 j iM ) ,  
in d o m e th a c in  (o r o th er N S A ID / in d o m e th a c in  a n a lo g u e s)  ( 2 7 .9 5 p M ) , o r 
c o m b in a tio n  o f  b o th  a d ria m y c in  and in d om eth ac in /co m p o u n d  o f  in terest, 
w a s  ad d ed . F la s k s  w e r e  in cu b a ted  at 3 7 ° C  fo r  a  p e r io d  o f  tw o  h ours.
2 .  A ft e r  th is tw o -h o u r in cu b atio n , the m e d ia  w a s  re m o v e d  fro m  a ll  f la sk s  
a n d  re p la c e d  w ith  fre sh  m e d ia , o r  m e d ia  co n ta in in g  in d om eth acin /
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in d o m eth ac in  a n a lo g u e  or a d ria m y e in , a s  th e e x p e rim e n t req u ired . T h e  
f la s k s  w e re  return ed  to  the 3 7 ° C  incubator,
A t  re le v a n t  t im e  p o in ts  the m e d ia  w a s  re m o v e d  fro m  th e  f la s k s  an d  the 
f la s k s  w e re  w a sh e d  tw ic e  w ith  P B S .  C e lls  w e re  th en  try p s in ise d  as 
d e sc r ib e d  in  sec tio n  2 .5 . 1  an d  co u n ted  a s  d e sc r ib e d  in  se c tio n  2 .5 .2 .  
P e lle ts  w e re  th en  w a sh e d  w ith  P B S  an d  fro z e n  a t - 2 0 ° C .
W h e n  re q u ire d  fo r  H P L C  a n a ly s is , th e  fr o z e n  p e lle ts  w e r e  th a w e d , 
re su sp e n d e d  in  10 0 p ,l  U H P  an d  a d d ed  to  g la s s  tu b e s  (te st sa m p le s) .
U n tre a te d  D L K P  c e l ls  w e r e  re su sp e n d e d  in  8 0 0 p l  U H P  an d  10 0 j.il  
a liq u o ts  o f  th is  w e r e  p la c e d  in to  8 g la s s  tu b e s . T h e s e  w e r e  the 
a d r ia m y e in  c o n tro l tu b es a n d  w e re  la b e lle d  a s  fo l lo w s :  50(j.g/m l, 
10 | ig / m l, 5 jog/m l, 2(xg/m l, 1 fig /m l, 0 .5 |j.g /m l, 0 .2 5 p g / m l, O pg/m l 
a d r ia m y e in .
l m l  o f  th e  a p p ro p ria te  c o n c e n tra tio n  o f  a d r ia m y e in  w a s  th en  a d d e d  to 
th e  a d r ia m y e in  c o n tro l tu b es.
A  v o lu m e  o f  lOO^il 3 3 %  a q u e o u s  s i lv e r  n itra te  ( S ig m a , S 6 5 0 6 )  w a s  
th en  a d d e d  to th e  p e lle ts  ( a ll  tu b es  fro m  4  a n d  5 ) ,  fo l lo w e d  b y  m ix in g  
fo r  5 m in u te s . A  q u a n tity  o f  3 0 0 p l  o f  th e  in te rn a l stan d ard  
(d a u n o ru b ic in , 6 u g /m l in  5 0 m ls  m e th a n o l)  w a s  th en  a d d e d  to  a ll  tu b es.
1 . 3 m l  H P L C  g ra d e  a c e to n itr ile  (L a b s c a n )  w a s  a d d e d  to  th e  test sa m p le  
tu b e s  o n ly . 3 0 0 p ,l H P L C  g ra d e  a ce to n itr ile  w a s  a d d e d  to  th e  a d r ia m y e in  
c o n tro l tu b es .
A l l  tu b e s  w e r e  m a in ta in e d  a t 4 ° C  fo r  1  h o u r. T h is  w a s  fo l lo w e d  b y  
c e n tr ifu g a t io n  at 4 0 0 0 rp m  fo r  1 5  m in u te s.
1 . 1 m l  o f  th e  su p ern a tan t w a s  re m o v e d  an d  a d d e d  to  H P L C  a u to sa m p le r  
v ia l s .  A l l  s o lv e n t  w a s  th en  re m o v e d  u n d e r a  s tre a m  o f  n itro g e n  g a s .
T h e  re m a in in g  s o lid s  w e re  re su sp e n d e d  in  5 0 jj.L  o f  H P L C  m o b ile  p h a se
T h e  H P L C  m o b ile  p h a se  w a s  p re p a re d  a s  fo l lo w s :  6 4 m l o f  0 . 1 M  
p h o sp h o r ic  a c id  ( S ig m a , P 6 5 6 0 )  w a s  a d d ed  to  4 8 8 m l U H P . T h e  p H  w a s  
th e n  a d ju ste d  to  2 .3  w ith  I N  p o ta ss iu m  h y d r o x id e  ( S ig m a  P 6 3 1 0 ) .  A  
v o lu m e  o f  2 4 8  m l a c e to n itr ile  w a s  ad d ed  f in a l ly  an d  th e  c o m p le te d  
m o b ile  p h a se  a l lo w e d  to  d e g a s  at 4 ° C  o v e rn ig h t .
1 3 .  2 0  1 o f  sa m p le  fo r  a n a ly s is  w a s  a u to m a tic a lly  in je c te d  in to  th e  H P L C  
s y s te m  (B e c k m a n  S y s te m  G o ld  5 0 7  a u to sa m p le r , 1 2 5  p u m p  an d  16 6  
d e tecto r). M o b ile  p h a s e  f lo w  ra te  w a s  set at 0 .5 m l p e r  m in u te  w ith  a 
to ta l ru n  t im e  o f  1 6  m in u te s . T h e  c o lu m n  u se d  fo r  H P L C  a n a ly s is  o f  
a d r ia m y c in  in  D L K P  w a s  a  C l 8 re v e rs e d  p h a se  P r o d ig y  5 p m  p a rtic le  
s iz e  O D S -3  c o lu m n  (P h e n o m e n e x , U .K .) .  A b s o r b a n c e  w a s  m o n ito re d  
a t 2 5 3 n m .
1 4 .  A  s tan d ard  c u rv e  o f  a d r ia m y c in  p e a k  a r e a  /d a u n o ru b ic in  in te rn a l 
s tan d ard  p e a k  a re a  v e r s u s  a d r ia m y c in  c o n c e n tra tio n  w a s  u se d  to 
q u a n t ify  th e  le v e ls  o f  a d r ia m y c in  p re se n t in  th e  s a m p le s . R e s u lt s  w e re  
f in a l ly  re p o rted  a s  th e  a m o u n t o f  a d r ia m y c in  p e r  m il l io n  c e lls .
2.14 Quantification o f indomethacin efflux in DLKP cells
1 .  D L K P  c e l ls  w e r e  p re p a re d  a n d  tre a te d  a s  in  step s  1 - 3  in  se c t io n  2 . 1 3 .
2 .  W h e n  re q u ire d  fo r  H P L C  a n a ly s is , th e  fro z e n  p e lle ts  w e r e  th aw ed , 
re su sp e n d e d  in  lOOOpl U H P  a n d  a d d ed  to  g la s s  tu b e s  (test sam p le s).
3 . U n tre a te d  D L K P  c e l ls  w e r e  re su sp e n d e d  in  8 .5 m l U H P  and 9 0 0 p l 
a liq u o ts  o f  th is  w e re  p la c e d  in to  8 g la s s  tu b e s . T h e s e  w e re  the 
in d o m e th a c in  co n tro l tu b e s  a n d  w e r e  la b e lle d  a s  fo l lo w s : 8 p g/m l, 
4 p g / m l, 2 p g / m l, lp g / m l, 0 .5 p g / m l, O .lp g / m l, 0 .0 5 jig /m l, 0 p g /m l 
in d o m e th a c in .
4 . 10 0  p L  o f  th e a p p ro p ria te  in d o m e th a c in  d ilu tio n  ( lO x )  w a s  a d d e d  to the 
c o rre sp o n d in g  la b e lle d  in d o m e th a c in  co n tro l tu b e s .
5 . In to  a ll o f  th e  tu b e s  (test s a m p le s  an d  in d o m e th a c in  c o n tro l sa m p le s)  
th e  fo llo w in g  w a s  a d d ed : 1 0 0  p L  m e fe n a m ic  a c id  ( in tern a l stan d ard ) 
( lO p g /m l) , 5 0 0 p L  1 M  c itra te  b u f fe r  (p H  3 .0 ) , 7 m l d ich lo ro m e th a n e .
6 . A l l  tu b es  w e re  m ix e d  fo r  1 0  m in u te s  an d  w e r e  th e n  c e n tr ifu g e d  at
4 ,0 0 0  r .p .m  fo r  1 5  m in u te s.
7 . 1 . 1 m l w a s  re m o v e d  fro m  th e  d ic h lo ro m e th a n e  p h a se  (b o tto m  p h ase) 
an d  a d d e d  to  H P L C  a u to sa m p le r  v ia ls . T h e  v ia ls  w e r e  le ft  in  a  
fu m e h o o d  o v e r n ig h t  to  a l lo w  e v a p o ra t io n  o f  th e  so lv e n t .
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8 . T h e  re m a in in g  s o lid s  w e r e  re su sp e n d e d  in  5 0 p ,L  o f  H P L C  m o b ile  p h a se
9 . T h e  H P L C  m o b ile  p h a se  w a s  p re p a re d  a s  fo l lo w s :  2 0 0 m l o f  0 .0 2 M  
so d iu m  a c e ta te  w a s  a d d e d  to  a  H P L C  f la s k  a n d  th e  p H  w a s  a d ju ste d  to
3 .6  w ith  a c e t ic  a c id . A  v o lu m e  o f  8 0 0 m l m e th a n o l (L a b s c a n )  w a s  
a d d e d  f in a l ly  a n d  th e  c o m p le te d  m o b ile  p h a se  a llo w e d  to d e g a s  at 4 ° C  
o v e rn ig h t.
1 0 .  2 0  1 o f  sa m p le s  fo r  a n a ly s is  w e r e  a u to m a tic a lly  in je c te d  in to  th e H P L C  
s y s te m  ( B e c k m a n  S y s t e m  G o ld  5 0 7  a u to sa m p le r , 1 2 5  p u m p  an d  16 6  
d e tecto r). M o b i le  p h a se  f lo w  ra te  w a s  se t  at 1 m l  p e r  m in u te  w ith  a  to ta l 
ru n  t im e  o f  1 6  m in u te s . T h e  c o lu m n  u se d  fo r  H P L C  a n a ly s is  o f  
in d o m e th a c in  in  D L K P  w a s  a  C l  8 r e v e rs e d  p h a se  P r o d ig y  5 ¡am  p a rt ic le  
s iz e  O D S - 3  c o lu m n  (P h e n o m e n e x , U .K .) .  A b s o rb a n c e  w a s  m o n ito re d  
at 3 2 0 n m .
1 1 .  A  stan d ard  c u r v e  o f  in d o m e th a c in  p e a k  a re a /m e fe n a m ic  in te rn al 
stan d ard  p e a k  a r e a  v e r s u s  in d o m e th a c in  c o n c e n tra tio n  w a s  u se d  to  
q u a n t ify  th e  le v e ls  o f  in d o m e th a c in  p re se n t in  th e sa m p le s . R e s u lts  
w e r e  f in a l ly  re p o rte d  a s  th e  co n ten t o f  in d o m e th a c in  p e r  m ill io n  c e lls .
2.15 Preparation for RNA analysis.
D u e  to  th e  la b ile  n a tu re  o f  R N A  an d  th e  h ig h  a b u n d a n ce  o f  R N a s e  e n z y m e s  in  
th e  e n v iro n m e n t a  n u m b e r o f  p re c a u tio n a ry  ste p s  w e r e  fo llo w e d  w h e n  
a n a ly s in g  R N A  th ro u g h o u t th e c o u rse  o f  th e se  stu d ie s.
•  G e n e ra l la b o ra to ry  g la s s w a r e  and p la s t ic w a r e  a re  o fte n  co n ta m in a ted
b y  R N a s e s .  T o  re d u c e  th is  r is k , g la s s w a r e  u se d  in  th e se  stu d ie s  w e re  
b a k e d  a t 1 8 0 ° C  (a u to c la v in g  at 1 2 1 ° C  d o e s  n o t d e s tro y  R N a s e  
e n z y m e s)  fo r  at le a s t  8hr. S te r ile , d isp o sa b le  p la s t ic w a re  is  e s s e n t ia lly  
f r e e  o f  R N a s e s  a n d  w a s  th e re fo re  u se d  fo r  th e  p re p a ra t io n  an d  sto ra g e  
o f  R N A  w ith o u t  p re -trea tm e n t. P o ly a l lo m e r  u ltra c e n tr ifu g e  tu b es , 
e p p e n d o r f  tu b e s , p ip e tte  t ip s  e tc ., w e re  a ll a u to c la v e d  b e fo re  u se . A l l  
sp a tu la s  w h ic h  c a m e  in to  co n ta ct  w ith  a n y  o f  th e  so lu tio n  co m p o n en ts  
w e r e  b a k e d , c h e m ic a ls  w e r e  w e ig h e d  o u t o n to  b a k e d  a lu m in iu m -fo il
100
a n d  a  s to c k  o f  c h e m ic a ls  fo r  " R N A  a n a ly s is  o n ly "  w a s  k e p t  se p a ra te  
f r o m  a l l  o th e r  la b o ra to ry  a g en ts .
•  A l l  s o lu t io n s  (w h ic h  c o u ld  b e  a u to c la v e d )  th at c a m e  in to  co n ta c t  w ith  
R N A  w e r e  a l l  p re p a re d  fro m  s te r ile  u ltra -p u re  w a te r  an d  tre a te d  w ith
0 . 1 %  d ie th y l p y ro c a rb o n a te  ( D E P C )  (S ig m a , D 5 7 5 8 )  b e fo re  
a u to c la v in g  (a u to c la v in g  in a c t iv a te s  D E P C ) .
•  D is p o s a b le  g lo v e s  w e r e  w o r n  at a ll  t im e s  to  p ro te c t  b o th  th e  o p e ra to r  
an d  th e e x p e r im e n t (h a n d s a re  a n  a b u n d an t so u rc e  o f  R N a s e  e n z y m e s) . 
T h is  p re v e n ts  th e in tro d u c tio n  o f  R N a s e s  a n d  fo r e ig n  R N A / D N A  in  to  
th e  re a c t io n s . G lo v e s  w e re  c h a n g e d  fre q u e n tly .
•  A l l  p ro c e d u re s  w e re  c a rr ie d  o u t u n d e r  s te r i le  co n d it io n s  w h e n  fe a s ib le .
2.15.1 Total RNA extraction from cultures cell lines.
1 .  A d h e re n t  c e l ls  w e re  g r o w n  in  7 5 c m 2 f la s k s  u n til a p p ro x im a te ly  8 0 %
c o n flu e n t.
2 .  M e d ia  w a s  re m o v e d  a n d  1 m l  o f  T R I  re a g e n t p e r  7 5  c m 2 f la s k s  ( S ig m a , 
T - 9 4 2 4 )  w a s  a d d e d  to th e  f la s k  fo r  5 m in u te s  e n su r in g  th at a ll  c e l ls  are  
c o v e r e d  w ith  th e so lu tio n . T R I  re a g e n t is  a  m ix tu re  o f  g u a n id in e  
th io c y a n a te  and p h e n o l in  a  m o n o -p h a se  so lu tio n . I t  e f fe c t iv e ly  
d is s o lv e s  D N A , R N A ,  an d  p ro te in  on  ly s is  o f  c e l l  cu ltu re  sa m p le s . 
A f t e r  a d d it io n  o f  th e  re a g e n t, th e  c e l l  ly sa te  w a s  p a s se d  s e v e r a l  t im e s  
th ro u g h  a  p ip e tte  to  fo rm  a  h o m o g e n o u s  ly sa te .
3 .  T o  e n su re  c o m p le te  d isa s s o c ia t io n  o f  n u c le o p ro te in  c o m p le x e s , the 
sa m p le  w a s  a llo w e d  to  stan d  fo r  5 m in u te s  at ro o m  tem p era tu re .
4 . 0 .2 m l o f  c h lo ro fo rm  (n o t c o n ta in in g  is o a m y l a lc o h o l o r a n y  o th er
a d d it iv e )  p e r  m l o f  T R I  re a g e n t  w a s  a d d ed  to th e c e l l  ly sa te . T h e
s a m p le  w a s  c o v e r e d  t ig h t ly , sh a k e n  v ig o r o u s ly  fo r  1 5  se c o n d s  an d
a llo w e d  to stan d  fo r  2 - 1 5  m in u te s  at ro o m  tem p era tu re .
5 . T h e  re su lt in g  m ix tu re  w a s  c e n tr ifu g e d  at 1 2 ,0 0 0 g  fo r  1 5  m in u te s  at 
4 ° C .  C e n tr ifu g a t io n  se p a ra te d  th e m ix tu re  in to  3  p h a se s : an  o rg a n ic
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p h a se  (c o n ta in in g  p ro te in ), an  in te rp h a se  (c o n ta in in g  D N A )  an d  a  
c o lo u r le s s  u p p e r  a q u e o u s  p h a s e  (c o n ta in in g  R N A ) .
6 . T h e  a q u e o u s  p h a se  w a s  tra n s fe rre d  to  a  f r e s h  tu b e  a n d  0 .5 m l o f
is o p ro p a n o l p e r  m l o f  T R I  re a g e n t  u se d  in  sa m p le  p re p a ra tio n  an d  
m ix e d . T h e  sa m p le  w a s  a llo w e d  to  stan d  fo r  5 - 1 0  m in u te s  at ro o m  
te m p e ra tu re .
7 . T h e  sa m p le  w a s  th en  c e n tr ifu g e d  at 1 2 ,0 0 0 g  fo r  1 0  m in u te s  at 4 ° C .  T h e
R N A  p re c ip ita te  fo rm e d  a  p e lle t  o n  th e  s id e  a n d  th e  b o tto m  o f  th e  tu b e.
8 . T h e  su p ern atan t w a s  re m o v e d  a n d  th e  R N A  p e lle t  w a s  w a s h e d  b y
a d d in g  1 m l  (m in im u m ) o f  7 5 %  eth a n o l p e r  1 m l  o f  T R I  re ag en t. T h e  
s a m p le  w a s  v o r te x e d  an d  c e n tr ifu g e d  a t 7 ,5 0 0 g  fo r  5  m in u te s  a t 4 ° C .  
S a m p le s  c a n  b e  sto red  in  e th a n o l at 4 ° C  fo r  at le a s t  1  w e e k  an d  u p  to  
o n e  y e a r  a t - 2 0 ° C .
9. T h e  R N A  p e lle t  w a s  a ir -d r ie d  b r ie f ly . A p p r o x im a t e ly  5 0 ja l D E P C -
tre a te d  H 2O  w a s  a d d ed  to th e  p e lle t . T h e  R N A  w a s  th e n  sto re d  at - 8 0 ° C  
u n til re q u ire d  fo r  P C R  a n a ly s is .
2.15.2 RNA Quantitation
R N A  w a s  q u a n tifie d  sp e c tro p h o to m e tr ic a lly  at 2 6 0 n m  an d  2 8 0 n m . A n  o p tic a l 
d e n s ity  o f  1  a t 2 6 0 n m  is  e q u iv a le n t  to  4 0 m g /m l R N A .  A n  A 260/ A 280 ra tio  is  
u s e d  to  in d ic a te  th e  p u r ity  o f  th e  R N A .  P a r t ia l ly  s o lu b il is e d  R N A  h a s  a  ra tio  o f  
< 1 . 6  (A u s u b e l et a l ,  1 9 9 1 ) .  T h e  y ie ld  o f  R N A  fro m  m o st  l in e s  o f  cu ltu red  c e l ls  
is  10 0 -2 0 0 ( ig / 9 0 m m  p la te  (S a m b ro o k  et a l,  19 8 9 ) .
2.15.3 Reverse transcription of RNA isolated from cell lines
T h e  fo l lo w in g  c o m p o n e n ts  w e r e  u se d  in  th e r e v e r s e  tra n sc r ip ta se  ( R T )  re a c tio n  
fo r  R N A  is o la te d  fro m  c e l l  lin e s :
1 .  1  jal o l ig o  ( d T ) i2- i8 p r im e rs  ( l^ g / m l)  (p ro m e g a , C l  1 0 1 ) ,  l|_il o f  to ta l
R N A  ( 1  jog/m l), an d  3  p i  o f  D E P C - H 20  w e re  m ix e d  to g e th e r  an d  h ea ted
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at 7 0 ° C  fo r  1 0  m in  an d  th en  c h il le d  o n  ic e  to  r e m o v e  a n y  R N A  
se c o n d a ry  stru ctu re  fo rm a tio n  an d  a l lo w  o l ig o  (d T )  p r im e rs  to  b in d  to  
th e  p o ly  ( A ) + ta il  o n  th e  m R N A .
2 .  4 | i l  o f  a  5 X  b u ffe r  (c o n s is t in g  o f  2 5 0 m M  T R I S - H C L ,  p H  8 .3 ,  3 7 5 m M  
K C 1  a n d  1 5 m M  M g C fe ) , 2 ^ 1  o f  D T T  (lO O m M ), l j i l  o f  R N a s in  (40U /jo l) 
(P ro m e g a , N 2 5 1 1 ) ,  l ja l  o f  d N T P s  ( lO m M  e a c h  o f  d A T P , d C T P , d G T P  
a n d  d T T P ) , 6 (0,1 o f  w a te r  a n d  l ( i l  o f  M o lo n e y  m u rin e  le u k a e m ia  v iru s -  
r e v e r s e  tra n sc r ip ta se  ( M M L V - R T )  ( G ib c o ; 5 1 0 8 0 2 5  S A )  w a s  th en  
a d d e d  to  th e  h e a t-d e n a tu re d  R N A  c o m p le x  an d  th e  m ix tu re  w a s  
in c u b a te d  a t 3 7 ° C  fo r  1  h o u r  to  a l lo w  th e  M M L V - R T  e n z y m e  c a ta ly s e  
th e fo rm a tio n  o f  c D N A  o n  th e  m R N A  tem p late .
3 . T h e  e n z y m e  w a s  th en  in a c t iv a te d  a n d  th e  R N A  an d  c D N A  stra n d s 
se p a ra te d  b y  h e a tin g  to  9 5  ° C  fo r  2  m in . T h e  c D N A  w a s  u se d  
im m e d ia te ly  in  th e  P C R  re a c tio n  o r s to re d  at - 2 0 ° C  u n til re q u ire d  fo r  
a n a ly s is .
2.15.4 PCR analysis of cDNA formed from mRNA isolated from cell lines
T y p ic a l  P C R  re a c t io n s  w e re  se t  u p  a s  50fol v o lu m e s  u s in g  5(.il o f  c D N A  
fo rm e d  d u r in g  th e  R T  re a c t io n  (se e  se c t io n  2 . 1 7 . 2 ) .  c D N A  w a s  a m p lif ie d  fo r  
v a r y in g  c y c le  n u m b e rs  b u t, w h e re  p o s s ib le , a m p lif ic a t io n  w a s  c a rr ie d  o u t o n  
th e  e x p o n e n tia l p h a se  o f  a m p lific a t io n .
1 .  E a c h  P C R  re a c t io n  tu b e  c o n ta in e d  2 6 .5 ( i l  o f  w a te r , 5 ( il  1 0 X  b u f fe r  
( lO O m M  T R I S - H C L ,  p H  9 .0 , 5 0 m M  K C 1 ,  1 %  T r ito n  X - 1 0 0 ) ,  2\il 
2 5 m M  M g C b ,  1^-1 o f  f ir s t  stran d  ta rg e t  p r im e r  (250 n g /(o l), l(o l o f  
se c o n d  s tra n d  ta rg e t  p r im e r  (2 5 0 n g /| il) , 0 .5p ,l o f  f ir s t  stran d  e n d o g e n o u s  
c o n tro l p r im e r  (250 n g /|o l), a n d  0 .5 ( i l  o f  se c o n d  stran d  e n d o g e n o u s  
c o n tro l p r im e r  (250 n g /jo l) .
2 . 5 (0,1 o f  c D N A  (p re -h e a te d  to  9 5 ° C  fo r  3  m in . to se p a ra te  stra n d s an d  
re m o v e  a n y  se c o n d a ry  stru ctu re  i f  th e  sa m p le  h a d  b e e n  s to re d  a t - 2 0 ° C )
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w a s  a d d e d  to  th e  a b o v e  a n d  h e a te d  to  9 4 ° C  fo r  5 m in  (re d u c e s  n o n ­
s p e c i f ic  b in d in g  o f  p r im e rs  to  tem p late ).
3 . 8 (4.1 o f  1 .2 5 m M  d N T P  a n d  0.5(41 o f  T a q  D N A  P o ly m e r a s e  e n z y m e
(P ro m e g a , N 1 8 6 2 )  w a s  th en  a d d e d  to  th e a b o v e . T h e  c D N A  w a s  
a m p lif ie d  b y  P C R  u s in g  th e  fo llo w in g  p ro g ra m :
•  9 4 ° C  fo r  1 . 5  m in u te s  (d e n atu re  d o u b le  stra n d ed  D N A ) ;
•  1 5 - 3 5  c y c le s  9 4 ° C  fo r  1 . 5  m in . (d e n atu re  d o u b le  stra n d ed
D N A ) ;
4 2 - 6 2 ° C  *  fo r  1 m in . (an n e a l p r im e rs  to  c D N A )
7 2 ° C  fo r  3  m in  (e x te n s io n )
•  7 2 ° C  fo r  7  m in u te s  (e x te n s io n )
* A n n e a lin g  te m p e ra tu re s  f o r  M R P  p rim e rs  w e r e  as fo llo w s :
M R P 1 :  5 5 ° C ;
M R P 2  ( c M O A T ) : 5 3 ° C ;
M R P 3 :  6 3 ° C ;
M R P 4 : 4 2 °  C ;
M R P 5 :  4 9 ° C .
M R P 6 : 6 8 ° C .
4 . A l l  re a c t io n  tu b e s  w e r e  th e n  k e p t at 4 ° C  u n til a n a ly s e d  b y  g e l 
e le c tro p h o re s is  fo llo w e d  b y  d e n sito m e try .
5 . A  1 0 (4l  a liq u o t  o f  t ra c k in g  b u ffe r , c o n s is t in g  o f  0 .2 5 %  b ro m o p h e n o l
b lu e  ( S ig m a ; B 5 5 2 5 )  an d  3 0 %  g ly c e r o l  in  w a te r , w a s  a d d ed  to  ea ch  
tu b e  o f  a m p lif ie d  c D N A  p ro d u cts .
6 . 1 0 (4.1 o f  c D N A  p ro d u c ts  fro m  e a c h  tu b e w e r e  se p a ra te d  b y
e le c tro p h o re s is  fo r  a p p ro x . P /2 - 2  h o u rs  a t 1 0 0 V  th ro u g h  a  2 - 4 %
a g a r o s e  (P ro m e g a , V 3 1 2 2 )  g e l c o n ta in in g  e th id iu m  b ro m id e  (S ig m a ,
E 8 7 5 1 ) ,  u s in g  T B E  ( 2 2 .5 m M  T R I S - H C L ,  2 2 .5 m M  b o r ic  a c id  (S ig m a , 
B 7 9 0 1 ) ,  0 .5 m M  E D T A )  as ru n n in g  b u ffe r . M o le c u la r  w e ig h t  m a rk e rs  
"< |)-X 174 " H a e  I I I  d ig e s t  (P ro m e g a , G 1 7 6 1 )  w e re  ru n , s im u lta n e o u s ly  as 
s iz e  re fe re n c e .
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7 . T h e  re su lt in g  p ro d u c t b a n d s  w e r e  v is u a l is e d  a s  p in k  b a n d s  (d u e  to  
in te rc h e la tio n  o f  th e  c D N A  w ith  th e  e th id iu m  b ro m id e )  w h e n  th e g e ls  
w e r e  p la c e d  o n  a  tra n s illu m in a to r  ( U V P  T ra n s illu m in a to r) .
8 . T h e  g e ls  w e r e  p h o to g ra p h e d  a n d  th e n e g a t iv e s  p ro d u c e d  w e r e  a n a ly se d  
b y  d e n s ito m e try  ( Im a g in g  D e n s ito m e te r , B io - R a d . M o d e l  G S - 6 7 0 ) .
2.15.5 Densitometric analysis
D e n s ito m e tr ic  a n a ly s is  w a s  c a r r ie d  o u t u s in g  th e  M S  W in d o w s  3 . 1  c o m p a tib le  
M o le c u la r  A n a ly s t  so ftw a r e /P C  im a g e  a n a ly s is  so ftw a re  u s e d  w ith  th e 6 7 0  
Im a g in g  D e n s ito m e te r  ( B io - R a d . C A )  V e r s io n  1 . 3 .
N e g a t iv e s  o f  P C R  g e ls  w e r e  sc a n n e d  u s in g  tra n sm iss io n  l ig h t  a n d  th e  im a g e  
tra n s fe rre d  to  th e  co m p u te r . T h e  a m o u n t o f  lig h t  b lo c k e d  b y  th e D N A  b a n d  is  
in  d ire c t  p ro p o rtio n  to  th e  in te n s ity  o f  th e  D N A  p re sen t. A  s ta n d a rd  a re a  is  set 
w h ic h  is  sc a n n e d  an d  a  v a lu e  ta k e n  fo r  th e  O D  o f  c a c h  in d iv id u a l p ix e l  o n  th e 
sc re e n . T h e  a v e r a g e  v a lu e  o f  th is  O D  (w ith in  a  se t  a re a )  w a s  n o rm a lise d  fo r  
b a c k g ro u n d  o f  an  id e n tic a l se t  a rea . T h e  n o rm a lise d  re a d in g  w a s  ta k e n  a s  th e 
d e n s ito m e tr ic  v a lu e  u se d  in  a n a ly s is .
2.16 Statistical analysis.
A n a ly s is  o f  e x p e r im e n ts  in v e s t ig a t in g  p o s s ib le  s y n e r g y  b e tw e e n  c y to to x ic  
d ru g s  an d  c o m p o u n d s  su ch  a s  N S A I D s  w e re  p e r fo rm e d  in it ia l ly  u s in g  the 
fra c t io n a l p ro d u c t m e th o d . T h e  e q u a tio n  u s e d  w a s  a s  fo l lo w s :
Equation 2.16.1: F ra c t io n a l p ro d u c t eq u atio n .
( f u ) l , 2  =  ( f u ) l X ( f u ) 2
w h e r e : ( f  u) i ,2 =  E x p e c te d  fr a c t io n  u n a ffe c te d  b y  c o m b in in g  c o m p o u n d s  
1 an d  2
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( f  u ) i  =  A c tu a l  fra c t io n  u n a ffe c te d  b y  co m p o u n d  1 tre a tm e n t 
( f  u)2  =  A c tu a l  fra c t io n  u n a ffe c te d  b y  co m p o u n d  2  tre atm e n t
It  w a s  fo u n d  th a t ( f  u) i ,2 w a s  s ig n if ic a n t ly  g re a te r  th an  th e a c tu a l fra c t io n  
u n a ffe c te d  b y  c o m b in in g  c o m p o u n d s  1  a n d  2 , a  sy n e rg is t ic  le v e l  o f  c e l l  k i l l  
w a s  d e m o n stra te d . M u tu a l ly  e x c lu s iv e  d ru g s  sh a re  a  co m m o n  m e c h a n ism  o f  
a c tio n , su c h  a s  b in d in g  to  th e  sa m e  ta rg e t in  th e  c e ll. M u tu a lly  n o n -e x c lu s iv e  
d ru g s  h a v e  in d e p e n d e n t m e c h a n ism s  o f  a c tio n . T h e  fra c t io n a l p ro d u c t  m e th o d  
is  o n ly  th e o r e t ic a lly  a p p lic a b le  in  c a s e s  in v o lv in g  m u tu a lly  e x c lu s iv e  d ru g , an d  
so  w a s  o n ly  u s e d  a s  a  ra p id  a p p ro x im a t io n  to  in v e st ig a te  p o s s ib le  s y n e r g y  
b e tw e e n  d ru g s . F o r  th is  re a so n , re su lts  o b ta in e d  fro m  th e  a n a ly s is  o f  d ata  
u s in g  th e  fra c t io n a l m e th o d  w e r e  c o n firm e d  u s in g  a  co m p u te r  p a c k a g e  fo r  
m u lt ip le  d ru g  e f fe c t  a n a ly s is , “ D o s e - E f fe c t  A n a ly s is  w ith  M ic r o c o m p u te r s ” , 
(C h o u  a n d  C h o u , 1 9 8 7 ) .  T h e  p ro g ra m  p ro v id e s  co m b in a tio n  in d e x  ( C l)  v a lu e s  
w h ic h  a re  a  q u a n tita t iv e  s ta t is t ic a l m e a su re  o f  d ru g  in te ra c tio n  in  te rm s o f  an  
a d d it iv e  ( C l  = 1 ) ,  s y n e rg is t ic  ( C l  <  1 )  o r  a n ta g o n is tic  ( C l  > 1 )  e f fe c t  fo r  a  
g iv e n  e n d p o in t o f  th e  a s s a y  u se d , a d a p te d  fro m  C h o u  et ah, ( 1 9 8 3 ) .
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Results
S e v e r a l  n o n s te ro id a l a n t i- in fla m m a to ry  d ru g s , N S A I D s ,  h a v e  b e e n  re p o rte d  b y  
a  n u m b e r  o f  a u th o rs , in c lu d in g  D u f f y  e t al., ( 19 9 8 ) ,  D ra p e r  e t ah, ( 1 9 9 7 )  an d  
K o b a y a s h i  e t ah, ( 1 9 9 7 ) ,  to  h a v e  th e  a b il ity  to  e n h a n c e  th e  c y to to x ic ity  o f  a n ti­
c a n c e r  d r u g s  in vitro  w h e n  c o -a d m in is te re d  to  a  m u lt i-d ru g  re s is ta n t  c e l l  lin e  
w h ic h  o v e r e x p r e s s e s  M R P  ( S e e  se c t io n  1 .9 ) .
A n  in s p e c t io n  o f  th e  s c ie n t if ic  lite ra tu re  in d ic a te d  th at m o re  re se a r c h  h a d  b e e n  
c a r r ie d  o u t o n  in d o m e th a c in  th an  o n  a n y  o f  th e  o th e r N S A I D s ,  th u s it  w a s  
c h o s e n  a s  th e  le a d  ca n d id a te  fo r  fu rth e r  in v e s t ig a t io n  (se e  stru ctu re  p a g e  2 7 9 ) . 
T o  d e te rm in e  th e  S A R  (S tru c tu re  A c t iv i t y  R e la t io n s h ip )  o f  in d o m e th a c in , th e 
stru ctu re  o f  in d o m e th a c in  w a s  v a r ie d  to  g e n e ra te  a  n u m b e r o f  a n a lo g u e s  o f  th is  
N S A I D .  T h e s e  a n a lo g u e s  w e r e  su b se q u e n tly  a n a ly s e d  in  a  n u m b er o f  
e x p e r im e n ts  a n d  th e ir  a c t iv it ie s  w e r e  c o m p a re d  to  th a t o f  in d o m e th a c in  so  th at 
th e im p o rta n c e  o f  th e  v a r io u s  in d o m e th a c in  su b stitu e n ts  c o u ld  b e  d e term in ed . 
Note: T h e  c h e m ic a l  p ro p e rtie s  o f  th e  in d o m e th a c in  a n a lo g u e s  w e r e  th o ro u g h ly  
e x a m in e d  in  th e  a n a ly t ic a l  la b o ra to ry  in  U C C , a s  d e sc r ib e d  in  A p p e n d ix  D , 
p r io r  to  a n y  b io lo g ic a l  te s t in g  in  o u r  la b o ra to r ie s .
In vitro  te s t in g  w a s  c a rr ie d  ou t, in  th e  N C T C C ,  o n  2 3  in d o m e th a c in  a n a lo g u e s  
s y n th e s ise d  b y  D r . A n ita  M c G u ir e  a n d  D r . S te p h e n  P lu n k e tt  in  th e  C h e m istry  
d e p a rtm en t, U n iv e r s ity  C o lle g e  C o rk . 1 9  o f  th e se  c o m p o u n d s  w e r e  stru ctu ra l 
v a r ia t io n s  o f  in d o m e th a c in  an d  th e  re m a in in g  fo u r  c o m p o u n d s  w e r e  k n o w n  
P L A 2 in h ib ito rs  w ith  stru ctu res s im ila r  to  th at o f  in d o m e th a c in .
A  n u m b e r  o f  a s s a y s  w e r e  c a rr ie d  o u t o n  e a c h  o f  th e  in d o m e th a c in  a n a lo g u e s  to 
t ry  to  d e te rm in e  th e ir  S A R .  In d o m e th a c in  w a s  fo u n d  to  h a v e  th e  a b ility  to  
p o te n tia te  th e  t o x ic it y  o f  a d r ia m y c in , s p e c i f ic a l ly  in  c e l l  l in e s  e x p re s s in g  th e 
M u lt id ru g  R e s is ta n c e  P ro te in  ( M R P )  ( D u f fy  et al., 19 9 8 ) . C o m b in a tio n  
t o x ic it y  a s s a y s  w e r e  f ir s t ly  u t il is e d  to  g iv e  an  in d ic a t io n  a s  to  th e a b il ity  o f  a n y  
o f  th e  in d o m e th a c in  a n a lo g u e s  to  p o te n tia te  th e  to x ic it y  o f  a d r ia m y c in  in  o u r 
m in ia tu r ise d  in vitro  to x ic ity  a s s a y  a s  d e sc r ib e d  in  se c t io n  ( 2 .7 ) .  T o  fu rth e r 
in v e s t ig a te  th e  S A R  o f  in d o m e th a c in  an d  in d o m e th a c in  a n a lo g u e s  G S T  
(G lu ta th io n e  S -tra n s fe r a s e )  a s s a y s  w e r e  c a rr ie d  ou t, a c c o rd in g  to  s e c t io n  2 . 1 2 .  
1 0 V  ( In s id e  O u t V e s ic le )  a s s a y s  w e r e  su b se q u e n tly  c a rr ie d  o u t to  d e te rm in e  i f  
th e in d o m e th a c in  a n a lo g u e s  w e r e  c a p a b le  o f  in h ib it in g  th e  tra n sp o rt o f  th e 
M R P  su b stra te , L T C 4 . A s  D u f f y  et ah, ( 19 9 8 ) ,  h a v e  sh o w n  th at in d o m e th a c in
1 0 8
in h ib its  th e  tra n sp o rt  o f  th is  M R P  su b stra te  in  1 0 V s ,  th is  e x p e r im e n t w a s  
c a rr ie d  o u t to  a s s e s s  i f  s tru ctu ra l c h a n g e s  to  in d o m e th a c in  re d u c e d  th e a b il it y  
o f  th is  N S A I D  to in h ib it  L T C 4 tran sp o rt. C O X - 1  an d  C O X - 2  a s s a y s  w e re  
p e r fo rm e d  to a s s e s s  i f  th e  stru ctu ra l c h a n g e s  a lso  m o d ifie d  th e  a b il ity  o f  
in d o m e th a c in  to  in h ib it  th e  a c t iv ity  o f  th e se  c y c lo o x y g e n a s e  e n z y m e s.
3.1 Combination in vitro toxicity assays with adriamycin and 
indomethacin analogues.
In  th e se  p re lim in a ry  a s s a y s  th e  D L K P  c e l l  l in e  w a s  u se d . D L K P  is  a  h u m a n  
lu n g  c a rc in o m a  c e l l  lin e  w h ic h  e x p r e s s e s  M R P 1  an d  w a s  e s ta b lish e d  in  the 
N C T C C  ( L a w  e t al., 19 9 2 ) .  T h e  a n ti-c a n c e r  d ru g  u se d  in  th e se  a s s a y s  w a s  
a d r ia m y c in  (d o x o ru b ic in ) , a  w id e ly  u se d  c h e m o th e ra p e u tic  a g e n t, an d  
in d o m e th a c in  w a s  u s e d  a s  a  p o s it iv e  s y n e r g y  c o n tro l. T h e  a s s a y s  w e r e  c a rr ie d  
o u t in  tr ip lic a te . P r io r  to  c a r ry in g  o u t th e  c o m b in a tio n  to x ic ity  a s s a y s , e a c h  o f  
th e  in d o m e th a c in  a n a lo g u e s  w e r e  a n a ly s e d  in  t o x ic it y  a s s a y s , a c c o r d in g  to  the 
p ro c e d u re  d e s c r ib e d  in  se c tio n  2 . 7 . 1 a ,  to  a s s e s s  th e  h ig h e s t  n o n -to x ic  
co n c e n tra tio n s  o f  e a c h  o f  th e se  c o m p o u n d s . T h e  h ig h e st  n o n -to x ic  
c o n c e n tra tio n  fo r  in d o m e th a c in  a n d  th e  in d o m e th a c in  a n a lo g u e s  a re  l is te d  in  
ta b le  3 . 1 . 1 .
S in c e  th e  s c re e n in g  re su lts  are  d a ta - in te n s iv e  an d  re p e tit iv e , I w i l l  start w ith  a 
s u m m a ry  o f  th e  re su lts . T h e  d a ta  su p p o rtin g  th e  su m m a ry  fo llo w s .
D a ta  o b ta in e d  fr o m  th is  te stin g  in d ic a te d  th at n in e  o f  th e  in d o m e th a c in  
a n a lo g u e s , B R I  6 0 / 1 ,  8 8 / 1 ,  9 2 / 1 ,  10 4 / 2 , 1 1 4 / 2 ,  1 1 5 / 2 ,  1 5 3 / 1 ,  1 3 8 / 1  an d  2 0 3 / 1 ,  
w e r e  a ls o  c a p a b le  o f  in c re a s in g  th e  t o x ic i t y  o f  a d r ia m y c in . It  w a s  p o stu la te d  
th at in d o m e th a c in  an d  th e p o s it iv e  a n a lo g u e s  p o ten tia te d  th e to x ic it y  o f  
a d r ia m y c in  in  th e  c a n c e r  c e l l  b y  in h ib it in g  th e  a c t io n  o f  th e M R P  p u m p  in  the 
c e l l  a n d , in  so  d o in g , d e c re a s in g  th e  le v e l  o f  ch e m o th e ra p e u tic  d ru g  b e in g  
p u m p e d  ou t o f  th e  c e ll. A n  e n h a n c e m e n t o f  ch e m o th e ra p e u tic  d ru g  to x ic ity , 
c a u se d  a s  a  d ire c t  re su lt  o f  th e p re s e n c e  o f  an  N S A I D , w a s  re g a rd e d  as 
s ig n if ic a n t  i f  th e  le v e l  o f  c e l l  k i l l  a c h ie v e d  b y  th e c o m b in a tio n  w a s  
s ig n if ic a n t ly  g re a te r  th an  th e  p ro d u c t o f  th e  in d iv id u a l to x ic ity  o f  the d ru g  an d  
N S A I D  a s  a s s e s s e d  b y  C h o u  an d  T a la la y  a n a ly s is  (C h o u  et al., 19 8 3 ) .
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•  T h e  f ir s t  se t  o f  in d o m e th a c in  a n a lo g u e s  a n a ly s e d  w e r e  B R I  1 3 / 1 ,  B R I  
1 5 / 1 ,  B R I  1 7 / 1  a n d  B R I  1 8 / 1  (F ig u re s  3 . 1 . 1 - 3 . 1 . 4 ) .  T h e s e  w e r e  a n a lo g u e s  
o f  in d o m e th a c in  re ta in in g  th e  in d o le a c e t ic  a c id  stru ctu re  b u t w ith  
su b stitu e n t v a r ia t io n  to  e s ta b lis h  S A R .  T h e  m e th o x y  a n d  th e m e th y l 
g ro u p s , p re se n t  in  in d o m e th a c in , w e re  re m o v e d  fro m  a ll  fo u r  c o m p o u n d s  
a n d  th e  p a r a - s u b s t itu e n t  w a s  v a r ie d  in  B R I  1 5 / 1 ,  1 7 / 1  an d  1 8 / 1 .  T h e s e  
w e r e  s u b s e q u e n t ly  te s te d  in  th e  c o m b in a tio n  to x ic ity  a s s a y , a s  d e sc r ib e d  
p r e v io u s ly ,  a n d  w e r e  n o t fo u n d  to  p o ten tia te  th e  t o x ic it y  o f  a d r ia m y c in .
Figure 3.1.1: BR113/1
l-B en zy lin d o le -3 -a c e tic  a c id
Figure 3.1.2: BRI 15/1
1 -(4 -B rom oben zyl) indole—3 -a ce tic  ac id
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l-(4 -C h loroben zy l)in do le-3 --ace tic  ac id
Figure 3.1.3:BRI 17/1
Figure 3.1.4: B R I18/1
l-(4~M ethoxybenzyl) in d o le -3 -a ce tic  ac id
•  T h e  se c o n d  se t  o f  in d o m e th a c in  a n a lo g u e s , B R I  6 0 / 1 ,  B R I  5 9 / 1  an d  B R I  
6 9 /2  w e r e  a n a lo g u e s  o f  in d o m e th ac in  w ith  v a r ie d  su b stitu e n ts . T h e  re su lts  
fo r  th e se  c o m p o u n d s  a re  p re se n te d  in  T a b le  3 . 1 . 2 .  T h e  re su lts  sh o w e d  th at 
o n ly  B R I  6 0 / 1 ,  a  N -b e n z y l  a n a lo g u e  ( f ig u re  3 . 1 . 5 ) ,  w a s  p o s it iv e  in  the 
c o m b in a tio n  a s s a y . T h is  w a s  an  in te re stin g  re su lt  a s  it  sh o w e d  that th e 
c a rb o n y l g ro u p  w a s  n o t n e e d e d  fo r  th e  s y n e r g is t ic  e f fe c t  o f  th e  c o m p o u n d  
to  b e  m a n ife s te d . In d o m e th a c in  w a s  tre ate d  w ith  d ic y c lo h e x lc a r b o d iim id e  
( D C C ) ,  a  w e l l  k n o w n  c o u p lin g  re a g e n t w id e ly  u s e d  fo r  th e  p re p a ra tio n  o f  
e s te rs  an d  a m id e s  f ro m  c a r b o x y l ic  a c id s  to  g e n e ra te  tw o  in d o m e th a c in
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a n a lo g u e s , B R I  5 9 / 1  ( 3 . 1 .6 )  a n d  B R I  6 9 /2  ( 3 . 1 . 7 ) .  T h e s e  a n a lo g u e s  (N - 
b e n z o y l  a n a lo g u e s  w ith  a lte re d  a c e t ic  a c id  s id e  c h a in s)  w e r e  le s s  so lu b le  
th a n  B R I  6 0 / 1  a n d  w e r e  n e g a t iv e  in  th e  c o m b in a tio n  t o x ic it y  a s s a y . B R I  
6 9 /2  w a s  m o re  t o x ic  to  th e  D L K P  c e l ls  th an  B R I  5 9 / 1  a n d  B R I  6 0 / 1  at 
s im ila r  co n c e n tra tio n s .
Figure 3.1.5: BRI 60/1
l —(4-C hlorobenzyl)—5—m ethoxy—2-m ethylindole—3 -a ce tic  acid
Figure 3.1.6: BRI 59/1
M ethyl l-(4 -ch lo ro b en zo y l)—5—methoxy—2—m ethylindole—3-aceta te
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Figure 3.1.7: BRI 69/2
M ethyl l —(4 -chlorobenzoyl) - 5 -  m ethoxy-2 -  m ethylindole—3- acetate
•  T h e  th ird  se t o f  a n a lo g u e s  a n a ly s e d  w e r e  N -b e n z o y l in d o m eth ac in  
a n a lo g u e s , B R I  8 8 / 1 ,  B R I  9 2 / 1  an d  B R I  10 4 / 2 . T h e s e  a n a lo g u e s  o f  
in d o m e th a c in  w e r e  g e n e ra te d  to  in v e s t ig a te  th e  e f fe c t  o f  th e  a ry l 
su b stitu tio n  in  th e  a c t iv ity  o f  th e  b e n z o y l d e r iv a t iv e s  o f  in d o m e th ac in . T h e  
h ig h e s t  n o n -to x ic  c o n c e n tra tio n  o f  e a c h  co m p o u n d  u se d  w a s  5(j,g/m l. 
C h lo r in e  w a s  re m o v e d  fr o m  th e in d o m e th a c in  stru ctu re  to  fo rm  B R I  8 8 /1 
( F ig u r e  3 . 1 .8 ) .  T h e  c h lo r in e  su b stitu e n t o n  th e in d o m e th a c in  m o le c u le  w a s  
re p la c e d  w ith  a n o th er h a lo g e n , b ro m in e , to  fo r m  B R I  9 2 / 1  ( F ig u r e  3 . 1 .9 ) ,  
a n d  th e m e th o x y  g ro u p  w a s  re m o v e d  fro m  th e in d o m e th a c in  stru ctu re  to 
g e n e ra te  B R I  10 4 / 2  ( F ig u r e  3 . 1 . 1 0 ) .  In  th e c o m b in a tio n  to x ic ity  a s s a y  
(T a b le  3 . 1 . 3 )  a ll  th ree  w e r e  p o s it iv e , su g g e s t in g  th at th e su b stitu tio n  o f  th e  
c h lo r in e  w ith  b ro m in e , r e m o v a l  o f  th e  c h lo r in e  o r  re m o v a l o f  th e  m e th o x y  
g ro u p  d id  n o t a d v e r s e ly  e f fe c t  th e  e f f ic a c y  o f  th e  co m p o u n d s . (N o te : it 
a p p e a rs  th at c o m p o u n d s  w ith  th e h a lo g e n  o r m e th o x y  g ro u p  re m o v e d  are  
p o s it iv e  in  th e  c o m b in a tio n  a s s a y  o n ly  w h e n  c a rb o n y l g ro u p  is  p resen t).
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Figure 3.1.8: BRI 88/1
1 -Benzoyl-5-m ethoxy-2-m ethylindole-3-acetic ac id
Figure 3.1.9: BRI 92/1
l-(4-B rom obenzoyl)-5-m ethoxy-2-m ethylindole-3-acetic ac id
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Figure 3.1.10: B R I104/2
l —(4 -Chlorobenzoyl)—2—m ethylindole-3  -acetic ac id
•  T h e  fo u rth  se t o f  in d o m e th a c in  a n a lo g u e s  a n a ly s e d  w e r e  B R I  1 0 6 / 1 ,  B R I  
1 0 7 / 1 ,  B R I  1 1 3 / 1 ,  B R I  1 1 4 / 2 ,  B R I  1 1 5 / 2  an d  1 2 4 / 1 ,  N -b e n z y l  a n a lo g u e s  
o f  in d o m e th a c in . T h e s e  in d o m e th a c in  a n a lo g u e s  w e r e  d e v e lo p e d  to 
in v e s t ig a te  th e  sy s te m a t ic  v a r ia t io n  o f  th e p o s it io n  a n d  th e  n atu re  o f  th e 
b e n z e n e  r in g  su b stitu e n t in  b e n z y l d e r iv a t iv e s  o f  in d o m e th a c in . C h lo r in e  is  
in  th e  / ;a r a -p o s it io n  o n  th e b e n z en e  r in g  o f  th e  in d o m e th a c in  stru ctu re . 
T h is  c h lo r in e  w a s  m o v e d  to  e ith e r th e  m eta- o r  th e  o ri/zo -p o sitio n  ( B R I  
1 0 6 / 1  (F ig u r e  3 . 1 . 1 1 )  a n d  B R I  1 0 7 / 1  (F ig u re  3 . 1 . 1 2 )  r e sp e c t iv e ly ) . T h e  
n a tu re  o f  th e  su b stitu e n t a t th e / ? a ra -p o s it io n  w a s  a lso  v a r ie d  in  th e N -  
b e n z y l- in d o m e th a c in  a n a lo g u e s . In  B R I  1 1 3 / 1  ( F ig u r e  3 . 1 . 1 5 )  the 
su b stitu e n t in  th e  /> a ra -p o s it io n  w a s  re m o v e d  c o m p le te ly . A n a lo g u e s  o f  
in d o m e th a c in  w e r e  d e v e lo p e d  so  th at th e  c h lo r in e  w a s  re p la c e d  w ith  
b ro m in e  ( B R I  1 1 4 / 2 ,  F ig u r e  3 . 1 . 1 3 ) ,  w ith  f lu o r in e  ( B R I  1 1 5 / 2 ,  F ig u re  
3 . 1 . 1 4 )  a n d  w ith  a  m e th y lth io  su b stitu en t ( B R I  1 2 4 / 1 ,  F ig u r e  3 . 1 . 1 6 ) .  T w o  
o f  th e se  c o m p o u n d s , B R I  1 1 4 / 2 ,  an d  B R I  1 1 5 / 2 ,  w e r e  p o s it iv e  in  th e 
c o m b in a tio n  a s s a y  (T a b le  3 . 1 .4 ) .  T h e  h ig h e s t  n o n -to x ic  c o n c e n tra tio n  fo r  
th e se  tw o  c o m p o u n d s  w a s  10 |x g /m l. B R I  1 1 4 / 2  w a s  le s s  so lu b le  in  D M S O  
th an  B R I  1 1 5 / 2 .  F r o m  th e se  re su lts  w e  ca n  a ssu m e  th at th e  ¿> a ra -p o s itio n
o f  th e  h a lo g e n  is  im p o rta n t, a s  c o m p o u n d s  B R I  1 0 6 / 1  a n d  B R I  1 0 7 / 1 ,  w ith  
th e  h a lo g e n  in  th e  m et a  a n d  ortho  p o s it io n s  re s p e c t iv e ly , w e re  b o th  
n e g a t iv e .
Figure 3.1.11: BRI 106/1
l-(3-C hlorobenzyl)-5-m ethoxy-2-m ethylindole-3-acetic ac id
Cl
Figure 3.1.12-.BRI 107/1
l-(2-C hlorobenzyl)-5-m ethoxy-2-m ethylindole-3-acetic ac id
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Figure 3.1.13 BRI 114/2
l-(4-B rom obenzyl)-5-m ethoxy-2-m ethylindole-3-acetic a c id
F
Figure 3.1.14 BRI 115/2
l-(4-F luorobenzyl)-5~m ethoxy-2-m ethylindole-3-acetic ac id
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Figure 3.1.15: BRI 113/1
1 -B e n z y l-5 -m e th o x y -2 -m e th y lin d o le -3 -a c e t ic  a c id
Figure 3.1.16: BRI 124/1
l- (4 -M e th y llh io b e n z y l) -5 -m e th o x y -2 -m e th y lin d o le -3 -a c e t ic  a c id
•  T h e  p o s it io n  o f  th e flu o r in e  su b stitu e n t in  th e f lu o ro b e n z y l- in d o m e th a c in , 
B R I  1 1 5 / 2 ,  w a s  th en  v a r ie d  to a s s e s s  th e e f fe c t  o f  c h a n g in g  the p o s itio n  o f  
th e  f lu o r in e  fro m  th e / ja r a -p o s it io n  o n  th e b e n z e n e  rin g . T h is  re su lte d  in 
th e d e v e lo p m e n t  o f  B R I  1 3 8 / 1  ( f ig u re  3 . 1 . 1 7 ) .  P re v io u s  re su lts  fro m
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c o m b in a tio n  t o x ic it y  a s s a y s  u s in g  me (a- a n d  ortho- fo rm s  o f  th e  
in d o m e th a c in  a n a lo g u e s  w e r e  n e g a t iv e  a n d  it s e e m e d  th at th e  p a ra -  fo rm  
o f  th e  c o m p o u n d s  w a s  re q u ire d  to  e n h a n c e  th e  t o x ic it y  o f  th e  
ch e m o th e ra p e u tic  d ru g s . H o w e v e r , 1 3 8 / 1  p r o v e d  to  h a v e  a lm o st  a s  s tro n g  
a n  a b il ity  to  p o te n tia te  th e  t o x ic it y  o f  a d r ia m y c in  a s  its  p a ra -  co u n te rp art, 
1 1 5 / 2  ( T a b le  3 . 1 . 8 ) .  1 3 8 / 1  w a s  le s s  t o x ic  in  th e  c e l ls  a s  its  h ig h e s t  n o n ­
t o x ic  c o n c e n tra t io n  in  D L K P  c e l ls  w a s  1 5  jag/m l a s  o p p o se d  to  1 0  |o.g/ml 
fo r  B R I  1 1 5 / 2 .
Figure 3.1.17: BRI 138/1
l - ( 3 —F luorobenzyl)—5—methoxy—2—m ethylindole—3—acetic ac id
•  T h e  c h a ra c te r isa t io n  o f  N -b e n z y l- in d o m e th a c in  w a s  co n tin u e d  w ith  th e 
d e v e lo p m e n t o f  B R I  1 1 9 / 1  ( fig u re  3 . 1 . 1 8 )  in  w h ic h  th e  m e th o x y  
su b stitu e n t w a s  re m o v e d  to  a s s e s s  th e  e f fe c t  o f  r e m o v in g  b o th  th e  b e n z o y l 
u n it  an d  th e  m e th o x y  su b stitu e n t o n  th e a c t iv ity  o f  in d o m e th a c in . T o  a s s e ss  
th e  e f fe c t  o f  r e m o v in g  b o th  th e  b e n z o y l u n it  a n d  th e  m e th y l g ro u p  o n  
in d o m e th a c in  a c t iv ity , B R I  1 2 0 / 1  (F ig u r e  3 . 1 . 1 9 )  w a s  g e n e ra te d . T h e s e  
tw o  in d o m e th a c in  a n a lo g u e s  w e re  fo u n d  to b e  u n a b le  to  p o te n tia te  th e  
t o x ic ity  o f  a d r ia m y c in  in  th e  c o m b in a tio n  to x ic ity  a s s a y . T h e  re su lts  are  
p re se n te d  in  T a b le  3 . 1 . 5 .
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Figure 3.1.18 BRI 119/1
l - ( 4 - C h l o r o b e n z y l ) - 2 - m e t h y l ì n d o l e - 3 - a c e t i c  a c i d
Figure 3.1.18 BRI 120/1
I - ( 4 - C h l o r o b e n z y l ) - 5 - m e t h o x y i n d o l e - 3 - a c e t i c  a c i d
A s  in d o m e th a c in  is  a  w e l l  k n o w n  P L A 2 in h ib ito r  ( K a p la n  e t al., 19 7 8 ) ,  th e  
n e x t  co m p o u n d  to  b e  a n a ly se d , B R I  1 5 3 / 1 ,  (4 - [ [3 -a m id o m e th y l) -2 -e th y l- l-  
( p h e n y lm e th y l) - l- in d o l-5 -y l]o x y ]b u ta n o ic  a c id ), w a s  b a se d  o n  th e  
s tru ctu re s  o f  k n o w n  P L A 2 in h ib ito rs  d e v e lo p e d  b y  F le is c h  e t al., ( 19 9 6 ) ,  
an d  M ih e lic h  e t al., ( 19 9 7 ) ,  ( fig u re  3 . 1 . 2 0 ) .  T h is  co m p o u n d  w a s  
s tru c tu ra lly  s im ila r  to  in d o m eth ac in . I t  w a s  d e v e lo p e d  to  in v e s t ig a te  i f  a  
k n o w n  P L A 2 in h ib ito r  co u ld  p o ten tiate  th e to x ic ity  o f  c y to to x ic  d ru g s  in  a  
m a n n e r  s im ila r  to  in d o m e th ac in  i.e . a s w e l l  a s  h a v in g  th e  a b ility  to  in h ib it
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P L A 2 w o u ld  B R I  1 5 3 / 1  a ls o  h a v e  th e  a b il it y  to  in h ib it/in te rac t w ith  
M R P 1 ?  A t  50(j,g/m l B R I  1 5 3 / 1  d e m o n stra te d  s im ila r  p o te n tia tio n  a b ility  
to  in d o m e th a c in  a t 2.5(o,g/m l.
Figure 1.3.20 BRI 153/1
4-[[3-(am idom ethyl)-2-ethyl-l-(phenylm ethyl)-l H -indol-5-yl]  
oxyjbu ianoic acid
•  B R I  2 0 3 / 1  ( f ig u re  3 . 1 . 2 1 )  w a s  su b se q u e n tly  d e v e lo p e d , an d  w a s  s im ila r  to  
B R I  1 5 3 / 1  e x c e p t , in  B R I  2 0 3 / 1  a  m e th y l su b stitu e n t re p la c e d  th e  e th y l 
su b stitu e n t in  B R I  1 5 3 / 1  ( fig u re  3 . 1 . 2 1 ) .  T h e s e  P L A 2 in h ib ito rs  w e re  N -  
b e n z y l-2 - (m )e th y lin d o le -3 -a c e ta m id e s  fu n c t io n a lis e d  a t th e  5 -p o s it io n  w ith  
a  sh o rt-c h a in  a lk o x y  u n it  te rm in a ted  b y  a  c a r b o x y l ic  a c id . B R I  2 0 3 / 1  w a s  
p o s it iv e  in  th e  c o m b in a tio n  to x ic ity  a s s a y  a n d  its  h ig h e s t  n o n -to x ic  
c o n c e n tra tio n  in  D L K P  c e l ls  w a s  20(j.g/m l.
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conh2
C 0 2!
c h 3
Figure 3.1.21 BR I203/1
4-[[3-(am idom ethyl)-2-m ethyl-l-(phenylm ethyl)-l H -indol-5-yl]  
oxyjbu tanoic acid
•  B R I  2 0 5 / 4  ( F ig u r e  3 . 1 . 2 2 )  an d  B R I  2 1 5 / 1  (F ig u re  3 . 1 . 2 3 )  w e r e  th en  
d e v e lo p e d , th e  s tru ctu re s  o f  w h ic h  a re  a lso  b a se d  o n  th e  stru ctu re  o f  B R I  
1 5 3 / 1 .  T h e s e  c o m p o u n d s  w e r e  a lso  N -b e n z y l-2 - (m )e th y lin d o le -3 -  
a c e ta m id e s  fu n c t io n a lise d  a t th e  5 -p o s it io n  b u t th e  sh o rt-c h a in  a lk o x y  u n it 
w a s  te rm in a te d  b y  a  p h o sp h o n ic  a c id  re s id u e  in ste a d  o f  a  c a r b o x y l ic  a c id  
re s id u e . B R I  2 0 5 / 4  an d  B R I  2 1 5 / 1  a re  s tru c tu ra lly  id e n tic a l e x c e p t  th e 
m e th y l su b stitu e n t in  2 0 5 / 4  is  re p la c e d  w ith  a n  e th y l su b stitu e n t in  2 1 5 / 1  
a n d  th e  s tru ctu re s  o f  w h ic h  a re  s im ila r  to th e  b a c k b o n e  stru ctu re  o f  
in d o m e th a c in . H o w e v e r , B R I  2 0 5 / 4 , at its h ig h e s t  n o n -to x ic  co n c e n tra tio n  
o f  2 5 jo g /m l, an d  B R I  2 1 5 / 1 ,  at its  h ig h e s t  n o n -to x ic  c o n c e n tra tio n  o f  
50|i.g/m l, d id  n o t p o ten tia te  th e  t o x ic it y  o f  a d r ia m y c in  in  th e  co m b in a tio n  
to x ic it y  a s s a y s  (T a b le  3 . 1 . 7 ) .
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Figure 3.1.22: BRI 205/4
[3-[[3-(am idom ethyl)-2-m ethyl-l-(phenylm ethyl)-indol-5-yl]oxy]  
propylJphosphon ic a c id
c o n h 2
Figure 3.1.23: BRI 215/1
[3-[[3-(am idom ethyl)-2-ethyl-l-(phenylm ethyl)-indol-5-yl] 
oxyjphosphonic a c id
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T h e  re su lts  o f  th e  c o m b in a tio n  t o x ic it y  a s s a y s  in d ic a te  th at a lth o u g h  th ere  
a re  a  n u m b e r  o f  in d o m e th a c in  a n a lo g u e s  th at a re  c a p a b le  o f  p o te n tia tin g  
th e  t o x ic i t y  o f  a d r ia m y c in  in vitro , th e  p o ten tia tio n  a b il ity  o f  m o st  o f  th e se  
c o m p o u n d s  a re  o n ly  c o m p a ra b le  to  in d o m e th a c in  at h ig h e r  co n c e n tra tio n s  
th an  th o se  u s e d  fo r  in d o m e th a c in  (T a b le  3 . 1 .9 ) .  T h e  h ig h e s t  n o n -to x ic  
c o n c e n tra tio n  o f  in d o m e th a c in  w a s  2 .5p .g /m l. O n ly  s i x  o f  th e  p o s it iv e  
in d o m e th a c in  a n a lo g u e s  w e r e  a n a ly s e d  at th is  c o n c e n tra tio n  
(c o n c e n tra tio n s  g re a te r  th an  2 . 5 jag/m l w e r e  re q u ire d  fo r  B R I  1 3 8 / 1 ,  1 5 3 / 1  
a n d  2 0 3 / 1  fo r  a  p o te n tia tio n  e f fe c t  to  b e  e v id e n t) . C o m p a r in g  the 
c o m b in a tio n  in d e x  v a lu e s  fo r  in d o m e th a c in  an d  in d o m e ta h c in  a n a lo g u e s  at 
2 .5 [x g /m l in d ic a te d  th at o f  th e  n in e  p o s it iv e  in d o m e th a c in  a n a lo g u e s , B R I  
10 4 / 2 , 9 2 / 1  a n d  1 1 4 / 2  h a d  s im ila r  p o te n tia tio n  a b il ity  to  in d o m e th a c in  ( i.e . 
e q u iv a le n t  e f fe c t  at th e  sa m e  co n c e n tra tio n ).
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Compound ( ig/m l Molar conc. (mM)
Indomethacin 2 .5 0 .0 0 7
BRI 60/1 5 .0 0 .0 1 5
BRI 59/1 5 .0 0 .0 1 3
BRI 69/2 2 .5 0 .0 0 6
BRI 88/1 5 .0 0 .0 1 6
BRI 92/1 5 .0 0 . 0 1 2
BRI 104/2 5 .0 0 .0 1 5
BRI 106/1 10 .0 0 .0 2 9
BRI 107/1 5 .0 0 .0 1 5
BRI 114/2 10 .0 0 .0 2 6
BRI 115/2 10 .0 0 .0 3 1
BRI 113/1 10 .0 0 .0 3 2
BRI 119/1 5 .0 0 .0 1 6
BRI 120/1 5 .0 0 .0 1 5
BRI 124/1 5 .0 0 .0 1 3
BRI 153/1 5 0 .0 0 . 1 3 0
BRI 203/1 20 .0 0 .0 5 4
BRI 205/4 2 5 .0 0 .0 6 2
BRI 215/1 5 0 .0 0 . 1 1 9
BRI 138/1 1 5 .0 0 .0 4 6
Table 3.1.1: H ig h e s t n o n -to x ic  co n c en tra tio n s o f  in d o m e th a c in  a n d
in d o m e th a c in  a n a lo g u e s  u s e d  in  th e  c o m b in a tio n  t o x ic it y  a s s a y s  in  D L K P  
c e l ls .  T h e  n o n -to x ic  c o n c e n tra t io n  o f  e a c h  co m p o u n d  w a s  d e te rm in e d  u s in g  
d a ta  f r o m  th re e  se p a ra te  e x p e r im e n ts .
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Combination toxicity assay: DLKP and Adriamycin + Indomethacin
1 0 0
Figure 3.1.24: Combination Toxicity assay: DLKP c e ll s u rv iv a l +  
a d ria m y c in  in  co m b in a tio n  w ith  n o n -to x ic  co n cen tra tio n s  o f  in d om eth ac in . 
T h e  g ra p h  d e m o n stra te s  th e ab ility  o f  in d o m eth ac in  to  p o te n tia te  th e 
to x ic ity  o f  a d ria m y c in  in  a  co n c en tra tio n  d ep en d en t m an n er in v i tr o .
T h e  re su lts  a re  th e  a v e ra g e  o f  tr ip lic a te  d eterm in ation s in  th re e  se p e ra te  
ex p e rim e n ts.
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DLK P, A driam ycin and Indom ethacin, BR I 60/1, BRI 59/1, BRI 69/2,
Test Sample % Cell Survival S.D.
Adr. 10ng/ml 58 .6 1 .7
Indo (2.5|og/ml) 9 4 .1 4.4
Indo + Adr 24.5 1.1
Indo (1.25(J.g/ml) 9 7 .7 7.4
Indo + Adr 30.7 1.7
Indo (0.625jxg/ml) 9 5 .1 2 . 1
Indo + Adr 36.3 1.0
60/1 (5p,g/ml) 93.8 0.9
60/1 + Adr 20.3 1.8
60/1 (2.5|ig/ml) 98.6 0.8
60/1 + Adr 31.5 2.8
60/1 (1.25ng/ml) 10 1 .0 2 .3
60/1 + Adr 40.3 13.5
59/1 (5|J.g/ml) 1 0 1 . 1 5.6
59/1 + Adr 54.1 3.1
59/1 (2.5fj.g/ml) 1 0 1 .3  . 0.6
59/1 + Adr 57.5 4.4
59/1 (1.25|J,g/mI) 9 7 .3 5.4
59/1 + Adr 59.0 5.5
69/2 (5|j.g/ml) 6 1 .8 2 .5
69/2 + Adr 24.7 2.7
69/2 (2.5jxg/ml) 97.9 0.9
69/2 + Adr 59.4 1.6
69/2 (1.25jxg/ml) 10 7 .7 1 .2
69/2 + Adr 63.5 2.6
Table 3.1.2: %  S u r v iv a l  o f  D L K P  c e lls  in  th e  p re s e n c e  o f  v a r io u s  
c o n c e n tra t io n s  o f  a d r ia m y c in  an d  in d o m e th a c in  (P o s . co n tro l) , B R I  6 0 / 1 ,  5 9 / 1  
an d  6 9 /2  a s  fo u n d  u s in g  th e  p ro to c o l d e ta ile d  in  se c t io n  2 .7 .3 .  S u r v iv a l  is  
re p re se n te d  a s  a  %  o f  th e  g ro w th  o f  u n tre a te d  c e l ls  in  th e  sa m e  p la te  +  S .D . 
R e s u lt s  a re  th e  a v e r a g e  o f  t r ip lic a te  d e te rm in a tio n s  in  th re e  se p a ra te  
e x p e r im e n ts .
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DLKP, Adriamycin and Indom ethacin, 88/1, 92/1 and 104/2
Test Sample % Cell Survival S.D.
Adr. lOng/ml 42 .9 6.8
Indo (2.5(Ag/ml) 98.6 4.5
Indo + Adr 21.8 2.5
Indo (1.25(J,g/ml) 98.4 1 .7
Indo + Adr 24.8 2.5
Indo (0.625p.g/ml) 9 7 .7 6.0
Indo + Adr 28.1 2.9
88/1 (5|j.g/ml) 94.7 2.0
88/1 + Adr 25.9 1.9
88/1 (2.5|og/ml) 99.3 4 .2
88/1 + Adr 23.7 0.4
88/1 (1.25ng/ml) 99.2 1 .4
88/1 + Adr 32.2 4.4
92/1 (5|xg/ml) 9 3 .7 4 .7
92/1 + Adr 20.1 1.6
92/1 (2.5|ig/ml) 96.8 0.9
92/1 + Adr 21.4 0.3
92/1 (1.25ng/ml) 98.7 2 .1
92/1 + Adr 23.7 0.4
104/2 (5(j,g/ml) 9 6 .1 0 .7
104/2 + Adr 18.5 2.5
104/2 (2.5fig/ml) 99.7 2 .4
1 104/2 + Adr 18.3 2.7
104/2 (1.25jig/ml) 99.5 2.6
104/2 + Adr 22.4 3.3
Table 3.1.3: %  S u r v iv a l  o f  D L K P  c e lls  in  th e  p re s e n c e  o f  v a r io u s  
co n c e n tra tio n s  o f  a d r ia m y c in  an d  in d o m e th ac in  (P o s . c o n tro l) , B R I  8 8 / 1 , 9 2 / 1  
a n d  10 4 / 2  a s  fo u n d  u s in g  th e  p ro to c o l d e ta ile d  in  se c t io n  2 .7 . 3 .  S u r v iv a l  is  
re p re se n te d  a s  a  %  o f  th e  g ro w th  o f  u n treated  c e l ls  in  th e  sa m e  p la te  ±  S .D . 
R e s u lt s  a re  th e  a v e r a g e  o f  t r ip lic a te  d e te rm in a tio n s  in  th re e  sep a ra te  
e x p e r im e n ts .
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DLKP, Adriamycin and Indomcthacin, 106/1,107/1,114/2 and 115/2
Test Sample % Cell Survival S.D.
Adr. 10ng/ml 44.9 5.5
Indo (2.5|ag/ml) 98.6 4.5
Indo + Adr 21.7 1.1
Indo (1.25|ig/ml) 98.4 1 .7
Indo + Adr 24.8 2.5
Indo (0.625(J.g/ml) 9 7 .7 6.0
Indo + Adr 28.1 2.9
106/1 (10|ig/ml) 99 .5 0.5
106/1 + Adr 39.4 5.4
106/1 (5|ig/ml) 98.8 3 . 1
106/1 + Adr 42.7 1.1
106/1 (2.5ug/ml) 10 0 .7 3 .5
106/1 + Adr 41.8 1.3
107/1 (5fig/ml) 9 6 .7 4 .2
107/1 + Adr 34.1 2.8
107/1 (2.5jig/ml) 98.9. 4 .1
107/1 + Adr 38.0 1.5
107/1 (1.25|ig/ml) 99.0 4.5
107/1 + Adr 41.0 1.0
114/2 (10|ag/ml)) 99 .2 2 .5
114/2 + Adr 10.3 1.2
114/2 (5|ig/ml) 10 4 .2 2 .7
114/1 + Adr 12.3 1.8
114/2 (2.5fj.g/ml) 10 3 .3 3 .4
114/2 + Adr 18.4 2.7
115/2 (10ug/ml) 9 3 .1 6 .7
115/2 + Adr 18.6 0.5
115/2 (5fig/ml) 9 3.0 7 .7
115/2 + Adr 24.3 2.0
115/2 (2.5(j,g/ml) 94.5 3 .2
115/2 + Adr 30.4 3.7
Table 3.1.4: %  S u r v iv a l  o f  D L K P  c e l ls  in  th e  p re se n c e  o f  v a r io u s  
co n c e n tra tio n s  o f  a d r ia m y c in  a n d  in d o m e th a c in  (P o s . c o n tro l) , B R I  1 0 6 / 1 ,  
1 0 7 / 1 ,  1 1 4 / 2  a n d  1 1 5 / 2  a s  fo u n d  u s in g  th e p ro to c o l d e ta ile d  in  se c tio n  2 .7 .3 .  
S u r v iv a l  is  re p re se n te d  a s  a  %  o f  th e  g ro w th  o f  u n trea ted  c e lls  in  th e  sa m e  
p la te  ±  S .D . R e s u lt s  a re  th e  a v e r a g e  o f  tr ip lic a te  d e te rm in a tio n s  in  th ree  
se p a ra te  e x p e r im e n ts .
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DLKP, Adriaraycin and Indomethacin, BRI 113/1,119/1,120/1 and 124/1.
Test Sample % Cell Survival S.D.
Adr. 10ng/ml 5 2 .5 4.0
Indo (2.5|ug/ml) 98.6 4.5
Indo + Adr 21.8 1.1
Indo (1.25p.g/ml) 98.5 1 .7
Indo + Adr 24.8 2.5
Indo (0.625|Og/mI) 9 7 .7 6.0
Indo + Adr 28.2 3.0
113/1 (10|ig/ml) 98.4 1 .2
113/ 1 + Adr 37.6 4.7
113/1 (5|j.g/ml) 97.6 2 .5
113/1 + Adr 45.3 0.8
113/1 (2.5^g/ml) 10 0 .1 2.8
113/1 + Adr 47.3 2.5
119/1 (5ng/ml) 97.4 0.6
119/1 + Adr 50.0 1.8
119/1 (2.5|ig/ml) 96.5 2 .1
119/1 + Adr 57.3 3.5
119/1 (1.25fig/ml) 99.0 0.5
119/1 + Adr 55.8 3.1
120/1 (5fig/ml) 98.0 5.6
120/1 + Adr 41.0 3.6
120/1 (1.25/ag/mI) 10 0 .5 4 .2
120/1 + Adr 48.1 2.6
120/1 (0.625/J.g/ml) 9 6 .1 2 .5
120/1 + Adr 51.7 3.6
124/1 (5ng/ml) 99.0 7.7
124/1 + Adr 42.2 3.3
124/1 (2.5jog/ml) 10 0 .3 0.9
124/1 + Adr 47.9 5.3
124/1 (1.25fig/ml) 99.3 3 . 1
124/1 + Adr 50.0 2.7
Table 3.1.5: %  S u r v iv a l  o f  D L K P  c e l ls  in  th e p re s e n c e  o f  v a r io u s  
c o n c e n tra t io n s  o f  a d r ia m y c in  a n d  in d o m e th ac in  (P o s . c o n tro l) , B R I  1 1 3 / 1 ,  
1 1 9 / 1 ,  1 2 0 / 1  a n d  1 2 4 / 1  a s  fo u n d  u s in g  th e p ro to c o l d e ta ile d  in  se c t io n  2 .7 .3 .  
S u r v iv a l  is  re p re se n te d  a s  a  %  o f  th e  g ro w th  o f  u n trea ted  c e l ls  in  th e  sa m e  
p la te  ±  S .D . R e s u lt s  a re  th e  a v e r a g e  o f  tr ip lic a te  d e te rm in a tio n s  in  th ree  
se p a ra te  e x p e r im e n ts .
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DLK P, A driam ycin and BR I 153/1
Test Sample % Cell Survival S.D.
Adr. 10ng/ml 4 1 .2 8 9.48
Indo (2.5(J.g/ml) 98.6 4.5
Indo + Adr 15.9 6.6
Indo (1.25|i.g/ml) 9 7.6 0.4
Indo + Adr 19.7 8.28
Indo (0.625jj.g/ml) 10 2 . 1 2 .6 2
Indo +A dr 24.5 1 1 . 0
153/1 (50jJ.g/ml) 97.8 3 . 1
153/1 + Adr 13.2 2.9
153/1 (25(J,g/ml) 9 9 .1 1 .4
153/1 +A dr 15.7 3.8
153/1 (12.5fig/ml) 99.5 2 .1
153/1 + Adr 23.2 8.5
Table 3.1.6: %  S u r v iv a l  o f  D L K P  c e l ls  in  th e p re s e n c e  o f  v a r io u s  
c o n c e n tra t io n s  o f  a d r ia m y c in  a n d  in d o m e th a c in  (P o s . c o n tro l) , a n d  B R I  1 5 3 / 1  
a s  fo u n d  u s in g  th e  p ro to c o l d e ta ile d  in  se c t io n  2 .7 .3 .  S u r v iv a l  is  re p re se n te d  a s  
a  %  o f  th e  g ro w th  o f  u n trea ted  c e l ls  in  th e  sa m e  p la te  ±  S .D . R e s u lt s  a re  th e 
a v e r a g e  o f  t r ip lic a te  d e te rm in a tio n s  in  th re e  sep a ra te  e x p e r im e n ts .
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DLKP, Adriamycin and Indomethacin, BRI 203/1,205/4 and 215/4
Test Sample % Cell Survival S.D.
Adr. lOng/ml 5 7 .6 1 . 1
Indo (5jig/ml) 91.2 0.3
Indo + Adr 14.8 0.5
Indo (2.5fj.g/ml) 95.4 0.5
Indo + Adr 23.2 1.4
Indo (1.25fxg/ml) 94.7 0.8
Indo + Adr 37.0 0.3
203/1 (20jig/ml) 99.9 0.5
203/1 + Adr 26.9 0.1
203/1 (10fAg/ml) 10 0 .3 0.0
203/1 + Adr 38.9 1.3
203/1 (5|ig/ml) 100.6 0.3
203/1 + Adr 49.0 3.0
205/4 (25|xg/ml) 86.8 10 .4
205/4 + Adr 52.1 1 1 . 0
205/4 (12.5ng/ml) 9 5.5 5.4
205/4 + Adr 52.4 12.4
205/4 (6.25fjg/ml) 97.9 4.5
205/4 + Adr 51.5 13.6
215/1 (50jJ,g/mI) 10 0 .4 0.1
215/1 + Adr 49.3 3.5
215/1 (25^g/ml) 9 2.0 3 .1
215/1 + Adr 60.6 3.5
215/1 (12.5jjg/ml) 10 0 .9 0.1
215/1 + Adr 63.3 5.1
Table 3.1.7: %  S u r v iv a l  o f  D L K P  c e l ls  in  th e p re se n c e  o f  v a r io u s  
c o n c e n tra t io n s  o f  a d r ia m y c in  a n d  in d o m e th a c in  (P o s . c o n tro l) , B R I  2 0 3 / 1 ,  
2 0 5 / 4  an d  2 1 5 / 4  a s  fo u n d  u s in g  th e  p ro to c o l d e ta ile d  in  se c t io n  2 .7 .3 .  S u r v iv a l  
i s  re p re se n te d  a s  a  %  o f  th e g ro w th  o f  u n tre a te d  c e l ls  in  th e  sa m e  p la te  ±  S .D . 
R e s u lt s  a re  th e  a v e r a g e  o f  t r ip lic a te  d e te rm in atio n s  in  th ree  se p a ra te  
e x p e r im e n ts .
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DLKP, Adriamycin and Indomethacin and BRI 138/1
Test Sample % Cell Survival S.D.
Adr. 10ng/ml 5 7 .6 1 . 1
Indo (2.5^g/ml) 9 1 .2 0.3
Indo + Adr 10.8 0.5
Indo (1.25|ug/ml) 9 5 .4 0.5
Indo +A dr 23.2 1.4
Indo (0.625fxg/ml) 9 4 .7 0.8
Indo +A dr 37.0 0.3
138/1 (15jo.g/mI) 9 3 .6 1.8
138/1 + Adr 13.4 2.0
138/1 (7.5ug/ml) 98.0 1.9
138/1 + Adr 24.0 0.8
138/1 (3.75ng/ml) 9 8 .1 1.8
138/1 + Adr 55.7 0.7
Table 3.1.8: %  S u r v iv a l  o f  D L K P  c e l ls  in  th e  p re s e n c e  o f  v a r io u s  
c o n c e n tra t io n s  o f  a d r ia m y c in  a n d  in d o m e th a c in  (P o s . co n tro l)  an d  B R I  1 3 8 / 1  
a s  fo u n d  u s in g  th e  p ro to c o l d e ta ile d  in  se c t io n  2 .7 .3 .  S u r v iv a l  is  re p re se n te d  as  
a  %  o f  th e  g ro w th  o f  u n treated  c e l ls  in  th e  sa m e  p la te . R e s u lt s  a re  th e  a v e ra g e  
o f  t r ip lic a te  d e te rm in a tio n s  in  th re e  se p a ra te  ex p e rim e n ts .
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No Anticancer 
agent
+ Adriamycin  
(lOng/ml)
Cl value*
No NSAID 1 0 0  +  0.0 5 2 .5  ±  4 .0 0.000
Indo.(2.S(ag/inl) 9 8 .6  +  4 .5 2 1 . 8  ±  1 . 1 0 .5 5 7
60/1 (5|.ig/ml) 9 3 .8  +  0 .9 2 0 .3  ±  1 .8 0 .4 8 3
59/1 (5[.ig/nil) 1 0 1 . 1  +  0.6 5 4 . 1  ±  3 . 1 1 .0 2 4
69/2 (2.5jag/ml) 9 7 .9  ± 0 . 9 5 9 .4  ±  1 .6 1 .2 8 6
88/1 (5[.ig/ml) 9 4 .7  ±  2 .0 2 5 .9  ±  1 .9 0 .6 0 9
92/1 (5|o.g/ml) 9 3 .7  ± 4 . 7 2 0 . 1  ±  1 .6 0 .5 6 6
104/2 (5|ag/ml) 9 6 .1  ± 0 . 7 1 8 .5  ±  2 .5 0 .5 5 0
106/1 (10(.ig/ml) 9 9 .5  ±  0 .5 3 9 .4  ±  5 .4 1 . 0 3 5
107/1 (5(.ig/ml) 9 6 .7  ± 4 . 2 3 4 . 1  ±  2 .8 1 .0 0 0
113/1 (lO^ig/nd) 9 8 .4  ±  1 . 2 3 7 .6  ±  4 .7 1 .0 2 0
114/2 (10|.ig/ml) 9 9 .2  ±  2 .2 1 0 .3  ±  1 . 2 0 .4 3 7
115/2 (10 jig/ml) 9 3 . 1  ±  6 .7 1 8 .6  ±  0 .5 0 .5 6 3
119/1 (5|ug/ml) 9 7 .4  ±  0 .6 5 0 .0  ±  1 .8 1 .0 4 4
120/1 (5(ig/ml) 9 8 .0  ±  5 .6 4 1 . 0  ±  3 .6 1 .0 7 4
124/1 (10|ig/m l) 9 9 .0  ±  7 .7 4 2 .3  ±  3 .3 1 .0 0 0
153/1 (50|.ig/ml) 9 7 .8  ±  3 . 1 1 3 . 2  ±  2 .9 0 .3 9 7
203/1 (20|.ig/ml) 9 9 .9  ±  0 .5 2 6 .9  ±  0 . 1 0 .5 5 1
205/4 (25|ig/m l) 86.8  ±  10 .4 5 2 . 1  ±  1 1 . 0 1 . 3 8 5
215/1 (50|j.g/ml) 10 0 .4  ±  0 .1 4 9 .3  ±  3 .5 1 .0 5 0
138/1 (15|ag/ml) 9 3 .6  ±  1 .8 1 3 .4  ± 2 . 0 0 .3 4 0
*CI: Combination Index
Table 3.1.9: T a b le  s h o w in g  re su lts  o f  c o m b in a tio n  o f  in d o m e th a c in  an d  
in d o m e th a c in  a n a lo g u e s , a t th e ir  h ig h e s t  n o n -to x ic  co n c e n tra tio n s , w ith  
a d r ia m y c in  in  D L K P  c e l ls .  D a ta  a re  e x p re s se d  a s  %  c e ll  su rv iv a l  ±  stan d ard  
d e v ia t io n  fo r  a  m in im u m  o f  th ree  d e te rm in a tio n s .
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Figure 3.1.25: Combination Toxicity assay: DLKP + A d ria m y c in  
in  co m b in a tio n  w ith  th e  h ig h est n o n -to x ic  co n c en tra tio n s  o f  in d om eth ac in  
and p o s it iv e  in d o m eth ac in  a n a lo g u es.
T h e  g ra p h  d e m o n stra te s  th e  ab ility  th e se  co m p o u n d s to  p o te n tia te  th e 
t o x ic ity  o f  a d ria m ycin  in  D K L P  ce lls  in vitro.
T h e  re su lts  are  th e  a v e ra g e  o f  tr ip lic a te  d eterm in ation s in  th re e  sep e ra te  
e x p e rim e n ts.
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Molar conc. 
in assay 
(mM)
No Anticaneer 
agent
+ Adriamycin 
(10ng/ml)
Cl value
No NSAID 100 ± 0 . 0 5 2 .5 4  ± 4 . 0 4 0.0
Indo.(2.5|og/ml) 0 .0 0 7 0 9 8 .6 3  ± 4 . 5 0 2 1 . 7 8  ±  1 .0 8 0 .5 5 7
60/1 (2.5|ig/ml) 0 .0 0 7 5 9 3 .7 7  ± 0 . 9 3 1 . 5  ± 2 . 8 0 .6 1 9
88/1 (2.5fog/ml) 0 .0 0 8 0 9 4 .6 7  ± 2 . 0 1 2 5 .9  ±  1 .9 0 .6 1 9
92/1 (2.5fj.g/ml) 0 .0 0 6 2 9 3 .6 8  ± 4 . 7 2 2 1 . 4  ± 0 . 3 4 0 .5 6 6
104/2
(2.5(ag/ml)
0 .0 0 7 5 9 6 .0 9  ± 0 . 7 1 8 .3  ± 2 . 7 0 .5 4 4
114/2
(2.5f.ig/ml)
0 .0 0 6 4 9 9 .1  ± 2 . 5 1 8 .4  ± 2 . 6 0 .5 7 1
115/2
(2.5jog/ml)
0 .0 0 7 6 9 4 .5  ± 3 . 2 3 0 .4 4  ±  1 . 7 0 .7 5 4
Table 3.1.10: T a b le  c o m p a r in g  sy n e rg is t ic  c o m b in a tio n  o f  in d o m e th a c in  an d  
in d o m e th a c in  a n a lo g u e s  at 2 .5 |x g /m l, w ith  a d r ia m y c in  in  D L K P  c e lls . D a ta  are  
e x p r e s s e d  a s  %  c e l l  s u r v iv a l  ±  stan d ard  d e v ia t io n  fo r  a  m in im u m  o f  th ree  
d e te rm in a tio n s .
136
Combination toxicity assay: DLKP and Adriamycin + 
Indomcthacin/Indomethacin analogues
60 i------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Figure 3,1.26: Combination Toxicity assay: D L K P  +  A d ria m y c in  
in  co m b in a tio n  w ith  in d o m eth ac in  and p o s it iv e  in d o m eth ac in  a n a lo g u e s  
a t  2 .5 u g /m l.
T h e  g ra p h  c o m p a re s  th e  ab ility  o f  in d o m eth ac in  and a n a lo g u e s  to  
p o te n tia te  th e  to x ic ity  o f  a d ria m ycin  at id en tica l co n cen tra tio n s.
T h e  re su lts  a re  th e  a v e ra g e  o f  tr ip lic a te  d eterm in ation s in  th re e  sep e ra te  
ex p e rim e n ts.
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3.2 Glutathione S-transferase
T o  fu rth e r  d e te rm in e  th e  S A R  o f  th e  co m p o u n d s , G lu ta th io n e  S -tra n s fe r a s e  
( G S T )  a s s a y s  w e r e  c a rr ie d  ou t fo r  tw o  re a so n s :
•  O n e  p o s s ib le  e x p la n a t io n  fo r  th e  m e c h a n ism  b y  w h ic h  th e  in d o m e th a c in  
a n a lo g u e s  h a v e  th e ir  to x ic ity  e n h a n c in g  e f fe c t  o n  th e  ch e m o th e ra p e u tic  
d ru g  is  th ro u g h  in h ib it in g  th e  o p e ra tio n  o f  M R P .  G lu ta th io n e  c o n ju g a te s  
a re  tra n sp o rte d  v e r y  e f fe c t iv e ly  b y  M R P  a n d  th e se  g lu ta th io n e  c o n ju g a te s  
a re  fo rm e d  b y  th e  G lu ta th io n e -S -  tra n s fe ra se  e n z y m e  ( G S T ) .
•  In d o m e th a c in  i s  a ls o  a  c la s s ic  in h ib ito r  o f  G S T  so  th e  G S T  a s s a y  is  c a rr ie d  
o u t o n  th e  in d o m e th a c in  a n a lo g u e s  to  a s s e s s  i f  th e y  a ls o  h a v e  th is  G S T  
in h ib ito ry  a c t iv ity .
T h e  G S T  a s s a y  w a s  c a rr ie d  ou t a c c o rd in g  to  se c tio n  2 . 1 2  to  d e term in e  i f  G S T  
in h ib it io n  b y  th e  a n a lo g u e  w a s  re q u ire d  fo r  th e  s y n e r g is t ic  a c t iv ity  se e n  in  th e  
c o m b in a tio n  t o x ic i t y  a s s a y s  in  se c tio n  3 . 1 .  O n ly  th re e  o f  th e  in d o m e th a c in  (N -  
b e n z o y l)  a n a lo g u e s , B R I  8 8 / 1 , 9 2 / 1  a n d  10 4 / 2 , w h ic h  w e r e  p o s it iv e  in  th e  
c o m b in a tio n  t o x ic it y  a s s a y  w ith  D L K P ,  s h o w  c o m p a ra b le  G S T  in h ib ito ry  
a c t iv ity  to  in d o m e th a c in . T h e  re su lts  in d ic a te  th at B R I  9 2 / 1  is  c o m p a ra b le  to  
in d o m e th a c in  a s  a n  in h ib ito r  o f  G S T . T h e  re m a in d e r  o f  th e in d o m e th a c in  
a n a lo g u e s  th at w e r e  p o s it iv e  in  th e  c o m b in a tio n  t o x ic it y  a s s a y , 6 0 / 1 ,  1 1 4 / 2 ,  
1 1 5 / 2  an d  1 5 3 / 1 ,  2 0 3 / 1  a n d  1 3 8 / 1 ,  w e re  n o t g o o d  G S T  in h ib ito rs  (T a b le  3 . 2 . 1  
a n d  F ig u r e  3 . 2 . 1 ) .  I t  is  u n d e rsto o d  th at g lu ta th io n e  ( G S H )  is  re q u ire d  to  k e e p  
M R P  in  a  c o n fo rm a t io n a l state  th at a llo w s  th e  tra n sp o rt o f  n eu tra l o r  p o s it iv e ly  
c h a rg e d  m o le c u le s  — p e rh a p s  a s  a  te rn a ry  c o m p le x . H e n c e , it w a s  p o s tu la te d  
th a t i f  G S T  w a s  in h ib ite d , le s s  c o n ju g a te s  w o u ld  b e  fo rm e d  w ith in  th e c e ll  a n d , 
a s  a  re su lt , le s s  m o le c u le s  w o u ld  b e  p u m p e d  o u t o f  th e  c e ll . H o w e v e r , th e  
re su lts  o b ta in e d  s t r o n g ly  su g g e s t  that th e  e f fe c t  o n  th e  M R P  p u m p  is  n o t 
th ro u g h  in h ib it io n  o f  G S T .  T h e se  re su lts  s u g g e s t  that th e  a b il ity  o f  th e  
c o m p o u n d s  to  e n h a n c e  th e  to x ic ity  o f  th e c h e m o th e ra p e u tic  d ru g  in vitro  is  d u e  
to  a  d ire c t  in te ra c t io n  w ith  th e  M R P  p u m p .
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Compound Molarity of comp, in test 
solution (mM)
Average % Inhibition
Indomethacin 0.9 93.1 ± 3.5
B R I60/1 1.0 7.2 ± 1.0
B R I59/1 0.9 0.1 ± 0.1
BRI 69/2 0.8 0.1 ± 0.1
BRI 88/1 1.0 70.9 ± 4.7
BRI 92/1 0.9 94.3 ± 2.6
BRI 104/2 1.0 74.0 ± 3 . 8
BRI 106/1 1.0 2.0 ± 0.2
BRI 107/1 1.0 46.7 ± 0.7
BRI 113/1 1.1 17.6  ± 2.3
BRI 114/2 1.0 15 .1  ± 2.7
BRI 115/2 1.0 21.2 ± 2.6
BRI 119/1 1.1 4.0 ± 0.3
BRI 120/1 1.0 0.1 ± 0.1
BRI 124/1 0.9 0.0 + 0.0
BRI 203/1 0.8 12 .1  ± 0.9
BRI 153/1 0.8 13 .4  ± 1.2
BRI 205/4 0.8 9.7 ± 1.4
BRI 138/1 1.0 8.2 ± 0.8
BRI 215/1 0.8 1 1 . 7  ± 2.1
DMSO Control 0.9+ 1.3
Table 3.2.1: G S T  a s s a y  re su lts  s h o w in g  th e  %  in h ib it io n  o f  p ro d u c tio n  o f  
g lu ta th io n e  c o n ju g a te s  b y  in d o m e th a c in  a n d  in d o m e th a c in  a n a lo g u e s . R e s u lt s  
a re  th e  a v e r a g e  o f  a  m in im u m  o f  tw o  re a d in g s  fo r  e a c h  c o m p o u n d  fro m  a  
m in im u m  o f  th re e  a s s a y  re p e a ts .
D a t a  is  e x p r e s s e d  a s  %  in h ib it io n  re la t iv e  to  a n  u n trea ted  c o n tro l (N e g a t iv e  
c o n tro l) .
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Figure 3.2.1: G ST assay results showing th e  %  inhibition o f  p roduction  o f  
g lu tathione conjugates by indom ethacin and indom ethacin analogues.
The results are the  average o f  tw o readings fo r each com pound from  a m inimum 
o f  th ree  assay repeats.
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3.3 Inside Out Vesicle Assay
P ro tein  analysis studies failed  to  show  the existence o f  M R P pro tein  in  w hole 
cell extracts o f  D LK P. It had  been  dem onstrated  that all o ther cell lines in  
w hich  the tox icity  enhancem ent effect had been  found to  occur expressed M RP 
(D uffy  et al., 1998). The drug p rofile  for w hich  the N S A ID -m ediated  toxicity  
enhancem ent effect w as found to  occur w as exactly  sim ilar to the range o f  
drugs believed  to  be  transported  by  M RP. This suggested that co-treatm ent o f  
M R P-expressing  cells w ith  an  M R P-substra te  drug and an N SA ID  w ith  the 
ability  to  in terfere w ith  the drug pum ping  ab ility  o f  M RP, m ay  have resulted  in 
increased reten tion  o f  drug w ith in  the  cell. This w ould  u ltim ately  cause an 
enhancem ent o f  cytotoxic drug-induced  cell kill. A lthough the toxicity  
enhancem ent effect w as found to  occur in  D L K P, M R P expression had  not 
been  detected  in  th is cell line. It w as suggested  tha t D L K P expressed M R P at 
levels undetectab le  by W estern  b lo tting  o f  w hole cell extracts. In  order to 
iso late  the  p lasm a m em brane from  these cells and specifically  target W estern 
b lo tting  analysis to the area in  w hich  the M R P m olecule m ay have localised, 
Inside O ut V esicles w ere p repared  from  D L K P cells. It w as found that M RP 
w as detectable by W estern  b lotting , in 10V s isolated from  D LK P. The level o f  
M R P  pro tein  in D L K P w as significantly  low er than  the levels found in  IOVs 
iso lated  from  H L 60/A D R  cells bu t th is level appears to  be functionally  
effective for d rug  transport ou t o f  the cell (D uffy  et al., 1998; E llio tt, 1997).
T he glutath ione conjugate, L T C ^ w as found to  be transported  into vesicles in  
an  A T P-dependent m anner (Jed litsch ly  et al., 1994 and L eier et al., 1994). 
D uffy  et al., (1998), dem onstrated  the  influence o f  various N S A ID s on  M RP 
activ ity  in  H L 60/A D R  IO V s by m easuring the ability  o f  the com pounds to 
inh ib it the  transport o f  L T C 4. The authors reported  tha t that the positive 
N S A ID s, especially  sulindac and indom ethacin , have M R P pum p inhibitory 
activ ity , w hereas, inactive N S A ID s, naproxen  and  piroxicam , do not.
To further determ ine i f  indom ethacin  and the  indom ethacin  analogues w ere 
acting on  M R P, an  assay w as devised in  w h ich  a  pure p repara tion  o f  M R P (an 
active enzym e preparation) w as used along w ith a radiolabelled  M RP 
substrate, L T C4. T his pure p reparation  o f  M R P w as contained  w ith in  vesicles, 
p repared  from  H L 60/A D R  cells, w hich  w ere subsequently  turned inside out. 
(To a llow  m easurem ent o f  the  transport o f  L T C4 - instead o f  M R P pum ping
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the substrate  ou t o f  the  vesicle it no w  pum ped it in  to the vesicle using  A T P as 
an energy source). The ability  o f  the indom ethacin  analogues to  inh ib it M R P 
w as determ ined  by  m easuring  their ability  to  inh ib it the uptake o f  Leukotriene 
C4 into the  vesicle.
The results o f  the  Inside O ut V esicle assay show  that all bu t one o f  the 
com pounds, positive  in  the com bination  tox icity  assay, w ere effective 
inhibitors o f  M R P. F rom  the  data, the  strongest M RP inhibitors appeared  to be 
B R I 92/1 and 153/1, fo llow ed closely b y  88/1, 115/2 and 114/2. O f  the 
positive group, B R I 60/1 and 104/2 w ere the  w eakest inhibitors o f  the uptake 
o f  LTC4 in  to th e  vesicle. C om pounds, w hich  w ere negative in  the 
com bination  tox ic ity  assay, w ere used  as negative controls and the results 
(Figure 3 .4.12) ind icate  that these com pounds are no t inhibitors o f  M R P 
activity  in  the  IO V s.
Therefore, there  appears to  be a  good corre la tion  betw een the com bination  
tox icity  assay  and  the  IO V  assay in  th a t it seem s likely tha t indom ethacin  and 
its analogues po ten tia te  the  tox icity  o f  adriam ycin  on the cancer cells by 
inhibiting  the  expu lsion  o f  the  chem otherapeutic  drug  from  the cell by  M R P. 
H ow ever, th e  one exception  w as com pound B R I 138/1, the meta- fo rm  o f 
com pound 115/2. T hough th is com pound w as very  positive in  the com bination  
toxicity  assay in the  D LK P cells w ith  adriam ycin, it w as only w eakly  positive  
in  the  IO V  assay. This resu lt w ould  suggest that this com pound is n o t exerting 
its effect th rough  an  in teraction w ith  M RP1 or perhaps its m eta-structure is 
effecting the  affin ity  o f  th is com pound fo r M R P1. It m ay be possib le th a t th is 
analogue o f  indom ethacin  is potentiating the  toxicity  o f  adriam ycin  th rough  an 
in teraction w ith  another form  o f  M RP1 or possib ly  by interacting w ith  Pgp 
(M D R 1) w h ich  is also expressed  in  D L K P cells.
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Comp. Molarity of 
compound in test 
solution
Average %  
Inhibition
S.D.
Indom ethacin 46.0joM 83.1 10.4
B R I 60/1 47.6fxM 57.7 4.7
B R I 88/1 51.0fiM 64.4 7.8
B R I 92/1 41 .0pM 85.0 2.8
B R I 104/2 50.2p.M 60.4 8.0
B R I 115/2 50.1p,M 67.1 13.5
B R I 153/1 41.8jj.M 85.0 9.0
B R I 205/4 39.8|oM 0.0 0.8
B R I 114/2 47.2(iM 66.9 7.7
B R I 203/1* 13.3pM 65.1 19.5
B R I 138/1 50 .1pM 26.8 5.2
B R I 215/1 38.2|xM 22.5 5.6
T a b le  3 .3 .1 : E ffec t o f  indom ethacin  and selected analogues on transport o f  
[3H ]-L T C4 in  to  inside-out vesic les from  H L 60/A D R  cells.
T he rela tive A T P-dependen t rates are expressed as a  percen tage o f  un treated  
control, taken  as 100% , by  subtracting the  rate  in  the p resence  o f  A M P, w hich  
w as used  as the  b lank.
%  inhib ition  w as calcu lated  using the fo llow ing form ula:
£LTCi uptake @ T180 seconds (untreated) - Levels of LTCa @ T180 seconds (+ compound) )x  J0O 
LTC4 uptake @ T180 seconds (untreated)
D ata  g iven  are from  a  m in im um  o f  three assay repeats.
* Indom ethacin  analogue 203/1 proved  very d ifficult to  dissolve in  the 
reac tion  m ix ture  — results show n m ay be a  reflection  o f  so lubility  problem s 
and n o t a  true reflec tion  o f  the inhibiting ability  o f  the com pound.
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Figure 3.3.1 : Graph showing the effect o f indomethacin and indomethacin analogues 
on the transport o f [3H]-LTC4 in to inside-out vesicles from HL60/ADR cells.
Data are the average o f at least three minimum repeats.
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Figure: 3.3.2: Time course of LTC4 transport into IOVs isolated from the HL60/ADR
cell line in the presence of ATP, AMP or a combination of ATP and indomethacin 
Similar results were obtained in at least one additional experiment.
Figure: 3.3.3: Time course of LTC4 transport into IOVs isolated from the HL60/ADR 
cell line in the presence of ATP, AMP or a combination of ATP and BR1 60/1 
Similar results were obtained in at least one additional experiment.
Figure: 3.3.4: Time course of LTC4 transport into IOVs isolated from the HL60/ADR
cell line in the presence of ATP, AMP or a combination of ATP and BRI 88/1
Similar results were obtained in at least one additional experiment.
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Figure: 3.3.5: Time course of LTC4 transport into IOVs isolated from the HL60/ADR 
cell line in the presence of ATP, AMP or a combination of ATP and BRI 92/1 
Similar results were obtained in at least one additional experiment.
Figure: 3.3.6: Time course of LTC4 transport into IOVs isolated from the HL60/ADR 
cell line in the presence of ATP, AMP or a combination of ATP and BRI 104/2 
Similar results were obtained in at least one additional experiment.
Figure: 3.3.7: Time course of LTC4 transport into IOVs isolated from the HL60/ADR
cell line in the presence of ATP, AMP or a combination of ATP and BRI114/2
Similar results were obtained in at least one additional experiment.
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Figure: 3.3.8: Time course of LTC4 transport into IOVs isolated from the HL60/ADR 
cell line in the presence of ATP, AMP or a combination of ATP and BRI 115/2 
Similar results were obtained in at least one additional experiment.
Figure: 3.3.9: Time course of LTC4 transport into IOVs isolated from the HL60/ADR 
cell line in the presence of ATP, AMP or a combination of ATP and BRI138/1 
Similar results were obtained in at least one additional experiment.
Figure: 3.3.10: Time course of LTC4 transport into IOVs isolated from the HL60/ADR
cell line in the presence of ATP, AMP or a combination of ATP and BRI 153/1
Similar results were obtained in at least one additional experiment.
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Figure: 3.3.11: Time course of LTC4 transport into lGVs isolated from the HL60/ADR 
cell line in the presence of ATP, AMP or a combination of ATP and BRI 203/1 
Similar results were obtained in at least one additional experiment.
Figure: 3.3.12: Time course of LTC4 transport into IOVs isolated from the HL60/ADR 
cell line in the presence of ATP, AMP or a combination of ATP and BRI205/4 
Similar results were obtained in at least one additional experiment.
Figure: 3.3.13: Time course of LTC4 transport into IOVs isolated from the HL60/ADR
cell line in the presence of ATP, AMP or a combination of ATP and BRI 215/1
Similar results were obtained in at least one additional experiment.
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3.4.1 Cyclooxygenase 1 assays
Further in vitro testing  w as carried  out on  the  indom ethacin  analogues, 
particu larly  on the  positive  com pounds, to  determ ine i f  they  had  any inhibitory 
activ ity  on  either C yclooxygenase 1 (C O X -1) or C yclooxygenase 2 (COX -2). 
The anti-inflam m atory  properties o f  N SA ID s are know n to  be m ediated  by 
C O X  inhib ition  and m any  have attributed their an tineoplastic  properties to  
reduction  o f  p rostag land in  levels in  the  target tissue  (V ane et al., 1991; V ainio 
eta!., 1997; Levy et al., 1997; V ane et al., 1996 and A bram son et al., 1989). It 
is possib le  that C O X  inhib ition  does not m ediate the  anti-neoplastic  properties 
o f  N SA ID s and th is is o f  considerable clin ical significance because a 
reduction  in  prostag land in  levels, th rough inhib ition  o f  CO X -1, is know n  to be 
responsib le fo r the gastro intestinal and renal tox ic ity  that accom panies chronic 
N S A ID  adm inistration. I f  C O X  inhib ition  is no t necessary  o r sufficient for the 
an ti-neoplastic  properties o f  N SA ID s it should  be  feasib le to  develop less 
tox ic  N S A ID -like drugs to  aid  in  the treatm ent o f  cancer (P iazza et al., 1997). 
COX-1 is the constitu tive form  o f  the C ox enzym es w hereas CO X -2 is the 
induced  form . Inh ib ition  o f  C ox explains bo th  the therapeutic  effects 
(inh ib ition  o f  C O X -2) and side effects (inhibition  o f  C O X -1) o f  N SA ID s. A n 
N SA ID , w h ich  selectively  inhibits CO X -2, is like ly  to  reta in  m axim al an ti­
inflam m atory  efficacy com bined w ith  less toxicity.
The C yclooxygenase 1 assay is a  spectrophotom etric  assay, based on  the  assay 
used  by  B oopathy  et al., (1986) and P iazza et al., (1997), to  m easure inh ib ition  
o f  COX-1 by  various com pounds. The experim ental m ethod is as per section 
2.8. In  brief, COX-1 w as incubated w ith  1 OOjim arachidonic acid and 
cofactors (0 .5m M  glutath ione, 0 .5m M  hydroquinone, 0.625(xm haem oglobin  
and 1.25m M  C aC l2 in  lOOmM TR IS-H C L, pH  7.4-8 .0) at 37°C for 20 m in  in 
the p resence o f  various N SA ID s or their so lvent (1%  D M SO  final 
concentration). T he reaction  w as term inated by the  addition  o f  trichloroacetic  
acid. E nzym e activ ity  w as m easured by  the th iobarb ituric  acid colour reaction 
o f  m alonaldehyde form ed in the reaction  and determ ined by a  
spectrophotom eter a t 530nm .
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R esults ob tained  from  th e  COX-1 assay (T able 3.4.1.1 and  F igure 3.4.1.1) 
ind icated  that, o f  the  positive  indom ethacin  analogues, B R I 60/1, 114/2, 115/2 
153/1 and  138/1 w ere n o t good  inhib itors o f  CO X -1. A nalogues B R I 88/1 and 
B R I 104/2 com pared  favourably  w ith  the  CO X-1 inhibitory  ability  o f  
indom ethacin . The resu lts  fo r B R I 92/1 ind ica ted  th a t i t  m igh t be a  stronger 
COX-1 inh ib ito r than  indom ethacin. O verall, the  strongest COX-1 inhibitor 
appeared  to  be  B R I 92/1 and  the  w eakest inhibitors w ere B R I 153/1 and 138/1. 
The rem ainder o f  the com pounds tested  w ere poor inh ib itors o f  CO X -1. The 
com pounds can  be  listed  in  order o f  decreasing  ab ility  to  inh ib it COX-1 as 
fo llow s: B R I 92/1 >  B R I 88/1 >  indom ethacin  >  B R I 104/2 >  B R I 114/2 >  
B R I 115/2 >  B R I 60/1 >  B R I 153/1 > B R I  138/1.
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Compound
(1 2 pg/ml)
Molar conc. of 
compound in
assay (pM)
Average % 
Inhibition of 
CO X -1
%  S.D.
Indom ethacin 0.033 60.9 12.2
B R I 60/1 0.035 16.3 12.4
B R I 88/1 0.038 59.9 13.2
B R I 92/1 0.030 79.0 11.3
B R I 114/2 0.030 24.5 5.8
B R I 104/2 0.037 57.3 12.9
B R I 115/2 0.037 26.6 9.9
B R I 153/1 0.031 -0.1 7.4
B R I 138/1 0.037 0.8 3.6
BR I 203/1 0.032 22.1 8.2
B R I 215/1 0.030 1.7 8.1
B R I 205/4 0.037 -7.4 2.8
B R I 113/1 0.038 -1.0 7.4
N o  com pound (C ontrol) N /A 0.0 0.0
W ith  D M SO  (no com pound) N /A -1.3 9.0
T a b le  3 .4 .1 .1 : Cyclooxygenase-1 (C O X -1) assay resu lts show ing the %  
inhib ition  o f  CO X -1 activ ity  b y  indom ethacin  and indom ethacin  analogues.
A ll o f  the indom ethacin  analogues analysed, except B R I 215/1, 205/4 and 
113/1, w ere positive  in  the  com bination tox icity  assays.
T he results are  the  average o f  a  m inim um  o f  three assay repeats. D ata  is 
expressed as %  inhib ition  relative to  an  un treated  control.
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Figure 3.4.1: G raph show ing the  %  inhibition o f  COX-1 activity by 
indom ethacin and indom ethacin analogues.
T he results are the average o f  a m inimum o f  three assay repeats. 
D a ta  is expressed as %  inhibition relative to  an un trea ted  control.
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3.4.2. Cyclooxygenase 2 assays
C ytokines such as IL-1 are produced  by m any cells and  appear to bring about 
the effects o f  d isease or dam age such as fever and inflam m ation. IL - ip  can act 
directly  and/or stim ulate the release o f  o ther pro-inflam m atory  cytokines and 
grow th factors, w h ich  then  act upon target cells. T hese actions include the up- 
regulation  o f  certain  key enzym es involved in  the  generation o f  eicosanoids 
such as PLA 2 and CO X -2 (C roxtall et al., 1996; E ndo et al., 1995). Typically 
the release o f  arachidonic acid  and PgE 2 is increased follow ing IL - ip  
trea tm ent o f  m any cells (C roxtall et al., 1996).
The cell line, A 549, a hum an lung adenocarcinom a, w as chosen for the 
experim ent as it was dem onstrated  by A sano et al., (1996), that CO X-2 is the 
constitu tive and dom inant isoform  in unstim ulated  and  stim ulated cultured 
hum an  lung epithelial cells. A 549 cells express CO X-2 m R N A  and pro tein  
w hen  they  are stim ulated  w ith  epiderm al grow th factor or pro-inflam m atory 
cytokines such as IL - lp  (A sano et al., 1996).
A  prelim inary  E L IS A  for PgE 2 w as carried  ou t on  A549 cells, treated w ith 
vary ing  concentrations o f  IL-1 P (Ong/mL -2 Ong/mL), and it w as found that the 
optim um  level o f  PgE 2 production in  the A549 cells w as obtained w ith 
lOng/m L IL - lp . W estern  blotting  w as carried  out on pro tein  extracted from  
A 549 cells trea ted  w ith  Ong/mL and lOng/m L IL - lp  to assess the expression 
o f  COX-2. E xpression  o f  CO X -2 could not be detected  in  A 549 cells treated  
w ith  Ong/mL IL-1 p. H ow ever, low  expession o f  CO X-2 was observed in  the 
cells treated  w ith  5ng/m l IL - lp  and expression o f  CO X-2 w as increased in 
those A 549 cells trea ted  w ith  1 Ong/mL IL-1 p.
Figure 3.4.2.1: W estern  blot analysis o f  CO X -2 pro tein  from  A549 cells 
treated  w ith vary ing  concentrations o f  IL-1 P
Ong/mL IL -1 p 1 Ong/mL IL -1P 5ng/m L IL -1P
C O X -2—>
L
♦
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A  study w as carried  out to  investigate i f  co-treatm ent o f  the  A 549 cell line 
w ith  IL - ip  and indom ethacin  or indom ethacin  analogues, resu lted  in  inh ib ition  
o f  the p roduction  o f  PgE2 by  CO X -2. A  PgE2 E L ISA  assay w as u sed  to 
quantify  the  P gE2 p roduction  by  A 549 cells during treatm ent w ith  IL - ip , 
indom ethacin  and B R I com pounds. The experim ental p ro tocol used  in  these 
experim ents is de ta iled  in  section  2.8. In  sum m ary, cells w ere seeded at a 
density  o f  1.5 x  10s cells per w ell in  6 w ell p lates and  allow ed to attach 
overnight. The w aste  m ed ia  w as then  rem oved  and rep laced  w ith freshly  
prepared  m ed ia  contain ing  the  com pounds o f  interest. Indom ethacin  and 
indom ethacin  analogues (those com pounds positive  in  the com bination 
tox icity  assays) w ere  added  w ith  and w ithout IL - ip  to  ensure  that the addition  
o f  indom ethacin  and  the  indom ethacin  analogues alone d id  not induce the 
p roduction  o f  C O X -2. A fter a  further 24 hours, aliquots o f  m edia w ere th en  
rem oved from  each  o f  the  trea ted  w ells and added  to  the  E L ISA  p late  for 
analysis. The resu lts  o f  th is study are analysed in  tab le  3.5.2.1. A nalysis o f  the  
resu lts dem onstrated  th a t w hen  the  unstim ulated  PgE2 p roduction  is taken  as 
zero, IL - ip -  induced  A 549 cells produced approxim ately  112 pg PgE2 p e r 105 
cells. lOnM  o f  indom ethacin  and indom ethacin  analogue w ere added to  the 
A 549 cells and it w as found tha t indom ethacin , B R I 60/1, 88/1, 92/1 and 104/2 
w ere m ost capable o f  inh ib iting  PgE2 production  (90.2 - 73.6 % inhib ition  o f  
P gE 2). B R I 92/1 w as the m ost po ten t inh ib itor o f  PgE2 p roduction (90.2%  
inhib ition  o f  PgE2). B R I 114/2, 115/2 w ere only  capable o f  inhibiting C O X -2 
by  39.7 and 33 .6%  respectively  w hereas indom ethacin  analogues 153/1, 
203/1 , and 138/1 w ere  n o t capable o f  inhibiting PgE2 p roduction  by CO X -2. 
B R I 215/1, w h ich  w as negative in  the com bination  tox icity  assay, w as also 
negative in  the C O X -2 assay.
154
T re a tm e n t
%  In h ib itio n  
o f  p ro d u c tio n  o f  P g E 2 by 
Cox-2
S.D .
C ell control 0.0 0.0
IL -1B  (10m g/m l) 0.0 0.0
Indom ethacin  (lO nM ) +  IL-1B 86.1 5.9
60/1 (lO nM ) +  IL-1B 78.1 11.1
88/1 (lO nM ) +  IL-1B 80.4 12.7
9 2 /l(1 0 n M ) +  IL-1B 88.1 4.4
104/2 (lO nM ) +  IL-1B 79.6 12.2
114/2 (lO nM ) +  IL-1B 44.1 12.2
115/2 (lO nM ) +  IL-1B 40.1 18.5
153/1(1 OnM) +  IL-1B 14.7 15.0
138/1 (lO nM ) +  IL-1B 13.6 10.6
203/1 (1 O nM )+  IL -IB 24.2 8.1
215/1 (lO nM ) +  IL-1B 0.2 0.3
2 0 5 /4 (1  O nM )+  IL-1B 48.0 0.0
T a b le  3 .4 .2 .1 : E ffect o f  indom ethacin  and analogues on p roduction  o f  PgE 2 by 
C O X -2. R esults are represented  as m eans ±  S.D. for duplicate determ inations 
carried  o u t on  three separate occasions. Inh ib ition  is expressed as a percentage 
o f  un trea ted  contro l (IL-1(3 (10m g/m l)), taken  as 100%.
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Figure: 3.4.2: G raph show ing %  inhibition o f  CO X -2 enzyme by indom ethaci 
and indom ethacin analogues. Results are represented as m eans +/- S.D. for 
triplicate determ inations carried out on  three separate occasions.
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Combination GST IOV Cox-1 Cox-2
Toxicity
Assay
Indomethacin +++ +++ +++ ++ +++
BRI 60/1 +++ - ++ + +++
BRI 59/1 - - - i
BRI 69/2 - - -
sSBraB 1 -
BRI 88/1 +++ ++ ++(+) ++ +++
BRI 92/1 +++ +++ +++ +++ +++
BRI 104/2 +++ ++ ++ ++ +++
BRI 106/1 
BR1107/1 - +/-
■
’.'ilfe AK-ÿv
. 4 r 1, '•') 1rJCHL
- .• ■
■ .■ ■■ ■ •
' ÿ W ’r
BRI 114/2 +++ - ++(+) + ++
BRI 115/2 +++ +/- +++ + ++
BRI 113/1 - +/- - ^ ■ l  I
BR1124/1 - - I  H i
BRI 119/1 - - -
BRI 120/1 - - - H ’-W -o r:-■■■, ■
BRI 153/1 +++ - +++ - +/-
BRI 203/1 +++ - ++ + +
BRI 205/4 - - - - ++
BRI 215/1 - - +/- +/- -
BR1138/1 + + + - + - + / -
T a b le  3.4 .3 : Sum m ary table o f  all results from  investigations o f  the  SA R  
(S tructure A ctiv ity  R elationship) o f  indom ethacin  (section  3.1 to  section  3.4).
+ + +  V ery strong positive; ++  Strong positive; +  positive; +/- w eakly  positive; 
-  negative.
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3.5 Indomethacin and adriamycin efflux studies using HPLC  
analysis.
3.5.1 A d r ia m y c in  e fflux  s tud ies
T here is strong  ev idence to suggest tha t indom ethacin  and analogues potentiate  
the  tox ic ity  o f  adriam ycin  by in teracting  w ith  M RP. It is postu la ted  th a t these 
com pounds have a  strong affinity  fo r M R P and w hen  added to  an M R P- 
expressing cell line, in  com bination w ith  a  chem otherapeutic  drug, the 
com pounds inh ib it o r interfere w ith  the  activ ity  o f  the pum p and reduce the 
rate at w h ich  the chem otherapeutic drug  is effluxed. I t is possib le tha t the 
active com pounds m ay also be very  good substrates for M R P and com pete 
w ith  the chem otherapeutic  drug fo r th is protein. A driam ycin  quantita tion  w as 
carried  ou t o n  D L K P cells treated  w ith  a com bination  o f  adriam ycin  and 
indom ethacin  o r indom ethacin  analogues. T he cells, w h ich  w ere
t 'y
approxim ately  80%  confluent in 75cm  flasks, w ere 'loaded' for tw o hours at 
37°C  w ith  IOjoM  adriam ycin  alone, or, adriam ycin  and 28fxM indom ethacin  
com bined. A fter th is  initial loading period, the  m ed ia  w as rem oved from  the 
cells (TO hr) the flasks w ere w ashed  tw ice  w ith  fresh  m edia  and m edia 
contain ing  the  test com pound (indom ethacin /indom ethacin  analogue), m inus 
adriam ycin , w as added  to  the appropriate flasks. The cells w ere incubated  fo r a 
further 5 hours (T5 hr). A t required  tim e poin ts, the cells w ere rapidly  
trypsin ised , counted, pelle ted  and frozen  a t -20°C  until analysed by  H PLC  as 
described  in  section  2.13. A n  analogue o f  indom ethacin , w h ich  w as positive  in  
the  com bination  tox ic ity  assay (138/1) and a negative analogue (205/4) w ere 
also used  in  th is  assay.
The resu lts o f  th is  H PL C  analysis show ed a  notab le  d ifference in  the cellular 
adriam ycin  conten t in  D L K P cells incubated  w ith  10jj.m adriam ycin  alone 
versus D L K P cells incubated w ith  adriam ycin  and  28 (am indom ethacin  or 
138/1 com bined. A fter the initial 2 hour loading period, there w as sim ilar 
accum ulation  o f  adriam ycin  in  the cells trea ted  w ith  adriam ycin  alone (2.4foM 
adriam ycin /m illion  cells) and the  cells treated  w ith  a  com bination o f  
adriam ycin  +  indom ethacin  or 138/1 (2.2(j,M adriam ycin  /m illion  cells). W hen 
the  levels o f  indom ethacin  and 138/1 w ere m ain tained  in  the cells for a  further 
five hours the  level o f  adriam ycin  w ere only sligh tly  decreased in  these cells
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(1.8 -  1.9|xM adriam ycin /m illion  cells). H ow ever, there w as decreased 
accum ulation o f  adriam ycin  in  those cells treated  w ith  adriam ycin alone 
(1.0|j.M  adriam ycin /m illion  cells). The negative indom ethacin  analogue, B R I 
205/4, had  no  effect on  the  accum ulation  o f  adriam ycin  in  the D LK P cells. 
M aintain ing the  levels o f  B R I 205/4 in  the  m edium , during the five hour 
incubation period , d id  n o t reduce the efflux  o f  adriam ycin  from  the cells. The 
results suggest tha t the  export o f  adriam ycin  from  M R P-expressing cells can 
be  inh ib ited  by  indom ethacin  and it's active analogues.
Time Treatment Average fiM 
adriamycin per 
million cells
S.D.
TO A driam ycin  alone 2.4 0.05
T5 A driam ycin  alone 1.0 0.09
TO A driam ycin  +  Indom ethacin 2.3 0.15
T5 (+) Indom ethacin 1.8 0.17
T5 (-) Indom ethacin 1.2 0.17
TO A driam ycin  + 1 3 8 /1 2.3 0.12
T5 (+) 138/1 1.9 0.07
T5 (-) 138/1 1.0 0.22
TO A driam ycin  +  205/4 2.0 0.17
T5 (+) 205/4 0.9 0.09
T5 (-) 205/4 0.7 0.09
T a b le  3 .5 .1 .1 : A driam ycin  levels in  D LK P cells trea ted  w ith  adriam ycin  alone 
versus D L K P cells trea ted  w ith  adriam ycin  and indom ethacin  / indom ethacin  
analogues com bined. D a ta  show n are the average o f  three separate 
determ inations.
TO: T im e po in t im m ediately  after initial 2  h our loading  period  
T5: T im e po in t 5 hours after in itial 2 hour loading period  
(+) Indom ethacin /analogue: F lasks re-fed  w ith  either indom ethacin or 
analogue after in itia l 2 ho u r loading period.
(-) Indom ethacin /analogue: F lasks re-fed  w ith  m ed ia  only after initial 2 hour 
loading  period.
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Adriamycin accumulation studies using HPLC analysis
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F ig u re  3.5 .1 : H P L C  analysis o f  the effect o f  indom ethacin and 
indom ethacin analogues on  adriamycin content in  D LK P cells.
R esults are represented as m eans +/- S.D. fo r triplicate determinations.
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3.5.2 Indomethacin efflux studies
Indom ethacin  e fflux  w as also analysed, by  H PLC , in  cells trea ted  w ith  
indom ethacin  alone o r adriam ycin  and indom ethacin  com bined. The cells, 
w h ich  w ere approxim ately  80%  confluent, w ere 'loaded' fo r tw o hours at 37°C  
w ith  28 p m  indom ethacin  alone, or indom ethacin  and 10pm  adriam ycin  
com bined. A fter the  in itial load ing  period  sam ples w ere taken  at TO and the 
rem ain ing  flasks w ere  re-fed  w ith  either fresh  m edia  or fresh  m ed ia  containing 
adriam ycin  to  assess i f  m ain tain ing  the  level o f  the an ticancer drug in  the  cells 
w ou ld  have an  effect on the  accum ulation o f  indom ethacin  in  the cells. The 
cells w ere incubated  fo r a  further 90 m inutes. (This tim e poin t w as chosen  as 
prelim inary  H P L C  experim ents indicated  th a t fo llow ing tw o hours incubation, 
a fter the  in itial loading  period, the levels o f  indom ethacin  in  the cells had 
decreased to  a lm ost undetectab le  levels).
T he results ind icate  tha t after the initial loading  period  the  level o f  
indom ethacin  in  the  cells w as h igher in  those cells trea ted  w ith  a  com bination  
o f  indom ethacin  and  adriam ycin  (0 .044pM  indom ethacin/m illion  cells) than  
the  level o f  indom ethacin  in  those cells treated  w ith  indom ethacin  alone 
(0 .03 jjM  indom ethacin /m illion  cells). In  those  cells incubated  w ith  bo th  
indom ethacin  and  adriam ycin  during the initial loading period, and then  refed  
w ith  adriam ycin  alone for a  further 90 m inutes, there w as alm ost no  efflux  o f  
indom ethacin  from  the  cells at the end o f  th is period  (0.03 pM  
indom ethacin /m illion  cells) as com pared to  those cells incubated  w ith  fresh  
m ed ia  alone (0.006p.M  indom ethacin /m illion  cells). This suggests that in  the 
p resence o f  ad riam ycin  the efflux  o f  indom ethacin  from  the cell is reduced.
A n  experim ent w as also carried  out to investigate i f  co-incubation o f  
indom ethacin  w ith  adriam ycin  during the in itial loading period  w as requ ired  
for m ain tanance o f  the cellu lar indom ethacin  content. The cells w ere loaded  
for tw o hours w ith  indom ethacin  and after th is in itial period  the  m edia  w as 
rem oved  from  the  cells and the cells w ere refed  w ith  adriam ycin  alone fo r 90 
m inutes incubation. A fter th is incubation the level o f  indom ethacin  in  the cells 
w as m easured  and w as found to have decreased  to  0 .007pM  
indom ethacin /m illion  cells (as com pared to  0 .3pM  indom ethacin  per m illion  
cells in  those cells  co-incubated w ith  indom ethacin  and adriam ycin). These
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resu lts  indicate th a t co-incubation  o f  indom ethacin  w ith  adriam ycin  is required  
fo r the  m ain tenance o f  cellu lar indom ethacin content. T his suggests tha t 
ad riam ycin  and indom ethacin  com pete for the sam e binding  site on  the M R P 
m olecu le  and the  resu lts  indicate th a t adding adriam ycin  to  the  cells after the 
in itia l loading period  only  w as n o t as effective as indom ethacin  had already 
bo u n d  to  the M R P b ind ing  site.
Time Treatment Average j.iM 
indomethacin per 
million cells
S.D.
TO Indom ethacin  alone 0.03 0.002
T 90m in Indom ethacin  alone 0.01 0.002
TO Indom ethacin  +  A driam ycin 0.04 0.008
T 90m in (+) A driam ycin 0.03 0.007
T 90m in (-) A driam ycin 0.01 0.001
T 90m in Indom ethacin  (+  A dr @ T0)* 0.01 0.002
T a b le  3 .5 .2 .1 : Indom ethacin  content in  D LK P cells trea ted  w ith  indom ethacin  
a lone versus D L K P cells treated  w ith  adriam ycin and indom ethacin  com bined. 
D a ta  show n are the  average o f  th ree separate determ inations.
TO: T im e poin t im m ediately  after in itial 2 hour loading  period
T 90m in: T im e po in t 90 m inutes after initial 2 hour loading period
(+) adriam ycin: F lasks re-fed  w ith  adriam ycin  after in itia l 2 hour loading
period .
(-) adriam ycin: F lasks re-fed  w ith  m edia only after in itia l 2 hour loading 
period .
* F lasks w ere incubated  w ith  indom ethacin  alone for the in itial 2 hour loading 
period  and w ere th en  w ashed  and refed  w ith  m edia  contain ing  adriam ycin. 
T hese  flasks w ere subsequently  incubated for a  further 90 m inu tes.
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F ig u re  3.5 .2 : H PL C  analysis o f  the effect o f  adriamycin on  indom ethacin 
conten t in D LK P cells.
R esults are represented  as m eans +/- S.D. for triplicate determ inations.
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3.6 In vitro combination toxicity assays -  CORL23 cell line
The resistan t varian t o f  the  cell line C O RL23, C O R L23(R ), overexpresses 
M RP1 w hich  is no t overexpressed by  the parental form , C O R L23(P) (Kool et 
al, 1998). A  W estern  b lo t carried  out on bo th  cell lines dem onstrates the 
d ifference in  the expression o f  M R P pro tein  in  the cell lines. There is a  very 
low  level o f  expression o f  M R P in  the CO RL23(P) cell line as opposed to  a 
very strong expression  in  the  C O R L23(R ) cell line (figure 3.6.1). As it was 
postu lated  th a t the N S A lD s and indom ethacin  analogues potentiated the 
toxicity  o f  chem otherapeutic  drugs by  inhibiting  M R P (D uffy  e t al., 1998), 
this d ifference in  expression o f  M R P  in  the  CO RL23 cells was exploited to 
further assess the m ode o f  ac tion  o f  the com pounds. A  num ber o f  the BRI 
com pounds, w hich  had been  positive in  the com bination toxicity  assay in 
D L K P cells (section  3.1), w ere added  a t non-toxic concentrations to  both the 
C O R L 23(R ) and C O R L23(P) cells, in  com bination w ith a  range o f  
chem otherapeutic  drugs. The expected  resu lt w as that the  active analogues 
w ould  poten tiate  toxicity  only  in  the  resistan t cell line.
(A) (B)
M RP1 (190kD ) ->
F igure 3.2a: W estern  b lo t analysis o f  CO RL23 variants fo r M RP1 expression 
using  an  M R P1 specific  m onoclonal antibody, M R P rl: (A) 
C O R L23(S); (B ) CO RL23(R).
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Indom ethacin , B R I 153/1, B R I 88/1 and B R I 92/1 in  com bination  w ith  the 
chem otherapeutic  drugs, v incristine , adriam ycin  and V P -16, resu lted  in  an 
increase in  the  tox ic ity  o f  the chem otherapeutic  drugs in  the  C O R L23(R ) cell 
line (Table 3.6 .6b, 3.6.9b and 3.6.15b). There w as ev idence o f  an  increase in  
the  tox ic ity  o f  the  sam e drugs in  the  C O R L23(P) cell line (Table 3.6.6a, 3.6 .9a 
and 3.6.15a). H ow ever, there is low  expression o f  M R P 1 in  th is parental cell 
line (K ool et ah, 1997) (and  as show n in  figure 3.2a) w hich  ind icates th a t th is 
po ten tia tion  o f  tox icity  by  the indom ethacin  analogues is ev ident even  in  the 
p resence o f  a  very  low  expression  o f  M R P1. The hypothesis tha t the 
com pounds in teract w ith  M R P w as further strengthened by  the results 
ob tained  in  the com bination  tox ic ity  assays on  the CO RL23 cell lines using 
the  indom ethacin  analogues and  the  M R P-negative chem otherapeutic  drugs 
5 ’F luorouracil and cisplatin. T here w as no evident increase in  tox ic ity  o f  these 
drugs in  any o f  the  tox icity  assays w hen  used  in  com bination w ith  B R I 88/1, 
92/1, 153/1, su lindac and indom ethacin  (Table 3.6.12b).
In teresting ly , su lindac, indom ethacin  and the  positive indom ethacin  analogues, 
B R I 88/1, 92/1 and  153/1 also poten tia ted  the  tox icity  o f  the  taxanes, taxol and 
taxotere, in  bo th  the  resistan t and  the  parental CO RL23 cell lines. There w as 
only  sligh tly  greater enhancem ent in  the resistan t cell line than  in  the  sensitive 
cell line. The com bination index  values for the short-term  com bination 
tox ic ity  assays w ere low er th an  those obtained w ith  the long-term  assays using 
the  sam e drug  com binations suggesting that sulindac is n o t as effective at 
po ten tia ting  the  tox icity  o f  these anticancer drugs in the short-term  assay and 
requires longer incubation  tim es to  exert the optim um  effect (see section 3.8). 
T axol and  taxo tere  toxicity  w as also analysed in  these cell lines in  
com bination  w ith  the negative indom ethacin  analogue 205/4. The results 
ind icated  that there  w as also no enhancem ent o f  the tox icity  o f  taxo l or 
taxo tere  by  th is  negative analogue. These resu lts w ould  suggest that the 
enhancem ent o f  the  tox icity  o f  taxol and taxotere, by the active com pounds, is 
th rough  the  sam e m echanism  by w hich  the toxicity  o f  adriam ycin , vincristine 
and V P -16 are potentiated . H ow ever, the taxanes had p reviously  been  reported  
by  a  num ber o f  authors including C ole et ah, (1992), and T w entym an  et ah, 
(1994), to  be poor M RP1 substrates.
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The resu lts  from  the  toxicity  assays on  the parental CO RL23 cell line, using  a  
com bination  o f  v incristine and indom ethacin , 88/1 o r 92/1 dem onstrated  a  
sign ificant enhancem ent o f  the tox ic ity  o f  the chem otherapeutic  drug. This 
enhancem ent w as com parable to  the  m agnitude o f  the enhancem ent effect in  
the  resistan t C O R L23 cell line. T he C O R L 23(R ) cells w ere m ore resistan t to 
the range o f  an ti-cancer drugs analysed in th is set o f  experim ents w hich  seem s 
to  correla te  w ith  the  overexpression o f  M RP1 in  the C O R L 23(R ) cell line. 
T here w as sligh tly  greater enhancem ent o f  adriam ycin, v incristine, Y P16, 
taxo l and taxotere  in  the C O R L23(R ) cell line than  in  the C O R L23(P) cell 
line. H ow ever, the  com bination index  values obtained  for bo th  o f  the  cell lines 
suggest tha t the  level o f  the expression o f  M R P does n o t appear to strictly 
correlate to  the  rate  o f  po ten tia tion  o f  the  an ticancer drug by  the positive  
N SA ID s. D uffy  et al., (1998), also dem onstrated  h igher levels o f  M R P pro tein  
expression  in  the A 549, a  hum an  lung adenocarcinom a cell line, than  in the 
D L K P cell line. Y et, the authors reported  com parable synergistic com bination 
o f  selected  N S A ID s w ith  certain  chem otherapeutic  drugs in  both  cell lines. 
N ote:
•  A ll tox ic ity  assays in  th is section, except for those specifically  referred  to 
as “ Short-term ” w ere carried according to section  2 .7 .3a i.e. 7 day tox icity  
assays w hereby  drug and/or com pound w ere added to the cells on D ay  2 
and  rem ain  in  the  cells until D ay 7 w hen  the cells w ere analysed.
•  T he Short-term  toxicity  assays referred  to  in  th is section w ere perform ed 
using  the  m ethod  described in  section  2 .7 .3b  i.e. 6 day toxicity  assays 
w hereby  the  cytotoxic drugs and test inhibitors are added to  the  cells on 
D ay  2 and w ere incubated in the assay for a  period  o f  four hours only. The 
cells w ere th en  re-fed  w ith  fresh m edia  and incubated  until D ay 6 w hen the 
cells w ere analysed.
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E
ORL23(P), Adriamycin + BRI 153/1 and Indomethacin.
est Sample % Cell Survival S.D.
dr. 20 ng/ml 52 .8  4 .7
Indo (2.5pg/ml) 1 0 1 . 6  5.6
Indo + Adr 31.9 6.4
|Indo (1.25fxg/ml) 10 4 .5  5 .7
Indo +A dr 32.9 4.3
Indo (0.625p.g/ml) 98.7  5 .0
Indo + Adr 38.5 5.7
153/1 (50p.g/ml) 97.5  5.9
153/1 + Adr 34.8 5.0
153/1 (25|og/mI) 10 5 .0  4.3
153/1 + Adr 38.1 9.0
153/1 (12.5]Lig/ml) 10 4 .2  4 .4
153/1 + Adr 41.4 5.1
Adr. 10 ng/ml 9 5 .4 5  4 .7
Indo (2.5pg/ml) 1 0 1 . 3  4 . 1
Indo + Adr 87.1 4.4
Indo (1.25p.g/ml) 1 0 1 . 4  2 .5
Indo + Adr 91.0 L9
Indo (0.625|og/ml) 10 0 .7  1 .9
Indo +A dr 95.2 1.6
153/1 (50|J.g/ml) 10 0 .3  4.7
153/1 + Adr 81.1 6.0
153/1 (25jJ.g/ml) 10 3 .7  3 .0
153/1 + Adr 86.0 1.6
153/1 (12.5|ag/ml) 10 3 .8  3 .8
153/1 + Adr 90.1 6.2
Table 3.6.1: %  Survival o f  CO RL23 (parental) cells in  the presence o f  various 
concentrations o f  adriam ycin , indom ethacin  and B R I 153/1 as found using the 
pro tocol detailed  in  section  2.7.3a. Survival is represen ted  as a  %  o f  the 
grow th o f  un trea ted  cells in  the sam e plate ±  S.D . R esults are the average o f  
trip licate determ inations in  three separate experim ents.
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CORL23(R), Adriamycin + B R I153/1 and Indomethacin. 
Test Sample % Cell Survival S.D.
Adr. 250ng/ml 46.7 3.1
Indo (2.5ng/ml) 98.1 3.8
Indo + Adr 16.1 5.7
Indo (1.25jJ,g/ml) 101.0 4.3
Indo +A dr 21.4 3.6
Indo (0.625|J.g/ml) 100.6 201
Indo + Adr 28.7 4.1
153/1 (50|Xg/ml) 103.4 5.8
153/1 + Adr 13.0 1.4
153/1 (25^ig/ml) 103.1 3.0
153/1 + Adr 25.7 3.8
153/1 (12.5|ag/ml) 106.5 5.1
153/1 + Adr 36.3 3.1
Adr. 125 ng/ml 74.6 2.8
Indo (2.5|og/ml) 102.3 3.7
Indo + Adr 31.2 7.5
Indo (1.25jo.g/ml) 102.0 3.6
Indo + Adr 47.0 5.1
Indo (0.625|J.g/ml) 99.1 7.6
Indo + Adr 60.2 6.5
153/1 (50|Og/ml) 102.2 4.4
153/1 + Adr 18.5 5.2
153/1 (25[ig/ml) 98.3 7.6
153/1 + Adr 48.8 2.9
153/1 (12.5fxg/ml) 105.0 4.6
153/1 + Adr 63.7 4.7
T a b le  3 .6 .2 : %  Survival o f  CO RL23 (resistant) cells in  the presence o f  various 
concentrations o f  adriam ycin, indom ethacin  and BR I 153/1 as found using  the 
p ro tocol detailed  in  section  2.7.3a. Survival is represented  as a  % o f  the  grow th  
o f  untreated  cells  in  the sam e plate ±  S.D. R esults are the average o f  trip licate  
determ inations in  three separate experim ents.
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CORL23(P), Adriamycin + BRI 88/1, 92/1 and Indomethacin. 
Test Sample % Cell Survival S.D.
Adr. 20 ng/ml 3 8 .0 7.2
Indo (2.5|xg/ml) 98.9 1 . 2
Indo +A dr 18.5 4.6
Indo (1.25|ig/ml) 1 0 1 . 7 2.8
Indo +A dr 21.04 11.1
Indo (0.625fO,g/ml) 10 0 .7 2.9
Indo +A dr 24.3 13.7
88/1 (5jJ,g/ml) 10 3 .0 5.6
88/1 + Adr 17.2 1.3
88/1 (2.5fxg/ml) 97.8 4.8
88/1 + Adr 19.1 1.6
88/1 (1.25fJ,g/ml) 9 7 . 1 6.8
88/1 + Adr 18.4 2.1
92/1 (5|ig/ml) 10 2 .0 1 1 . 7
92/1 + Adr 24.6 8.6
92/1 (2.5|i.g/ml) 10 7 .7 4 . 1
92/1 + Adr 25.2 9.8
92/1 (1.25fig/ml) 10 8 .4 9.5
92/1 + Adr 26.5 8.3
Table 3.6.3: %  Survival o f  CORL23 (parental) cells in  the presence o f  
20ng /m l adriam ycin  +  various concentrations o f  indom ethacin , B R I 88/1 or 
B R I 92/1, as found  using  the protocol detailed  in  section 2.7.3a. Survival is 
represen ted  as a  %  o f  the  grow th o f  untreated  cells in  the  sam e p late  ±  S.D. 
R esu lts  are the  average o f  triplicate determ inations in  three separate 
experim ents.
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CORL23(R), Adriamycin + BRI 88/1, 92/1 and Indomethacin. 
Test Sample % Cell Survival S.D.
Adr. 250 ng/ml 29 .2 1 1 . 4
Indo (2.5|0g/ml) 99.3 1 .4
Indo + Adr 13.0 2.9
Indo (1.25fJ.g/ml) 99.8 2 . 1
Indo +A dr 20.4 4.8
Indo (0.625|ig/ml) 1 0 1 . 0 4.8
Indo + Adr 31.9 12.8
88/1 (5|J.g/ml) 1 0 1 . 9 2.5
88/1 + Adr 5.8 1.0
88/1 (2.5ng/ml) 10 0 .9 5 .2
88/1 + Adr 7.8 0.7
88/1 (1.25(J,g/ml) 10 2 .4 5.9
88/1 (3) + Adr 11.1 1.8
92/1 (5|4,g/ml) 94.0 7.6
92/1 + Adr 9.7 0.2
92/1 (2.5^ig/ml) 10 0 .7 6.5
92/1 + Adr 14.9 1.0
92/1 (1.25^ig/ml) 10 3 .4 9 .1
92/1 + Adr 19.6 2.5
T a b le  3.6 .4 : %  Survival o f  CORL23 (resistant) cells in  the presence o f  
250ng/m l adriam ycin  +  various concentrations o f  Indom ethacin , B R I 88/1 or 
B R I 92/1, as found  using  the protocol detailed  in  section  2.7.3a. Survival is 
represented  as a  %  o f  the  grow th o f  untreated  cells in  the sam e plate ±  S.D. 
R esults are the  average o f  triplicate determ inations in  three separate 
experim ents.
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CORL23(P) A driam ycin and B R I 205/4 
Test Sample % Cell Survival S.D.
Adr. 20ng/ml 3 2 .7 4.6
205/4 (25|J,g/ml) 9 8 .1 6.0
205/4 + Adr 28.6 2.6
205/4 (12.5fig/ml) 9 7 .7 4 .7
205/4 + Adr 29.9 3.5
205/4 (6.25fig/ml) 98.2 3 . 1
205/4 + Adr 31.3 3.1
CORL23(R) Adriam ycin and BR I 205/4 
Test Sample % Cell Survival S.D.
Adr. 250ng/ml 50.8 2.9
205/4 (25|J,g/ml) 10 3 .2 6.4
205/4 + Adr 46.9 2.6
205/4 (12.5|J,g/ml) 96.4 3 . 1
205/4 + Adr 47.9 2.4
205/4 (6.25|4.g/ml) 10 3 .3 6.4
205/4 + Adr 51.1 4.3
T a b le  3.6 .5 : %  Survival o f  C O R L23(P) and C O R L23(R ) cells in  the presence 
o f  adriam ycin, in  com bination  w ith  205/4 as found using  the  protocol detailed  
in  section 2.7.3a. Survival is represented  as a %  o f  the grow th  o f  untreated  
cells in  the sam e p late  ±  S.D. R esults are the average o f  trip licate 
determ inations in  th ree  separate experim ents.
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No Anticancer 
agent
Adriamycin
(20ng/ml)
Cl values
No NSAID 10 0  +  0.0 52 .8  ± 4 . 7
Indomethacin 2.5|ig/ml 1 0 1 . 6  +  5.6 3 1 . 9  +  6.4 0.779
B R I153/1 50|ig/ml 9 7.5  +  5.9 34 .8  +  5 .0 0 .8 13
BQTi-. ’. * . • )
B  - . • | w ' i i v  ?  U M . ■ v .
No NSAID 10 0  +  0.0 3 8 .0  +  7 .2
Indomethacin 2.5(ig/ml 9 8 . 9 + 1 . 2 18 .5  +  4.6 0 .672
BRI 88/1 5jjg/ml 10 3 .0  +  5.6 1 7 . 2  +  1 .3 0.670
BRI 92/1 5 jog/ml 1 0 2 . 0 + 1 1 . 7 2 4 .6  ±  8.6 0.749
1 ‘ - - '
. . .
'• -'=: • •
No NSAID 10 0  +  0.0 3 8 .9  +  5.5
BRI 205/4 2.5(j.g/ml 9 8 . 1 + 6 . 0 3 6 . 3 + 4 . 2 1 .0
T a b le : 3 .6 .6a: C O R L 23(P), A driam ycin  +  h ighest non-toxic concentrations o f  
indom ethacin  and indom ethacin  analogues.
D ata  are expressed as % Cell Survival ±  standard dev iation  for a  m inim um  o f  
three assay repeats.
S tatistical w eight o f  the  resu lts is indicated  by  C l values (see section  2.16)
C l: C om bination  index  values.
C l < 1: synergism ; C l > 1: antagonism ; C l =  1: additive.
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No Anticancer  
agent
Adriainycin
(20ng/nil)
C l values
No NSAID 100 ± 0 . 0 46.7 ±3.1
Indomethacin 2.5(0,g/ml 98.1 ±3.8 16.1 ±5.7 0.542
BRI 153/1 50jxg/ml
No NSAID
10 3 .4  ± 5 . 9
100 ± 0.0
1 3 .0  ±  1 .4 0.382
2 9 .2  ±  1 1 . 4
Indom ethacin  2.5|a.g/ml 99.3 ±  1 .4 13 .0  ± 2 . 9 0.704
BRI 88/1 5(j.g/ml 1 0 1 . 9  ± 2 . 5 5.8 ± 1 . 0 0.432
BRI 92/1 5 fig/ml
No NSAID
94.0 ±  7.6
100 ± 0.0
9.7  ± 0 . 2 0.552
S . 7
50.8 ± 2 . 9
BRI 205/4 2.5|og/ml 10 3 .2  ± 6 . 4 4 7 .0  ± 2 . 6 1.0
T a b le : 3 .6 .6b : C O R L 23(R ), A driam ycin  +  h ighest non-toxic  concentrations 
o f  indom ethacin  and indom ethacin  analogues.
D ata  are  expressed  as %  Cell Survival ±  standard deviation for a  m inim um  o f  
three assay  repeats.
S tatistical w eigh t o f  the  resu lts is indicated  by C l values (see section  2.16)
C l : C om bination  index.
C l < 1: synergism ; C l > 1: antagonism ; C l =  1: additive.
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CORL23(P), Vincristine + BRI 88/1, 92/1 and Indomethacin.
Test Sample % Cell Survival S.D.
Vin. 1 ng/ml 42 .0 2 .4
Indo (2.5j.ig/ml) 99.3 0.9
Indo +V in 11.3 3.2
Indo (1.25|J.g/ml) 99.5 0.7
Indo + Vin 12.6 0.5
Indo (0.625|Xg/ml) 98.8 0.7
Indo +V in 16.4 3.4
88/1 (5fJ.g/ml) 90.5 5 . 1
88/1 + Vin 12.9 1.2
88/1 (2.5|J,g/mI) 9 7 . 1 8.5
88/1 + Vin 18.6 2.3
88/1 (1.25|Xg/ml) 1 0 1 . 3 6.2
88/1 + Vin 31.9 3.4
92/1 (5ng/ml) 106 .8 7.7
92/1 + Vin 19.0 2.4
92/1 (2.5ng/ml) 10 9 . 1 7.8
92/1 + Vin 20.6 0.9
92/1 (1.25fJ.g/ml) 10 8 .2 1 .9
92/1 + Vin 22.8 1.6
T a b le  3 .6 .7 : %  Survival o f  CO RL23 (parental) cells in  the presence o f  ln g /m l 
V incristine  +  various concentrations o f  indom ethacin  B R I 88/1, 92/1, as found 
using  the p ro toco l detailed  in  section 2.7.3a. Survival is represented as a  %  o f  
the  grow th  o f  un treated  cells in  the  sam e plate ±  S.D.
R esults are the  average o f  trip licate determ inations in  three separate 
experim ents.
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CORL23(R), Vincristine + BRI 88/1, 92/1 and Indomethacin.
Test Sample % Cell Survival S.D.
Vin. 12 ng/ml 57 .5 1 5 . 1
Indo (2.5|ag/ml) 98.9 1 . 7
Indo +V in 16.9 3.0
Indo (1.25)J.g/ml) 10 5 .0 4.4
Indo +V in 27.7 3.6
Indo (0.625)0g/ml) 10 5 .3 4.5
Indo +V in 38.7 3.2
88/1 (5|Xg/ml) 90.4 4.8
88/1 + Vin 15.2 1.5
88/1 (2.5|Og/ml) 92.0 8.0
88/1 + Vin 18.9 2.1
88/1 (1.25)ig/ml) 92.5 2.8
88/1 + Vin 44.4 1.43
92/1 (5|0g/ml) 93.3 7.3
92/1 + Vin 11.5 3.7
92/1 (2.5|0g/ml) 96.0 9.4
92/1 + Vin 17.7 6.9
92/1 (1.25)ig/ml) 10 0 .3 6.0
92/1 + Vin 25.0 10.4
T a b le  3.6 .8 : %  Survival o f  CO RL23 (resistant) cells in  the presence o f  12 
ng /m l V incristine  +  various concentrations o f  indom ethacin  B R I 88/1, 92/1, as 
found  using  the p ro toco l detailed  in  section 2.7.3a. Survival is represented as a 
%  o f  the grow th o f  un treated  cells in  the sam e plate ±  S.D.
R esults are the average o f  triplicate determ inations in  th ree separate 
experim ents.
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No Anticancer 
agent
Vincristine
(lng/.n l)
C l values
No NSAID 100 ± 0 . 0 42.0 ± 2 . 4
Indom ethacin 2.5p,g/ml 99.3 ± 0 . 9 11.3 ± 3 . 2 0.333
BRI 88/1 5(ag/ml 90.5 ± 5 .1 12.9 ±  1.2 0.554
BRI 92/1 5|ag/ml 106.8 ± 7 . 7 19.0 ± 2 . 3 6 0.532
Table: 3.6.9a: CO R L23(P), V incristine  +  highest non-toxic  concentrations o f  
indom ethacin  and indom ethacin  analogues.
D a ta  are expressed as % Cell Survival ±  standard dev iation  for a m inim um  o f  
th ree  assay repeats.
No Anticancer 
agent
Vincristine
(12ng/nil)
C l values
No NSAID 100 ± 0 . 0 57.5 ±  15.1
Indom ethacin 2.5fJ.g/ml 98.9  ± 1.7 16.9 ± 3 . 0 0.417
BRI 88/1 5(j.g/ml 90.4 ± 1.5 15.2 ±  1.5 0.329
BRI 92/1 5(J.g/ml 93.3 ± 7 .3 11.5 ±  3.7 0.284
Table: 3.6.9b: CO R L23(R ), V incristine  + h ighest non-toxic concentrations o f  
indom ethacin  and indom ethacin  analogues.
D ata  are expressed as %  C ell Survival ±  standard deviation  for a m inim um  o f  
th ree  assay repeats.
S tatistical w eight o f  the results is indicated by Cl values (see section  2.16)
Cl: Combination index values.
Cl < 1: synergism; Cl > 1: antagonism; Cl = 1: additive.
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I CORL23(P), 5-FU + BRI 92/1, 88/1 and Indomethacin.
Test Sample % Cell Survival S.D.
5-FU. 0.4 (ig/ml 28.9 1 . 1
Indo (2.5p,g/ml) 97.4 2 .8
Indo + 5-FU 27.7 7.0
Indo (1.25|Og/ml) 99.6 1.9
Indo + 5-FU 27.0 7.3
Indo (0.625)4g/ml) 98.8 1 .6
Indo + 5-FU 27.2 6.5
92/1 (5|xg/ml) 10 3 .5 1 1 . 6
92/1 + 5-FU 28.2 9.3
92/1 (2.5jog/ml) 10 3 .3 7.8
92/1 + 5-FU 27.7 8.8
92/1 (1.25|og/ml) 10 5 .2 8.2
92/1 (3) + 5-FU 28.7 9.2
88/1 (5ng/ml) 97.8 4.7
88/1 + 5-FU 28.4 3.1
88/1 (2.5|Og/ml) 9 9 .1 2 .0
88/1 + 5-FU 28.9 4.0
88/1 (1.25)og/ml) 99.0 4.3
88/1 + 5-FU 28.2 7.1
T a b le  3 .6 .10: %  Survival o f  C O R L23 (parental) cells in  the presence o f  0.4 
fog/ml 5 ’F luorouracil +  various concentrations o f  indom ethacin, BR I 88/1 and 
B R I 92/1, as found  using  the p ro tocol detailed  in  section 2.7.3a. Survival is 
represen ted  as a  %  o f  the grow th  o f  un treated  cells in  the sam e p late  ±  S.D. 
R esults are the average o f  trip licate determ inations in  three separate 
experim ents.
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CORL23(R), 5-FU + BRI 92/1, 88/1 and Indomethacin.
Test Sample % Cell Survival S.D.
5-FU. 0.4 jig/ml 15 .5 1 . 2
Indo (2.5|xg/ml) 99.0 4.6
Indo + 5-FU 14.0 5.0
Indo (1.25p,g/ml) 99.9 6.5
Indo + 5-FU 14.0 4.0
Indo (0.625jag/ml) 1 0 1 . 9 6.3
Indo (4) + 5-FU 14.2 3.5
92/1 (5fj.g/ml) 94.6 0.9
92/1 + 5-FU 15.7 3.5
92/1 (2.5|i.g/ml) 92.9 1 .8
92/1 + 5-FU 15.3 3.0
92/1 (1.25/ig/ml) 9 7 . 1 8.2
92/1 (3) + 5-FU 15.4 3.5
88/1 (5(4,g/ml) 98.8 5.8
88/1 + 5-FU 14.9 1.4
88/1 (2.5jo.g/ml) 9 9 .1 2.0
88/1 + 5-FU 15.1 1.8
88/1 (1.25|4g/ml) 99.0 4.3
88/1 + 5-FU 15.6 1.8
T a b le  3 .6 .11 : %  Survival o f  C O R L23 (resistant) cells in  the  presence o f  2.0 
fxg/ml 5 ’F luorouracil +  various concentrations o f  indom ethacin, B R I 88/1 and 
B R I 92/1, as found using  the p ro tocol detailed  in  section 2 .7.3a. Survival is 
represen ted  as a %  o f  the grow th  o f  untreated  cells in  the sam e p late  ±  S.D. 
R esu lts are the average o f  trip licate determ inations in  th ree  separate 
experim ents.
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No Anticancer 
agent
5-FU
(0.4|.ig/ml)
Cl values
No NSAID 100 ± 0 . 0 28.9 ± 1.1
Indomethacin 2 .5 |4.g/ml 97.4 ± 2 . 8 27.7 ±  7.0 1.000
BRI 88/1 5jig/ml 97.8 ± 4 . 7 28.4 ± 3 .1 1.000
BRI 92/1 5(j,g/ml 103.5 ±  11.6 28.2 ± 9 . 3 1.146
Table: 3.6.12a: C O R L23(P), 5-FU  +  h ighest non-toxic  concentrations o f  
indom ethacin  and indom ethacin  analogues.
D ata  are expressed  as %  C ell Survival ±  standard dev iation  fo r a m inim um  o f  
th ree assay  repeats.
No Anticancer 
agent
5-FU
(2 .0ng/ml)
Cl values
No NSAID 100 +  0.0 15.45 ±  1.2
Indomethacin 2.5 fig/ml 99.0 ±  4.6 14.0 +  5.2 1.114
BRI 88/1 5fig/ml 98.8 +  5.8 14.9 ±  1.4 1.151
BRI 92/1 5|j.g/ml 94.6 ±  0.9 15.7 ±  3.5 1.127
Table: 3.6.12b: C O R L 23(R ), 5-FU  +  h ighest non-toxic concentrations o f  
indom ethacin  and indom ethacin  analogues*.
D ata  are expressed  as %  Cell Survival ±  standard deviation  fo r a  m inim um  o f  
th ree  assay  repeats.
S tatistical w eigh t o f  the  results is indicated by  C l values (see section  2.16)
Cl: Combination index values.
Cl < 1: synergism; Cl > 1: antagonism; Cl = 1: additive.
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CORL23(P), VP-16 + BRI 88/1, BRI 92/1 and Indomethacin
Test Sample % Cell Survival S.D,
VP-16. 0.4 |xg/ml 2 3 .4 2.8
Indo (2.5|Jg/mI) 99.0 4.6
Indo + VP-16 15.5 6.7
Indo (1.25jig/ml) 99.9 6.5
Indo + VP-16 18.5 2.1
Indo (0.625|ug/ml) 1 0 1 . 9 6.3
Indo + VP-16 21.7 1.7
88/1 (5jig/ml) 90.8 3.6
88/1 + VP-16 16.2 1.3
88/1 (2.5|ig/ml) 10 2 .6 8.0
88/1 + VP-16 20.7 3.7
88/1 (1.25fig/ml) 1 0 1 . 2 3 .9
88/1 + VP-16 22.1 7.2
92/1 (5(ig/ml) 96.0 7 . 1
92/1 + VP-16 16.8 4.4
92/1 (2.5|ig/ml) 98.7 7.8
92/1 + VP-16 19.2 3.6
92/1 (1.25/o.g/ml) 1 0 1 . 4 8.5
92/1 + VP-16 20.4 3.0
T a b le  3 .6 .13: %  Survival o f  CO RL23 (parental) cells in  the presence o f  
0.1(j.g/ml V P-16 + various concentrations o f  indom ethacin , B R I 88/1 and BRI 
92/1 as found  using the  p ro tocol detailed  in  section 2.7.3a. Survival is 
represen ted  as a  %  o f  the grow th  o f  un treated  cells in  the sam e plate ±  S.D. 
R esults are the average o f  trip licate determ inations in  three separate 
experim ents.
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CORL23(R), VP-16 + BR1 88/1, BRI 92/1 and Indomethacin
Test Sample % Cell Survival S.D.
VP-16.2.5 jig/ml 3 4 .5 5.3
Indo (2.5fj.g/ml) 99.0 4.6
Indo + VP-16 9.9 3.4
Indo (1.25|J.g/ml) 99.9 6.5
Indo + VP-16 15.1 7.2
Indo (0.625fxg/ml) 1 0 1 . 9 6.3
Indo + VP-16 19.0 4.4
88/1 (Sfig/ml) 93.8 3.6
88/1 + VP-16 9.8 1.1
88/1 (2.5ng/ml) 94.5 3.6
88/1 + VP-16 13.1 2.3
88/1 (1.25^g/ml) 9 8 .1 5 . 1
88/1 + VP-16 19.8 3.5
92/1 (5jJ.g/ml) 96.0 7 . 1
92/1 + VP-16 10.1 5.1
92/1 (2.5jig/ml) 98.7 7.8
92/1 + VP-16 14.6 1.5
92/1 (1.25jxg/ml) 1 0 1 . 4 8.5
92/1 + VP-16 21.2 3.3
L _         _
T a b le  3 .6 .14 : %  Survival o f  C O R L23 (resistant) cells in  the presence o f  
2.5|Xg/ml V P 16 +  various concentrations o f  BR I 88/1, B R I 92/1 and 
indom ethacin  as found  using  the p ro tocol detailed  in  section 2.7.3a.
Survival is represented  as a %  o f  the  grow th o f  untreated cells in  the sam e 
plate  ±  S.D . R esu lts are the average o f  trip licate determ inations in  three 
separate experim ents.
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No Anticancer 
agent
VP-16
(O.lfig/ml)
Cl values
No NSAID 100 ± 0 . 0 28.9 ±  1.1
Indomethacin 2.5|ig/ml 99.0 ± 4 . 6 15.5 ± 6 . 7 0.893
BRI 88/1 5jJ,g/ml 90.8 ± 3 . 6 16.2 ±  1.3 0.922
BRI 92/1 5(J.g/ml 96.0 ± 7 .1 16.8 ± 4 . 4 0.895
T a b le : 3 .6 .15a : C O R L23(P), V P 16 + h ighest non-toxic concentrations o f  
indom ethacin  and indom ethacin  analogues.
D ata  are expressed  as %  Cell Survival ±  standard deviation for a m in im u m  o f  
three assay  repeats.
No Anticancer 
agent
VP-16
(2.5^g/ml)
Cl values
No NSAID 100 ± 0 . 0 34.5 ± 5 . 3
Indomethacin 2.5|ag/ml 99.0 ± 4 . 6 9.9 ± 3 . 4 0.572
BRI 88/1 5(j,g/ml 93.8 ± 3 . 6 9.8 ±  1.1 0.569
BRI 92/1 5(j,g/ml 96.0 ± 7 .1 10.1 ± 5 .1 0.541
T a b le : 3 .6 .15b : C O R L23(R ), V P16 +  h ighest non-toxic concentrations o f  
indom ethacin  and indom ethacin  analogues.
D ata are  expressed  as %  Cell Survival ± standard deviation for a m in im um  o f  
three assay  repeats.
S tatistical w eigh t o f  the results is indicated by  C l values (see section  2.16)
Cl: Combination index values.
Cl < 1: synergism; Cl > 1: antagonism; Cl = 1: additive.
182
CORL23, Taxol, Taxotere & Sulindac
Test Sample % Cell Survival S.D.
CORL23(P) Taxotere and Sulindac
Taxotere. 1.0ng/ml 45 .7  4.9
Sul (8jig/ml) 9 2 .1  0.4
Sul + Taxotere 23.9 2.1
Sul(4ng/ml) 98.7 2 . 1
Sul + Taxotere 32.5 3.9
Sul (2|4g/ml) 1 0 1 . 1  2 .0
Sul + Taxotere 40.4 11.0
CORL23(R) Taxotere and Sulindac
Taxotere. 2.0ng/ml 50.7 6.6
Sul (8fjg/ml) 9 1 .0  0 . 1
Sul + Taxotere 27.7 1.7
Sul (4^g/ml) 98.9 2 .5
Sul + Taxotere 31.5 3.5
Sul (2jag/ml) 10 2 .5  3 .5
Sul + Taxotere 33.6 0.1
CORL23(P) Taxol and Sulindac
Taxol. 1.0ng/ml 34.5  4 .2
Sul (8ng/ml) 93.8 1 .9
Sul + Taxol 16.8 0.5
Sul (4|4,g/ml) 99 .1  4 .5
Sul + Taxol 23.4 5.5
Sul (2|xg/ml) 104 .9  1 .9
Sul + Taxol 25.1 7.4
CORL23(R) Taxol and Sulindac
Taxol. 7.0ng/ml 39.5  3 .8
Sul (8ng/ml) 94.0 2 .8
Sul + Taxol 22.1 0.9
Sul (4|ug/ml) 98.4 1 .8
Sul + Taxol 28.5 2.4
Sul (2|xg/ml) 1 0 2 . 1  2 .6
Sul + Taxol 33.6 0.6
Table 3.6.16: %  Survival o f  C O R L23(P) and  C O R L23(R ) cells in  the 
presence o f  T axo tere  and Taxol, in  com bination  w ith  sulindac, as found  using 
the p ro tocol detailed  in  section 2.7.3a. Survival is represented  as a  %  o f  the 
grow th o f  un trea ted  cells in  the sam e plate  ±  S.D . R esults are the average o f 
trip licate de term inations in  three separate experim ents.
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SHORT TERM  ASSAY: CORL23, Taxol, Taxotere & Sulindac
Test Sample % Cell Survival S.D.
CORL23(P) Taxotere and Sulindac
Taxotere. 4.0ng/ml 46.4 1.9
Sul (8jig/ml) 92.4 0.3
Sul + Taxotere 22.4 2.1
Sul (4|xg/ml) 98.6 5.3
Sul + Taxotere 29.0 0.4
j Sul (2jjg/ml) 99.6 0.6
Sul + Taxotere 31.9 1.8
CORL23(R) Taxotere and Sulindac
Taxotere. 8.0ng/ml 48 .2 1.9
Sul (8jjg/ml) 99.6 0.6
Sul + Taxotere 28.4 4.8
Sul (4fjg/ml) 10 0 .5 1 .4
Sul + Taxotere 33.3 1.7
Sul (2fig/ml) 99.6 0.6
Sul (3 ) + Taxotere 36.0 4.4
CORL23(P) Taxol and Sulindac
Taxol. 90ng/tnl 4 3 .4 0.2
Sul (8|4g/ml) 1 0 1 . 3 0.7
Sul + Taxol 29.7 4.4
Sul (4fjg/ml) 99.9 0.5
, Sul + Taxol 36.4 0.1
Sul (2 fig/ml) 98.9 0.5
Sul + Taxol 38.0 1.0
CORL23(R) Taxol and Sulindac
Taxol. 180ng/ml 5 5 .7 4.6
Sul (8j.ig/ml) 96.3 7.4
Sul + Taxol 39.9 4.0
Sul (4(xg/ml) 97.5 3 .6
i Sul + Taxol 43.3 1.9
Sul (2|jg/ml) 1 0 1 .9 2.0
Sul + Taxol 48.4 3.8
T a b le  3 .6 .17: %  Survival o f  C O R L23(P) and C O R L23(R ) cells in  the 
p resence o f  Taxotere and Taxol, in  com bination  w ith  sulindac, as found using 
the  p ro tocol detailed  in  section 2.7 .3b (Short term  assay). Survival is 
represented  as a %  o f  the grow th o f  un treated  cells in the  sam e plate ±  S.D. 
R esults are the average o f  trip licate determ inations in  three separate 
experim ents.
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Long-term assay
No NSAID Sulindac
(8 |.ig/ml)
Cl values
CORL23(P) [
ferUL" ... i . . t - . '. : . :i
No Anticancer agent 100 ± 0 . 0 92.1 ± 0 . 4
Taxol 1.0ng/ml 34.5 ± 4 . 2 16.8 ± 0 . 5 7 0.652
Taxotere 1.0ng/ml 45.7  ± 4 . 9 23.9 ± 2 .1 0.679
CORL23(R)
•
No Anticancer agent 100 ± 0 . 0 94.0 ± 2 . 8
Taxol 7.0ng/ml 39.5 ± 3 . 8 22.1 ± 0 . 9 0.559
Taxotere 2.0ng/ml 50.7 ± 6 . 6 27.7 ±  1.7 0.474
Table: 3.6.18a: Long-term  assay: CO RL23 cell lines +  Taxol/Taxotere +  
H ighest non-toxic  concentrations o f  Sulindac.
D ata  are expressed  as % Cell Survival ±  standard deviation  for a m inim um  o f  
th ree  assay repeats.
Short-term assay
No NSAID Sulindac 
(8 ng/ml)
Cl values
CORL23(P)
■ .■ ■ .. . . -•
No Anticancer agent 100 ± 0 . 0 96.3 ± 7 . 4
Taxol 90.0ng/ml 43.4 ± 0.2 29.7 ± 4 . 4 0.905
Taxotere 4.0ng/ml 46.4 ± 1 . 9 22.4 ± 2 .1 0.779
CORL23(R)
No Anticancer agent 100 ± 0 . 0 96.3 ±  7.4
Taxol 180.0ng/ml 55.7 ± 4 . 6 39.9 ± 4 . 0 0.852
Taxotere 8.0ng/ml 48.2 ±  1.9 28.4 ± 4 . 8 0.729
Table: 3.6.18b: Short-term  assay: CO RL23 ce 1 lines +  T axol/Taxotere +
H ighest non-toxic concentrations o f  Sulindac.*
D ata  are expressed  as %  C ell Survival ±  standard deviation for a  m inim um  o f  
th ree  assay repeats.
Cl: C om bination  index values.
C l < 1 : synergism ; C l >  1 : antagonism ; C l =  1 : additive.
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CORL23 cell lines + Taxol and Indomethacin
Test Sample % Cell Survival S.D
CORL23(P) Taxol and Indomethacin
Taxol. 1.0ng/ml 3 3 . 1 2 .7
Indo (2.5jxg/ml) 10 0 .5 0.8
Indo + Taxol 17.0 2.1
Indo (1.25jJ.g/ml) 100 .6 1 .5
Indo + Taxol 23.2 2.4
Indo (0.625jxg/ml) 97.7 0.8
Indo + Taxol 25.8 2.4
CORL23(R) Taxol and Indomethacin
Taxol. 7.0ng/ml 4 1 . 2 0 .1
Indo (2.5|ig/ml) 96.5 3 .5
Indo + Taxol 26.3 0.8
Indo (1.25|xg/ml) 100.0 0 .1
Indo + Taxol 28.8 1.6
Indo (0.625jag/ml) 100.9 2 .3
Indo + Taxol 31.2 0.3
CORL23(P) Taxol and BRI 153/1
Taxol. 1.0ng/ml 30.8 3 .2
153/1 (50ng/ml) 94.5 0.9
153/1 + Taxol 9.8 2.6
153/1 (25jxg/ml) 96.7 0.4
153/1 + Taxol 17.9 1.7
153/1 (12.5(j.g/ml) 98.9 0.0
153/1 + Taxol 21.2 1.0
CORL23(R) Taxol and BRI 153/1
Taxol. 7.0ng/ml 4 2 . 1 1 .7
153/1 (50|ig/ml) 94.6 0.2
153/1 + Taxol 17.6 0.2
153/1 (25(j,g/ml) 98.5 2 .7
153/1 + Taxol 23.7 1.3
153/1 (12.5}xg/ml) 10 0 .4 0.6
153/1 + Taxol 23.4 0.2
T a b le  3 .6 .19 : %  Survival o f  C O R L23(P) and CO R L23(R ) cells in  the  
presence o f  taxol, in  com bination w ith  indom ethacin  and BR I 153/1 as found 
using  the p ro toco l detailed  in  section 2.7.3. Survival is represented as a  %  o f  
the grow th  o f  un trea ted  cells in  the sam e plate ±  S.D. R esults are the  average 
o f  trip licate  de term inations in  three separate experim ents.
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Test Sample % Cell Survival S.D.
CORL23(P) Taxol and BRI 205/4
Taxol. 1.0ng/ml 38.9 5.5
205/4 (25fig/ml) 96.8 3 .0
205/4 + Taxol 36.3 4.2
205/4 (12.5jo.g/ml) 100 .9 0.6
205/4 + Taxol 37.2 4.5
205/4 (6.25|4,g/ml) 10 0 .7 0.6
205/4 + Taxol 38.1 5.6
CORL23(R) Taxol and BRI 205/4
Taxol. 7.0ng/ml 39.9 4.9
205/4 (25|xg/ml) 99.2 5 . 1
205/4 + Taxol 34.4 5.4
205/4 (12.5^g/ml) 10 0 .7 2.4
205/4 + Taxol 35.7 5.6
205/4 (6.25|4g/ml) 1 0 1 . 1 1 .9
205/4 + Taxol 39.7 2.8
T a b le  3 .6 .20: %  Survival o f  C O R L23(P) and C O R L23(R ) cells in  the 
p resence o f  T axol, in  com bination w ith  205/4 as found using  the protocol 
detailed  in  section  2.7.3a. Survival is represented  as a  %  o f  the grow th  o f  
un trea ted  cells in  the  sam e plate ±  S.D. R esults are the  average o f  trip licate 
determ inations in  th ree  separate experim ents.
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No Anticancer 
agent
Taxol
(1 .0|ig/inl)
Cl values
No NSAID 100 +  0.0 33.1 ± 2 . 7
Indomethacin 2.5|J,g/ml 100.5 +  0.8 17.0 ± 2 . 1 0.659
B R I153/1 50|xg/ml 94.5 ±  0.2 9.8 ± 2 . 6 0.352
B R I205/4 25jJ.g/ml 96.8 ± 3 . 0 36.3 ± 4 . 2 1.365
Table: 3.6.21a: C O R L23(P), T axol +  H ighest non-toxic  concentrations o f  
Indom ethacin  and Indom ethacin  analogues.
D ata  are expressed  as %  C ell Survival ±  standard dev iation  for a  m in im um  o f  
th ree assay repeats.
No Anticancer 
agent
Taxol
(7.0f.ig/iiil)
C! values
No NSAID 100 ± 0 . 0 42.1 ±  1.7
Indomethacin 2.5|_ig/nil 96.5 ± 3 . 5 23.3 ± 0 . 8 0.688
BRI 153/1 50jj.g/ml 94.6 ±  0.2 17.6 ± 0 . 2 0.337
BRI 205/4 25ng/ml 103.2 ±  6.4 46.9 ± 2 . 6 1.045
Table: 3.6.21b: C O R L23(R ), V P16 +  H ighest non-toxic concentrations o f  
Indom ethacin  and Indom ethacin  analogues.
D ata  are expressed  as % C ell Survival ± standard deviation  for a  m in im um  o f  
three assay repeats.
Cl: Combination index values.
Cl < 1: synergism; Cl > 1: antagonism; Cl =  1: additive.
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CORL23 (S) Adr. Vin. VP-16 5-FU Taxol Taxoterc
Indo. 0.725 0.333 0.893 1.000 0.659
Sulindac
'
.
0.652 0.679
B R I88/1 0.670 0.554 0.922 1.000
llSff # f!l
B R I92/1 0.749 0.532 0.895 1.146
BRI 153/1 0.813
I K
0.352 Sill
BRI 205/4 1.000 1.365
Table 3.6.22a: Sum m ary table o f  C l values from  com bination tox ic ity  assays 
in  C O R L 23(P) cells in  section 3.6.
C l: C om bination  index  values.
C l <  1: synergism ; C l >  1: antagonism ; C l =  1: additive.
CORL23(R) A dr . Vin. VP-16 5-FU T axo l T a x o te rc
Indo. 0.626 0.417 0.572 1.114 0.688
Sulindac IIn :' ||| 0.559 0.474
BRI 88/1 0.432 0.329 0.569 1.151 jp l
BRI 92/1 0.552 0.284 0.541 1.127
BRI 153/1 0.382 l i f 0.337
BRI 205/4 1.000 1.045
■
Table 3.6.22b: Sum m ary table o f  C l values from  com bination tox icity  assays 
in  C O R L 23(R ) cells in  section 3.6.
C l: C om bination  index  values.
C l <  1: synergism ; C l >  1: antagonism ; C l =  1: additive.
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3.7 cMOAT experiments in HepG2, lung carcinoma cell line.
A  hum an  hepatic  cancer cell line, H epG 2, w as reported  by  a num ber o f  authors 
to  express a  h igh  level o f  cM O A T  (M R P2), bo th  at p ro te in  (K oike et al,
1997), and m R N A  levels (N arasaki et al, 1997). K ool et al., (1997), 
T anaguchi et al, (1996) and  K oike et al (1997), p rov ide indirect evidence that 
an  organic pum p, no tab ly  cM O A T , could  contribute to  cisp latin  resistance by 
exporting the c isp latin  -G SH  com plex. B u t they  also agree that other 
m echanism s m ay  contribute to  resistance. In  a m ore recent paper O guri et al., 
(1998), observed  no association  betw een  ante-m ortem  platinum  drug exposure 
and steady state cM O A T  m R N A  and suggests tha t cM O A T  does not p lay  a 
m ajor ro le in  p latinum  drug  resistance or transport. T hey  also suggest that the 
increased expression o f  cM O A T  m R N A , after exposure to  p latinum  drugs, is 
part o f  the norm al stress response to  xenobiotics.
3.7.1 Combination toxicity assays in the HepG2 cell line
D uffy  et al., (1998), reported  th a t the positive N S A ID s and indom ethacin 
analogues w ere unable to  po ten tia te  the toxicity  o f  cisplatin.
C om bination  tox icity  assays w ere carried  out on  the  H epG 2 cell line using a 
com bination  o f  adriam ycin  and indom ethacin, or c isp latin  and indom ethacin to  
assess i f  indom ethacin  w as capable o f  potentiating the  tox icity  o f  the cytotoxic 
drug in  cM O A T -overexpressing  H epG 2 cells. P rev iously  the com bination 
tox ic ity  assays w ere carried  out on  cell lines, w hich  overexpress MRP1 
(D LK P and CO R L23). C isp latin  is no t a  substrate for M RP1 (D uffy et al.,
1998). The m echanism  by  w hich  cells develop resistance to cisplatin  is 
p resently  unclear bu t it is postu lated  tha t th is resistance m ay be a  result o f  the 
activ ity  o f  the M R P analogue, cM O A T  in  certain  cell lines. The com bination 
tox ic ity  assay w as carried  out on  th is cell line using  a  com bination o f  cisplatin  
and indom ethacin  to  try  to  assess i f  M R P analogues, o ther than  M R P1, could 
be inh ib ited  in  the sam e w ay  as M R P1.
T he resu lts dem onstrated  th a t indom ethacin  w as capable o f  potentiating the 
tox ic ity  o f  adriam ycin  in  H epG 2 and D LK P cells (Table 3.7.1). The highest 
non-toxic  concentration  o f  indom ethacin  used  in  the H epG 2 cells w as 10|og/ml 
as com pared  to  2.5(o,g/ml for D L K P cells. H ow ever, results from  the
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com bination  tox ic ity  assays w ith  c isp latin  and indom ethacin  in  H epG 2 and 
D L K P cells revealed  that indom ethacin  w as no t capable o f  po ten tia ting  the 
tox icity  o f  c isp la tin  in  these cells (3.7.2). In terestingly  the tox ic ity  o f  cisplatin  
seem ed to  decrease w hen  com bined  w ith  indom ethacin  in  the H epG 2 and 
D L K P cell lines. The results indicate tha t either indom ethacin  is n o t a good 
substrate fo r cM O A T  (M R P2) and  is unable to  inhibit the activ ity  o f  th is pum p 
in  the  H epG 2 cells. O r they  m ay also indicate that cisp latin  is n o t a  substrate 
for cM O A T  and  inhib ition  o f  the activ ity  o f  cM O A T in  the H epG 2 cells by 
indom ethacin  d id  n o t affect the  transport o f  cisplatin  out o f  the  cell. K oike el 
al. (1997) d id  n o t detect M RP1 pro te in  expression in  the  H epG 2 cell line. 
H ow ever, N arasak i et al., (1997), reported  tha t H epG 2 cells expressed  M RP1 
at m R N A  levels. It is possib le th a t the enhancem ent o f  adriam ycin  tox icity  by 
indom ethacin  in  th e  H epG 2 cells is entirely  due to  the expression  o f  M RP1 
and m ay  n o t be  attributed to  the expression  o f  M RP2.
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DLKP, Adriamycin and Indomethacin
Test Sample % Survival S.D.
Adr. lOng/ml 46.5 1.7
Indo. (2.5fig/ml) 96..9 2.7
Indo. + Adr 11.5 6.5
Indo. (1.25|j,g/ml) 102.7 1.5
Indo. + Adr 14.1 0.9
Indo. (0.625fjg/ml) 102.5 1.4
Indo. +A dr 19.6 4.35
HepG2, Adriamycin and Indomethacin
Test Sample % Survival S.D.
Adr. 20ng/ml 58.3 1.3
Indo. (lOfig/ml) 82.7 2.7
Indo. +A dr 20.6 6.2
Indo. (5(J.g/ml) 91.4 2.5
Indo. + Adr 20.5 0.5
Indo. (2.5|j.g/ml) 102.7 1.4
Indo. + Adr 23.6 3.2
Table 3.7.1: %  Survival o f  D L K P and H epG 2 cells in  the  p resence o f  various 
concentrations o f  adriam ycin  and indom ethacin  as found using  the protocol 
detailed  in  section  2.7.3a. Survival is represented as a  %  o f  the grow th o f  
u n trea ted  cells in  the  sam e plate ±  S.D. R esults are the  average o f  trip licate 
de term inations in  th ree separate experim ents.
D LK P, Cisplatin and Indomethacin
Test Sample % Survival S.D.
Cis. 250ng/ml 3 3 .6 2.9
Indo. (2.5|xg/ml) 95 .5 1 .3
Indo. + Cis 44.1 4.2
Indo. (1.25(o.g/ml) 10 0 .7 0.9
Indo. + Cis 38.1 2.4
Indo. (0.625(j.g/ml) 10 4 .5 5.6
Indo. + Cis 35.9 3.5
H epG 2, C isplatin and indomethacin
Test Sample % Survival S.D.
Cis. 250ng/ml 3 2 .8 0.9
Indo. (10|ig/ml) 9 6 .1 1 .8
Indo. + Cis 46.7 4.5
Indo. (5|jg/ml) 10 6 .3 7.4
Indo. + Cis 49.4 0.5
Indo. (2.5ng/ml) 1 0 0 . 1 1 .4
Indo. + Cis 40.4 3.2
T a b le  3.7 .2 : Survival o f  D LK P and H epG 2 cells in  the p resence o f  various 
concentrations o f  cisplatin  and indom ethacin  as found using  the protocol 
detailed  in  section  2.7.3a. Survival is represen ted  as a %  o f  the  grow th  o f  
un treated  cells in  the  sam e plate ±  S.D. R esults are the average o f  trip licate 
determ inations in  three separate experim ents.
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3.8: In Vitro Combination Toxicity Assays: 2008 cell line.
C ertain  N S A ID s can  poten tiate  the  tox icity  o f  a  num ber o f  anticancer drugs in  
cell lines w h ich  overexpress M R P1, e.g. C O R L23(R ), D LK P, H L 60/A D R  and 
A 549 cell lines (D uffy  et al., 1998). W estern  B lo t analysis has indicated  that 
the over-expression  o f  M R P 1 is the  m ain  m ode o f  resistance in  these cell lines 
(D uffy et al., 1998; K ool et al., 1997 and C onnolly , 1999). It is now  know n 
th a t there  are a t least 6 m em bers o f  the  hum an  M R P fam ily, M R P 1-6 (B orst et 
al., 1999). A nalysis for the presence o f  a  selection  o f  M R P hom ologues w as 
undertaken  to  assess i f  the poten tia tion  o f  the tox ic ity  o f  the an ticancer drugs 
w as associated  w ith  expression o f  one m em ber o f  the  M R P fam ily  or i f  th is 
effect w as also ev iden t in  cell lines expressing different m em bers o f  th is 
transport fam ily.
T hree cell lines w ere generated by  transfec tion  o f  an  ovarian  carcinom a cell 
line, 2008, w ith  the cD N A  for M R P1, M R P2 or M RP3 and w ere used  in  a  
num ber o f  experim ents to  assess the effect o f  the  expression o f  these proteins 
o n  the tox ic ity  o f  a  num ber o f  anticancer drugs. T hese cell lines w ere received  
as a k ind  g ift from  D r. M arcel K ool and  Prof. P ie t B orst from  the D epartm ent 
o f  M olecu lar B io logy , N etherlands C ancer Institu te, A m sterdam .
T he L ong-term  tox ic ity  assays referred  to  in  th is section w ere carried  out using  
th e  sam e procedure used  fo r the tox icity  assays carried  out in  section 3.1 and 
according to  section  2 .7 .1a  and 2 .7 .3a  (i.e. 7 day tox icity  assays w hereby drug 
and/or com pound  w ere added to the cells on D ay 2 and rem ain  in  the  cells 
un til D ay  7 w hen  the  cells w ere analysed).
T he Short-term  tox icity  assays referred  to  in  this section w ere perfo rm ed  using 
the  m ethod  described  in  section 2 .7 .1b and 2 .7 .3b  (i.e. 6 day toxicity  assays 
w hereby  the  drug/com pound w ere added to  the cells on D ay 2 and w ere 
incubated  in  the cells for a period  o f  four hours only. The cells w ere then  re ­
fed  w ith  fresh  m ed ia  and w ere incubated until D ay  6 w hen the cells w ere 
analysed) (K ool et al., 1999). R easons fo r using  Short-term  toxicity  assays 
versus L ong-term  toxicity  assays to analyse the effects o f  chem otherapeutic  
drug  on  these cell lines are described in  detail in  section 4.11.
T he drug  resistance profile  o f  the 2008 parental and transfected  cell lines is 
p rov ided  in  tab le  3 .8 .1a (Long-term  toxicity  assays) and 3.8.1b (Short-term  
tox ic ity  assays).
194
Long-term
Adr.
ng/ml
MTX 
fig/m I
Taxol
ng/ml
Taxotere
ng/ml
Cisplatin
ng/ml
2008 P 21.0 ± 1.2 5.0 ± 0.6 7.18 + 1.1 0.98 ± 0.11 202.9 ± 15.4
2008 MRP1 117.5 ± 4.2 4.8 ± 0.2 3.0 ± 0.5 1.02 + 0.09 52.1 + 3.7
2008 MRP2 10.0 ± 0.5 5.1 ± 0.3 2.94 ± 0.7 0.95 ± 0.08 15.6 ± 1.3
2008 MRP3 19.2 ± 1.8 5.1 ± 0.2 3.1 ± 1.5 1.08 ± 0.10 31.1 + 0.8
Table 3.8.1a: IC50 values o f  chem otherapeutic drugs in  2008 parental and 
transfected  cell lines determ ined  using the long-term  toxicity  assay. These 
values are identified  as the  drug concentrations giving rise to 50%  cell kill 
relative to  un treated  control cells according to  protocol detailed  in  section 
2.7.1a.
Short-term
Adr.
ng/ml
MTX
Hg/ml
Taxol
ng/ml
Taxotere
ng/ml
2008 P 82.3+ 5.7 10.4 ± 1.1 984 ±41.0 50.6 ± 4.4
2008 MRP1 246.6 ± 9.8 903.2 + 25.2 2011 + 27.4 4.0 ± 0.5
2008 MRP2 129.0 ± 6.5 312.7 ± 19.6 968 ± 31.8 49.8 ± 5.9
2008 MRP3 250.4 ± 11.2 888.1 ± 30.4 1992 ± 20.7 26.4 ±2 .1
Table 3.8.2a: IC50 values o f  chem otherapeutic drugs in  2008 parental and 
transfected  cell lines determ ined using the short-term  toxicity  assay. These 
values are identified  as the  drug concentrations giving rise to  50%  cell kill 
relative to  un treated  control cells according to protocol detailed  in  section 
2.7.1b.
3.8.1 Analysis of 2008 cells for enhancement of adriamycin, 
methotrexate and cisplatin toxicities by indomethacin.
Toxicity  assays w ith  adriam ycin  and m ethotrexate w ere carried  on the four cell 
lines, 2008 P  (parental), 2008 M RP1, 2008 M R P2 and 2008 M R P3, to assess 
their tox icity  profile. T he results obtained from  the long-term  toxicity  assays 
w ith  adriam ycin  (table 3.8.1a) indicated that 2008 M RP1 w as approxim ately
195
6-10 fo ld  m ore resistan t to  adriam ycin  than  the o ther three cell lines. 2008 
M R P3 and 2008 P  cells w ere tw o-fo ld  m ore resis tan t to  adriam ycin  than  2008 
M R P2. These resu lts suggested  tha t overexpression o f  M RP1 resulted  in  the 
g reatest level o f  resistance to  adriam ycin. Short-term  toxicity  assays on the 
2008 cells using  adriam ycin  (table 3.8.1b) ind icated  that, in  short-term  
exposure experim ents, w here the cells w ere exposed  to the anticancer drug for 
four hours only  (as described  in  section 2.7.1b), there  w as equal resistance to 
adriam ycin  in  b o th  the  M RP1 and M RP3 transfected  cells. These cell lines 
w ere only  tw o-fo ld  m ore resis tan t to  adriam ycin  th an  2008 M R P2 and th ree­
fo ld  m ore resis tan t than  the 2008 parental cells. In itia l long-term  toxicity  
assays on these cell lines using  m ethotrexate (M TX ) (table 3.8.1a) failed  to 
dem onstrate any difference in  resistance levels be tw een  the parental and the 
M R P-transfected  cells. H ow ever, short-term  M T X  tox icity  assays on  the  2008 
cells show ed 2008 M RP1 and 2008 M RP3 to be alm ost 100-fold m ore 
resistan t to  M T X  than  the parental cell line. 2008 M R P2 cells w ere 30-fold  
m ore resistan t to  M T X  than  the  parental cell line (table 3.8.1b).
B ecause o f  the  differences in  the  tox icity  profiles be tw een  the short-term  and 
the long-term  tox ic ity  assays, bo th  long-term  and  short-term  com bination 
tox icity  assays, w ith  indom ethacin  in  com bination  w ith  adriam ycin or M TX , 
w ere carried  out on  these cell lines. These assays w ere carried  out to  assess i f  
po ten tia tion  o f  the  tox icity  o f  either anti-cancer drug w as possib le using either 
m ethod. T he resu lts fo r adriam ycin  in  com bination w ith  indom ethacin  (Tables
3.8.2 and 3.8.6) indicate tha t the  toxicity  o f  adriam ycin  w as potentiated  by  
indom ethacin  in  the  long term  assay, in  all four cell lines, particularly  in  the 
2008 M RP1 cells. In  the short term  assay there w as po ten tia tion  o f  the tox icity  
o f  adriam ycin  by  indom ethacin  in  the M R P 1-transfected  cells and to a  lesser 
ex ten t in  the M R P3-transfected  cells. There w as no poten tia tion  o f  adriam ycin  
tox icity  by  indom ethacin  in  either the parental or 2008 M R P2 cells. 
Indom ethacin  has been  show n, using  Inside O ut V esicles prepared from  M RP1 
overexpressing  H L 60/A D R  cells, to be a good substrate  fo r M RP1 (see section 
3.3). The resu lts from  the com bination toxicity  assays in  2008 cells indicate 
tha t indom ethacin  m ay  also be a  substrate for M R P2 and M RP3. W estern  B lot 
analysis o f  the  2008 cell lines indicated a  strong expression  o f  the transfected  
M RP1 in  the  2008 M RP1 transfected  cell line. H ow ever, basal expression  o f  
M RP1 w as detected  in  the 2008 P, 2008 M R P2 and 2008 M RP3 cells
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(C onnolly, 1999). R esults from  previous experim ents in  the  CO RL23 cell lines 
(Section  3.6) ind ica ted  tha t M RP1 pro tein  levels d id  n o t correlate w ith  the 
m agnitude o f  enhancem ent by  indom ethacin  and rela ted  active com pounds in 
these cell lines. R T -P C R  analysis show ed that M RP1 w as expressed at m R N A  
levels in  all the  2008 cell lines. The expression  o f  M RP1 m R N A  w as only 
sligh tly  stronger in  the M RP1 transfected  cell line (section 3.16). Together 
these  results m ay  indicate tha t indom ethacin  is a better substrate for M RP1 
th an  M R P2 and  M RP3 and  the poten tiation  o f  adriam ycin  by indom ethacin  
m ay  sim ply be due to  the expression  o f  M R P 1 in  all the cell lines. The poorest 
com bination  index  values for adriam ycin in  com bination w ith  indom ethacin  
w ere obtained  in  the 2008 M R P2 cells (Table 3.8.5). In  the  short-term  assays 
the  low  po ten tia tion  o f  adriam ycin  by indom ethacin  m ay suggest tha t a  four 
h our exposure period  in  the  cells is insufficient for indom ethacin  to  exert its 
po ten tia tion  effec t on  2008 cells. It appears tha t indom ethacin  is requ ired  in 
the  cells fo r a  longer period  o f  tim e for sufficient po ten tia tion  o f  adriam ycin  
tox ic ity  to occur.
Indom ethacin  poten tia ted  the  toxicity  o f  M T X  in  2008 M RP1 and to a  lesser 
ex ten t in  the  2008 M RP3 cells only, in  the long-term  toxicity  assay (Table 
3.8.4). H ow ever, in  the short-term  com bination  tox ic ity  assays there  w as 
increased  po ten tia tion  o f  M T X  in both  the  2008 P and 2008 M RP1 cells. There 
w as poorer po ten tia tion  o f  M T X  toxicity  in  the 2008 M R P3 cells in  the short­
term  assay than  in  the  long-term  assay. The poorest com bination  index values 
for m etho trexate  in  com bination  w ith  indom ethacin  w ere obtained in  the 2008 
M R P2 cells (T able 3.8.5) w here there w as no evidence o f  po ten tia tion  o f  M T X  
tox ic ity  by indom ethacin  in  the  2008 M R P2 cell line in  either the long-term  or 
the short-term  assays.
P oten tial indom ethacin  interactions w ith  cisplatin  w ere investigated  using 
long-term  tox ic ity  assays. The results clearly  show  that there  w as no 
po ten tia tion  o f  th e  tox icity  o f  cisplatin  by  indom ethacin  in  any o f  the 2008 cell 
lines (Table 3 .8 .4  and 3.8.5). In terestingly , co-incubating cisp latin  w ith  
indom ethacin  appeared  to  increase the resistance o f  the cells to the an ti-cancer 
drug  instead  o f  increasing the toxicity o f  the drug as m igh t be expected. The 
resu lts indicate th a t c isp latin  is not a  good substrate fo r any o f  the M R P
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hom ologues expressed  in  the  2008 cells. In teresting ly , com paring the  IC 50 
resu lts  fo r c isp la tin  in  the  2008 cell lines ind icate  tha t the  paren tal cell line  is 
m ore  resistan t to  cisp latin  (200ng/m l) th an  the  transfec ted  2008 cells (50, 15 
and  30ng/m l fo r M R P1, M R P2 and M RP3 transfec ted  cells respectively).
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LONG TERM  ASSAY
Test Sam ple % Cell Survival S.D.
2008 P Adriam ycin and Indom ethacin
Adriamycin 20ng/ml 56 .4 8.8
Indo (1) 97.6 3 .7
Indo (1) + Adriamycin 33.3 7.9
Indo (2) 9 9 .1 1 .5
Indo (2) + Adriamycin 39.8 7.6
Indo (3) 10 0 .0 1 .0
Indo (3) + Adriamycin 41.6 8.7
2008 M RP1 Adriam ycin and Indom ethacin
Adriamycin 120ng/ml 55 .6 6.6
Indo (1) 93.5 3 .0
Indo (1) + Adriamycin 15.7 1.2
Indo (2) 9 9 .1 3 .4
Indo (2) + Adriamycin 20.7 5.1
Indo (3) 99.0 3 .5
Indo (3) + Adriamycin 25.0 3.4
2008 M RP2 Adriam ycin and Indom ethacin
Adriamycin 10ng/ml 47.8 1 .3
Indo (1) 98.9 2 .3
Indo (1) + Adriamycin 28.9 0.6
Indo (2) 10 0 .2 2.6
Indo (2) + Adriamycin 31.0 2.1
Indo (3) 99.2 1 .2
Indo (3) + Adriamycin 32.0 0.8
2008 M RP3 Adriam ycin and Indom ethacin
Adriamycin 20ng/ml 70 .7 2 .4
Indo (1) 95.0 0.8
Indo (1) + Adriamycin 45.9 4.0
Indo (2) 98.0 1 .8
Indo (2) + Adriamycin 52.4 2.1
Indo (3) 99.0 2 .3
Indo (3) + Adriamycin 53.8 1.7
Table 3.8.2a: % Survival o f  2008 P, 2008 M R P1, 2008 M R P2 and 2008 
M R P3 cells in  the  presence o f  adriam ycin, in  com bination  w ith  indom ethacin, 
as found using  the pro tocol detailed  in  section 2.7.3a. Survival is represented 
as a %  o f  the  grow th  o f  un treated  cells in  the sam e p late  ±  S.D. R esults are the 
average o f  trip licate  determ inations in  th ree separate experim ents. The 
concentrations o f  indom ethacin  were: (1) lO^ig/ml; (2) 5fj,g/ml; (3) 2.5p.g/ml.
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SHORT TERM ASSAY f-Indomethacin <®T4 hours)
Test Sample % Cell Survival S.D.
2008 P Adriamycin and Indomethacin
Adriamycin 80ng/ml 57 .4 2 .5
Indo (1) 9 2 .2 0.8
Indo (1) + Adriamycin 49.5 1.9
Indo (2) 93.0 2 . 1
Indo (2) + Adriamycin 50.2 1.4
Indo (3) 9 5 .7 1 .8
Indo (3) + Adriamycin 52.2 0.2
2008 MRP1 Adriamycin and Indomethacin
Adriamycin 250ng/ml 74 .2 2.9
Indo (1) 92.6 1 .7
Indo (1) + Adriamycin 43.8 5.0
Indo (2) 94.6 1 .7
Indo (2) + Adriamycin 52.4 8.0
Indo (3) 9 6 .1 4 . 1
Indo (3) + Adriamycin 59.0 5.8
2008 MRP2 Adriamycin and Indomethacin
Adriamycin 125ng/ml 72 .0 4.4
Indo (1) 9 0 .1 2 .5
Indo (1) + Adriamycin 58.6 4.0
Indo (2) 98.0 7.3
Indo (2) + Adriamycin 63.8 4.9
Indo (3) 1 0 1 . 1 9 .7
Indo (3) + Adriamycin 67.6 5.6
2008 MRP3 Adriamycin and Indomethacin
Adriamycin 250ng/ml 54.6 3 .3
Indo (1) 97.4 2.9
Indo (1) + Adriamycin 41.3 1.0
Indo (2) 96.5 3 .2
Indo (2) + Adriamycin 42.7 0.9
Indo (3) 96.0 3 .2
Indo (3) + Adriamycin 47.3 4.4
Table 3.8.2b: %  Survival o f  2008 P, 2008 M R P1, 2008 M R P2 and 2008 
M R P3 cells in  the presence o f  adriam ycin, in  com bination  w ith  indom ethacin, 
as found using  the  pro tocol detailed  in  section 27.3b (Short term  assay). 
Survival is represented  as a  %  o f  the  grow th o f  untreated  cells in  the  sam e 
plate ±  S.D . R esults are the average o f  trip licate determ inations in  three 
separate experim ents. The concentrations o f  indom ethacin  were: (1) 100 
|j.g/ml; (2) 50 |ig /m l; (3) 25 (xg/ml.
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LONG TERM ASSAY
Test Sample % Cell Survival S.D.
2008 P Methotrexate and Indomethacin
Methotrexate 5fig/ml 25.5 7.6
Indo (1) 96.9 1.2
Indo (1) + Methotrexate 22.5 4.2
Indo (2) 99.4 0.9
Indo (2) + Methotrexate 23.8 1.8
Indo (3) 102.3 2.3
Indo (3) + Methotrexate 24.8 2.6
2008 MRP1 Methotrexate and Indomethacin
Methotrexate 5|ag/ml 28.5 3.6
Indo (1) 93.5 0.6
Indo (1) + Methotrexate 14.1 5.2
Indo (2) 93.9 2.6
Indo (2) + Methotrexate 22.4 4.8
Indo (3) 96.7 1.0
Indo (3) + Methotrexate 25.6 3.6
2008 MRP2 Methotrexate and Indomethacin
Methotrexate 5 jag/ml 30.1 9.6
Indo (1) 90.2 4.2
Indo (1) + Methotrexate 27.0 4.1
Indo (2) 97.1 2.7
Indo (2) + Methotrexate 28.1 5.4
Indo (3) 98.2 1.4
Indo (3) + Methotrexate 29.7 9.0
2008 MRP3 Methotrexate and Indomethacin
Methotrexate 5 jig/ml 50.3 0.8
Indo (1) 95.5 3.8
Indo (1) + Methotrexate 36.6 5.9
Indo (2) 97.9 2.2
Indo (2) + Methotrexate 46.5 1.5
Indo (3) 99.9 0.7
Indo (3) + Methotrexate 46.4 4.0
T a b le  3 .8 .3a : %  Survival o f  2008 P, 2008 M R P1, 2008 M R P2 and 2008 
M R P3 cells in  the presence o f  m ethotrexate, in  com bination  w ith 
indom ethacin , as found u sing  the protocol detailed  in  section 2.7.3a. Survival 
is represented  as a  %  o f  th e  grow th o f  untreated  cells in  the sam e plate ±  S.D. 
R esults are the  average o f  triplicate determ inations in  three separate 
experim ents. T he concentrations o f  indom ethacin were: (1) 10|ag/ml; (2) 
5j_ig/ml; (3) 2.5(-ig/ml.
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SHORT TERM ASSAY (-Indomethacin @T4 hours)
Test Sample % Cell Survival S.D.
2008 P Methotrexate and Indomethacin
Methotrexate lOng/ml 53.3 6.9
Indo(l) 93.4 1.7
Indo (1) + Methotrexate 21.0 5.5
Indo (2) 96.4 2.0
Indo (2) + Methotrexate 25.8 7.9
Indo (3) 95.3 1.4
Indo (3) + Methotrexate 35.3 9.3
2008 MRP1 Methotrexate and Indomethacin 
Methotrexate 900ng/ml 42.5 1.7
Indo (1) 98.5 2.0
Indo (1) + Methotrexate 22.8 3.0
Indo (2) 96.1 4.1
Indo (2) + Methotrexate 34.2 5.0
Indo (3) 100.7 4.3
Indo (3) + Methotrexate 36.4 3.3
2008 MRP2 Methotrexate and Indomethacin 
Methotrexate 300ng/ml 30.0 4.7
Indo (1) 90.0 2.9
Indo (1) + Methotrexate 24.7 2.9
Indo (2) 92.8 0.6
Indo (2) + Methotrexate 26.6 2.6
Indo (3) 95.8 1.8
Indo (3) + Methotrexate 27.6 2.8
2008 MRP3 Methotrexate and Indomethacin 
Methotrexate 900ng/ml 37.4 3.9
Indo (1) 96.4 1.2
Indo (1) + Methotrexate 28.2 7.5
Indo (2) 97.6 3.2
Indo (2) + Methotrexate 29.3 7.5
Indo (3) 100.4 2.0
Indo (3) + Methotrexate 30.3 4.8
Table 3.8.3b: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of methotrexate, in combination with 
indomethacin, as found using the protocol detailed in section 2.7.3b (Short 
term assay). Survival is represented as a % of the growth of untreated cells in 
the same plate ± S.D. Results are the average of triplicate determinations in 
three separate experiments. The concentrations of indomethacin were: (1) 100 
|j.g/ml; (2) 50 p.g/ml; (3) 25 jj.g/ml.
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LONG TERM ASSAY
2008 P Cisplatin and Indomethacin
Cisplatin 200ng/ml 55.5 7.6
Indo (1) 98.2 5.8
Indo (1) + Cisplatin 76.8 6.5
Indo (2) 102.6 5.0
Indo (2) + Cisplatin 69.1 8.5
Indo (3) 102.5 4.2
Indo (3) + Cisplatin 60.2 6.9
2008 MRP1 Cisplatin and Indomethacin 
Cisplatin 50ng/ml 59.5 3.1
Indo (1) 96.4 0.9
Indo (1) + Cisplatin 59.2 4.7
Indo (2) 95.9 4.8
Indo (2) + Cisplatin 59.1 10.0
Indo (3) 99.7 1.9
Indo (3) + Cisplatin 58.0 7.9
2008 MRP2 Cisplatin and Indomethacin 
Cisplatin 15ng/ml 61.7 9.2
Indo (1) 103.5 4.2
Indo (1) + Cisplatin 75.0 4.4
Indo (2) 103.4 2.6
Indo (2) + Cisplatin 68.7 7.6
Indo (3) 103.6 4.5
Indo (3) + Cisplatin 61.9 8.1
2008 MRP3 Cisplatin and Indomethacin 
Cisplatin 30ng/ml 75.1 3.5
Indo (1) 92.3 3.2
Indo (1) + Cisplatin 84.4 6.4
Indo (2) 104.8 1.2
Indo (2) + Cisplatin 79.8 6.1
Indo (3) 104.4 1.5
Indo (3) + Cisplatin 76.9 5.7
Test Sample % Cell Survival S.D.
Table 3.8.4: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 MRP3 
cells in the presence of cisplatin, in combination with indomethacin, as found 
using the protocol detailed in section 2.7.3a. Survival is represented as a % of 
the growth of untreated cells in the same plate ± S.D. Results are the average 
of triplicate determinations in three separate experiments. The concentrations 
of indomethacin were: (1) 10[o.g/ml; (2) 5 jig/ml; (3) 2.5jxg/ml.
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Adr + Indo 
L.T S.T
MTX + Indo 
L.T S.T
Cis + Indo 
L.T
2008P 0.488 1.048 1.056 0.372 2.422
MRP1 0.186 0.683 0.653 0.581 1.345
MRP2 0.493 0.958 1.064 1.000 2.030
MRP3 0.433 0.860 0.738 0.879 2.198
Table 3.8.5: Summary of combination index (Cl) values for adriamycin (Adr), 
methotrexate (MTX) or cisplatin (Cis) in combination with indomethacin, 
obtained using the method of Chou and Talalay as described in section 2.16 
(Cl < 1: synergism; Cl > 1: antagonism; Cl = 1: additive.)
L.T: Long-term assay as described in section 2.7.3a
S.T (1): Short-term assay. Drug and compound removed from the cells after 4 
hours incubation and replaced with fresh medium only as described in section 
2.7.3b
S.T (2): Short-term assay. Drug and NSAID removed from the cells after 4 
hours incubation and replaced with NSAID only as described in section 2.7.3b
3.8.2 Analysis of 2008 cells for enhancement of adriamycin or 
methotrexate toxicities by sulindac.
To further investigate the effects of drug combinations in the transfected 
2008cell lines, long-term and short-term combination toxicity assays were 
carried out using a number of anti-cancer drugs in combination with the active 
NSAID, sulindac. Duffy et al., (1998), previously reported the ability of 
sulindac to enhance the anti-cancer effect of a number of chemotherapeutic 
drugs in MRP-overexpressing cell lines. The results for the long-term toxicity 
assays with adriamycin in combination with sulindac were similar to those 
obtained with adriamycin in combination with indomethacin (Table 3.8.6). 
Sulindac potentiated the toxicity of adriamycin in all of the 2008 cell lines, 
particularly in the 2008 P and 2008 MRP1 cell lines. In the long term assays
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the concentration of sulindac used in the assays (35|j.g/ml (98.3(J.M)) was 3- 
fold higher than the indomethacin concentrations used in these cells (10[j,g/ml 
(28|aM)) as sulindac was less toxic to the cells than indomethacin. This could 
account for the greater potentiation of adriamycin by sulindac in the 2008 cells 
in the long-term assay. The results suggest that sulindac is a better substrate 
for MRP1 than MRP2 and MRP3 in the long-term combination assays. The 
short-term combination toxicity assays with adriamycin and sulindac (Table 
3.8.7) also produced similar results to those obtained with adriamycin and 
indomethacin. There was no potentiation of adriamycin toxicity in the 2008 P 
and 2008 MRP2 cell lines. There was reduced potentiation of adriamycin 
toxicity by sulindac in the 2008 MRP1 and MRP3 cells as compared to that 
observed in the long-term assays. As the short-term combination assays with 
indomethacin indicated that short-term exposure to indomethacin is 
insufficient to significantly enhance the toxicity of adriamycin, an experiment 
was carried out to assess if  re-addition of the NSAID, after removing the anti­
cancer drug and NSAID from the medium at the end of the four hour exposure 
time, would increase the potentiation of the drug toxicity by the NSAID. There 
was increased potentiation of adriamycin in the short term assay after re­
addition of sulindac (Table 3.8.6a) compared to the short-term assay where 
sulindac was completely removed from the medium (Table 3.8.6b). However, 
the combination effect was less than that obtained in the long-term toxicity 
assay. This may be due to adriamycin being effluxed during the washing stage 
of the short-term assay as described in section 2.7.1b. The procedure requires 
four washes to ensure complete removal of the drug from the medium (Kool et 
al., 1999), so by the time sulindac-containing medium was added to the cells it 
is possible that there was less adriamycin in the cells on which to exert its 
effect.
Identical experiments were carried out using methotrexate in combination with 
sulindac and the results indicated that there was poorer potentiation of MTX 
toxicity in the long-term combination toxicity assays (Table 3.8.7a) than in the 
short-term assays for 2008 P and 2008 MRP1 cells (Table 3.8.7b). The re­
addition of sulindac in the short-term assay further enhanced the toxicity of 
methotrexate in these cells which indicates that long-term maintenance of 
sulindac levels is required for optimal potentiation of the drug to occur (Table 
3.8.7c). There was poor potentiation of MTX toxicity by sulindac in both the
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2008 MRP2 and MRP3 cells in both the long term and the short term assays. 
Re-addition of sulindac to the medium in the short-term assay did not 
significantly increase the potentiation of methotrexate toxicity. The results 
suggest that MRP2 and MRP3 are also poorer transporters of sulindac than 
MRP1.
3.8.3 Analysis of 2008 cells for enhancement of taxol and taxotere 
toxicities by sulindac.
The effect of sulindac on taxotere and taxol was subsequently analysed to try 
to assess other possible substrates for MRP 1-3 and also to assess if  synergism 
between the anticancer drug and the NSAID would occur. Initial long-term 
and short-term toxicity assays were carried out to assess the toxicity profile of 
these drugs in the 2008 cell lines. In the long-term assay the IC5o values for 
taxotere were the same for all the 2008 cells (lng/ml). In the short-term assay 
the IC50 value increased to 50ng/ml for both the parental and MRP2- 
transfected cells and 25ng/ml for 2008 MRP3. However, a most unexpected 
result was obtained for 2008 MRP1. The IC50 value for 2008 MRP1 increased 
only to 4ng/ml, 12-fold less resistant than the parental and 2008 MRP2 cells. 
The result indicate that overexpression of MRP1 resulted in decreased 
resistance to taxotere in the short-term assays. The toxicity results for taxol 
show the parental 2008 cells to be approximately 2-fold more resistant to taxol 
than the transfected cell lines (7ng/ml versus 3ng/ml). In the short-term 
toxicity assay the IC50 concentration for the parental and MRP2-transfected 
cell lines increased to lOOOng/ml and the IC50 concentration for 2008 MRP1 
and MRP3 increased to 2000ng/ml.
The combination toxicity assay results indicate that greater synergy between 
taxotere/taxol and sulindac was evident in the long-term combination toxicity 
assays than in the short-term toxicity assays (Tables 3.8.8a and 3.8.8b). Again, 
re-addition of sulindac in the short-term assay demonstrated that long term 
exposure to sulindac was more effective in enhancing the anti-cancer effect of 
the chemotherapeutic drugs. The combination index values indicate that there 
was a good combination effect between taxotere and sulindac in all of the cell 
lines (Table 3.8.10a). This effect was strongest in the MRP1 and parental 2008
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cell lines despite the reduced resistance associated with MRP1. In the case of 
taxol, there was excellent synergism in all cell lines between taxol and 
sulindac (Table 3.8.9a). The strongest synergism was observed in the 2008 
MRP 1-transfected cells and the lowest combination index value for this 
particular combination was obtained for the 2008 MRP2 cells (Table 3.8.10a). 
The results for taxotere followed the trend observed with methotrexate and 
adriamycin with the strongest combination effect observed in the MRP1 and 
parental cells and poorer effects observed in the 2008 MRP2 and MRP3 cells. 
However, the results for taxol are very surprising. The combination index 
results indicate that sulindac can potentiate the toxicity of taxol to a greater 
extent than any of the other chemotherapeutic drugs. It is possible that the 
effect of sulindac on taxol may not be entirely due to sulindac interacting with 
MRP1 and could be due to an additional mechanism of action (see section
4.11.2).
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LONG TERM ASSAY
Test Sample % Cell Survival S.D.
2008 P Adriamycin and Sulindac
Adriamycin 20ng/ml 65.4 5.1
Sul (1) 96.2 3.9
Sul (1) + Adriamycin 14.3 8.5
Sul (2) 99.4 2.6
Sul (2) + Adriamycin 24.4 4.5
Sul (3) 101.2 2.2
Sul (3) + Adriamycin 27.6 9.0
2008 MRP1 Adriamycin and Sulindac
Adriamycin 120ng/ml 61.9 7.0
Sul (1) 92.1 4.4
Sul (1) + Adriamycin 4.4 1.5
Sul (2) 97.6 1.0
Sul (2) + Adriamycin 26.9 6.0
Sul (3) 96.8 1.1
Sul (3) + Adriamycin 52.2 5.4
2008 MRP2 Adriamycin and Sulindac
Adriamycin lOng/ml 60.7 0.4
Sul (1) 95.2 3.1
Sul (1) + Adriamycin 34.3 6.6
Sul (2) 96.9 3.4
Sul (2) + Adriamycin 43.4 5.7
Sul (3) 101.7 3.6
Sul (3) + Adriamycin 44.9 4.6
2008 MRP3 Adriamycin and Sulindac
Adriamycin 20ng/ml 55.0 3.8
Sul (1) 93.9 7.2
Sul (1) + Adriamycin 30.9 2.1
Sul (2) 101.9 0.2
Sul (2) + Adriamycin 34.4 1.4
Sul (3) 97.8 3.8
Sui (3) + Adriamycin 35.1 4.1
Table 3.8.6a: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of adriamycin, in combination with sulindac, as 
found using the protocol detailed in section 2.7.3a. Survival is represented as a 
% of the growth of untreated cells in the same plate ± S.D. Results are the 
average of triplicate determinations in three separate experiments. The 
concentrations of sulindac were: (1) 35|ig/ml; (2) 17.5(ig/ml; (3) 8.75jj,g/ml.
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SHORT TERM ASSAY f-Sulindac ®T4 hours)
Test Sample % Cell Survival S.D.
2008 P Adriamycin and Sulindac
Adriamycin 80ng/ml 59.1 2.7
Sul (1) 97.3 3.6
Sul (1) + Adriamycin 59.3 6.4
Sul (2) 98.2 3.4
Sul (2) + Adriamycin 59.8 6.1
Sul (3) 99.4 1.4
Sul (3) + Adriamycin 60.5 6.4
2008 MRP1 Adriamycin and Sulindac
Adriamycin 250ng/ml 76.4 3.6
Sul (1) 92.8 2.8
Sul (1) + Adriamycin 45.0 10.8
Sul (2) 99.2 2.0
Sul (2) + Adriamycin 52.9 9.8
Sul (3) 98.0 1.4
Sul (3) + Adriamycin 61.6 9.5
2008 MRP2 Adriamycin and Sulindac
Adriamycin 125ng/ml 76.0 3.4
Sul (1) 92.8 2.3
Sul (1) + Adriamycin 71.9 1.8
Sul (2) 96.7 1.8
Sul (2) + Adriamycin 72.4 2.0
Sul (3) 101.4 2.9
Sul (3) + Adriamycin 74.4 2.9
2008 MRP3 Adriamycin and Sulindac
Adriamycin 250ng/ml 61.9 1.9
Sul (1) 96.1 1.9
Sul (1) + Adriamycin 47.5 4.2
Sul (2) 102.3 4.5
Sul (2) + Adriamycin 48.6 2.7
Sul (3) 97.7 2.4
Sul (3) + Adriamycin 50.1 5.6
Table 3.8.6b: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of adriamycin, in combination with sulindac, as 
found using the protocol detailed in section 2.7.3b (Short term assay). Survival 
is represented as a % of the growth of untreated cells in the same plate ± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of sulindac were: (1) 100 (J-g/ml; (2) 50 
jag/ml; (3) 25 jj,g/ml.
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SHORT TERM ASSAY i+Sulindac ®T4 hour)
Test Sample % Cell Survival S.D.
2008 P Adriamycin and Sulindac
Adriamycin 80ng/ml 59.5 2.7
Sul (1) 96.0 6.8
Sul (1) + Adriamycin 33.9 9.8
Sul (2) 99.7 3.2
Sul (2) + Adriamycin 47.3 4.1
Sul (3) 95.9 4.2
Sul (3) + Adriamycin 48.8 4.5
2008 MRP1 Adriamycin and Sulindac
Adriamycin 250ng/ml 76.7 2.1
Sul (1) 92.9 1.4
Sul (1) + Adriamycin 23.8 1.5
Sul (2) 93.9 1.6
Sul (2) + Adriamycin 48.2 6.7
Sul (3) 98.7 3.1
Sul (3) + Adriamycin 64.5 0.4
2008 MRP2 Adriamycin and Sulindac
Adriamycin 125ng/ml 57.7 2.7
Sul (1) 92.8 2.9
Sul (1) + Adriamycin 51.7 3.0
Sul (2) 100.3 0.3
Sul (2) + Adriamycin 54.4 6.2
Sul (3) 96.6 0.2
Sul (3) + Adriamycin 54.9 5.9
2008 MRP3 Adriamycin and Sulindac
Adriamycin 250ng/ml 51.5 10.7
Sul (1) 94.4 0.5
Sul (1) + Adriamycin 40.2 9.6
Sul (2) 100.4 7.2
Sul (2) + Adriamycin 40.4 11.2
Sul (3) 95.7 0.4
Sul (3) + Adriamycin 42.3 6.7
Table 3.8.6c: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of adriamycin, in combination with sulindac, as 
found using the protocol detailed in section 2.7.3b (Short term assay). Survival 
is represented as a % of the growth of untreated cells in the same plate ± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of sulindac were: @T0: (1) 100 ng/ml; (2) 50 
H-g/ml; (3) 25 (J-g/ml; @T4hours: (1) 35 |ig/ml; (2) 17.5 fag/ml; (3) 8.75 fig/ml
2 1 0
LONG TERM ASSAY
Test Sample % Cell Survival S.D.
2008 P Methotrexate and Sulindac 
Methotrexate 5fig/ml 21.2 5.3
Sul (1) 98.4 3.5
Sul (1) + Methotrexate 12.8 3.1
Sul (2) 101.8 2.1
Sul (2) + Methotrexate 14.4 3.3
Sul (3) 102.9 2.4
Sul (3) + Methotrexate 16.2 4.4
2008 MRP1 Methotrexate and Sulindac 
Methotrexate 5(ig/ml 24.2 2.2
Sul (1) 93.5 2.4
Sul (1) + Methotrexate 11.8 1.4
Sul (2) 96.5 4.8
Sul (2) + Methotrexate 14.5 2.8
Sul (3) 99.1 5.4
Sul (3) + Methotrexate 19.1 3.6
2008 MRP2 Methotrexate and Sulindac 
Methotrexate 5^g/ml 21.6 1.4
Sul (1) 98.1 2.2
Sul (1) + Methotrexate 17.6 0.7
Sul (2) 99.5 1.4
Sul (2) + Methotrexate 18.7 1.0
Sul (3) 98.9 1.8
Sul (3) + Methotrexate 18.7 0.2
2008 MRP3 Methotrexate and Sulindac 
Methotrexate 5|og/ml 30.6 1.5
Sul (1) 91.9 3.9
Sul (1) + Methotrexate 20.5 2.0
Sul (2) 101.1 2.1
Sul (2) + Methotrexate 26.8 3.8
Sul (3) 105.2 3.9
Sul (3) + Methotrexate 28.0 2.4
Table 3.8.7a: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of methotrexate, in combination with sulindac, as 
found using the protocol detailed in section 2.7.3a. Survival is represented as a 
% of the growth of untreated cells in the same plate ± S.D. Results are the 
average of triplicate determinations in three separate experiments. The 
concentrations of sulindac were: (1) 35|j.g/ml; (2) 17.5|ig/ml; (3) 8.75|ig/ml.
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SHORT TERM ASSAY t-Sulindac tffiT4 hours)
Test Sample % Cell Survival S.D.
2008 P Methotrexate and Sulindac
Methotrexate lOfig/ml 59.2 4.8
Sul (1) 93.5 5.8
Sul (1) + Methotrexate 38.2 7.9
Sul (2) 98.2 2.1
Sul (2) + Methotrexate 38.3 9.4
Sul (3) 99.6 2.4
Sul (3) + Methotrexate 41.5 9.9
2008 MRP1 Methotrexate and Sulindac
Methotrexate 900jxg/ml 32.1 1.9
Sul (1) 97.7 2.0
Sul (1) + Methotrexate 18.3 1.6
Sul (2) 98.3 2.0
Sul (2) + Methotrexate 22.7 2.8
Sul (3) 96.7 3.6
Sul (3) + Methotrexate 28.6 2.4
2008 MRP2 Methotrexate and Sulindac
Methotrexate 300frg/ml 20.2 6.9
Sul (1) 93.2 3.1
Sul (1) + Methotrexate 14.3 5.8
Sul (2) 103.3 8.4
Sul (2) + Methotrexate 15.4 6.7
Sul (3) 97.8 4.3
Sul (3) + Methotrexate 17.2 6.2
2008 MRP3 Methotrexate and Sulindac
Methotrexate 900jig/ml 28.1 3.7
Sul (1) 95.8 6.4
Sul (1) + Methotrexate 22.9 4.3
Sul (2) 97.2 4.6
Sul (2) + Methotrexate 24.6 5.9
Sul (3) 101.5 4.6
Sul (3) + Methotrexate 26.6 6.5
Table 3.8.7b: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of methotrexate, in combination with sulindac, as 
found using the protocol detailed in section 2.7.3b (Short term assay). Survival 
is represented as a % of the growth of untreated cells in the same plate± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of sulindac were: (1) 100 ng/ml; (2) 50 
(j,g/ml; (3) 25 jag/ml.
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SHORT TERM ASSAY i+Sulindac (a).T4 hours)
Test Sample % Cell Survival S.D.
2008 P Methotrexate and Sulindac
Methotrexate 10fag/ml 50.9 6.2
Sul (1) 92.7 1.0
Sul (1) + Methotrexate 16.7 7.7
Sul (2) 98.6 1.0
Sul (2) + Methotrexate 20.8 7.4
Sul (3) 102.6 7.8
Sul (3) + Methotrexate 30.9 7.3
2008 MRP1 Methotrexate and Sulindac
Methotrexate 900|xg/ml 45.0 5.2
Sul (1) 92.0 3.3
Sul (1) + Methotrexate 16.4 2.0
Sul (2) 96.0 3.6
Sul (2) + Methotrexate 27.8 6.7
Sul (3) 102.5 6.3
Sul (3) + Methotrexate 35.0 5.4
2008 MRP2 Methotrexate and Sulindac
Methotrexate 300|ig/ml 25.5 1.4
Sul (1) 95.7 4.0
Sul (1) + Methotrexate 19.2 1.5
Sul (2) 100.1 2.0
Sul (2) + Methotrexate 20.4 3.2
Sul (3) 101.0 2.2
Sul (3) + Methotrexate 22.2 3.1
2008 MRP3 Methotrexate and Sulindac
Methotrexate 900|a,g/ml 31.2 6.7
Sul (1) 92.0 0.2
Sul (1) + Methotrexate 17.8 2.3
Sul (2) 99.7 3.8
Sul (2) + Methotrexate 21.9 1.0
Sul (3) 100.9 3.4
Sul (3) + Methotrexate 25.5 2.4
Table 3.8.7c: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of methotrexate, in combination with sulindac, as 
found using the protocol detailed in section 2.7.3b (Short term assay). Survival 
is represented as a % of the growth of untreated cells in the same plate± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of sulindac were: @T0: (1) 100 |j.g/ml; (2) 50 
(ig/ml; (3) 25 (J.g/ml; @T4hours: (1) 35 |xg/ml; (2) 17.5 |4g/ml; (3) 8.75 [xg/ml.
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LONG TERM ASSAY
2008 P Taxotere and Sulindac
Taxotere 1.0ng/ml 60.0 1.6
Sul (1) 95.1 2.7
Sul (1) + Taxotere 26.5 2.7
Sul (2) 96.7 1.5
Sul (2) + Taxotere 37.8 2.3
Sul (3) 94.5 3.2
Sul (3) + Taxotere 43.4 4.8
2008 MRP1 Taxotere and Sulindac 
Taxotere 1.0ng/ml 34.4 5.8
Sul (1) 89.5 2.3
Sul (1) + Taxotere 10.6 3.2
Sul (2) 94.8 2.8
Sul (2) + Taxotere 14.3 3.9
Sul (3) 99.5 2.5
Sul (3) + Taxotere 22.1 3.1
2008 MRP2 Taxotere and Sulindac 
Taxotere 1.0ng/ml 34.2 6.9
Sul (1) 95.9 2.9
Sul (1) + Taxotere 15.3 2.3
Sul (2) 99.2 0.5
Sul (2) + Taxotere 26.5 0.7
Sul (3) 97.7 0.8
Sul (3) + Taxotere 31.0 3.5
2008 MRP3 Taxotere and Sulindac 
Taxotere 1.0ng/ml 54.1 9.2
Sul (1) 93.5 3.8
Sul (1) + Taxotere 32.1 6.9
Sul (2) 101.5 4.8
Sul (2) + Taxotere 45.1 8.4
Sul (3) 102.5 0.6
Sul (3) + Taxotere 47.0 10.6
Test Sample % Cell Survival S.D.
Table 3.8.8a: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of taxotere, in combination with sulindac, as found 
using the protocol detailed in section 2.7.3a. Survival is represented as a % of 
the growth of untreated cells in the same plate ± S.D. Results are the average 
of triplicate determinations in three separate experiments. The concentrations 
of sulindac were: (1) 35|ag/ml; (2) 17.5(ig/ml; (3) 8.75(j,g/ml.
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SHORT TERM ASSAY f-Sulindac @T4 hours)
Test Sample % Cell Survival S.D.
2008 P Taxotere and Sulindac
Taxotere 50.0ng/ml 47.5 1.4
Sul (1) 96.5 2.3
Sul (1) + Taxotere 43.9 4.5
Sul (2) 102.5 6.1
Sul (2) + Taxotere 43.1 5.6
Sul (3) 100.5 4.0
Sul (3) + Taxotere 44.4 4.7
2008 MRP1 Taxotere and Sulindac 
Taxotere 4.0ng/ml 56.5 4.5
Sul (1) 95.3 1.2
Sul (1) + Taxotere 46.6 7.1
Sul (2) 102.5 4.5
Sul (2) + Taxotere 50.4 4.9
Sul (3) 97.9 4.1
Sul (3) + Taxotere 51.6 6.8
2008 MRP2 Taxotere and Sulindac 
Taxotere 50ng/ml 47.7 6.3
Sul (1) 94.8 1.5
Sul (1) + Taxotere 35.7 9.8
Sul (2) 98.6 2.3
Sul (2) + Taxotere 36.6 9.2
Sul (3) 99.4 1.0
Sul (3) + Taxotere 40.3 8.7
2008 MRP3 Taxotere and Sulindac 
Taxotere 25ng/ml 48.1 4.9
Sul (1) 92.9 3.5
Sul (1) + Taxotere 38.2 4.7
Sul (2) 100.6 4.4
Sul (2) + Taxotere 47.0 4.7
Sul (3) 97.9 0.7
Sul (3) + Taxotere 47.0 3.4
Table 3.8.8b: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of taxotere, in combination with sulindac, as found 
using the protocol detailed in section 2.7.3b (Short term assay). Survival is 
represented as a % of the growth of untreated cells in the same plate ± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of Sulindac were: (1) 100 |J.g/ml; (2) 50 
(ig/ml; (3) 25 (j,g/ml.
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SHORT TERM ASSAY i+Sulindac ®T4 hours)
Test Sample % Cell Survival S.D.
2008 P Taxotere and Sulindac
Taxotere 50.0ng/ml 49.3 4.2
Sul (1) 95.0 2.7
Sul (1) + Taxotere 12.5 3.2
Sul (2) 98.8 2.4
Sul (2) + Taxotere 31.5 3.0
Sul (3) 100.9 4.8
Sul (3) + Taxotere 38.6 8.5
2008 MRP1 Taxotere and Sulindac
Taxotere 4.0ng/ml 68.6 1.9
Sul (1) 91.01 1.2
Sul (1) + Taxotere 26.0 4.0
Sul (2) 93.6 1.7
Sul (2) + Taxotere 42.9 1.9
Sul (3) 98.7 2.0
Sul (3) + Taxotere 52.5 9.4
2008 MRP2 Taxotere and Sulindac
Taxotere 50ng/ml 37.1 6.7
Sul (1) 95.6 3.1
Sul (1) + Taxotere 21.9 4.2
Sul (2) 99.6 5.5
Sul (2) + Taxotere 30.0 8.3
Sul (3) 101.9 4.6
Sul (3) + Taxotere 32.9 6.9
2008 MRP3 Taxotere and Sulindac
Taxotere 25ng/ml 51.5 8.1
Sul (1) 92.6 4.2
Sul (1) + Taxotere 24.6 6.0
Sul (2) 98.9 1.4
Sul (2) + Taxotere 39.1 1.8
Sul (3) 97.7 2.1
Sul (3) + Taxotere 42.3 3.1
Table 3.8.8c: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of taxotere, in combination with sulindac, as found 
using the protocol detailed in section 2.7.3b (Short term assay). Survival is 
represented as a % of the growth of untreated cells in the same plate ± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of sulindac were: @T0: (1) 100 n-g/ml; (2) 50 
Hg/ml; (3) 25 ng/ml; @T4hours: (1) 35 (ig/ml; (2) 17.5 fJg/ml; (3) 8.75 |Jg/ml
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LONG TERM ASSAY
2008 P Taxol and Sulindac
Taxol 7.0ng/ml 35.2 3.6
Sul (1) 98.0 2.1
Sul (1) + Taxol 7.8 4.7
Sul (2) 97.7 1.2
Sul (2) + Taxol 14.3 2.4
Sul (3) 99.7 1.9
Sul (3) + Taxol 19.7 4.0
2008 MRP1 Taxol and Sulindac 
Taxol 3.0ng/ml 46.3 1.1
Sul (1) 96.1 1.0
Sul (1) + Taxol 5.0 0.9
Sul (2) 101.1 4.8
Sul (2) + Taxol 11.4 1.3
Sul (3) 100.9 2.9
Sul (3) + Taxol 30.3 1.8
2008 MRP2 Taxol and Sulindac 
Taxol 3.0ng/ml 35.9 1.1
Sul (1) 99.6 2.0
Sul (1) + Taxol 13.3 1.7
Sul (2) 100.8 0.4
Sul (2) + Taxol 18.9 1.5
Sul (3) 100.1 0.4
Sul (3) + Taxol 24.3 5.2
2008 MRP3 Taxol and Sulindac 
Taxol 3.0ng/ml 40.3 5.7
Sul (1) 95.4 3.8
Sul (1) + Taxol 8.4 5.5
Sul (2) 103.2 4.3
Sul (2) + Taxol 13.0 5.3
Sul (3) 102.5 4.0
Sul (3) + Taxol 15.8 4.6
Test Sample % Cell Survival S.D.
Table 3.8.9a: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of taxol, in combination with sulindac, as found 
using the protocol detailed in section 2.7.3a. Survival is represented as a % of 
the growth of untreated cells in the same plate ± S.D. Results are the average 
of triplicate determinations in three separate experiments. The concentrations 
of sulindac were: (1) 35|_ig/ml; (2) 17.5jag/ml; (3) 8.75|.ig/ml.
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Test Sample %  Cell Survival S.D.
2008 P Taxol and Sulindac
Taxol 1000ng/ml 50.0 7.4
Sul (1) 98.3 2.3
Sul (1) + Taxol 33.9 10.5
Sul (2) 94.7 2.0
Sul (2) + Taxol 35.7 11.2
Sul (3) 99.3 3.0
Sul (3) + Taxol 41.1 10.6
2008 MRP1 Taxol and Sulindac 
Taxol 2000ng/ml 48.9 2.8
Sul (1) 94.0 4.6
Sul (1) + Taxol 29.3 8.7
Sul (2) 97.5 0.4
Sul (2) + Taxol 40.3 12.5
Sul (3) 100.7 0.4
Sul (3) + Taxol 42.3 5.6
2008 MRP2 Taxol and Sulindac 
Taxol 1000ng/ml 59.8 0.3
Sul (1) 97.1 0.7
Sul (1) + Taxol 34.2 0.6
Sul (2) 100.5 4.2
Sul (2) + Taxol 54.7 8.9
Sul (3) 99.9 3.1
Sul (3) + Taxol 54.5 3.3
2008 MRP3 Taxol and Sulindac 
Taxol 2000ng/ml 62.6 1.5
Sul (1) 96.1 3.4
Sul (1) + Taxol 50.5 0.8
Sul (2) 97.3 1.0
Sul (2) + Taxol 59.0 4.2
Sul (3) 96.9 4.5
Sul (3) + Taxol 59.6 0.6
Table 3.8.9b: % Survival of 2008 P, 2008 MRP I, 2008 MRP2 and 2008 
MRP3 cells in the presence of taxol, in combination with sulindac, as found 
using the protocol detailed in section 2.7.3b (Short term assay). Survival is 
represented as a % of the growth of untreated cells in the same plate± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of sulindac were: (1) 100 (ag/ml; (2) 50 
|j,g/ml; (3) 25 [ag/ml.
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Taxotere + Sulindac Taxol + Sulindac
L.T S.T(l) S.T(2) L.T S.T(l)
2008P 0.371 1.365 0.324 0.172 0.631
MRP1 0. 465 0.963 0.279 0.046 0.652
MRP2 0.612 0.977 0.851 0.283 0.590
MRP3 0.516 0.996 0.537 0.199 0.780
Table 3.8.10a: Combination index (CF' values for taxote
combination with sulindac obtained using the method of Chou and Talalay as 
described in section 2.16.
Methotrexate + Sulindac 
L.T S.T(l) S.T(2)
Adriamycin + Sulindac 
L.T S.T(l) S.T(2)
2008P 0.729 0.550 0.220 0.218 1.082 0.534
MRP1 0. 591 0.357 0.343 0.091 0.528 0.357
MRP2 0.883 0.823 0.792 0.463 1.009 0.918
MRP3 0.709 0.790 0.640 0.509 0.786 0.658
Table 3.8.10b: Combination index (Cl) values for taxotere or taxol in 
combination with sulindac obtained using the method of Chou and Talalay as 
described in section 2.16.
(Cl < 1: synergism; Cl > 1: antagonism; Cl = 1: additive.)
L.T: Long-term assay as described in section 2.7.3a
S.T (1): Short-term assay. Drug and compound removed from the cells after 4 
hours incubation and replaced with fresh medium only as described in section 
2.7.3b
S.T (2): Short-term assay. Drug and NSAID removed from the cells after 4 
hours incubation and replaced with NSAID only as described in section 2.7.3b.
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3.8.4 Analysis of 2008 cells for enhancement of adriamycin, taxol, 
taxotere and cisplatin toxicides by B R I138/1 and piroxicam.
Long-term and short-term combination toxicity assays were carried out on the 
2008 cells using taxol and taxotere in combination with piroxicam. Duffy el 
al., (1998), reported that piroxicam was not an MRP substrate and did not 
potentiate the toxicity of any of the chemotherapeutic drugs analysed. Hence, 
this NSAID was used in the combination toxicity assays as a negative control. 
The results for taxotere in combination with piroxicam in both the long-term 
and the short-term assays indicate that there is no significant synergy between 
piroxicam and taxotere in the 2008 cell lines (Table 3.8.11 and 3.8.17a). 
However, the results for taxol and piroxicam are interesting. There 
appears to be some potentiation of the toxicity of taxol by the NSAID 
piroxicam in the long-term toxicity assay (Table 3.8.12). The combination 
index values for taxol and piroxicam in the 2008 cell lines range from 0.795 
for 2008 MRP1 to 0.820 for 2008 P (Table 3.8.17a). These results indicate 
significant potentiation of the toxicity of taxol by piroxicam in the long-term 
toxicity assay. Considering these results, it is possible that there is an 
alternative or additional mechanism of taxol toxicity potentiation by NSAIDs. 
BRI 138/1, an indomethacin analogue was found to be positive in the 
combination toxicity assays in both DLKP and CORL23 cells. BRI 138/1 was 
analysed in the 2008 cell lines in combination with taxol and taxotere to assess 
if this compound was also active in an ovarian carcinoma cell line. The results 
obtained from these assays indicate that BRI 138/1 potentiated the toxicity of 
taxol, taxotere and adriamycin in the long-term combination toxicity assays 
(Tables 3.8.13, 3.8.14 and 3.8.15). Again, the toxicity of taxol was potentiated 
to a greater extent by BRI 138/1 as compared to the potentiation of adriamycin 
and taxotere by this indomethacin analogue. There was no significant 
potentiation of the toxicity of the chemotherapeutic drugs in the short-term 
assays suggesting that BRI 138/1 required a longer period of time in the cells 
to exert its enhancement effect. This indomethacin analogue, like 
indomethacin, was not able to potentiate the toxicity of cisplatin in the 2008 
cells (Table 3.8.16). This result suggests that cisplatin is not an MRP substrate.
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LONG TERM ASSAY
2008 P Taxotere and Piroxicam
Taxotere l.Ong/ml 58.9 4.8
Pirox (1) 92.4 2.1
Pirox (1) + Taxotere 48.8 2.4
Pirox (2) 99.7 0.9
Pirox (2) + Taxotere 48.8 3.5
Pirox (3) 100.6 1.6
Pirox (3) + Taxotere 51.2 1.8
2008 MRP1 Taxotere and Piroxicam
Taxotere l.Ong/ml 50.7 6.2
Pirox (1) 93.3 1.7
Pirox (1) + Taxotere 45.7 5.2
Pirox (2) 95.5 3.5
Pirox (2) + Taxotere 47.6 4.0
Pirox (3) 94.2 6.2
Pirox (3) + Taxotere 49.8 4.4
2008 MRP2 Taxotere and Piroxicam
Taxotere l.Ong/ml 44.0 10.9
Pirox (1) 97.6 1.1
Pirox (1) + Taxotere 39.4 6.6
Pirox (2) 100.2 2.8
Pirox (2) + Taxotere 40.0 3.9
Pirox (3) 96.8 0.5
Pirox (3) + Taxotere 41.8 4.1
2008 MRP3 Taxotere and Piroxicam
Taxotere l.Ong/ml 47.4 9.1
Pirox (1) 98.1 1.1
Pirox (1) + Taxotere 43.4 0.9
Pirox (2) 99.1 0.5
Pirox (2) + Taxotere 45.5 3.7
Pirox (3) 98.3 2.8
Pirox (3) + Taxotere 46.8 5.4
Test Sample % Cell Survival S.D.
Table 3.8.11a: Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 MRP3 
cells in the presence of taxotere, in combination with piroxicam, as found 
using the protocol detailed in section 2.7.3a. Survival is represented as a % of 
the growth of untreated cells in the same plate± S.D. The untreated cell 
survival % is taken as 100%. Results are the average of triplicate 
determinations in three separate experiments. The concentrations of piroxicam 
were: (1) 40|xg/ml; (2) 20fj,g/ml; (3) 10jj.g/ml.
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2008 P Taxotere and Piroxicam
Taxotere 50.0ng/ml 47.2 1.8
Pirox (1) 98.8 1.8
Pirox (1) + Taxotere 45.0 2.4
Pirox (2) 98.7 1.0
Pirox (2) + Taxotere 47.0 2.1
Pirox (3) 99.1 1.0
Pirox (3) + Taxotere 46.6 1.7
2008 MRP1 Taxotere and Piroxicam 
Taxotere 4.0ng/ml 41.6 7.1
Pirox (1) 99.6 3.1
Pirox (1) + Taxotere 40.9 6.4
Pirox (2) 100.3 2.7
Pirox (2) + Taxotere 41.3 7.1
Pirox (3) 100.6 0.9
Pirox (3) + Taxotere 41.6 7.1
2008 MRP2 Taxotere and Piroxicam 
Taxotere 50ng/ml 50.6 6.6
Pirox (1) 99.9 1.0
Pirox (1) + Taxotere 47.5 5.8
Pirox (2) 99.2 1.1
Pirox (2) + Taxotere 49.4 6.6
Pirox (3) 94.8 0.6
Pirox (3) + Taxotere 49.4 8.2
2008 MRP3 Taxotere and Piroxicam 
Taxotere 25ng/ml 57.8 1.8
Pirox (1) 95.2 1.1
Pirox (1) + Taxotere 56.9 0.9
Pirox (2) 95.9 1.3
Pirox (2) + Taxotere 57.6 1.9
Pirox (3) 98.2 2.6
Pirox (3) + Taxotere 58.1 0.3
Test Sample % Cell Survival S.D.
Table 3.8.11b: Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 MRP3 
cells in the presence of taxotere, in combination with piroxicam, as found 
using the protocol detailed in section 2.7.3b (Short term assay). Survival is 
represented as a % of the growth of untreated cells in the same plate ± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of piroxicam were: (1) 100 ng/ml; (2) 50 
(j.g/ml; (3) 25 ng/ml.
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2008 P Taxol and Piroxicam
Taxol 7.0ng/ml 48.9 5.0
Pirox (1) 98.4 1.5
Pirox (1) + Taxol 36.1 5.5
Pirox (2) 96.5 2.6
Pirox (2) + Taxol 37.7 7.8
Pirox (3) 99.6 1.7
Pirox (3) + Taxol 39.9 3.2
2008 MRP1 Taxol and Piroxicam 
Taxol 3.0ng/ml 51.2 3.5
Pirox (1) 97.7 1.6
Pirox (1) + Taxol 38.3 5.7
Pirox (2) 101.4 0.3
Pirox (2) + Taxol 42.4 3.0
Pirox (3) 102.6 4.1
Pirox (3) + Taxol 49.1 6.2
2008 MRP2 Taxol and Piroxicam 
Taxol 3.0ng/ml 50.2 2.9
Pirox (1) 96.9 0.5
Pirox (1) + Taxol 39.8 6.1
Pirox (2) 97.8 0.3
Pirox (2) + Taxol 42.6 4.8
Pirox (3) 99.1 0.2
Pirox (3) + Taxol 44.1 5.1
2008 MRP3 Taxol and Piroxicam 
Taxol 3.0ng/ml 55.5 5.2
Pirox (1) 97.4 2.0
Pirox (1) + Taxol 42.3 2.5
Pirox (2) 99.1 0.2
Pirox (2) + Taxol 45.9 5.0
Pirox (3) 100.3 2.3
Pirox (3) + Taxol 51.9 8.0
LONG TERM ASSAY
Test Sample %  Cell Survival S.D.
Table 3.8.12a: Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 MRP3 
cells in the presence of taxol, in combination with piroxicam, as found using 
the protocol detailed in section 2.7.3a. Survival is represented as a % of the 
growth of untreated cells in the same plate± S.D. Results are the average of 
triplicate determinations in three separate experiments. The concentrations of 
piroxicam were: (1) 40(j.g/ml; (2) 20fo,g/ml; (3) 10(ig/ml.
223
SHORT TERM ASSAY
Test Sample % Cell Survival S.D.
2008 P Taxol and Piroxicam
Taxol lOOOng/ml 57.6 0.8
Pirox (1) 99.0 0.4
Pirox (1) + Taxol 51.5 4.8
Pirox (2) 95.1 1.6
Pirox (2) + Taxol 52.8 1.9
Pirox (3) 97.9 3.6
Pirox (3) + Taxol 57.2 1.0
2008 MRP1 Taxol and Piroxicam 
Taxol 2000ng/ml 53.7 3.0
Pirox (1) 98.9 0.6
Pirox (1) + Taxol 50.6 1.2
Pirox (2) 101.2 4.1
Pirox (2) + Taxol 51.2 0.7
Pirox (3) 99.7 0.9
Pirox (3) + Taxol 53.4 1.0
2008 MRP2 Taxol and Piroxicam 
Taxol lOOOng/ml 52.3 0.8
Pirox (1) 96.5 1.9
Pirox (1) + Taxol 50.5 0.8
Pirox (2) 97.7 0.4
Pirox (2) + Taxol 50.9 1.0
Pirox (3) 99.0 1.0
Pirox (3) + Taxol 51.2 0.6
2008 MRP3 Taxol and Piroxicam 
Taxol 2000ng/ml 59.4 6.2
Pirox (1) 98.8 1.1
Pirox (1) + Taxol 55.9 3.0
Pirox (2) 99.3 0.7
Pirox (2) + Taxol 57.2 1.3
Pirox (3) 101.9 4.5
Pirox (3) + Taxol 57.5 0.9
Table 3.8.12b: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of taxol, in combination with piroxicam, as found 
using the protocol detailed in section 2.7.3b (Short term assay). Survival is 
represented as a % of the growth of untreated cells in the same plate± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of piroxicam were: (1) 100 |ig/ml; (2) 50 
fig/ml; (3) 25 ng/ml.
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Test Sample % Cell Survival S.D.
2008 P Taxotere and BRI 138/1
Taxotere 1.0ng/ml 42.8 9.2
138/1(1) 95.6 1.8
138/1 (1) + Taxotere 20.6 0.5
138/1 (2) 100.0 2.5
138/1 (2) + Taxotere 27.9 3.0
138/1 (3) 100 7.2
138/1 (3) + Taxotere 33.8 1.3
2008 MRP1 Taxotere and 138/1 
Taxotere 1.0ng/ml 43.6 5.4
138/1 (1) 96.7 3.2
138/1 (1) + Taxotere 9.2 1.9
138/1 (2) 100.0 0.8
138/1 (2) + Taxotere 13.2 0.9
138/1 (3) 100.2 0.8
138/1 (3) + Taxotere 21.8 1.3
2008 MRP2 Taxotere and 138/1 
Taxotere 1.0ng/ml 38.1 3.9
138/1(1) 91.4 5.4
138/1 (1) + Taxotere 16.0 3.0
138/1 (2) 101.9 4.4
138/1 (2) + Taxotere 17.0 0.8
138/1 (3) 100.9 3.1
138/1 (3) + Taxotere 19.1 2.0
2008 MRP3 Taxotere and 138/1 
Taxotere 1.0ng/ml 40.0 7.7
138/1 (1) 93.3 2.5
138/1 (1) + Taxotere 9.5 0.9
138/1(2) 95.5 1.5
138/1 (2) + Taxotere 10.5 3.7
138/1 (3) 99.9 2.8
138/1 (3) + Taxotere________122_______   5.4
Table 3.8.13a: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of taxotere, in combination with BRI 138/1, as 
found using the protocol detailed in section 2.7.3a. Survival is represented as a 
% of the growth of untreated cells in the same plate± S.D. Results are the 
average of triplicate determinations in three separate experiments. The 
concentrations of 138/1 were: (1) 35p,g/ml; (2) 17.5(j.g/ml; (3) 8.75(j,g/ml.
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Test Sample % Cell Survival S.D.
2008 P Taxotere and 138/1
Taxotere 50.0ng/ml 47.3 3.2
138/1 (1) 93.6 5.7
138/1 (1) + Taxotere 35.2 4.5
138/1 (2) 98.5 4.3
138/1 (2) + Taxotere 40.5 3.7
138/1 (3) 100.1 0.6
138/1 (3) + Taxotere 43.2 2.6
2008 MRP1 Taxotere and 138/1
Taxotere 4.0ng/ml 60.6 2.7
138/1 (1) 94.8 2.8
138/1 (1) + Taxotere 51.4 6.6
138/1 (2) 96.8 0.5
138/1 (2) + Taxotere 56.1 8.3
138/1 (3) 101.5 1.1
138/1 (3) + Taxotere 59.4 4.9
2008 MRP2 Taxotere and 138/1
Taxotere 50ng/ml 44.5 0.6
138/1 (1) 91.3 0.1
138/1 (1) + Taxotere 32.9 2.8
138/1 (2) 95.9 8.9
138/1 (2) + Taxotere 40.3 3.4
138/1 (3) 100.0 2.6
138/1 (3) + Taxotere 40.5 3.2
2008 MRP3 Taxotere and 138/1
Taxotere 25ng/ml 43.6 7.1
138/1(1) 94.3 3.0
138/1 (1) + Taxotere 31.2 7.5
138/1 (2) 95.6 2.3
138/1 (2) + Taxotere 34.9 6.7
138/1 (3) 100.7 6.9
138/1 (3) + Taxotere 37.0 5.0
Table 3.8.13b: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of taxotere, in combination with BRI 138/1, as 
found using the protocol detailed in section 2.7.3b (Short term assay). Survival 
is represented as a % of the growth of untreated cells in the same plate± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of 138/1 were: (1) 100 |J.g/ml; (2) 50 (ig/ml; 
(3) 25 |j.g/ml.
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2008 P Taxol and BRI 138/1
Taxol 7.0ng/ml 39.6 0.5
138/1 (1) 96.6 3.1
138/1 (1) + Taxol 10.4 1.0
138/1 (2) 98.9 2.7
138/1 (2) + Taxol 15.6 1.6
138/1 (3) 100.3 0.8
138/1 (3) + Taxol 24.0 1.0
2008 MRP1 Taxol and BRI 138/1 
Taxol 3.0ng/ml 35.4 1.2
138/1 (1) 96.5 3.9
138/1 (1) + Taxol 5.6 2.9
138/1(2) 97.2 1.3
138/1 (2) + Taxol 15.3 0.7
138/1(3) 99.3 1.3
138/1 (3) + Taxol 23.1 2.4
2008 MRP2 Taxol and BRI 138/1 
Taxol 3.0ng/ml 35.3 7.2
138/1 (1) 93.9 2.2
138/1 (1) + Taxol 7.6 5.1
138/1(2) 98.0 1.5
138/1 (2) + Taxol 15.6 8.2
138/1 (3) 100.3 1.9
138/1 (3) + Taxol 20.5 8.3
2008 MRP3 Taxol and BRI 138/1 
Taxol 3.0ng/ml 32.6 7.1
138/1 (1) 90.5 10.3
138/1 (1) + Taxol 3.4 0.6
138/1 (2) 99.8 0.3
138/1 (2) + Taxol 11.0 1.9
138/1(3) 101.5 2.5
138/1 (3) + Taxol 21.8 6.5
LONG TERM ASSAY
Test Sample % Cell Survival S.D.
Table 3.8.14a: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of taxol, in combination with BRI 138/1, as found 
using the protocol detailed in section 2.7.3a. Survival is represented as a % of 
the growth of untreated cells in the same plate± S.D. Results are the average of 
triplicate determinations in three separate experiments. The concentrations of 
BRI 138/1 were: (1) 35|ig/ml; (2) 17.5jxg/ml; (3) 8.75|ag/ml.
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2008 P Taxol and B R I138/1
Taxol lOOOng/ml 52.9 2.6
138/1(1) 93.0 3.2
138/1 (1) + Taxol 43.5 1.8
138/1 (2) 97.6 0.6
138/1 (2) + Taxol 47.8 0.5
138/1 (3) 98.6 1.6
138/1 (3) + Taxol 50.3 2.3
2008 MRP1 Taxol and BRI 138/1 
Taxol 2000ng/ml 49.6 1.0
138/1 (1) 92.5 0.6
138/1 (1) + Taxol 44.5 1.3
138/1 (2) 97.7 2.6
138/1 (2) + Taxol 46.5 0.1
138/1 (3) 99.3 1.9
138/1 (3) + Taxol 48.5 1.0
2008 MRP2 Taxol and BRI 138/1 
Taxol lOOOng/ml 54.6 2.1
138/1 (1) 95.6 2.7
138/1 (1) + Taxol 51.6 4.3
138/1 (2) 96.5 2.4
138/1 (2) + Taxol 51.6 4.1
138/1(3) 94.1 1.7
138/1 (3) + Taxol 56.8 0.9
2008 MRP3 Taxol and BRI 138/1 
Taxol 2000ng/ml 46.1 1.0
138/1(1) 93.8 1.7
138/1 (1) + Taxol 35.3 3.0
138/1 (2) 94.3 2.9
138/1 (2) + Taxol 40.9 2.3
138/1(3) 101.7 2.4
138/1 (3) + Taxol 39.2 0.6
Test Sample % Cell Survival S.D.
Table 3.8.14b: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of taxol, in combination with BRI 138/1, as found 
using the protocol detailed in section 2.7.3b (Short term assay). Survival is 
represented as a % of the growth of untreated cells in the same plate± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of BRI 138/1 were: (1) 100 |J.g/ml; (2) 50 
fxg/ml; (3) 25 fig/ml.
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2008 P Adriamycin and BRI 138/1
Adriamycin 20ng/ml 54.1 2.4
138/1 (1) 93.9 4.0
138/1 (1) + Adriamycin 25.7 2.4
138/1 (2) 100.4 2.6
138/1 (2) + Adriamycin 38.3 1.2
138/1 (3) 103.7 4.0
138/1 (3) + Adriamycin 48.1 1.1
2008 MRP1 Adriamycin and BRI 138/1 
Adriamycin 120ng/ml 49.3 3.7
138/1(1) 94.5 4.1
138/1 (1) + Adriamycin 12.6 3.2
138/1 (2) 98.7 4.9
138/1 (2) + Adriamycin 25.1 3.3
138/1 (3) 101.5 3.1
138/1 (3) + Adriamycin 32.8 1.3
2008 MRP2 Adriamycin and BRI 138/1 
Adriamycin 10ng/ml 46.5 5.5
138/1(1) 92.2 1.3
138/1 (1) + Adriamycin 22.6 3.5
138/1(2) 94.5 1.6
138/1 (2) + Adriamycin 33.2 2.2
138/1 (3) 100.2 4.4
138/1 (3) + Adriamycin 36.7 4.8
2008 MRP3 Adriamycin and BRI 138/1 
Adriamycin 20ng/ml 75.9 3.2
138/1(1) 93.1 2.1
138/1 (1) + Adriamycin 49.2 4.8
138/1 (2) 95.7 1.7
138/1 (2) + Adriamycin 54.4 5.8
138/1 (3) 98.0 2.0
138/1 (3) + Adriamycin 63.4 4.0
Test Sample % Cell Survival S.D.
Table 3.8.15: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of adriamycin, in combination with BRI 138/1, as 
found using the protocol detailed in section 2.7.3a. Survival is represented as a 
% of the growth of untreated cells in the same plate± S.D. Results are the 
average of triplicate determinations in three separate experiments. The 
concentrations of BRI 138/1 were: (1) 35fig/ml; (2) 17.5|j.g/ml; (3) 8.75fxg/ml.
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Test Sample % Cell Survival S.D.
2008 P Cisplatin and B R I138/1
Cisplatin 200ng/ml 56.7 8.3
138/1 (1) 93.9 5.9
138/1 (1) + Cisplatin 74.9 9.7
138/1 (2) 97.6 1.6
138/1 (2) + Cisplatin 70.4 7.9
138/1 (3) 98.9 5.5
138/1 (3) + Cisplatin 64.7 7.4
2008 MRP1 Cisplatin and BRI 138/1
Cisplatin 50ng/ml 58.0 4.9
138/1 (1) 93.0 2.9
138/1 (1) + Cisplatin 59.1 4.0
138/1 (2) 99.2 8.2
138/1 (2) + Cisplatin 58.6 6.6
138/1 (3) 101.2 7.0
138/1 (3) + Cisplatin 58.0 5.8
2008 MRP2 Cisplatin and BRI 138/1
Cisplatin 15ng/ml 58.0 3.8
138/1 (1) 94.0 8.9
138/1 (1) + Cisplatin 64.2 3.5
138/1 (2) 96.1 2.1
138/1 (2) + Cisplatin 62.2 5.0
138/1 (3) 100.7 7.3
138/1 (3) + Cisplatin 59.5 7.0
2008 MRP3 Cisplatin and BRI 138/1
Cisplatin 30ng/ml 78.4 0.8
138/1 (1) 92.0 3.4
138/1 (1) + Cisplatin 90.1 6.8
138/1 (2) 108.0 0.1
138/1 (2) + Cisplatin 83.0 9.1
138/1 (3) 110.4 11.5
138/1 (3) + Cisplatin 81.5 0.3
Table 3.8.16: % Survival of 2008 P, 2008 MRP1, 2008 MRP2 and 2008 
MRP3 cells in the presence of cisplatin, in combination with BRI 138/1, as 
found using the protocol detailed in section 2.7.3a. Survival is represented as a 
% of the growth of untreated cells in the same plate± S.D. Results are the 
average of triplicate determinations in three separate experiments. The 
concentrations of BRI 138/1 were: (1) 35[ig/ml; (2) 17.5 jig/ml; (3) 8.75|j,g/ml.
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Taxotere+ Piroxicam 
L.T S.T
Taxol + Piroxicam 
L.T S.T
2008P 0.978 0.960 0.820 1.007
MRP1 0.942 1.004 0.795 1.042
MRP2 0.938 0.978 0.817 1.000
MRP3 0.954 1.026 0.801 0.930
Tabic 3.8.17a: Combination index (Cl) values for taxotere or taxol in 
combination with piroxicam, obtained using the method of Chou and Talalay 
as described in section 2.16.
Taxotere +138/1 
L.T S.T
Taxol +138/1 
L.T S.T
Adr.+138/l
L.T
Cis. +138/1 
LT
2008P 0.576 0.940 0.580 1.212 0.476 1.007
MRP1 0.340 1.000 0.230 1.336 0.222 1.042
MRP 2 0.649 0.927 0.235 1.503 0.454 1.000
MRP3 0.438 0.930 0.227 1.188 0.724 0.930
Table 3.8.17b: Combination index (Cl) values for taxotere, taxol, adriamycin 
(Adr) or cisplatin (Cis) in combination with BRI 138/1, obtained using the 
method of Chou and Talalay as described in section 2.16.
(Cl < 1: synergism; Cl > 1: antagonism; Cl = 1: additive.)
L.T: Long-term assay as described in section 2.7.3a
S.T (1): Short-term assay. Drug and compound removed from the cells after 4 
hours incubation and replaced with fresh medium only as described in section 
2.7.3b
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Adriamycin Methotrexate Cisplatin
Indomethacin LT ST(1) ST(2) LT ST(1) ST(2) LT
2008 P 0.488 1.048 1.056 0.372 2.422
2008 MRP1 0.186 0.683 0.653 0.581 1.345
2008 MRP2 0.493 0.958 1.064 1.000 2.030
2008 MRP3 0.433 0.860 0.738 0.879 2.198
Sulindac
2008 P 0.218 1.082 0.534 0.729 0.550 0.220
2008 MRP1 0.091 0.528 0.357 0.591 0.357 0.343
2008 MRP2 0.463 1.009 0.918 0.883 0.823 0.792
2008 MRP3 0.509 0.786 0.658 0.709 0.790 0.640
B.RI 138/1
2008 P 0.476 1.007
2008 MRP1 0.222 1.042
2008 MRP2 0.454 1.000
2008 MRP3 0.724 0.930
Table 3.8.18a: Summary table with Combination index (Cl) values for the 
highest concentrations of adriamycin, methotrexate and cisplatin in 
combination with indomethacin, sulindac, BRI 138/1 and piroxicam.
(Cl < 1: synergism; Cl > 1: antagonism; Cl = 1: additive.)
L.T: Long-term assay as described in section 2.7.3a.
S.T (1): Short-term assay. Drug and compound removed from the cells after 4 
hours incubation and replaced with fresh medium only as described in section 
2.7.3b.
S.T (2): Short-term assay. Drug and NSAID removed from the cells after 4 
hours incubation and replaced with NSAID only as described in section 2.7.3b.
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Taxol Taxotere
LT ST(1) LT ST(1) ST(2)
Sulindac
2008 P 0.172 0.631 0.371 1.365 0.324
2008 MR IM 0.046 0.652 0.465 0.963 0.279
2008 MRP2 0.283 0.590 0.612 0.977 0.851
2008 MRP3 0.199 0.780 0.516 0.996 0.537
BRI 138/1
2008 P 0.580 1.212 0.576 0.940
2008 MRP1 0.230 1.336 0.340 1.000
2008 MRP2 0.235 1.503 0.649 0.927
2008 MRP3 0.227 1.188 0.438 0.930
Piroxicam
2008 P 0.820 1.007 0.978 0.960
2008 MRP1 0.795 1.042 0.942 1.004
2008 MRP2 0.817 1.000 0.938 0.978
2008 MRP3 0.801 0.930 0.954 1.026
Table 3.8.18b: Summary table with Combination index (Cl) values for the 
highest concentrations of taxol and taxotere in combination with 
indomethacin, sulindac, BRI 138/1 and piroxicam.
(Cl < 1: synergism; Cl > 1: antagonism; Cl = 1: additive.)
L.T: Long-term assay as described in section 2.7.3a.
S.T (1): Short-term assay. Drug and compound removed from the cells after 4 
hours incubation and replaced with fresh medium only as described in section 
2.7.3b.
S.T (2): Short-term assay. Drug and NSAID removed from the cells after 4 
hours incubation and replaced with NSAID only as described in section 2.7.3b.
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3.9 RT-PCR analysis o f 2008(P), 2008 M RP1, 2008 M RP2 and 
2008 M RP3 cell lines.
RT-PCR analysis was carried out on all the 2008 cell lines to characterise the 
MRP mRNA expression in these cells and to compare the levels of MRP 
mRNA to protein expression in the analysed cells. Photographs of the RT-PCR 
gels and densitometric analysis of the bands are in section 3.16. The sequences 
for the primers used for MRP 1-5 PCR were identical to those used by Kool et 
al., (1997). The sequence for the primers for MRP6 were obtained from 
O’Neill et al, 1998.
3.9.1 MRP1 mRNA expression
MRP1 RT-PCR analysis of the 2008 P, 2008 MRP1, MRP2 and MRP3 cells 
indicated that there was very little difference in expression of MRP 1 in all of 
the 2008 cell lines. There appeared to be an up-regulation of MRP 1 expression 
in the transfected 2008 MRP1 cell line and slight down regulation of MRP1 
mRNA in the 2008 MRP3 cells (Figure 3.16.1a). Western blot analysis of 
these cell lines using the MRP specific rat monoclonal antibody (MAb), 
MRPrl, demonstrated a very strong expression of MRP1 in the MRP1 
transfected cells. However, there was also a low level of MRP expression in 
the 2008 P, 2008 MRP2 and 2008 MRP3 cells (Connolly, 1999). The results 
indicate that regulation of MRP1 expression may be post-transcriptional and 
that MRP1 mRNA expression does not correlate with MRP1 protein levels in 
these 2008 cell lines.
3.9.2 MRP2 mRNA expression
MRP2 RT-PCR analysis of the 2008 P, 2008 MRP1, MRP2 and MRP3 cells 
indicated that there was a very low expression of MRP2 in the parental 2008 
cell line. MRP2 was upregulated in the 2008 MRP1 and MRP3 transfected cell 
lines as compared to the parental cell line. However, the expression of MRP2 
mRNA was strongest in the 2008 cell line transfected with MRP2 cDNA 
(Figure 3.16.2a). Western blot analysis of these cell lines using the MRP2 
specific, mouse MAb, M2III-6, demonstrated a very strong expression of
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MRP2 in the MRP2-transfected cells only (Connolly, 1999). There appeared to 
be no expression of MRP2 in the parental and MRP1 and MRP3 transfected 
2008 cell lines.
3.9.3 MRP3 mRNA expression
MRP3 RT-PCR analysis of the 2008 P, 2008 MRP1, MRP2 and MRP3 cells 
indicated that there was highest expression of MRP3 mRNA in the 2008 
MRP3- transfected cell line. There were similarly low levels of MRP3 mRNA 
expression in the 2008 parental and 2008 MRP1 cell lines. The expression of 
MRP3 mRNA was down-regulated in the 2008 MRP2-transfected cell line as 
compared to expression of MRP3 mRNA in the parental 2008 cell line (Figure
3.16.3). Western blot analysis of these cell lines using the MRP3 specific 
mouse MAb, M311-21, demonstrated a very strong expression of MRP3 in the 
MRP3 transfected cells only (Connolly, 1999). There seemed to be no 
expression of MRP3 in the parental and MRP1 and MRP2-transfected 2008 
cell lines.
3.9.4 MRP4 mRNA expression
MRP4 RT-PCR analysis of the 2008 P, 2008 MRP1, MRP2 and MRP3 cells 
indicated that there was a low expression of MRP4 mRNA in the 2008 
parental cell line. A similar level of expression of MRP4 mRNA was observed 
in the 2008 MRP3 transfected cell line. There was an up-regulation of MRP4 
mRNA in the MRP2 2008 transfected cells as compared to the 2008 parental 
cell line. The expression of MRP4 mRNA was strongest in the 2008 MRP1 
transfected cell line (Figure 3.16.4a). Western Blot analysis for MRP4 was not 
carried out on these cell lines.
3.9.5 MRP5 mRNA expression
MRP5 RT-PCR analysis of the 2008 P, 2008 MRP1, MRP2 and MRP3 cells 
indicated that MRP5 mRNA was expressed in all four cells lines. There 
appeared to be down-regulation of MRP5 mRNA in the 2008 MRP1, MRP2 
and MRP3 transfected cell lines as compared to the level of MRP5 mRNA in
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the parental cell line (Figure 3.16.5a). Western Blot analysis for MRP5 was 
not carried out on these cell lines.
3.9.6 MRP6 mRNA expression
MRP6 RT-PCR analysis of the 2008 P, 2008 MRP1, MRP2 and MRP3 cells 
indicated that MRP6 mRNA was expressed in all four cells lines. There 
appeared to an up-regulation of MRP6 mRNA in the 2008 MRP1, MRP2 and 
MRP3 transfected cell lines as compared to the level of MRP6 mRNA in the 
parental cell line (Figure 3.16.6). The highest expression of MRP6 mRNA was 
evident in the 2008 MRP2 cell line. Western Blot analysis for MRP6 was not 
carried out on these cell lines.
3.9.7 MDR1 mRNA expression
MDR1 RT-PCR analysis of the 2008 P, 2008 MRP1, MRP2 and MRP3 cells 
indicated that MDR1 mRNA was expressed in all four cells lines. There 
appeared to an up-regulation of MDR1 mRNA in the 2008 MRP1 and MRP2 
transfected cell lines as compared to the level of MDR1 mRNA in the parental 
2008 and MRP3 transfected cell lines (Figure 3.16.7). The highest expression 
of MDR1 mRNA was evident in the 2008 MRP2 cell line. Western Blot 
analysis for MDR1 was not carried out on these cell lines.
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3.10 Investigation of enhancem ent of chemotherapeutic drugs by 
sulindac and indomethacin in a range o f cancer cell lines.
To investigate if  the potentiation of taxol and taxotere by sulindac and 
indomethacin was limited to particular cell lines, combination toxicity assays 
using taxol, taxotere and adriamycin in combination with indomethacin or 
sulindac were carried out on four more cell lines. The cell lines analysed were 
a breast cancer cell line, MCF-7, a poorly differentiated human lung cancer 
cell line, DLKP, and a human lung adenocarcinoma cell line, A549, from two 
different sources, the NCTCC cell culture collection (originally from the 
ATCC) and Quintiles. Long-term combination toxicity assays were used to 
analyse these cell lines as it had been demonstrated in section 3.8 that both 
indomethacin and sulindac required longer incubation periods in the cells to 
exert their enhancement effect. As it was already known that indomethacin 
enhances the toxicity of adriamycin in the DLKP cell line (section 3.1), initial 
combination toxicity assays were carried out to assess if this effect was similar 
in the other cell lines. The results indicate that indomethacin also potentiated 
the toxicity of adriamycin in the MCF-7 and A549 cell lines, although the 
enhancement effect was not as good as that observed in the DLKP cells (Table
3.10.1).
The toxicity of taxol or taxotere in combination with indomethacin was 
subsequently analysed in the four cell lines. The results indicated that 
indomethacin was unable to significantly potentiate the toxicity of taxol in the 
DLKP, MCF-7 and A549 cell lines (Table 3.10.2). There is a small 
enhancement of the toxicity of taxotere by indomethacin in the DLKP and 
MCF-7 cell lines (Table 3.10.3) but no enhancement of the toxicity of this 
drug by indomethacin in the A549 cell lines.
Taxol and taxotere were then analysed in these cell lines in combination with 
sulindac and the results showed that there is very good synergism between 
taxol + sulindac and taxotere + sulindac in the DLKP cell line. There was 
average potentiation of taxol by sulindac in the MCF-7 cell line and only a 
very weak potentiation of taxotere by sulindac in the same cell line. Sulindac 
was unable to potentiate the toxicity of taxol or taxotere in either the A549 
cells (Tables 3.10.5, 3.10.6 and 3.10.7).
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Test Sample % Cell Survival
DLKP, Adriamycin and Indomethacin
Adr. 10ng/ml 46.6 5.1
Indo (1) 96.0 2.4
Indo (1) + Adr 12.9 1.1
Indo (2) 95.7 2.4
Indo (2) + Adr 28.1 3.9
Indo (3) 99.3 0.4
Indo (3 ) + Adr 40.1 1.1
1.8
2.7
5.3 
2.5
5.4 
3.9
7.4
5.0
6.5
5.2 
0.4
5.2
1.3
A549 (Quintiles) Adriamycin and Indomethacin
Adr. 50ng/ml 48.2 3.6
Indo (1) 93.6 2.6
Indo (1) + Adr 28.9 3.6
Indo (2) 98.4 1.9
Indo (2) + Adr 34.1 0.5
Indo (3) 98.6 1.3
Indo (3) + Adr 39.4 2.7
Table 3.10.1: % Survival of DLKP, MCF-7 (Quintiles), A549 (Quintiles) and 
A549 (NCTCC) cells in the presence of various concentrations of adriamycin 
and indomethacin as found using the protocol detailed in section 2.7.3a. 
Survival is represented as a % of the growth of untreated cells in the same 
plate ± S.D. Results are the average of triplicate determinations in three 
separate experiments. The concentrations of indomethacin were: (1) 2.5 |j.g/ml; 
(2) 1.25 ng/ml; (3) 0.625 ng/ml.
MCF-7 (Quintiles) Adriamycm and Indometha
Adr. 30ng/ml 54.0
Indo (1) 96.0
Indo (1) + Adr 29.1
Indo (2) 97.0
Indo (2) + Adr 37.0
Indo (3) 98.3
Indo (3) + Adr 41.8
A549 (NCTCC) Adriamycin and Indomethacin
Adr. 50ng/ml 47.2
Indo (1) 94.6
Indo (1) + Adr 24.2
Indo (2) 100.3
Indo (2) + Adr 36.4
Indo (3) 99.3
Indo (3) + Adr 41.7
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Test Sample % Cell Survival S.D.
DLKP, Taxol and Indomethacin
Taxol. 1.0ng/ml 59.0 6.2
Indo (1) 97.8 4.7
Indo (1) + Taxol 50.7 3.9
Indo (2) 100.7 1.1
Indo (2) + Taxol 56.1 3.5
Indo (3) 93.9 0.7
Indo (3 ) + Taxol 57.5 4.4
MCF-7 (Quintiles) Taxol and Indomethacin
Taxol. 2.0ng/ml 33.6 7.9
Indo (1) 96.0 2.3
Indo (1) + Taxol 27.7 8.5
Indo (2) 102.3 1.5
Indo (2) + Taxol 31.9 5.2
Indo (3) 108.5 7.5
Indo (3 ) + Taxol 30.2 1.9
A549 (NCTCC) Taxol and Indomethacin
Taxol. 1.2ng/ml 78.4 9.4
Indo (1) 92.6 3.5
Indo (1) + Taxol 65.8 6.9
Indo (2) 91.7 4.0
Indo (2) + Taxol 67.7 8.0
Indo (3) 99.2 3.3
Indo (3 ) + Taxol 72.4 3.9
A549 (Quintiles) Taxol and Indomethacin
Taxol. 1.2ng/ml 50.0 4.7
Indo (1) 95.6 1.5
Indo (1) + Taxol 42.7 0.6
Indo (2) 99.8 2.2
Indo (2) + Taxol 50.9 1.9
Indo (3) 95.8 5.1
Indo (3 ) + Taxol 46.7 3.2
Table 3.10.2: % Survival of DLKP, MCF-7 (Quintiles), A549 (Quintiles) and 
A549 (NCTCC) cells in the presence of various concentrations of taxol and 
indomethacin as found using the protocol detailed in section 2.7.3a. Survival is 
represented as a % of the growth of untreated cells in the same plate ± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of indomethacin were: (1) 2.5 (ig/ml; (2) 1.25 
|o,g/ml; (3) 0.625 fig/ml.
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Test Sample % Cell Survival S.D.
DLKP, Taxotere and Indomethacin
Taxotere. 1.0ng/ml 46.0 4.8
Indo (1) 96.8 0.9
Indo (1) + Taxotere 38.0 2.9
Indo (2) 98.2 1.7
Indo (2) + Taxotere 39.4 1.6
Indo (3) 96.7 5.5
Indo (3) + Taxotere 41.4 5.1
MCF-7 (Quintiles) Taxotere and Indomethacin 
Taxotere. 2.0ng/ml 26.5 5.9
Indo (1) 102.7 7.3
Indo (1) + Taxotere 20.4 2.2
Indo (2) 97.3 1.2
Indo (2) + Taxotere 21.3 1.9
Indo (3) 98.3 2.8
Indo (3) + Taxotere 22.2 2.0
A549 (NCTCC) Taxotere and Indomethacin 
Taxotere. 1.2ng/ml 42.1 6.5
Indo (1) 98.3 1.7
Indo (1) + Taxotere 33.1 7.7
Indo (2) 102.1 5.3
Indo (2) + Taxotere 36.2 6.1
Indo (3) 102.7 2.6
Indo (3) + Taxotere 39.2 5.4
A549 (Quintiles) Taxotere and Indomethacin 
Taxotere. 1.2ng/ml 42.0 5.9
Indo (1) 93.9 1.2
Indo (1) + Taxotere 36.2 3.9
Indo (2) 97.3 3.2
Indo (2) + Taxotere 39.6 2.5
Indo (3) 96.6 2.0
Indo (3) + Taxotere 40.0 3.2
Table 3.10.3: % Survival of DLKP, MCF-7 (Quintiles), A549 (Quintiles) and 
A549 (NCTCC) cells in the presence of various concentrations of taxotere and 
indomethacin as found using the protocol detailed in section 2.7.3a. Survival is 
represented as a % of the growth of untreated cells in the same plate ± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of indomethacin were: (1) 2.5 H-g/ml; (2) 1.25 
fj.g/ml; (3) 0.625 (j.g/ml.
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Adr + Indo 
L.T
Taxol + Indo 
L.T
Taxotere + Indo 
L.T
DLKP 0.319 0.930 0.851
MCF7 0.507 1.213 0.856
AS49 0.564 1.066 0.952
A549Q 0.607 1.166 1.464
Table 3.10.4: Combination index (Cl) values for Adriamycin (Adr), taxol or 
taxotere in combination with indomethacin, obtained using the method of 
Chou and Talalay as described in section 2.16.
(Cl < 1: synergism; Cl > 1: antagonism; Cl = 1: additive.)
L.T: Long-term assay as described in section 2.7.3a
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Test Sample % Cell Survival
DLKP, Taxol and Sulindac
Taxol. 1.0ng/ml 51.6 3.1
Sul (1) 94.5 2.6
Sul (1) + Taxol 18.8 5.4
Sul (2) 98.7 0.9
Sul (2) + Taxol 41.8 2.4
Sul (3) 98.9 3.3
Sul (3 ) + Taxol 48.2 2.4
MCF-7 (Quintiles) Taxol and Sulindac 
Taxol. 2.0ng/ml 43.7 5.1
Sul (1) 95.6 4.4
Sul (1) + Taxol 26.5 6.6
Sul (2) 101.7 1.1
Sul (2) + Taxol 35.7 8.0
Sul (3) 100.8 3.7
Sul (3 ) + Taxol 36.5 4.9
A549 (NCTCC) Taxol and Sulindac 
Taxol. 1.2ng/ml 77.2 8.5
Sul (1) 90.1 2.7
Sul (1) + Taxol 59.1 6.1
Sul (2) 92.0 3.0
Sul (2) + Taxol 68.3 3.5
Sul (3) 95.8 5.4
Sul (3) + Taxol 71.2 1.5
A549 (Quintiles) Taxol and Sulindac 
Taxol. 1.2ng/ml 54.4 3.8
Sul (1) 94.2 2.2
Sul (1) + Taxol 40.5 2.4
Sul (2) 98.0 0.9
Sul (2) + Taxol 41.6 1.7
Sul (3) 102.2 5.9
Sul (3) + Taxol 48.9 4.1
Table 3.10.5: % Survival of DLKP, MCF-7 (Quintiles), A549 (Quintiles) and 
A549 (NCTCC) cells in the presence of various concentrations of taxol and 
sulindac as found using the protocol detailed in section 2.7.3a. Survival is 
represented as a % of the growth of untreated cells in the same plate ± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of sulindac were: (1) 8|wg/ml; (2) 4(ig/ml; (3) 
2(j.g/ml.
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Test Sample % Cell Survival S.D.
DLKP, Taxotere and Sulindac
Taxotere. 0.5ng/ml 46.3 2.3
Sul (1) 97.7 2.6
Sul (1) + Taxotere 11.5 0.4
Sul (2) 99.7 2.2
Sul (2) + Taxotere 21.3 4.3
Sul (3) 100.4 2.4
Sul (3) + Taxotere 24.4 7.8
MCF-7 (Quintiles) Taxotere and Sulindac 
Taxotere. 1.5ng/ml 34.2 5.0
Sul (1) 98.7 1.6
Sul (1) + Taxotere 24.7 4.0
Sul (2) 94.9 2.4
Sul (2) + Taxotere 26.1 4.8
Sul (3) 96.5 6.1
Sul (3) + Taxotere 27.2 5.0
A549 (NCTCC) Taxotere and Sulindac 
Taxotere. 1.2ng/ml 28.9 7.7
Sul (1) 94.6 2.7
Sul (1) + Taxotere 23.7 6.1
Sul (2) 98.3 1.1
Sul (2) + Taxotere 25.9 7.1
Sul (3) 98.4 3.2
Sul (3) + Taxotere 28.6 7.9
A549 (Quintiles) Taxotere and Sulindac 
Taxotere 1.2ng/ml 33.6 7.3
Sul (1) 97.5 1.3
Sul (1) + Taxotere 27.4 6.1
Sul (2) 98.8 1.0
Sul (2) + Taxotere 31.1 6.3
Sul (3) 98.8 3.6
Sul (3) + Taxotere 31.5 7.6
Table 3.10.6: % Survival of DLKP, MCF-7 (Quintiles), A549 (Quintiles) and 
A549 (NCTCC) cells in the presence of various concentrations of taxotere and 
sulindac as found using the protocol detailed in section 2.7.3a. Survival is 
represented as a % of the growth of untreated cells in the same plate ± S.D. 
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of sulindac were: (1) 8 fig/ml; (2) 4|j,g/ml; (3) 
2ng/ml.
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Taxol + Sulindac 
L.T
Taxotere + Sulindac 
L.T
DLKP 0.323 0.261
MCF7 0.686 0.915
A549 1.062 1.338
A549Q 1.094 1.122
Table 3.10.7: Combination index (Cl) values for Taxol or Taxotere in 
combination with Sulindac, obtained using the method of Chou and Talalay as 
described in section 2.16
L.T: Long-term assay as described in section 2.7.3a
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3.11 Pulse selection of DLKP cells with indomethacin.
Results obtained from the IOV assays (section 3.3), drug efflux experiments 
(section 3.5) and combination toxicity assays carried out in DLKP, CORL23 
and 2008 cell lines (section 3.1, 3.6, and 3.8 respectively) strongly indicated 
that indomethacin is a good substrate for MRP. Pulse selection of DLKP cells 
with indomethacin for a period of 6 weeks was carried out (i.e. 4 hour pulse 
with indomethacin once each week after which the cells were re-fed in fresh 
media) to assess the effect of this NSAID on the resistance profile of the 
DLKP cells. The DLKP cells were grown up in 25 cm2 flasks until 
approximately 80% confluent and then pulsed with 300|_ig/ml indomethacin. 
This concentration of indomethacin was found to kill approx. 80-90% of the 
DLKP cells in the 25cm2 flasks.
3.11.1 IC50 values
The IC50 values for a range of chemotherapeutic drugs and indomethacin were 
obtained after pulsing the DLKP cells for four weeks (DLKP Indo4) and six 
weeks (DLKP Indo6) (Table 3.11.1).
DLKP DLKP lndo4 DLKP Indo6
Adriamycin (ng/ml) 12.7 ±0.38 16.1 ±0.35 19.0 ±0.14
Vincristine (ng/ml) 1.41 ±0.23 1.80 ±0.28 2.05 ± 0.28
VP-16 (ng/ml) 96.7 + 16.0 160.5 ±12.02 190.0 ±7.1
5-FU (ng/ml) 483.3 ±30.6 1410 ± 147.3 1860 ± 410.1
Cisplatin (ng/ml) 310.0 ±20.1 500.0 ±28.3 610.7 ± 15.2
Indomethacin (p.g/ml) 15.4 ± 1.24 31.4 ± 3.9 34.1 ±4.7
Table 3.11.1: IC50 values for adriamycin, vincristine, VP-16, 5-FU, cisplatin 
and indomethacin on parental DLKP cells and DLKP cells pulsed with 
300|o,g/ml indomethacin for four weeks (DLKP Indo4) and six weeks (DLKP 
Indo6). Data are the average of results from three separate experiments.
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The results indicate an increase in IC50 values for all drugs analysed. A 
particularly significant increase in the IC50 value was evident for the non-MRP 
substrate, 5-FU, which was increased more than 4-fold after pulsing for 6 
weeks. Resistance to cisplatin, a non-MRP 1 substrate was also increased two­
fold in the pulsed cell lines as compared to the parental DLKP cells. 
Approximately, a 2-fold increase in resistance was evident with the MRP 
substrates adriamycin, vincristine, VP 16 and indomethacin after pulsing the 
DLKP cells with indomethacin for 6 weeks.
3.11.2 RT-PCR analysis of DKLP and DLKP pulsed cells.
RT-PCR analysis of DLKP, DLKP Indo4 and DLKP Indo6 was carried out to 
assess if  pulse selecting DLKP cells for a number of weeks with indomethacin 
resulted in a change in the expression of the multidrug resistance associated 
proteins expressed in DLKP cells. The results indicated an up-regulation of 
MRP1 mRNA in the both DLKP Indo4 and DLKP Indo6 cells. The highest 
expression of MRP 1 was observed in the DLKP Indo-6 cells (Figure 3.16.1a). 
There also appeared to be slight up-regulation of MRP2 in both the pulsed cell 
lines as compared to the parental DLKP cells (Figure 3.16.2a). Again the 
highest expression of MRP2 was in the cells pulsed for six weeks with 
indomethacin. There was no detectable expression of MRP3 mRNA in the 
parental DLKP and pulsed DLKP cells indicating that the increased drug 
resistance in the DLKP cells, pulsed with indomethacin, was not due to 
expression of MRP3 (Figure 3.16.3). MRP4 RT-PCR analysis of the DLKP 
cell lines, indicated that there is an increased expression of MRP4 mRNA in 
the DLKP Indo4. This expression was further increased in the DLKP Indo6 
cells (3.16.4a). These results suggest that pulsing the DLKP cells with 
indomethacin resulted in an up-regulation of MRP4 (Figure 3.16.4) and MRP6 
mRNA (Figure 3.16.6). The results for RT-PCR analysis of the DLKP cell 
lines indicated that there was a very slight down-regulation of MRP5 in both 
the DLKP Indo4 and DLKP Indo6 cells as compared to the parental DLKP 
cells (Figure 3.16.5a).. MDR1 RT-PCR analysis of the DLKP cells indicate 
that there was almost undetectable levels of MDR1 in the parental DLKP cells. 
There was no increase in MDR1 expression after pulsing these cells with 
indomethacin for 6 weeks (Figure 3.16.7). These results indicate that pulsing
246
DLKP cells with indomethacin for 4-6 weeks resulted in an up-regulation of 
MRP1, 2, 4 and 6 mRNA expression and a down-regulation of MRP5 mRNA 
expression. MRP3 and MDR1 do not appear to be associated with the drug 
resistance mechanisms in the DLKP and DLKP pulsed cells.
3.11.2 Combination toxicity assays in DLKP and DLKP pulsed cells
Combination toxicity assays were then carried out on the DLKP and DLKP 
Indo4 and DLKP Indo6 cell lines, using indomethacin in combination with 
adriamycin, to assess if an increase in the resistance to indomethacin in the 
pulsed cells resulted in a loss of the combination effect already shown to be 
present in DLKP cells (section 3.1). The results indicate that although there 
was an increase in resistance to both indomethacin and adriamycin, both the 
pulsed cell lines demonstrated a combination effect equal to that achieved in 
the parental cell line (Table 3.11.2).
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DLKP, Adriamycin and Indomethacin
Test Sample % Cell Survival S.D.
Adr. 10ng/ml 46.6 5.1
Indo (2.5|ig/ml) 96.0 2.4
Indo + Adr 12.9 1.1
Indo (1.25|ag/ml) 95.7 2.4
Indo + Adr 28.1 3.9
Indo (0.625|ag/ml) 99.3 0.4
Indo +Adr 40.1 1.1
DLKP Indo4, Adriamycin and Indomethacin
Adr. 20ng/ml 44.8 1.8
Indo (2.5ng/ml) 99.9 1.2
Indo + Adr 11.6 4.3
Indo (1.25[ag/ml) 99.9 1.2
Indo + Adr 16.6 4.7
Indo (0.625}J,g/ml) 99.3 1.1
Indo + Adr 27.5 0.5
DLKP Indo6 , Adriamycin and Indomethacin
Adr. 20ng/ml 47.3 0.3
Indo (2.5jug/ml) 99.3 3.4
Indo + Adr 10.0 4.5
Indo (1.25|J.g/mI) 101.6 3.2
Indo + Adr 16.9 2.6
Indo (0.625jJ,g/ml) 98.9 2.3
Indo + Adr 27.8 3.1
Table 3.11.2: % Survival of DLKP (parental), DLKP Indo4 and DLKP Indo6 
cells in the presence of various concentrations of adriamycin and 
Indomethacin as found using the protocol detailed in section 2.7.3a. Survival is 
represented as a % of the growth of untreated cells in the same plate ± S.D. 
Results are the average of triplicate determinations in three separate 
experiments.
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3.12 Effect o f pulsing HepG2 cells with Cisplatin
HepG2 cells were pulse selected with cisplatin for four weeks i.e. 4 hour pulse
once each week after which the cells were re-fed in fresh media. The HepG2
*  2 •  • cells were grown up in 25 cm flasks until approximately 80% confluent and
then pulsed with 4000ng/mL cisplatin. This concentration of cisplatin was
found to kill approx. 80-90% of the HepG2 cells in the 25cm2 flasks.
3.12.1. Toxicity profile of cytotoxic drugs in HepG2 cell line
Toxicity assays were carried out on the HepG2 cell line, prior to pulsing and 
after pulsing for 1 0  weeks with cisplatin, to assess the toxicity profile of the 
chemotherapeutic drugs on this cell line and to assess if there was a difference 
in these toxicity profiles after pulsing. The IC5o of these drugs (the 
concentration of the drugs at which 50 % cell kill is obtained) in HepG2 
parental and pulsed cells were calculated after pulsing for 4 weeks and 10 
weeks (Table 3.12.1).
Drug HepG2 (parental) HepG2 4P HepG2 10P
Adriamycin 20.1 ± 4.7 ng/ml 13.0 ± 4.2 ng/ml 8.5 ± 3.5 ng/ml
Vincristine 4.2 ±1.1 ng/ml 3.5 ± 0.9 ng/ml 1.5 ± 0.6 ng/ml
5'fluorouracil 164.5 ± 36.3 ng/ml 380 ±32.1 ng/ml 400 ±35.1 ng/ml
VP-16 250.0 ± 25.1ng/ml 189 ± 15.1ng/ml 100 ± 7.5ng/ml
Cisplatin 215.0 ±35.4 ng/ml 2065 ±194 ng/ml 2518 ±202 ng/ml
Table 3.12.1: IC50 of Cytotoxic drugs in the HepG2 cell line pulsed with 
cisplatin. Results are the average of triplicate determinations in three separate 
experiments.
The results indicate that pulsing the HepG2 cells with 4000ng/ml cisplatin for 
4 weeks, resulted in a decrease in the resistance to adriamycin, vincristine and 
VP-16. These anti-cancer drugs are good substrates for MRP1, 2 and 3 
substrates (Duffy et al., 1998; Cole et al., 1994 and Hipfner et al., 1999, Borst 
et al, 1999 and Konig et al, 1999). However, the results indicate that the
249
resistance to both 5-FU and cisplatin increased after pulsing HepG2 cells with 
4000ng/ml cisplatin for four weeks. This resistance was further increased after 
pulsing these cells for a period of ten weeks. A number of authors including 
Duffy et al., (1998) and Nishiyama el al., (1999), reported that MRP did not 
seem to play an important role in 5-FU resistance. The mechanism of cisplatin 
resistance is uncertain and reports linking cisplatin resistance to MRP are 
inconclusive and conflicting. (See section 1.6.8).
3.12.2 RT-PCR analysis of HepG2 parental cells.
RT-PCR analysis was carried out on the HepG2 cell line to assess if  MRP was 
expressed at the RNA level and also to assess which form of MRP was 
expressed in the cell line. RT-PCR analysis was carried out on the HepG2 
cells, using primers for MRP1, cMOAT, MRP3 and MRP4, prior to pulsing. 
The results show that HepG2 cells express mRNA for MRP1 (3.12.1), MRP2 
(cMOAT) (3.12.2), MRP3 (3.12.2) and MRP4 (3.12.3). Narasaki et al., (1997), 
have demonstrated the presence of cMOAT and MRP1 but as of yet the 
presence of MRP3 and MRP4 in HepG2 cells had not previously been 
reported. RT-PCR was not carried out using primers for MRP5 and 6 but these 
primers will be included in future RT-PCR experiments on HepG2 parental 
and pulsed cells so that complete MRP expression in these cells can be 
assessed.
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Figure 3.12.1: RT-PCR analysis of MRP1 expression in HepG2 cells carried 
out according to the method described in section 2.15.
1. MRP2 2. MRP3
P-actin
MRP2/3
Figure 3.12.2: RT-PCR analysis of MRP2 and MRP3 expression in HepG2 
cells carried out according to the method described in section 2.15.
P actin 
MRP4
OAVH
Figure 3.12.3: RT-PCR analysis of MRP4 expression in HepG2 cells carried 
out according to the method described in section 2.15.
252
3.13 Investigation of the mechanism of resistance in DLKP C14 
cells
3.13.1 Toxicity profile of cytotoxic drugs in DLKPC 14 cell line
The parental cell line, DLKP, was exposed to varying concentrations of 
carboplatin to develop a resistant variant called DLKPC 14 (Cleary, 1995). 
The parental DLKP cells were initially exposed to l|xg/mL carboplatin and 
adjusted to growth in 6.2 (ig/mL and after approximately four months, to 
14(j.g/mL. The resistant cell line, selected to and maintained in 14|ig/mL 
carboplatin were designated DLKPC 14.
Toxicity assays were carried out on the parental DLKP and the DLKPC 14 
cell lines to assess the toxicity profile of the chemotherapeutic drugs on this 
cell line. The IC50 of these drugs (the concentration of the drugs at which 50 
% cell kill is obtained) in DLKPC 14 are as follows:
Cytotoxic drug ICso concentrations 
DLKP
IC50 concentrations 
DLKPC 14
Adriamycin 14.13 +2.7 ng/ml 15.1 ± 2.5 ng/ml
Vincristine 2.25 + 0.2 ng/ml 3.2 ± 0.22ng/ml
5-FU 590 ± 52.3 ng/ml 720 ±61.3 ng/ml
VP-16 112.5 ± 17.6ng/ml 210 ± 14.1ng/ml
Cisplatin 480.0 ± 35.4 ng/ml 3010.0 ± 156.4 ng/ml
Table 3.13.1: IC50 of Cytotoxic drugs in the DLKPC 14 cell line.
Results are the average of triplicate determinations in three separate 
experiments.
Immunocytochemical studies on the expression of the 190kDa protein, MRP, 
revealed no alteration in the level of MRP in the DLKPC 14 cell line when 
compared to the parental DLKP cell line (Cleary, 1995). These results suggest 
that MRP was not involved in cisplatin resistance in these cell lines. Further
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evidence to support this theory was obtained from RT-PCR studies, where no 
significant difference was observed in MRP1 mRNA levels (Lorraine 
O'Driscoll, personal communication). Cleary (1995), also reported no 
detectable levels of Pgp in the parental cells of the resistant variants.
3.13.2 Combination toxicity assays in DLKPC 14 cells
Combination toxicity assays were carried out on the DLKPC 14 cell line using 
a combination of adriamycin and indomethacin, or cisplatin and indomethacin. 
Previous experiments demonstrated that the cytotoxic drug was rendered more 
toxic in a number of cancer cell lines including DLKP (section 3.1), CORL23 
(section 3.6), HepG2 (section 3.7) and 2008 cells (section 3.8) when combined 
with indomethacin by a process involving inhibition of the activity of MRP1. 
The aims of carrying out the combination toxicity assays on the DLKPC 14 
cell line were to assess if  indomethacin (and analogues) were capable of 
potentiating the toxicity of the cytotoxic drugs, cisplatin and adriamycin, in a 
carboplatin and cisplatin resistant cell line.
The results of the combination toxicity assay are reported in Tables 3.13.2 and 
3.13.3. The results demonstrated that indomethacin was capable of 
potentiating the toxicity of adriamycin in DLKPC 14 and DLKP cells. The 
highest non-toxic concentration of indomethacin used in both the DLKPC 14 
and DLKP cells was 2.5fag/ml. However, results from the combination toxicity 
assays with cisplatin and indomethacin in DLKPC 14 and DLKP cells revealed 
that indomethacin was not capable of potentiating the toxicity of cisplatin in 
these cells. The toxicity of cisplatin seemed to decrease when combined with 
indomethacin in the DLKPC 14 and DLKP cell lines. This interesting effect 
was also evident in the HepG2 cells (section 3.7) treated with a combination of 
cisplatin and indomethacin and the in 2008 cell lines (section 3.8) treated with 
a combination of cisplatin with either indomethacin and sulindac. Combining 
an active NSAID, indomethacin or sulindac, with cisplatin, appears to render 
the cells more resistant to cisplatin.
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DLKP, Adriamycin and Indomethacin
Test Sample % Survival S.D.
Adr. lOng/ml 46.5 1.7
Indo. (2 .5 |o.g/ml) 96.9 2.7
Indo. + Adr 11.5 6.5
Indo. (1.25fig/ml) 102.7 1.5
Indo. + Adr 14.1 0.9
Indo. (0.625|ig/ml) 102.5 1.4
Indo. +Adr 19.6 4.35
DLKP C14, Adriamycin and indomethacin
Test Sample % Survival S.D.
Adr. lOng/ml 43.2 7.5
Indo. (2.5|ig/ml) 89.1 4.4
Indo. + Adr 6.5 3.6
Indo. (1.25ng/ml) 90.4 2.5
Indo. + Adr 8.4 1.5
Indo. (0.625) 103.0 3.2
; Indo. + Adr 10.6 6.2
Table 3.13.2: % Survival of DLKP and DLKP C14 cells in the presence of 
various concentrations of adriamycin and indomethacin as found using the 
protocol detailed in section 2.7.3a. Survival is represented as a % of the 
growth of untreated cells in the same plate± S.D. The untreated cell survival % 
is taken as 100%.
Results are the average of triplicate determinations in three separate 
experiments. The concentrations of the compounds were: (1) 2.5 fag/ml; (2) 
1.25 (ig/ml (3) 0.625 |a.g/ml
DLKP, Cisplatin and Indomethacin
Test Sample % Survival S.D.
Cis. 250ng/ml 33.6 2.9
Indo. (2.5(J.g/ml) 95.5 1.3
Indo. + Cis 44.1 4.2
Indo. (1.25|ig/ml) 100.7 0.9
Indo. + Cis 38.1 2.4
Indo. (0.625|xg/ml) 104.5 5.6
Indo. + Cis 35.9 3.5
DLKP C l4, Cisplatin and Indomethacin
Test Sample % Survival S.D.
Cis. 3000ng/ml 19.1 2.9
Indo. (2.5jig/ml) 96.1 2.5
Indo. + Cis 20.5 2.2
Indo. (1.25jig/ml) 98.6 6.8
Indo. + Cis 19.4 2.6
Indo. (0.625|Xg/ml) 99.4 0.9
Indo. + Cis 19.2 5.1
Table 3.13.3: % Survival of DLKP and DLKP C14 cells in the presence of 
various concentrations of cisplatin and indomethacin as found using the 
protocol detailed in section 2.7.3a. Survival is represented as a % of the 
growth of untreated cells in the same plate ± S.D. Results are the average of 
triplicate determinations in three separate experiments.
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3.14 Analysis of Adriamycin Metabolite
One of the problems associated with using adriamycin as a chemotherapeutic 
drug in human cancers is the cardiotoxicity associated with long-term 
adriamycin use in vivo. This toxicity is primarily associated with the primary 
metabolite of adriamycin, adriamycinol. Adriamycinol was analysed in 
toxicity assays and combination toxicity assays to assess if  this metabolite of 
adriamycin was as toxic as adriamycin in DLKP cells and if  the toxicity of this 
drug was also enhanced by indomethacin. adriamycinol was found to have an 
IC50 value of 40.3 ± 2.5ng/ml in DLKP cells as compared to an IC50 value of
12.7 ± 0.38 for adriamycin in these cells.
Combination toxicity assays were carried out using both adriamycin and the 
adriamycinol in combination with indomethacin to compare the potentiation of 
toxicity of both these drugs when combined with indomethacin. The results 
indicate that there is a poorer combination effect in the cells treated with 
indomethacin and adriamycin metabolite. The toxicity o f the metabolite is 
potentiated by indomethacin but not to the same extent as adriamycin (Table
3.14.1). Combination toxicity assays were also carried out on A549 cells 
treated with epirubicin in combination with sulindac. Epirubicin has been 
reported by Minotti et al., (1999), and Stewart et al., (1993), to be an analogue 
of adriamycin which causes less cardiotoxicity. These combination toxicity 
assays were carried out to assess if  sulindac was capable of enhancing the 
toxicity of epirubicin as effectively as it enhances the toxicity of adriamycin. 
The results indicate that this is the case (3.14.2). There was greater 
potentiation of epirubicin by sulindac in the A549 cell line than was observed 
when adriamycin was combined with sulindac. It is also interesting to note that 
the concentration of epirubicin used in the A549 cells was 4-fold less than the 
concentration of adriamycin. These results indicate that epirubicin is more 
effective than adriamycin in this cell line and greater potentiation of this 
chemotherapeutic drug can be achieved when combined with sulindac.
257
DLKP, Adriamycin and Indomethacin
Test Sample % Cell Survival S.D.
Adr. lOng/ml 45.2 4.9
Indo (2.5[ag/ml) 95.5 2.2
Indo +Adr 10.3 5.2
Indo (1.25|0.g/ml) 97.3 2.4
Indo + Adr 28.1 3.6
Indo (0.625ng/ml) 98.0 2.6
Indo + Adr 37.2 5.7
DLKP, Adriamycinol and Indomethacin
Adr. 40ng/ml 53.5 1.5
Indo (2.5fJ,g/ml) 96.9 3.3
Indo + Adrol 33.4 2.9
Indo (1.25|Xg/ml) 99.9 3 .6
Indo + Adrol 44.0 3.5
Indo (0.625) 100.8 1.4
Indo + Adrol 50.4 1.0
Table 3.14.1: % Survival of DLKP (parental) cells in the presence of various 
concentrations of adriamycin /adriamycinol and indomethacin. Survival is 
represented as a % of the growth of untreated cells in the same plate ± S.D. 
Results are the average of triplicate determinations in three separate 
experiments.
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A549, Adriamycin and Sulindac
Test Sample %  Cell Survival S.D.
Adr. 50ng/ml 52.3 4.7
Sul (8.0|xg/ml) 96.0 5.4
Sul + Adr 25.1 3.6
Sul (4.0jig/ml) 100.1 2.4
Sul + Adr 31.5 6.2
Sul (2.0ng/ml) 101.0 0.9
Sul + Adr 42.5 3.3
A549, Epirubicin and Sulindac
Epi. 12ng/ml 72.7 2.1
Sul (8.0|j.g/ml) 97.5 3.3
Sul + Epi 26.0 1.4
Sul (4.0jxg/ml) 99.9 1.0
Sul + Epi 40.9 5.0
Sul (2.0ng/ml) 98.7 1.7
Sul + Epi 57.1 1.9
Table 3.14.2: % Survival of A549 cells in the presence of various 
concentrations of adriamycin/epirubicin and sulindac as found using the 
protocol detailed in section 2.7.3. Survival is represented as a % of the growth 
of untreated cells in the same plate ± S.D. Results are the average of triplicate 
determinations in two separate experiments.
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3.15 Investigation o f other drugs as possible M RP1 substrates
Studies were carried out on a number of TB/AIDS related drugs to determine 
if there was a correlation between acquisition of chemotherapeutic resistance 
mechanisms and resistance to TB and /or AIDS drugs.
Hollo et al. (1996), reported that the antimalarial compound quinine is a 
substrate of MRP. Rifampicin, an anti-TB agent, had previously been reported 
to down-modulate Pgp mediated drug efflux (Fardel et al., 1995 and Furusara 
et al., 1997). It is now reported that rifampicin can increase the accumulation 
of two MRP substrates, vincristine and calcein, in GLC4/ADR, an adriamycin 
resistant human lung cancer cell line (Courtois et al., 1999). There is no 
evidence to date that AZT (Zidovudine), an anti-AIDs drug or tetracycline, an 
antibiotic, are substrates for MRP but it is possible that one of the mechanisms 
by which cells develop resistance to these compounds is through the activity of 
a cellular pump with actions similar to MRP.
Combination toxicity assays were carried out in DLKP cells using 
indomethacin and varying concentrations of the compounds, AZT, rifampicin, 
quinine and tetracycline. These assays were carried out to assess if  these 
compounds, were substrates for MRP and to determine if indomethacin could 
potentiate the toxicity of compounds other than the chemotherapeutic drugs 
already known to be substrates of MRP1. The compounds were analysed in the 
DLKP cells at non-toxic concentrations.
Of the four compounds analysed, both rifampicin and quinine were found to 
potentiate the toxicity of adriamycin in the DLKP cells (Cl values of 0.833 and 
0.769 respectively). AZT and tetracycline had no effect on the toxicity of 
adriamycin in the DLKP cells (Figures 3.15.1 and 3.15.2). The results indicate 
that quinine and rifampicin may be substrates for MRP and are effective in 
reducing the efflux o f adriamycin from the cells
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DLKP, Adriamycin and AZT, Rifampicin, Quinine and Tetracycline
Test Sample %  Cell Survival S.D.
Adr. lOng/ml 56.9 3.1
AZT (50p.g/ml) 96.2 1.9
AZT + Adr 52.6 2.2
AZT (25|a.g/ml) 97.9 1.6
AZT + Adr 54.2 2.7
AZT (12.5jig/ml) 102.5 1.6
AZT + Adr 57.3 1.9
Adr. lOng/ml 59.8 7.7
Rif (15jo.g/ml) 94.8 0.6
Rif + Adr 44.1 3.9
Rif(7.5ng/ml) 98.3 1.7
Rif + Adr 50.6 5.9
Rif (3.75/xg/ml) 100.4 1.3
Rif + Adr 54.1 4.7
Adr. lOng/ml 61.4 9.4
Quin (15|j,g/ml) 95.0 1.2
Quin + Adr 42.2 6.1
Quin (7.5fig/ml) 96.7 . 2.9
Quin + Adr 54.4 4.3
Quin (3.75ng/ml) 99.4 0.6
Quin + Adr 61.1 7.0
Adr. lOng/ml 59.3 5.7
Tetra (5(j.g/ml) 90.3 1.5
Tetra + Adr 56.4 4.1
Tetra (2.5/a.g/ml) 100.5 1.3
Tetra +Adr 55.6 3.7
Tetra (1.25(J.g/ml) 100.2 3.6
Tetra + Adr 56.9 5.2
Table 3.15.1: % Survival of DLKP cells in the presence of various 
concentrations of adriamycin and AZT, Rifampicin (Rif), Quinine (Quin) and 
Tetracycline (Tetra) as found using the protocol detailed in section 2.7.3a. 
Survival is represented as a % of the growth of untreated cells in the same 
plate ± S.D. Results are the average of triplicate determinations in three 
separate experiments.
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No Anticanccr 
agent
Adr.*
(10ng/ml)
Cl values
No compound
100 ± 0.0 59.3 + 5.7
AZT 50)a.g/ml
96.2 ± 1.9 52.6 ±2.2 1.578
Rifampicin lS^ig/ml
94.8 ± 0.6 44.1 ±3.9 0.833
Quinine 15|ig/ml
95.0. ± 1.2 42.2 ±6.1 0.769
Tetracycline 5fo,g/ml
90.3 ± 1.5 56.4 ±4.1 1.701
Table: 3.15.2: DLKP and Adriamycin + highest non-toxic concentrations of 
AZT, Rifampicin, Quinine and Tetracycline.
*Data are expressed as % Cell Survival ± standard deviation for a minimum of 
three assay repeats.
C l : Combination index.
(Cl < 1: synergism; Cl > 1: antagonism; Cl = 1: additive.)
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3.16 RT-PCR analysis of MRP1, MRP2, MRP3, MRP4, MRP5, 
MRP6 and MDR1 mRNA expression in cancer cell lines.
RT-PCR analysis was carried out on RNA extracted from DLKP, DLKP 
Indo4, DLKP Indo6, A549, 2008 P, 2008 MRP1, 2008 MRP2, 2008 MRP3, 
HL60 (S) and HL60/ADR cells to determine the expression of MRP 1-6 and 
MDR1 mRNA these cell lines. The RT-PCR procedure was carried out 
according to section 2.15. The primers used in the detection if the MRP and 
MDR genes are described in Appendix A.
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3.16 RT-PCR analysis of MRP1, MRP2, MRP3, MRP4, MRP5, 
MRP6 and MDR1 in cancer cell lines.
Figure 3.16.1a RT-PCR analysis of MRP1 expression
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(Note: DLKP P4 = DLKP Indo4; DLKPP6 = DLKP Indo6)
* O.D. is presented as the ratio of the levels of each specific gene product to
the internal P-actin.
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Figure 3.16.1b RT-PCR analysis of MRP1 expression in HL60(S) and
HL60/ADR cell lines
MRP1 HL60 - densitometric analysis
*
P
o
8.00
6.00
4.00
2.00 
0.00
HL60(S)
y  - /
s
/
HL60/ADR
* O.D. is presented as the ratio of the levels of each specific gene product to 
the internal P-actin.
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Figure 3.16.2a RT-PCR analysis of MRP2 expression
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(NoterDLKP P4 = DLKP Indo4; DLKPP6 = DLKP Indo6)
* O.D. is presented as the ratio of the levels of each specific gene product to
the internal P-actin.
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Figure 3.16.2b RT-PCR analysis of MRP2 expression in HL60(S) and
HL60/ADR
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MRP2 HL60 - densitometric analysis
* O.D. is presented as the ratio of the levels of each specific gene product to 
the internal P-actin.
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Figure 3.16.3 RT-PCR analysis of MRP3 expression
MRP3
!Q-actin
MRP3 - densitometric analysis
3.00
2.50
2.00
*
«  i.5oo
1.00
0.50
0.00
(Note: DLKP P4 = DLKP Indo4; DLKPP6 = DLKP Indo6)
* O.D. is presented as the ratio of the levels of each specific gene product to
the internal (3-actin.
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Figure 3.16.4a RT-PCR analysis of MRP4 expression
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* O.D. is presented as the ratio of the levels of each specific gene product to
the internal (3-actin.
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Figure 3.16.4b RT-PCR analysis of MRP4 expression in HL60(S) and
HL60/ADR
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MRP4 HL60 - densitometric analysis
* O.D. is presented as the ratio of the levels of each specific gene product to 
the internal (3-actin.
270
Figure 3.16.5a RT-PCR analysis ofMRP5 expression
M RP5 - densitometric analysis
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* O.D. is presented as the ratio of the levels of each specific gene product to
the internal P-actin.
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Figure 3.16.5b RT-PCR analysis of MRP5 expression in HL60(S) and
HL60/ADR
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Figure 3.16.6 RT-PCR analysis of MRP6 expression
MRP6 - densitometric analysis
P
o
(Note: DLKP P4 = DLKP Indo4; DLKPP6 = DLKP Indo6)
* O.D. is presented as the ratio of the levels of each specific gene product to
the internal P-actin.
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Figure 3.16.7 RT-PCR analysis of MDR1 expression
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Discussion
4.1 General discussion
Overexpression of the 170kDa drug efflux pump, P-glycoprotein, has been 
observed in many multidrug resistant cell lines and some human tumours 
(Gottesman et ah, 1993; Arceci, 1993; Aszalos et ah, 1998). However, it has 
been clear for some time that alternate mechanisms of multidrug resistance 
must exist both in vivo and in vitro. A number of multidrug resistant cell lines 
have been described that do not overexpress P-glycoprotein but display drug 
resistance profiles very similar to those that do (Mirski et ah, 1987; McGrath et 
ah, 1987; Hill et ah, 1993).
Until the early 1990s, non-Pgp-mediated multidrug resistance was generally 
attributed to a variety of mechanisms, including enhanced expression of drug 
detoxification enzymes and alterations in topoisomerase II (Cole et ah, 1990; 
1992a and 1992b). In addition, elevated levels of a number of uncharacteristic 
proteins had been reported in some non-Pgp multidrug-resistant cell lines. In 
1992, Cole et ah, cloned MRP and hence permitted the identification of one of 
these uncharacteristic proteins as a member of the ATP-binding cassette 
transporter superfamily as described in section 1.6. Grant et ah, (1994), 
subsequently demonstrated that MRP-overexpression was sufficient to confer 
multidrug resistance to previously sensitive cells. Since the cloning of MRP 
cDNA from the multidrug resistant H60Ar cell line, overexpression of MRP 
has been reported in many other previously described non-P-glycoprotein 
multidrug resistant cell lines (Cole et ah, 1992; Krishnamachary et ah, 1993; 
Zaman et ah, 1993; Barrand et ah, 1994; Kruh et ah, 1994). These observations 
suggest that MRP may be a relatively common mediator of resistance, at least 
in vitro.
As described in section 1.6, other homologues of MRP have now been 
identified, MRP2 (cMOAT), MRP3, MRP4, MRP5 and MRP6 (Kool et al., 
1997 and Borst et ah, 1999). The mechanisms of these transport proteins have 
yet to be fully elucidated but it is thought that these proteins may also have 
some role in drug transport and chemo-resistance.
During the last decade, there has been much research in the field of multidrug 
resistance circumvention. Fischer and Sikic (1995), carried out clinical trials 
using a range of Pgp modulators. The result of these clinical trials were
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relatively disappointing as it had been found that currently available Pgp 
modulators lack the potency to completely reverse the MDR phenotype at 
clinically achievable concentrations without significant side-effects or toxicity. 
A number of MRP-modulating agents have been described in section 1.6.9. 
Although some of these compounds seem promising in vitro it is not known if 
the MRP-modulating agents, listed in section 1.6.9, could be used to modulate 
MRP-mediated resistance in vivo. It is possible that these compounds could 
cause serious toxic side effects when added at concentrations required for 
modulation of MRP.
The NSAID, indomethacin, is a well-known inhibitor of prostaglandin 
synthesis (Vane et al, 1996) and has also been shown to be a potent inhibitor 
of glutathione-S-transferase (Primiano et al, 1993). It has previously been 
shown to enhance the anti-cancer activity of chlorambucil (Hall et al, 1989), 
methotrexate (Henderson et al, 1994), vincristine (Draper et al, 1997 and 
Kobayashi et al., 1997), VP-16, methotrexate (Maca, 1991), and adriamycin 
(Kobayashi et a l, 1997).
The concentrations at which indomethacin was effective in enhancing the 
cytotoxicity of the cancer cells was also reported by Kobayashi et al, (1997), 
to be clinically safe (approx. 2fag/ml).
Duffy et al., (1998), examined the effect on cytotoxicity of combining a range 
of clinically important non-steroidal anti-inflammatory drugs (NSAIDs) with a 
variety of chemotherapeutic drugs in the human lung cancer cell lines DLKP, 
A549, CORL23R and in the human leukemia cell line HL60/ADR. They found 
that a specific group of NSAIDs (indomethacin, sulindac, tolmetin, acemetacin, 
zomepirac and mefenamic acid) all at non-toxic levels, significantly increased 
the cytotoxicity of the anthracyclines (doxorubicin, daunorubicin and 
epirubicin), as well as tenopside, VP-16 and vincristine, but not the other vinca 
alkaloids, vinblastine and vinorelbine. Other anti-cancer drugs, including 
methotrexate, 5-fluorouracil, cytarabine, hydroxyurea, chlorambucil, cyclo­
phosphamide, cisplatin, carboplatin, mitoxantrone, actinomycin D, bleomycin, 
paclitaxel and camptothecin, were also tested but displayed no synergy in 
combination with the NSAIDs. The enhancement of cytotoxicity was observed 
in a range of tumour cell lines which over-expressed MRP but did not occur in 
multidrug resistant cell lines which overexpress P-170 (Pgp). As it appeared 
that the NSAIDs exerted their positive effect only in combination with MRP
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substrates and in MRP positive cell lines, it seemed logical to postulate that the 
NSAIDs were affecting the activity of MRP and reducing the expulsion of the 
chemotherapeutic drugs from the cell. This resulted in a reduction in the 
resistance of the cell to the chemotherapeutic drug.
The mechanism behind indomethacin’s ability to chemosensitise MRP- 
overexpressing cells remains uncertain. It is unlikely that the enhancement 
effect is due to the inhibition of prostaglandin synthesis as explained in section 
1.8. Therefore, it is most probable that indomethacin exerts its effect on the 
chemotherapeutic drugs through interacting with the functioning of MRP. 
Zaman et al., (1995), reported that MRP is an extremely effective transporter 
of glutathione conjugates. Drug transport in MRP- but not Pgp- overexpressing 
MDR tumour cell lines can be regulated by intracellular GSH levels 
(Versantvoort et al., 1995). Duffy et al., (1998), discovered that glutathione-S- 
transferase activity was inhibited by the NSAIDs found to have the ability to 
potentiate the toxicity of chemotherapeutic drugs, but not the inactive NSAIDs. 
Our group also found that the efflux of adriamycin from cells treated with 
indomethacin was significantly retarded relative to untreated cells or cells 
treated with the inactive NSAIDs. Therefore, it would appear that the positive 
NSAIDs might function by directly inhibiting the MRP pump and as a result of 
this binding, inhibit efflux of the drugs. Alternatively, the NSAIDs may act as a 
competitive substrate for MRP resulting in the NSAIDs being preferentially 
pumped out of the cells, therefore, allowing the cytotoxic drugs to remain in 
the cell for a longer period exerting their chemotherapeutic effect.
This thesis describes an investigation of the modulation of MRP by 
indomethacin and a number of indomethacin analogues. These experiments 
were carried out to:
i. Determine the structure activity relationship of MRP inhibition by 
indomethacin analogues
ii. Discover an analogue of MRP with greater MRP modulating activity 
than indomethacin at less toxic concentrations with less side effects;
iii. Determine the mechanism by which indomethacin and similar 
compounds potentiate the toxicity of a range of chemotherapeutic drugs.
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As a result of the results reported by Duffy et al., (1998), a study was 
undertaken by our group, in collaboration with the chemistry department in 
University College, Cork, to develop a series of compounds based on the basic 
structure of indomethacin. These indomethacin analogues were then analysed 
in a number of assays to determine the Structure Activity Relationship (SAR) 
of the compounds. The aim of such experiments was to find the structure with 
optimum ability to enhance the cytotoxicity of the chemotherapeutic drugs and 
to determine the function of the various substituents on the indomethacin 
structure.
4.2 Investigation of Structure Activity Relationship (SAR) of
indomethacin-mediated toxicity enhancement
W hat is the influence of this 
substituent? Is the carboxyl group 
significant?
C 02H
c h 3
QH Is the methyl group
significant?
What is the requirement 
for the aryl substituent?
Must the N substituent be 
benzoyl or will a benzyl 
group play the same role 
biologically?
Figure 4.1: Indomethacin structure indicating which substituents 
were varied to generate the indomethacin analogues.
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23 of these indomethacin analogues were generated (section 3.1). 19 of these 
compounds were directly related to indomethacin with substituent variation to 
determine the SAR of the compounds. The remaining four compounds were 
based on the structure of a known PLA2 inhibitor with a basic structure similar 
to that of indomethacin.
4.2.1 Investigation of ability of indomethacin analogues to enhance the 
toxicity of adriamycin in DLKP cells in vitro.
The compounds were initially assayed in combination toxicity assays in DLKP 
cells to assess their ability to enhance the cytotoxicity of the anthracycline, 
adriamycin, as compared to indomethacin. The highest non-toxic concentration 
of indomethacin, which exerted its positive effect, was 2.5|xg/ml. The 
concentrations of adriamycin used in the combination toxicity assays were 
lOng/ml and 5ng/ml. The IC50 of adriamycin in DLKP cells is approximately 
lOng/ml. The procedure for the combination toxicity assay was carried out as 
per section 2.7.3a. The structures of the compounds assayed are described in 
section 3.1.
The results obtained from the combination toxicity assays indicated that:
• The activity of the compounds was concentration dependent.
• A number of the substituents on the indomethacin structure were critical 
in the functioning of the compounds.
280
Figure 4.1a: Analogues of N-benzyl-indomethacin
C 0 2H
BRI60/I: A=MeO 
BRI 114/2: A=MeO 
BRI 115/2: A=MeO 
BRI 113/1: A=MeO 
BRI 124/1: A=MeO 
BRI 106/1: A=MeO 
BRI 107/1: A=MeO 
BRI 138/1: A=MeO 
BRI 119/1: A=H; 
BRI 120/1: A=MeO
B=CH3; X=C1; Y=H; Z=H 
B=CH3; X=Br; Y=H; Z=H 
B=CH3; X=F; Y=H; Z=H 
B=CH3; X=H; Y=H; Z=H 
B=CH3; X=MeS; Y=H; Z=H 
B=CH3; X=H; Y=C1; Z=H 
B=CH3; X=H; Y=H; Z=C1 
B=CH3; X=H; Y=F; Z=H 
B=CH3; X=C1; Y=H; Z=H 
B=H; X=C1; Y=H; Z=H
Figure 4.1b: Analogues of N-benzoyl-indomethacin
-W
Indo:
_Y BRI 59/1:
BRI 69/2:
BRI 88/1:
BRI 92/1:
BRI 104/2: W=C02H;
W=C02H; X=C1; Y=CH3; Z=CH30
W=COOMe; X=C1; Y=CH3; Z=CH30  
W=CONHTol; X=C1: Y=CH3; Z=CH30  
W=C02H; X=H; Y=CH3; Z=CH30  
W=C02H; X=Br; Y=CH3; Z=CH30  
X=C1; Y=CH3; Z=H
The first significant results from the combination toxicity assay demonstrated 
that the benzoyl substituent on the indole nitrogen atom was not required for 
the potentiation ability of indomethacin. This N-benzyl-indomethacin analogue 
(BRI 60/1) was found to be active in the combination toxicity assay and 
moreover, its activity was found to be comparable to that of indomethacin. 
Removing the benzoyl substituent also rendered this indomethacin analogue 
less toxic (2-fold) than N-benzoyl-indomethacin to the DLKP cells.
Subsequent assessment of a number of benzyl derivatives of indomethacin, 
with various substituent variations, demonstrated the importance of a number 
of these substituents for the enhancement of toxicity of adriamycin by 
indomethacin. Changing the position of the chlorine from the /?ara-position on 
the benzyl ring to the meta-position (BRI 106/1) or the ortho-position (BRI 
107/1) rendered N-benzyl-indomethacin incapable of potentiating the toxicity 
of adriamycin. Removing the halogen from the benzene ring (BRI 113/1) also
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resulted in loss of ability to enhance the toxicity of adriamycin. These results 
indicated that in the benzyl series, not only was the presence of a halogen 
necessary for the potentiating activity of N-benzyl indomethacin, but the para- 
position of the halogen was also critical for a positive effect in the combination 
toxicity assays. Further investigations indicated that the chlorine substituent in 
the pora-position on the benzene ring of N-benzyl-indomethacin could be 
replaced with either bromine (BRI 114/2) or fluorine (BRI 115/2) without loss 
o f activity in the combination toxicity assays. Replacing chlorine with fluorine 
very slightly reduced the potentiating activity of indomethacin. Replacing 
chlorine with bromine did not result in any notable decrease in activity and 
when analysed in the combination toxicity assays, this analogue of 
indomethacin was found to compare very favorably to indomethacin. In 
addition, replacing chlorine with bromine or fluorine resulted in a 2-fold 
decrease in toxicity to DLKP cells as compared to N-benzyl indomethacin and 
a 4-fold decrease in toxicity as compared to N-benzoyl indomethacin.
An additional benzyl-derivative was generated in which the fluorine, attached 
to the benzene ring in N-benzyl-indomethacin, was moved from the para- to 
the weta-position. Moving the chlorine from the para- to the meta and ortho- 
positions on the benzene ring in N-benzyl-indomethacin had already been 
shown to result in a loss of activity of these indomethacin analogues in the 
combination toxicity assay. However, moving the fluorine to the meta-position 
on the benzene ring resulted in the generation of an analogue of indomethacin 
that still demonstrated an ability to potentiate adriamycin in the combination 
toxicity assays (BRI 138/1). Although this analogue required concentrations 3- 
fold higher than N-benzyl-indomethacin to obtain a comparable potentiation 
effect, it was found to be 1.5-fold less toxic than the para-form of this 
indomethacin analogue and 3-fold less toxic than N-benzyl-indomethacin to 
the DLKP cells. The effect of moving fluorine to the ori/zo-posilion was not 
examined. In addition, the effect of moving bromine to either the meta- or the 
ortho-position was not investigated. The development and subsequent analysis 
of additional indomethacin analogues are required to fully elucidate the roles of 
these halogens on the N-benzyl-indomethacin structure.
Further analysis of N-benzyl-indomethacin analogues demonstrated that 
replacing chlorine on the benzene ring with a non-halogen substituent, a 
methylthio substituent (BRI 124/1), rendered this N-benzyl-indomethacin
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analogue inactive in the combination toxicity assays. This result indicated that 
a halogen was the desired substituent at this position on the benzyl- 
indomethacin structure.
Variations of the halogen group on the benzene ring in the N-benzoyl- 
indomethacin series were also investigated with the development of two 
benzoyl derivatives where the chlorine was completely removed from the 
benzene ring (BRI 88/1) or was replaced with bromine in the /?ara-position 
(BRI 92/1). Results from the combination toxicity assay showed these two 
compounds to be positive with comparable activity to indomethacin. However, 
both of these compounds were 2-fold less toxic to the DLKP cells than N- 
benzoyl-indomethacin. This result indicates that the presence of the halogen in 
the N-benzoyl-indomethacin series is not critical and when removed does not 
render the compound inactive in the combination toxicity assay. However, no 
compounds were developed in which the halogen was placed in the ortho- and 
meta- position in the N-benzoyl derivatives of indomethacin so one cannot 
affirm for certain that the positioning of the halogen is not critical.
In subsequent analysis of N-benzyl derivatives of indomethacin, two 
compounds were developed in which the methoxy (BRI 119/1) or the methyl 
substituents (BRI 120/1) were removed. Both analogues were inactive in the 
combination toxicity assay indicating that both these substituents were required 
for the benzyl compounds to be active. Another interesting result was obtained 
with the development of an analogue of N-benzoyl indomethacin in which the 
methoxy substituent was removed (BRI 104/2). Removal of this substituent 
was not tolerated in the N-benzyl series, but in the N-benzoyl derivative the 
removal of this substituent did not render the compound inactive. This 
analogue was comparable in activity to indomethacin in the combination 
toxicity assay when used at similar concentrations and was also found to be 2- 
fold less toxic than N-benzoyl-indomethacin in the DLKP cells.
The acetic acid side chain was manipulated in two of the N-benzoyl- 
indomethacin analogues in which this substituent was converted to a methyl 
ester or a tolyl amide. This structural change rendered both these compounds 
inactive in the combination toxicity assay. These compounds were relatively 
insoluble in DMSO and media and this was most likely due to the changes 
made to the acetic acid side chain as the rest of the indomethacin structure 
remained unchanged.
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Therefore, results obtained from analysis of the N-benzyl derivatives of 
indomethacin indicate that the nature and the position of the functional groups 
are critical when the benzoyl substituent is removed from the indomethacin 
structure. It appears that the presence of the benzoyl group on the indole 
nitrogen atom confers greater structure rigidity to N-benzoyl-indomethacin. 
There is a large barrier to free rotation associated with groups joined by a 
double bond (Solomon, 1996). Therefore, upon removal of this benzoyl group, 
the rigidity of the structure of indomethacin is affected which may affect the 
binding of the structure to MRP. As it is postulated that indomethacin 
potentiates the activity of adriamycin by binding to MRP and subsequently 
inhibiting the efflux of adriamycin (Duffy et ah, 1998), it is very likely that 
variations to the indomethacin structure can affect its binding to the MRP 
protein.
Seelig et al., (2000), suggested that MRP1 binds its substrates via hydrogen 
bond formation and that the transport of anionic substrates by MRP1 is 
facilitated by cationic amino acid residues present in the transmembrane 
helices of MRP I. The authors demonstrated that the compounds analysed in 
the study and found to interact with MRP1, carried units consisting of two 
electron donor groups with a spatial separation of 2.5 ± 0.3 Â (defined as type I 
units) or, less frequently, units consisting of three electron donor groups with 
the two outer groups exhibiting a spatial separation of 4.6 ± 0.6 A (defined as 
type II units). They also reported that negatively charged electron donor units 
e.g. the carboxylic acid group, COO", are required for efficient transport by 
MRP1.
It appears that MRP transports amphiphilic anionic and some cationic 
substrates (section 1.6.6). The carboxyl (COOH) substituent is required on the 
indomethacin structure to render the indomethacin molecule more water- 
soluble. When the carboxyl group was substituted with either COOMe (BRI 
59/1) or CONHTol (BRI 69/2), in two N-benzoyl-indomethacin analogues, the 
potentiation ability of the compound was lost. Therefore, it is possible that 
altering the carboxyl side chain in N-benzoyl-indomethacin rendered these 
analogues too lipid soluble making them poor substrates for MRP. Substituting 
the carboxyl group may also have had the effect of reducing the ability of the
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analogues to bind to MRP due to the loss of this negatively charged electron 
donor group which appears to be necessary for substrate binding to MRP1.
It is postulated that when the benzoyl group is removed from the indomethacin 
structure, the chlorine substituent on the benzene ring functions to maintain the 
rigid structure o f indomethacin, which may be most suited to binding with 
MRP. If  the halogen is required in the /?ara-position on the benzene ring to 
maintain the rigid structure of indomethacin, it is difficult to explain why 
moving the fluorine group to the meta-position did not render the compound 
inactive. Fluorine is the least dense of the halogens and due to its smaller size 
(atomic mass of fluorine = 18.99) (chlorine = 35.45, bromine = 79.9) it is 
possible that moving its position to the meta-position did not have a large 
effect on the structure of indomethacin. But moving the larger chlorine 
structure resulted in a greater alteration to the shape of the indomethacin 
structure. Fluorine is more electronegative (4.1) than chlorine (2.8) or bromine 
(2.7), and has a greater dipole moment (1.91ja. (D)) than chlorine (1.08(j. (D)) or 
bromine (0.80fi (D)) when bonded to hydrogen. These properties may result in 
stronger binding of the meta-fluoro-benzyl indomethacin structure to the MRP 
molecule than if chlorine or bromine were in the meta-position.
Another hypothesis concerns the actual binding site on the MRP molecule. 
Perhaps one side of the indomethacin structure binds to a particular binding site 
on the MRP. Presumably the side that binds to the MRP binding site is that 
with the carboxylic acid group (Seelig et al., 2000). If this is so, it is possible 
that the position of the chlorine substituent, either in the ortho- or the meta­
position of the benzene ring, but on the same side of the indomethacin structure 
as the carboxylic acid group, might result in an indomethacin structure which is 
too large to bind to the MRP binding site. The smaller size of fluorine, when it 
is in the meta-position, may not render the indomethacin structure too large for 
the binding site on MRP.
It is also possible that the lipophilicity of the indomethacin structure is affected 
by the position of the halogen on the benzene ring and in particular in N- 
benzyl-indomethacin analogues. MRP transports amphiphilic anionic 
compounds and the chlorine substituent helps to maintain the lipophilic 
properties of certain compounds (O’Connor, 1995). Moving chlorine to the 
meta- or the ortho-position on the benzene ring may reduce the lipophilicity of 
N-benzyl-indomethacin rendering it a poorer substrate for MRP. However, this
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hypothesis is unlikely, as removing the halogen group completely from the 
benzene ring in the N-benzoyl-indomethacin analogues did not render the 
indomethacin analogues inactive. Therefore, it is most likely that the position 
and the nature o f the halogen in the N-benzyl-indomethacin analogues affect 
the overall conformation (i.e. size and electron distribution) of the compound 
and as a result, its ability to bind to MRP.
The fact that the removal of the methoxy substituent on the N-benzoyl 
indomethacin structure did not result in a loss of activity in the combination 
toxicity assays, but removing the same substituent in the N-benzyl analogue of 
indomethacin resulted in loss of activity, strongly suggests that the nature and 
the function of the substituents on the benzene ring are not as crucial for N- 
benzoyl-indomethacin due to the greater structural rigidity of the N-benzoyl 
substituted indole nucleus.
As indomethacin is a known PLA2 inhibitor (Kaplan et al., 1978; Lobo et al., 
1994), four compounds were developed which are PLA2 inhibitors, adapted 
from studies of Fleisch et al., (1996) and Mihelich et al., (1997), of Lilly 
research laboratories. Another suggested explanation for the ability of the 
NSAIDs to potentiate the toxicity of the chemotherapeutic drug, was through 
inhibition of the enzyme PLA2 by these compounds. It was postulated that 
through the inhibition of the production of arachidonic acid the NSAIDs might 
exert their cytotoxic enhancing effects. Arachidonic acid is released from 
phopholipid stores in the cell membrane by the action of phopholipase A2 (Lehr 
et al., 1997; Fleisch et al., 1996 and Fox et al., 1996). This polyunsaturated 
fatty acid is a substrate for the lipoxygenase and cyclooxygenase enzymes and 
leads to a family of bioactive lipids that include the leukotrienes, 
prostaglandins, prostacyclins and thromboxanes (Mann et al., 1994). Despite a 
great deal of investigation, the roles that these arachidonic acid metabolites 
play in cancer have yet to be fully elucidated. However, as described in section 
1.7, a number of studies, including those carried out by Mamett et al., (1992) 
and Ara et al., (1996), have discussed the lipoxygenase and cyclo-oxygenase 
inhibitory properties of NSAIDs and their effects on tumour growth and 
promotion.
The structures of the four PLA2 inhibitors developed for analysis, BRI 153/1, 
203/1, 205/4 and 215/1, are described in figures 3.1.20, 3.1.23 and 4.2 (below). 
BRI 153/1 and BRI 203/1 were N-benzyl-l-(m)ethylindole-3-acetamides
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functionalised at the 5-position with a short chain alkoxy unit terminated by a 
carboxylic acid unit. Both compounds were structurally identical except for an 
ethyl substituent in BRI 153/1 was replaced with a methyl substituent in BRI 
203/1. When analysed in the combination toxicity assay, BRI 153/1 was non­
toxic to the DLKP cells at concentrations up to 50ng/ml (0.130mM). It was 
only at this concentration that BRI 153/1 enhanced the toxicity of adriamycin 
in the DLKP cells at a level comparable that obtained by indomethacin at 
2.5(ag/ml (0.007mM), BRI 203/1 was more toxic to the cells than 153/1. The 
highest non-toxic concentration of BRI 203/1 was 20p,g/ml (0.054mM), 
indicating that the methyl substituent was involved in increasing the toxicity of 
the compound to the DLKP cells. At this highest non-toxic concentration BRI 
203/1 was positive in the combination toxicity assay but at its highest non-toxic 
concentration was not as effective in enhancing the toxicity of adriamycin as 
indomethacin at 2.5¡ag/ml.
co nh2
X
BRI 203/1: X=CH3 
BRI 153/1/1: X=CH2CH3
c o n h2
X
BRI 205/4: v ~ ™  
BRI 215/1:
BRI 205/4 and BRI 215/1 were also developed with structures similar to that of 
153/1. These compounds were N-benzyl-2-(m)ethylindole-3-acetamindes, 
functionalised at the 5-position. However, the short-chain alkoxy unit was
terminated by a phosphonie acid residue instead of a carboxylic acid residue. 
Again, BRI 205/4 and BRI 215/1 were structurally identical except for an ethyl 
substituent in BRI 215/1 was replaced with a methyl substituent in BRI 205/4. 
In the combination toxicity assay BRI 205/4 was negative. This compound had 
no cytotoxic enhancing ability when used at its highest non-toxic concentration 
of 25[j.g/ml (0.062mM). BRI 215/1 could also be used at concentrations up to 
50fj.g/ml (0.119mM), again indicating that the replacing of the ethyl substituent 
for a methyl substituent increases the toxicity of the compound in the cells. 
Although BRI 215/1 was at such high concentrations it was only weakly 
positive as compared to indomethacin. The results obtained in the combination 
toxicity assay for the four PLA2 inhibitors, indicate that BRI 153/1 and BRI 
203/1 were most positive. This indicates that the phosphonie acid residue, 
terminating the short chain alkoxy unit in BRI 215/1 and 205/4 had a negative 
effect on the ability of these compounds to enhance the toxicity of adriamycin. 
As explained previously, Seelig et al., (2000), reported that the carboxylic acid 
residue is a typical, negatively charged type I unit, (unit consisting of two 
electron donor groups with a spacial separation 2.5 ± 0.3 Á) suitable for 
substrate binding to MRP. Therefore, it is possible that when the carboxylic 
acid residue on the short chain alkoxy unit of BRI 153/1 and 203/1 is removed, 
and replaced with a phosphonie acid residue on BRI 205/4 and 215/1, these 
compounds lose their ability to bind to MRP. As a result BRI 205/4 and 215/1 
cannot potentiate the toxicity of adriamycin. The results also suggested that the 
ethyl substituent was the most favourable in terms of lower toxicity in the cell. 
At its highest non-toxic concentration, BRI 153/1 was the most positive of the 
PLA2 compounds analysed. Yet it could only achieve enhancement of the 
toxicity of adriamycin, comparable to that obtained by indomethacin at 
2.5 fig/ml, when used at 50(a.g/ml. These results suggest that the potentiating 
ability of indomethacin and positive indomethacin analogues is not through 
PLA2 inhibition.
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Combination
Toxicity
Assay
Combination
Toxicity
Assay
Indomethacin + BR1115/2 +
BRI 60/1 + BR1113/1 -
BRI 59/1 - BR1124/1 -
BRI 69/2 - BR1119/1 -
BRI 88/1 + BR1120/1 -
BRI 92/1 + BR1153/1 +
BRI 104/2 + BRI 203/1 +
BRI 106/1 - BRI 205/4 -
BRI 107/1 - BRI 215/1 -
BRI 114/2 + BR1138/1 +
Table 4.2.1: Summary table of results from combination toxicity assays. 
+ Positive; - Negative.
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One postulated mode by which the chemotherapeutic drugs are transported by 
MRP is through the formation of glutathione conjugates, which are then 
effluxed from the cell by MRP, resulting in the development of multidrug 
resistance (Paul et al., 1996). The findings that MRP can transport cysteinyl 
leukotrienes (e.g. LTC4) as well as other GSH conjugates suggest that this 
protein may be a GSH conjugate/organic anion transporter (Leier et al, 1994; 
Jedlitschly et al., 1994; Loe el al, 1996 and Cole et al., 1994). However, this 
theory is questionable as glutathione conjugates of the natural drug products 
for which MRP confers resistance have not been isolated (Tew et al, 1994) 
and MRP transfectants do not exhibit increased resistance to alkylating agents, 
a class of drugs for which glutathione conjugation is known to occur (Grant et 
al, 1994). Loe et al, (1996), demonstrated the direct uptake of unmodified 
vincristine by MRP-enriched vesicles in an ATP and GSH-dependent manner 
and that the tripeptide structure of GSH is a requirement for stimulation of 
VCR transport to occur. However, co-transport mechanisms still cannot 
explain all MRP-mediated resistance mechanisms, in particular with respect to 
the anthracycline antibiotics since GSH displays little or no ability to enhance 
either the transport directly or their ability to inhibit ATP-dependent, MRP- 
mediated LTC4 transport (Loe et al, 1996b).
Our group postulated that the mode of action of indomethacin and positive 
indomethacin analogues, in circumventing resistance in MRP positive cell 
lines, was through some form of inhibition of the activity of MRP. An 
investigation was carried out to assess if  these positive compounds were active 
against MRP through inhibition of the enzyme glutathione S-transferase (GST) 
which is the enzyme involved in the formation of glutathione conjugates (Yang 
et al, 1992). Hall et al, (1989), showed a partial reversal of chlorambucil 
resistance in Chinese hamster ovary cells by preincubation of the cells with 
indomethacin. These CHO cells were found to exhibit resistance to 
bifunctional nitrogen mustards while maintaining sensitivity to a range of other 
alkylating agents. This enhanced drug resistance was associated with a greater 
than 40-fold increase in the level o f GST as compared to the parental, CHO-K1 
cell line (Robson et al, 1986). Hall et al, (1989), found that indomethacin was
290
4.2.2 Investigation of the ability of indomethacin and indomethacin
analogues to inhibit Glutathione S-transferase activity.
an inhibitor of GST enzyme activity and also demonstrated that following 
exposure of the CHO cells to 500|im of indomethacin, the cytotoxicity of 
chlorambucil was potentiated. In contrast, the anti-inflammatory agent 
acetylsalicylic acid (aspirin) failed to inhibit the activity of GST and caused no 
potentiation of chlorambucil activity, suggesting that the potentiation by 
indomethacin is not due to the effects of this drug on prostaglandin synthesis. 
These studies led the authors to believe that GSTs may be involved in the 
development of resistance to bifimctional alkylating agents and suggest that 
indomethacin, or agents with similar activities may be of value as an adjunct to 
chemotherapy in some patients with tumours resistant to treatment with 
alkylating agents.
Results from the GST assays demonstrated varying ability among 
indomethacin and analogues to inhibit GST. Indomethacin was used as the 
positive compound control as its GST inhibiting ability was known and DMSO 
was used as the negative control (no compound). At approx. 500(am, 
indomethacin was found to inhibit GST by approx. 50% and l,000|xm inhibited 
GST activity by approx. 100%. The indomethacin analogues were analysed at 
similar concentrations. The results obtained from these assays were interesting. 
BRI 60/1, 88/1, 92/1, 104/2, 114/2, 115/2, 153/1, 138/1 and 203/1 were 
positive in the combination toxicity assays in DLKP cells. However, only three 
of those compounds, BRI 88/1, 92/1, 104/2, positive in the combination 
toxicity assay, were strongly positive in the GST assay. GST inhibition by BRI 
92/1 was comparable to that of indomethacin whereas the other two 
compounds were slightly less inhibitory. It was also interesting to note that 
indomethacin and BRI 88/1, 92/1, 104/2, are N-benzoyl compounds and vary 
only with indomethacin by the removal/replacement of one substituent in each 
of the compounds (Figures 1.10.5 - 1.10.7). The remaining indomethacin 
analogues, positive in the combination assay, are N-benzyl derivatives of 
indomethacin, and demonstrate insignificant or no GST inhibitory ability. This 
suggests that the GST active site is more selective for substrate binding than 
the MRP active site and the rigid structure of N-benzoyl-indomethacin is 
required for binding to this GST active site. The results indicate that inhibition 
of GST is not important for the enhancement of the toxicity of the 
chemotherapeutic by indomethacin and the active indomethacin analogues.
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GST 
Assay Results
GST 
Assay Results
Indomethacin +++ BRI 115/2 +/-
BRI 60/1 - BRI 113/1 +/-
BRI 59/1 - BRI 124/1 -
BRI 69/2 - BRI 119/1 -
BRI 88/1 ++ BRI 120/1 -
BRI 92/1 +++ BR1153/1 -
BRI 104/2 ++ BRI 203/1 -
BR1106/1 - BRI 205/4 -
BR1107/1 +/- BRI 215/1 -
BR1114/2 - BRI 138/1 -
Table 4.2.2: Summary table of results from GST assay
+++ Very strong positive; ++ Strong positive; + positive; +/- poor positive;
- negative.
4.2.3 Investigation of MRP inhibiting ability of indomethacin and 
indomethacin analogues using a membrane-enriched preparation of MRP.
Western blotting analysis failed to demonstrate expression of MRP protein in 
whole cell extracts of DLKP (Duffy el ah, 1998). This contradicted the 
suggestion that NSAIDs interfered with MRP-mediated drug efflux resulting in 
chemotherapeutic drug toxicity enhancement. It was found, however, that MRP 
was detectable by Western blotting of inside-out vesicles (IOVs) isolated from 
DLKP. The levels were relatively low in comparison to the levels present in 
IOVs isolated from the MRP- overexpressing cell line HL60-ADR, but these 
levels were sufficient to render the cells less sensitive to chemotherapeutic 
drug and to allow circumvention of the resistance by the active NSAIDs 
(Elliott, 1997 and Duffy et ah, 1998).
The precise mechanism by which MRP renders the cells resistant to cytotoxic
insults has not been definitely established but it is believed (at least as one
possible mechanism) to act as an efflux pump for GSH conjugates of
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xenobiotics (Ishikawa et al., 1994). Active NSAIDS, indomethacin, sulindac 
and tolmetin have previously been demonstrated by our group to inhibit the 
uptake of leukotriene C4, an MRP substrate, using inside-out vesicles prepared 
from the plasma membrane of HL60/ADR cells (Duffy et al., 1998).
To gain insight into the mechanism of action of indomethacin and its 
analogues, the in vitro substrate specificity of MRP was examined by analysing 
the uptake of LTC 4  into membrane vesicles prepared from MRP- 
overexpressing HL60/ADR cells in the presence or absence of indomethacin or 
its analogues. Membrane vesicles were prepared as described in section 2.10, 
and according to the methods described by Paul et al., (1996), and Leier et al., 
(1994b). Uptake of LT C 4  was measured by the rapid filtration technique 
described by Horio et al., (1988), and Paul et al., (1996).
The results obtained from these assays demonstrated that approximately 50mM 
indomethacin inhibited the transport of LTC4 by approx. 80%. Similar molar 
concentrations of each of the active analogues were assayed and the results 
demonstrated that, of the nine indomethacin analogues active in the 
combination toxicity assay, eight of these compounds were very positive in the 
IOV assay. Analogues of indomethacin that were found to be negative in the 
combination toxicity assay were also found to be negative in the IOV assay in 
that they failed to inhibit the uptake of LTC4. These results strengthen the 
theory that the enhancement of the toxicity of the chemotherapeutic drug is 
through the interaction of the positive analogues with MRP. It is suggested that 
indomethacin and its analogues exerted their positive effect through inhibition 
of the pumping ability of MRP either by:
i. Binding to MRP and inhibiting the activity of the pump;
ii. Competing with LTC4 for a particular binding site on the MRP 
molecule, inhibiting the binding of LTC4 to MRP and curtailing the 
pumping of this substrate;
iii. Competitively inhibiting the pumping of L T C 4  by MRP, causing the 
MRP pump to preferentially transport indomethacin and its analogues 
from the cell (i.e. indomethacin and analogues may be competitive 
substrates for MRP).
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The glutathione conjugate transporter is also believed to be involved in the 
transport of cytotoxic drugs (Paul et al, 1996; Ishikawa et al, 1995; Shen et 
al, 1996) (Section 1.6.6). This may indicate that the NSAIDs and the 
indomethacin analogues potentiate the toxicity of the chemotherapeutic drugs 
through direct interaction with the MRP pump, causing a reduction in the 
amount of drug being pumped out of the cell and as a result increasing the 
toxicity of the drug to the cell.
However, one of the indomethacin analogues, BRI 138/1 (meta-fluorobenzyl- 
indomethacin), which was active in the combination toxicity assay in DLKP 
cells, was only weakly positive in the IOV assay. Approximately 50(jM of BRI 
138/1 was only capable of inhibiting the uptake of LTC4 by approx. 20% as 
compared to approx. 80% inhibition by equivalent concentrations of 
indomethacin. This would suggest that BRI 138/1 is a very poor MRP 
inhibitor/substrate even though it potentiated very strongly the toxicity of 
adriamycin in the combination toxicity assay, (although a potentiation ability 
comparable to indomethacin was only evident when BRI 138/1 was added to 
the combination toxicity assay at 6-times the concentration of indomethacin).
It may be possible that BRI 138/1 is exerting its effect on a different analogue 
of MRP which might have different substrate specificities than MRP1. RT- 
PCR analysis of DLKP cells (Section 3.11.2) has demonstrated a strong 
expression of MRP1 in these cells. Low expressions of MRP2, -4, -5 and -6  
mRNA have also been detected in DLKP cells (Section 3.16). mRNA 
expression of the various homologues of MRP was also investigated in the 
HL60/ADR cell line, the cell line from which the IOVs were prepared. Again, 
a strong expression of MRP1 mRNA was detected in these cells with lower 
levels of MRP2, -5 and -6  mRNA expression also detected. There are no 
detectable levels of MRP4 or MRP3 in the HL60/ADR cells (Section 3.16). 
Perhaps BRI 138/1 potentiated the toxicity of adriamycin by interacting with 
MRP4 which was detectable in DLKP cells but not in HL60/ADR cells. 
However, there is no evidence to date to suggest that adriamycin or 
indomethacin/indomethacin analogues are substrates for MRP4.
BRI 138/1 was negative in the GST assays so its activity is most likely not 
through inhibition of the formation of glutathione conjugates. BRI 115/2, the 
para-form of BRI 138/1, was positive in the IOV assay. It may be possible that
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because of its particular meta-structure (other meta-analogues of benzyl 
indomethacin were inactive in the combination toxicity assay), BRI 138/1 has a 
lower affinity for the binding site on the MRP molecule than LTC4 and the 
other active analogues. As a result of this, if the actual mode of action by 
which the positive analogues work is via competitive inhibition of MRP it may 
be unable to compete with LTC4 for preferential pumping by MRP. In contrast, 
in the combination toxicity assay, the levels of BRI 138/1 added to the cells is 
quite high, (15fag/ml (46|iM)), when compared to the concentration of 
adriamycin added (lOng/ml (17.2nM)) to the same cells. As a result BRI 138/1 
may be capable of competing with adriamycin for preferential pumping by the 
MRP pump due to the greater concentration of this compound in the cell. 
Hence, affinities of the compounds for the MRP binding site may not be so 
critical in the combination toxicity assay.
The comparison between the concentrations of indomethacin and indomethacin 
analogues used in both the combination toxicity assay and the IOV assay is 
also of interest. In the combination toxicity assay, BRI 138/1 was required at 6- 
times the concentration of indomethacin to produce a similar potentiation effect 
whereas, BRI 153/1 was required at 50-times the concentration of 
indomethacin. In comparison, in the IOV assay, the concentration of BRI 153/1 
(42|oM) was similar to that of indomethacin (46|aM), with similar abilities to 
inhibit LTC4 transport. However, BRI 138/1 at a concentration of 50(.iM was 3- 
fold less effective than indomethacin in the IOV assay. The fact that 
indomethacin and BRI 153/1 could be used at similar concentrations in the 
IOV assay, but not in the combination toxicity assay suggests differences in 
substrate requirements for binding to MRP between both assays. It appears 
that, although the fluorine in the meta-position on BRI 138/1 did not affect 
binding to the MRP binding site in the combination toxicity assay, the position 
of this halogen rendered BRI 138/1 a poor substrate in the IOV assay. It is 
possible that the procedure of turning vesicles inside-out, and thus, the 
direction of transport by MRP, affected, in some way, the conformation of the 
MRP active site which resulted in less effective binding by BRI 138/1. 
Alternatively, this discrepancy with the results obtained with BRI 138/1 may 
be simply due to the solubility of the compound in the IOV assay. Moving the 
fluorine from the para-to the meta-position in fluorobenzyl indomethacin may 
effect the solubility and electronegativity of the compound. MRP seems to
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have a preference for amphiphilic xenobiotics (Cole et al., 1994 and Loe et al., 
1996a). Fluorine is a smaller molecule (MW 18.998) than chlorine (MW 
35.453) and bromine (MW 79.904) and is also more electronegative which 
may be associated with reduced lipophilicity. In the combination toxicity assay, 
BRI 138/1 was dissolved in DMSO and added to medium prior to adding to the 
cells. However, in the IOV assay, BRI 138/1 was dissolved in DMSO and then 
added to an incubation buffer, which consisted of a high concentration (8% 
w/v) of sucrose in lOmM TRIS-HCL. Therefore, the solubility of BRI 138/1 in 
this buffer and, thus, in the IOV assay, may have been affected by the fluorine 
in the meta-position.
Further experiments are required to determine if BRI 138/1 is exerting its effect 
through an interaction with MRP and if its mode of action is similar to that of 
the other active indomethacin analogues. Efflux studies (section 3.5) suggest 
that the DLKP cells efflux chemotherapeutic drug, in combination with BRI 
138/1, in a manner similar to the efflux of drug with indomethacin. These 
efflux experiments may also be expanded to determine preferential pumping of 
one indomethacin analogue over another. The affinity of BRI 138/1 versus 
other indomethacin analogues for MRP may be analysed here.
IOV Assay 
Results
IOV Assay 
Results
Indomethacin ++ + BRI 115/2 +++
BRI 60/1 ++ BRI 113/1 N/D
BRI 59/1 - BRI 124/1 N/D
BRI 69/2 - BRI 119/1 -
BRI 88/1 + + (+ ) BRI 120/1 -
BRI 92/1 ++ + BR1153/1 +++
BRI 104/2 ++ BRI 203/1 ++
BRI 106/1 N/D BRI 205/4 -
BRI 107/1 N/D BRI 215/1 + /-
BRI 114/2 + + (+ ) BRI 138/1 +
Table 4.2.3: Summary table of results from IOV assay
+++ Very strong positive; ++ Strong positive; + positive; +/- poor positive; 
negative.
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Indomethacin has been shown by a number of researchers (Vane et al., 1996; 
Engelhardt et al., 1996; Mitchell et al., 1993) to be an inhibitor of both 
cyclooxygenase-1 and -2 (COX-1 and COX-2). This NSAID is slightly more 
potent against COX-1 than COX-2 but is generally considered as a non- 
selective NSAID (Reindeau et al., 1997). Indomethacin is also known for its 
propensity to cause gastric damage (Bateman, 1994).
It is unlikely that the cyclooxygenase inhibitory activity of the NSAIDs is 
involved in the enhancement of the cytotoxicity of chemotherapeutic drugs 
because:
• Many NSAIDs known to be cycloxygenase inhibitors have been shown in
our laboratories not to have the ability to potentiate the toxicity of
chemotherapeutic drugs. These negative NSAIDs include aspirin,
diclofenac, fenoprofen, flufenamic acid, naproxen and piroxicam (Duffy et 
al., 1998).
• Sulindac sulfone, a metabolite of sulindac, is an active toxicity enhancer
(Duffy et al., 1998), although it does not possess cyclo-oxygenase
inhibitory activity (Piazza et al, 1995; 1997a; 1997b and Levy et al,
1997).
• The addition of PgD2 or PgE2 does not reverse the enhancement effect 
(Duffy et al., 1998; De Mello et al., 1980; Elliot 1997).
NSAIDs are reported to inhibit the synthesis of cytoprotective prostaglandins 
by COX-1 in the gastrointestinal tract leading to the accumulation of surplus 
arachidonic acids. These can enhance the generation of leukotrienes via the 
lipoxygenase pathway inducing neutrophil adhesion to endothelium and
vasoconstriction. The NSAIDs containing a carboxyl group also inhibit oxidative 
phosphorylation (OXPHOS) lowering adenosine-triphosphate (ATP) generation, 
leading to loss of mucosal cell tight junctions and increased mucosal permeability 
(Fosslien, 1998). Inhibition of COX-2 by NSAIDs reduces synthesis of pro- 
inflammatory prostaglandins and produces analgesia (Fosslien, 1998). Evidence, 
therefore, suggests that the GI toxicity associated with NSAID use is primarily
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4.2.4 Investigation of the ability of indomethacin and indomethacin
analogues to inhibit the cycloxygenase enzymes, COX-1 and COX-
2.
the result of inhibition of COX-1 and anti-inflammatory effects are largely due to 
the inhibition of COX-2. An NSAID, which selectively inhibits COX-2, and has 
little effect on COX-1, would be ideal for the purpose of our work especially 
since COX-2 inhibitors may have anti-tumour activity (section 1.7). Therefore, 
the indomethacin analogues were analysed to investigate their COX-1 and COX- 
2 inhibitory abilities and to assess if one of the analogues of indomethacin, 
positive in the combination toxicity assay, might be capable of exerting its effect 
on the chemotherapeutic drug without causing the gastric damage customarily 
associated with NSAIDs, including indomethacin.
Indomethacin was used as the positive control in both the COX-1 and COX-2 
assays as its ability to inhibit both enzymes was known. BRI 215/1 and 205/4 
were also analysed in the COX assays to assess if  analogues of indomethacin, 
which were negative in the combination toxicity assay, would also be devoid of 
COX-inhibitory activity. Separate assays were utilised to analyse the inhibitory 
effect of the compounds on the enzymes. The COX-1 assay was a 
spectrophotometric assay based on the assays utilised by Boopathy et al., 
(1986), and Piazza et al., (1997). The assay used to measure the inhibition of 
COX-2 was an ELISA- based assay and the experiment was based on the fact 
that COX-2 is the constitutive and dominant isoform in stimulated and 
unstimulated cultured human lung epithelial cells (Asano et al., 1996). The cell 
line A549, a human lung adenocarcinoma, was shown to express COX-2 
mRNA and protein when it is stimulated with epidermal growth factor or pro- 
inflammatory cytokines such as IL-ip.
The compounds analysed in both the COX-1 and COX-2 assays were those 
compounds that were positive in the combination toxicity assay in DLKP cells. 
O f the agents analysed, the results indicate that only four of the compounds 
positive in the combination toxicity assay, including indomethacin were good 
inhibitors of both COX-1 and COX-2. The indomethacin analogues most 
effective at inhibiting COX-1 and COX-2 were BRI 88/1, 92/1 and 104/2. Of 
these compounds BRI 92/1, bromo-indomethacin, was most effective at 
inhibiting both enzymes and seemed to be slightly more effective than 
indomethacin. 12|j.g/ml (33nM) indomethacin inhibited COX-1 by 60.9 ± 
12.2% and at slightly lower molar concentrations BRI 92/1 at 30nM inhibited 
COX-1 by 79.0 ± 11.3%. Indomethacin at lOnM inhibited the activity of COX- 
2 by 86.1 ± 5.9%. BRI 92/1 at lOnM inhibited the activity of COX-2 by 88.1 ±
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4.4%. Indomethacin, BRI 88/1 and BRI 104/2 (N-benzoyl-indomethacin 
analogues) had similar COX-inhibiting ability. Perhaps the replacement of the 
chlorine substituent with bromine in N-benzoyl indomethacin increased the 
COX- inhibitory ability of the compound.
BRI 60/1, BRI 114/2, BRI 115/2, BRI 203/1 and BRI 215/1 (negative control 
compound) inhibited COX-1 by approximately 20-30% (Table 3.4.1.1), so 
were relatively weak COX-1 inhibitors as they were approximately 50% less 
effective than indomethacin at inhibiting COX-1. These compounds are all N- 
benzyl derivatives o f indomethacin and this indicates that the N-benzoyl unit in 
indomethacin is critical in COX-1 inhibition and removal of this unit renders 
the compound too dissimilar to indomethacin to be an effective COX-1 
inhibitor. Zoete et al., (1999), reported that electron-donating properties are 
essential in the action of NSAIDs as inhibitors of prostaglandin 
cyclooxygenase activity. Perhaps removal of the benzoyl group diminishes the 
electron-donor ability of indomethacin rendering it unable to inhibit COX-1.
Of interest here are the compounds BRI 153/1 and BRI 138/1. These 
compounds demonstrated extremely low ability to inhibit the activity of COX- 
1. BRI 153/1 and BRI 138/1 had no inhibitory activity against COX-1. This 
suggests that as well as the N-benzoyl unit being critical for COX-1 inhibition^ 
the presence of the halogen in the /?ara-position also seems to be critical for 
inhibition of COX-1. Both these compounds were positive in the combination 
toxicity assays, BRI 153/1 was very positive in the IOV assay but BRI 138/1 
was only weakly positive. These compounds would be of clinical interest as 
they seem to both have a good enhancement effect on the chemotherapeutic 
drugs in vitro and have very weak COX-1 inhibitory ability. These properties 
would make them attractive as active compounds, with adriamycin potentiation 
ability, without the characteristic adverse side effects of NSAIDs which result 
from inhibition of COX-1.
BRI 60/1 was the only indomethacin analogue which exhibited a weak COX-1 
inhibitory activity but a strong COX-2 inhibitory activity comparable to that of 
indomethacin (« 85% inhibition of COX-2). BRI 114/2 and BRI 115/2 
inhibited COX-2 by approximately 40% which is only 50% the COX-2 
inhibitory ability of indomethacin. BRI 153/1, BRI 138/1 and BRI 203/1 only 
inhibited COX-2 by approx. 20%. BRI 215/1 exhibited no COX-2 inhibitory 
activity. BRI 60/1 was the only benzyl analogue of indomethacin to exhibit
299
strong COX-2 inhibitory activity. The results seem to indicate that there is a 
relationship between the benzoyl/benzyl unit and the halogen attached to the 
benzene ring. In the benzoyl series, removal of the halogen (BRI 88/1) or 
replacing it with another halogen (BRI 92/1) did not seem to effect the 
compounds ability to inhibit COX-2 activity once the benzoyl unit was present. 
However, in the benzyl series, removing the chlorine from the benzene ring, 
changing its position from para-, or replacing it with another halogen, affected 
the ability of the compound to inhibit COX-2. The COX active site is a long 
hydrophobic channel (Vane et al., 1996) and it is possible that changing the 
structure of indomethacin, in particular altering the halogen substituent, might 
result in a number of analogues becoming less lipophilic and incapable of 
binding to the COX active site as effectively as indomethacin. Meade et al., 
(1993), reported that the active site of COX-2 is larger than that of COX-1 and 
can accept a wider range of structures as substrates. Perhaps this explains why 
removal of the benzyl group in BRI 60/1 did not diminish its COX-2 inhibitory 
activity. The structure was too dissimilar to indomethacin for significant COX- 
1 inhibition but due to the wider substrate specificity of the COX-2 active site, 
BRI 60/1 was able to bind to the active site of enzyme.
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Combination
Toxicity GST lOV COX-1 COX-2
Assay
Indomethacin +++ +++ +++ ++ +++
BRI 60/1 +++ - ++ + +++
BRI 59/1 
BRI 69/2 - - -
S H B H i
BRI 88/1 +++ ++ ++(+) ++ +++
BRI 92/1 +++ +++ +++ +++ +++
BR1104/2 +++ ++ ++ ++ +++
BR1106/1 
BR1107/1 - +/-
• -p .'""mm
fflwauwB r, ■' '■'! Ilf
BR1114/2 +++ - ++(+) + ++
BR1115/2 +++ +/- +++ + ++
BR1113/1 - +/- -
BRI 124/1 -
•-•lÉlSBR1119/1 - - -
BR1120/1 - - -
BR1153/1 +++ - +++ - +/-
BRI 203/1 +++ - ++ + +
BRI 205/4 - - - - ++
BRI 215/1 - - +/- +/- -
BRI 138/1 + + + - + - + / -
Table 4.2.4: Summary table of results from investigation of SAR of indomethacin 
+++ Very strong positive; ++ Strong positive; + positive; +/- poor positive;
- negative.
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In summary, investigations of the structure activity relationship of 
indomethacin have indicated that the N-benzoyl substituent on the 
indomethacin structure is crucial for GST and COX-1 inhibitory activity. This 
substituent does not seem to be as critical in N-benzyl-indomethacin analogues, 
for inhibition of COX-2. But, this is only so when the halogen group is present 
and in the /rara-position which suggests, in the absence of the N-benzoyl 
substituent, that the para-halogen bonds to a particular part of the active site of 
COX-2, locking the compound in to position. Analysis of the indomethacin 
analogues in the S AR assays has yielded a number of interesting indomethacin 
analogues. Of primary interest are those compounds which were found to be 
active in the combination toxicity assay. Six of these compounds, N-benzyl 
indomethacin analogues, BRI 60/1, 114/2 and 115/2, and N-benzoyl 
indomethacin analogues, BRI 88/1 92/1 and 104/2, demonstrated potentiating 
ability similar to indomethacin at similar concentrations but they also 
demonstrated reduced toxicity in the DLKP cells as compared to indomethacin. 
These indomethacin analogues were 2-fold (BRI 60/1, 88/1 and 92/1), and 4- 
fold (BRI 114/2 and BRI 115/2) less toxic than indomethacin in the DLKP 
cells. The required concentrations of the remaining active indomethacin 
analogues, BRI 138/1, 153/1 and 203/1, are higher than the required 
concentration of indomethacin, for enhancement of adriamycin toxicity. 
However, although they are less potent than indomethacin, these analogues are 
also less toxic to the DLKP cells than indomethacin. As a result, these 
indomethacin analogues may prove to be more clinically beneficial than 
indomethacin for enhancement of chemotherapeutic drug activity due to their 
reduced toxicity.
Of particular interest also, are those indomethacin analogues with reduced 
COX-1 inhibitory ability. The N-benzyl-indomethacin analogues demonstrated 
reduced ability to inhibit COX-1 as compared to the indomethacin and the N- 
benzoyl indomethacin analogues. This reduced COX-1 inhibition would be of 
great benefit, as the toxicity of the anticancer drugs could be enhanced by the 
active indomethacin analogues without the gastrointestinal toxic side effects 
associated with indomethacin. In particular, BRI 138/1 and 153/1, N-benzyl 
indomethacin analogues, were active in the combination toxicity assay, were 
less toxic than indomethacin and demonstrated no COX-1 and some COX-2 
inhibitory activity. BRI 60/1 also demonstrated very low COX-1 inhibitory
302
ability but, in contrast to BRI 138/1 and 153/1, this indomethacin analogue was 
also a very strong COX-2 inhibitor. The results for BRI 60/1 suggest a 
potential clinical application due to possible lower toxic side effects than 
indomethacin and in addition, increased ability as a tumour suppresser due to 
inhibition of COX-2.
Duffy et al., (1998), reported that indomethacin was unable to potentiate the 
toxicity of chemotherapeutic drugs in Pgp-overexpressing cell lines. Therefore, 
indomethacin and indomethacin analogues function as selective inhibitors of 
MRP-mediated efflux of the chemotherapeutic drugs from MRP- 
overexpressing cell lines and are effective at biologically relevant 
concentrations. There is enough evidence to suggest that these compounds 
interact with MRP1. The implications of using these compounds in cell lines 
which express MRP homologues other than MRP1 are discussed in section 
4.11 of this thesis.
The active indomethacin analogues are promising candidates for future clinical 
applications, in particular those with reduced toxicity and COX-1 inhibitory 
activity. Two of the active indomethacin analogues with reduced COX-1 
inhibitory activity, BRI 115/2 and 138/1, are completely novel (Dr. Anita 
Maguire, personal communication) and so may also be promising candidates 
for patent and commercial applications.
However, extensive biological analysis of these compounds in animal 
experiments, clinical trials etc. are required to fully elucidate the effectiveness 
of these compounds before they can be used in the treatment of human cancers.
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4.3.1 Investigation o f Adriamycin efflux
Drug efflux experiments were carried out to determine the accumulation of 
adriamycin in DLKP cells in the presence of indomethacin/indomethacin 
analogues and the accumulation of indomethacin in the cells in the presence of 
adriamycin.
The results of the adriamycin efflux studies (Table 3.5.1) showed a notable 
difference in the levels of cellular adriamycin content in DLKP cells incubated 
with lOfim (5.44(j,g/ml) adriamycin alone versus co-incubation of adriamycin 
and 28jj.m (10|a.g/ml) indomethacin. After the initial 2 hour loading period, 
there was similar accumulation of adriamycin in the cells treated with 
adriamycin alone and adriamycin + indomethacin. When the levels of 
indomethacin were maintained in the cells for a further five hours the level of 
adriamycin remained almost constant with only a slight decrease evident after 
this time. When indomethacin was removed from the medium after the initial 
loading period, the concentration of adriamycin in the cells greatly decreased. 
However, there was a decrease in the levels of adriamycin in those cells treated 
with adriamycin alone.
4.3.2 Effect of indomethacin analogues on adriamycin efflux
Similar results to indomethacin were obtained with BRI 138/1. BRI 138/1 was 
positive in the combination toxicity assay (section 3.1), in that it could 
potentiate the toxicity of adriamycin in DLKP cells. The efflux of adriamycin 
from the DLKP cells was also reduced in the presence of BRI 138/1, also at 
28|im, as compared to cells incubated with adriamycin alone. Removing BRI 
138/1 from the DLKP cells also resulted in a decrease in adriamycin 
accumulation. However, when this experiment was carried out using an 
analogue of indomethacin, BRI 205/4, which was negative in the combination 
toxicity assay (section 3.1), the efflux of adriamycin from the cells was similar 
to that observed in cells treated with adriamycin alone i.e. this negative
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4.3 Adriamycin and indomethacin accumulation studies using
drug efflux studies.
indomethacin analogue had no effect on adriamycin accumulation in the DLKP 
cells. The results suggest that the efflux of adriamycin from MRP-expressing 
cells can be significantly reduced by indomethacin and BRI 138/1 and as a 
result can lead to greater adriamycin toxicity to the cell. This supports results 
obtained in the combination toxicity assay (section 3.1) in which in the 
presence of indomethacin and BRI 138/1, the toxicity of adriamycin was 
potentiated in the DLKP cells. It appears that the active compounds have direct 
inhibitory potential against the activity of MRP. It is possible that 
indomethacin and indomethacin analogues exert their positive effect through 
inhibition of the pumping ability of MRP either by:
i. Binding to MRP and inhibiting the activity of the pump.
ii. Competing with an MRP substrate, such as LTC4 or chemotherapeutic 
drug, for a particular binding site on the MRP molecule, inhibiting the 
binding of the substrate.
iii. Competitively inhibiting the pumping of the substrate by MRP, causing
the MRP pump to preferentially transport active NSAIDs such as 
indomethacin (competitive substrate).
4.3.3 Investigation of Indomethacin efflux
An investigation was then carried out to assess the effect of adriamycin on the 
efflux of indomethacin from the DLKP cell.
The results indicate that after the initial loading period, the level of 
indomethacin in the cells was higher in those cells treated with a combination 
of indomethacin and adriamycin, than in those cells treated with indomethacin 
alone. After the cells were refed with fresh media alone, subsequent to loading 
with both adriamycin and indomethacin, the concentration of indomethacin in 
the cells decreased considerably. However, there was almost no efflux of 
indomethacin from the cells refed with adriamycin and incubated for a further 
90 minutes. The results indicate that in the presence of adriamycin the efflux 
of indomethacin from the DLKP cells is notably reduced. These experiments 
demonstrate that indomethacin as well as adriamycin is effluxed from the 
DLKP cells. This suggests that both compounds are competitive substrates for
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MRP1 and reduce the efflux of one another from the DLKP cells by competing 
for the same binding site on the MRP protein and competing for preferential 
pumping from the cell by MRP1.
An experiment was also carried out to investigate if co-incubation of 
indomethacin with adriamycin during the initial loading period was required 
for maintenance of the cellular indomethacin content. The cells were loaded 
for two hours with indomethacin and after this initial period the medium was 
removed from the flask and the cells were refed with adriamycin containing 
medium alone for 90 minutes incubation. The level of indomethacin in the 
cells was found to have decreased to similar levels observed in the cells treated 
with indomethacin alone, indicating that co-incubation of indomethacin with 
adriamycin is required for the maintenance of cellular indomethacin content.
Adriamycin also seems to have exerted an effect on the initial uptake of 
indomethacin by the DLKP cells. The results indicate that in the presence of 
adriamycin there was a greater uptake of indomethacin in the cell than when 
the cells were incubated with indomethacin alone (23.3ng/million cells and 
12.8 ng/million cells respectively). It is possible that indomethacin is such a 
good substrate for MRP due to its amphiphilic anionic properties and the 
presence of the carboxylic acid group which seems to be required for binding 
to MRP, that it is effluxed from the cell almost immediately, resulting in the 
low levels of indomethacin being present in the cells after the initial 'loading1 
period. In the presence of adriamycin, the efflux of indomethacin seems to be 
reduced, resulting in a greater net uptake of indomethacin in the cell after the 
initial 'loading' period.
The concentrations at which indomethacin and adriamycin are added to the 
DLKP cells must also be taken in to consideration. A concentration of 
27.95|iM indomethacin was added to the DLKP cells in comparison to 10f,iM 
adriamycin. Perhaps indomethacin is only capable of competing with MRP 
when present in the cell at such high concentrations. However, preliminary 
drug efflux experiments which were carried out to determine the length of time 
adriamycin or indomethacin were detectable in the DLKP cells demonstrated 
that five hours after the initial loading period, low levels of adriamycin was
306
i
still detected in the DLKP cells. In contrast, very low levels of indomethacin 
could only be detected up to 2 hours after the initial loading period.
These preliminary results thus indicate that indomethacin is pumped out of the 
cells at a much faster rate than adriamycin, suggesting that indomethacin 
/indomethacin analogues are pumped preferentially by MRP1 when combined 
with adriamycin, resulting in increased toxicity of the chemotherapeutic drug 
to the cells. As mentioned previously, this preferential binding is possibly due 
to the amphiphilic anionic properties of indomethacin in contrast to the more 
hydrophilic, cationic properties of adriamycin. Although MRP is reported to 
transport both of these compounds (section 1 .6) it seems to have a preference 
for amphiphilic anionic substrates with negatively charged substituents (e.g. 
the carboxylic acid substituent on indomethacin) (Seelig et al., 2000).
Thus, it appears that these active compounds compete with the 
chemotherapeutic drugs, which are MRP1 substrates, for a binding site on the 
MRP pump and are preferentially pumped out of the cell. As a result of this, 
while MRP is effluxing the active NSAIDs out of the cell, there is less efflux of 
the chemotherapeutic drug resulting in greater accumulation of the 
chemotherapeutic drug in the cell and greater cell kill.
Interesting future experiments could include similar drug efflux studies with 
DLKP cells using combinations of adriamycin and a number of the active and 
inactive indomethacin analogues. The concentrations of adriamycin and 
indomethacin/indomethacin analogues used in these efflux studies were chosen 
as initial experiments carried out in our laboratory indicated that these 
concentrations were the minimum concentrations required for detection by the 
HPLC apparatus (Dr. Robert O’ Connor, personal communication). It would be 
interesting to add both the compound and the drug to the cell at the same 
concentrations to analyse the effect.
These drug efflux studies have been carried out with adriamycin only, in 
combination with indomethacin and indomethacin analogues. Preliminary work 
has been carried out on a number of other chemotherapeutic drugs to validate 
protocols for measuring these drugs using HPLC analysis. To further elucidate 
the mechanisms by which the active NSAIDs potentiate the anticancer drugs a 
large number of drug efflux experiments are required using 
indomethacin/indomethacin analogues and other NSAIDs such as sulindac and
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piroxicam in combination with a range of anti-cancer drugs which were shown 
to be potentiated or unpotentiated in the combination toxicity assays. These 
experiments would determine if  the toxicity of the anticancer drugs were 
potentiated by the active NSAIDs by a reduction of efflux from the cells or if 
there are different mechanisms of toxicity enhancement by the active NSAIDs 
other than modulation of efflux. Efflux studies using other cell lines such as 
MRP+ and MRP- cell lines and cell lines which over-express Pgp, could also 
be carried out to compare the rate of efflux of indomethacin, indomethacin 
analogues and other active NSAIDs in these cell lines.
4.4 Investigation o f potentiation o f adriam ycin, vincristine, VP-16  
and 5-FU  by indom ethacin and indom ethacin analogues in the  
C O R L23 parental and resistant cell lines.
From the human lung cancer cell line CORL23, a resistant variant was 
developed by growth of the parental cells in increasing concentrations of 
doxorubicin over a period of eight weeks (Mirski et al., 1987 and Twentyman 
et al., 1994). This CORL23(R) subline does not overexpress Pgp but has high 
levels of a 190-kDa protein we now know to be MRP1. Borst et al., (1997), 
and Kool et al., (1997), characterised the CORL23 cell line and determined the 
levels of MRP present in the parental and resistant variants. Both variants do 
not express Pgp. The parental CORL23 cell line expresses only very low levels 
of MRP1 and MRP4, and a very low level of MRP5 was detected. After 
continuous selection of the cell line with adriamycin, the CORL23(R) cell line 
was found to highly overexpress MRP1. This overexpression of MRP1 in the 
resistant cell line resulted in a ten-fold increase in resistance to vincristine and 
adriamycin, and a 6-fold increase in resistance to VP-16. As the resistant 
variant does not express Pgp, even after continuous exposure to adriamycin, 
this resistance can be attributed to the over expression of MRP 1.
This characteristic of the CORL23 cell line was exploited to further analyse a 
number of the indomethacin analogues, combination toxicity assays were 
carried out on both the CORL23(P) and CORL23(R) to determine if  those 
compounds, which enhanced the toxicity of chemotherapeutic drugs in DLKP
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cells, were active in another MRP positive cell line (CORL23(R)). Experiments 
had previously been carried out on the CORL23(R) cell line, by Duffy el al., 
(1998), and it was found that the positive NSAIDs, including indomethacin, 
potentiated the toxicity of a range of chemotherapeutic drugs in this cell line. 
Therefore, indomethacin was used as the positive control NSAID in these 
combination toxicity assays. Duffy et al., (1998), also reported that 
5’fluorouracil displayed no synergy in combination with NSAIDs in the MRP1 
overexpressing cell lines so 5’fluorouracil was used as the negative control 
chemotherapeutic drug in these assays. BRI 205/4, an indomethacin analogue, 
negative in the combination toxicity assay in DLKP cells, was used as a 
negative control compound in these assays. The results show that BRI 205/4 
was also found to be unable to potentiate the toxicity of the anti-cancer drugs in 
the CORL23 cell lines. These results indicate that indomethacin and 
indomethacin analogues are potentiating the toxicity of the chemotherapeutic 
drugs using a mechanism similar to that observed in the DLKP cells.
A number of the active indomethacin analogues were found to potentiate the 
toxicity of MRP1 substrates, adriamycin, VP-16 and vincristine, in the MRP 
overexpressing cell line, CORL23(R). There was also a potentiation of the 
same drugs in the parental CORL23 cell line when combined with the active 
analogues. MRP1 is expressed in both the CORL23 variants (Borst et al.,\991 
and Kool et al.,\991), albeit very little expressed in the CORL23 parental cells. 
However, the fact that MRP1 is expressed at such a low level in DLKP cells 
(i.e. it was only visible on Western blots when a concentrated plasma 
membrane preparation was used (Duffy et al., 1998)), indicates that even the 
presence of a small amount of functional MRP1 may be sufficient to render 
cells less sensitive to chemotherapeutic drugs. The results obtained in the 
CORL23(R) and parental cell lines suggest that the level of expression of MRP 
does not appear to strictly correlate to the rate of the potentiation of the 
anticancer drug by the positive NSAIDs. Duffy et al., (1998), also 
demonstrated higher levels of MRP 1 protein expression in A549, a human lung 
adenocarcinoma cell line, than in the DLKP cell line. Yet the authors reported 
comparable synergistic combination of selected NSAIDs with certain 
chemotherapeutic drugs in both cell lines. Therefore, it seems that the 
enhancement of toxicity of the chemotherapeutic drugs by the active compound
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MRP is understood to not play an important role in 5-FU resistance (Nishiyama 
et al., 1999). Kirihara et al, (1999), also report that the mechanisms of 5-FU 
resistance appear to be different from drug resistance associated with the 
multidrug resistance phenotype related to Pgp and MRP. Indomethacin and the 
active analogues were unable to potentiate the toxicity of 5-FU in both the 
CORL23 parental and resistant cell lines. These results concur with the 
hypothesis that the mode of action of the active NSAIDs is through an 
interaction with MRP.
Kobayashi et al, (1997), reported that vincristine is a most effective 
chemotherapeutic drug in combination with indomethacin in two pulmonary 
adenocarcinoma cell lines. In our experiments the active indomethacin 
analogues did not demonstrate as strong an ability to potentiate the toxicity of 
adriamycin and VP-16, in the parental cell line as they did in the resistant 
variant. However, the magnitude of the enhancement of the toxicity of 
vincristine by indomethacin, BRI 88/1 and BRI 92/1 was almost equivalent in 
the parental CORL23 and in the resistant cells. Vincristine is an extremely 
good substrate for MRP and Loe et al, (1996), demonstrated the direct uptake 
of unmodified vincristine by MRP in an ATP and GSH-dependent manner, this 
unmodified uptake has not been demonstrated for adriamycin or VP-16. It may 
be possible, due to the fact vincristine is a better substrate for MRP than 
adriamycin and VP-16, that inhibition of even low levels of MRP results in a 
dramatic potentiation of the toxicity of vincristine, as it appears that low levels 
of MRP would be capable of effluxing vincristine very effectively.
Alternatively, the greater increase in vincristine toxicity, in both the CORL23 
sensitive and resistant cell lines, by indomethacin and indomethacin analogues, 
may simply be as a result of the lower concentrations of this chemotherapeutic 
drug in the cells. In the parental CORL23 cells the IC50 for vincristine was 
lng/ml (1.21fj.M). 20ng/ml (34.4|jM) of adriamycin was required to achieve 
the same level of cell kill in these cells. Similarly, in the resistant CORL23 
cells 50% cell kill was achieved using vincristine at 12ng/ml (14.52|iM) as 
compared to 250ng/ml (430p.M) for adriamycin. Therefore, this data indicates 
that indomethacin may potentiate the toxicity of vincristine better than
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is not dependent on the level of expression of MRP1 protein or perhaps a
plateau of MRP activity is reached at low protein level.
adriamycin and VP-16 due to the lower concentrations of vincristine with 
which it has to compete for a binding site on the MRP protein.
The mechanisms of action of the drugs used in this combination assay may also 
contribute to an explanation for the strong potentiation of the toxicity of 
vincristine in the parental CORL23 cell as opposed to a lower potentiation of 
adriamycin and VP-16. Both VP-16 and adriamycin interact with the DNA of 
the cell. The major actions of adriamycin include high affinity binding to DNA 
through intercalation, with consequent blockade of the synthesis of DNA and 
RNA, and DNA strand scission through effects on topoisomerase II. The mode 
of action of VP-16 (etoposide) involves inhibition of topoisomerase II which, 
results in DNA damage through strand breakage induced by the formation of a 
ternary complex of drug, DNA and enzyme. However, the mode of action of 
vincristine does not involve binding to DNA. Its mechanism of action involves 
depolymerisation of microtubules, which are an important part of the 
cytoskeleton and the mitotic spindle. The drug binds specifically to the 
microtubular protein tubulin in dimeric form; the drug-tubulin complex adds to 
the forming end of the microtubules to terminate assembly, and 
depolymerisation of the microtubules then occurs. This results in mitotic arrest 
at the metaphase, dissolution of the mitotic spindle, and interference with 
chromosome segregation (Pratt et al., 1994; Katzung, 1998). Hence, due to the 
fact that vincristine does not bind to DNA in the nucleus, it is possible that 
there is more vincristine freely available in the outer part of the cells, for 
effluxing from the cell by MRP. As a result any inhibition of the MRP pump 
may result in a large increase in the amount of vincristine within in the cell, 
resulting in a greater level of toxicity to the cells.
If the proposed working model for MRP, described in section 1.6.8.1a, which 
involves the presence of two co-operative binding sites, is correct, it may 
support an additional hypothesis for the superior enhancement of vincristine 
toxicity in the CORL23 cell lines. As vincristine transport is reported by Loe et 
al., (1996) to require co-transport with GSH, it is postulated that vincristine 
binds to the D-site while GSH binds to the G-site. Indomethacin is reported by 
Borst et al., (1999), to stimulate GSH transport in MDCKII-MRP2 cells. 
Therefore, it appears that indomethacin preferentially binds to the D-site of the 
MRP protein, reducing the amount of vincristine bound to this site, resulting in 
reduced efflux of this chemotherapeutic drug from the cell. Whereas, it is
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postulated that adriamycin and VP-16, chemotherapeutic drugs which do not 
appear to form glutathione conjugates or require co-transport with GSH (Tew 
et al., 1994 and Loe et al., 1996b), can bind to both the G- and the D-sites 
(Borst et al., 1999). Therefore, modification of the efflux of these 
chemotherapeutic drugs requires binding to both the G- and the D- site by 
indomethacin also. Or if indomethacin only binds to the D-site there still may 
be some transport of adriamycin and VP-16 attached to the G-site.
4.5 Investigation  o f potentiation o f  taxol and taxotere in  the  
C O R L 23 parental and resistant cell lines.
Taxanes are a new class of anti-mitotic anticancer drugs with a unique 
mechanism of action (Van Ark-Otte et al., 1998). Unlike vinca alkaloids, a 
group of antimicrotubule drugs which act mainly as spindle poisons and inhibit 
the polymerisation of tubulin, taxanes promote the polymerisation of tubulin 
(Jordan et al., 1993). Microtubules formed in the presence of taxanes are stable 
and non-functional, leading to cell death by disruption of the normal 
microtubule dynamics required for cell division and vital interphase processes 
(Van Ark-Otte et al., 1998). Taxol (paclitaxel), a compound derived from the 
bark of Taxus brevifolia, and taxotere (docetaxol), a semi-synthetic taxane 
extracted from the needles of Taxus baccata have both been shown to have 
significant activity in ovarian breast and non-small cell lung cancer (Rowinsky 
et al., 1995).
Previously, our group reported that the toxicity of taxol (paclitaxel) was not 
potentiated in A549 cells when in combination with the active NSAIDs (Duffy 
et al., 1998). However, when taxol was analysed in the CORL23 cells in 
combination with sulindac, indomethacin and BRI 153/1, the toxicity of the 
drug was increased in both the resistant and the sensitive variants. Taxol has 
been reported to be a substrate for Pgp (Germann, 1993). Cole et al., (1994), 
reported that when two different eukaryotic expression vectors containing 
MRP complementary DNA, were transfected into HeLa cells, the drug 
resistance patterns of the two MRP-transfected cell populations were similar 
and demonstrated a low (<3-fold) level of resistance to taxol. More recently
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there have been reports suggesting that these taxanes may be better MRP 
substrates than first believed (Vanhoefer et al, 1996 and 1997). Vanhoefer et 
al, (1996), demonstrated the ability of PAK-104P (see section 1.6.9) to 
completely reverse taxol resistance in HL60/ADR cells and concluded that this 
effect was due to an interaction with MRP1. PAK-104P was also shown to 
restore sensitivity to both taxol and taxotere (docetaxel) in MRP-expressing 
HT1080 (human sarcoma) tumour xenografts (Vanhoefer et al, 1997). The 
authors also reported that taxotere (docetaxol) at its Maximum Tolerated Dose 
(MTD) was more active against MRP-expressing tumour xenografts than taxol 
and that the observed resistance to taxol and taxotere appears to be related to 
MRP.
Combination toxicity assays were carried out in the CORL23 cells with 
taxotere in combination with sulindac. The results also demonstrated 
potentiation of taxotere by sulindac in both the resistant and parental CORL23 
cell lines. Slightly greater potentiation of this chemotherapeutic drug was 
observed in the resistant cell line than in the parental CORL23 cells which is 
most likely due to the higher expression of MRP1 in the resistant CORL23 
cells. However, there was no significant difference between the potentiation of 
taxol by indomethacin, sulindac and BRI 153/1 in the resistant and the 
sensitive CORL23 cell lines.
Indomethacin and sulindac were unable to potentiate the toxicity of a range of 
chemotherapeutic drugs in Pgp over-expressing cell lines, such as DLKPA 
(Duffy et al, 1998). Kool et al, (1997), did not detect mRNA expression for 
Pgp, MRP2, MRP3 in the CORL23 parental or resistant cells and there was 
only a very low expression of MRP4 and MRP5. Therefore, it appears that the 
enhancement of taxol and taxotere by indomethacin and the other active 
NSAIDs is MRP 1-related.
These results were extremely interesting as it was the first time the potentiation 
of taxol and taxotere by the active NSAIDs, indomethacin and sulindac (at 
non-toxic concentrations), had been demonstrated. Soriano et al, (December
1999) reported the ability of sulindac sulfone (exsulind), a metabolite of 
sulindac which does not inhibit COX enzymes, to potentiate the toxicity of 
taxotere, VP-16 and cisplatin in a number of non-small cell lung cancer cell 
lines. However, the concentrations of sulindac sulfone used by the authors to 
obtain potentiation of cisplatin and taxotere toxicities were quite toxic
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Van Ark-Otte et al, (1998), reported that taxol and taxotere achieved greater 
cell kill in a non-small cell lung cancer (NSCLC) cell line, SW-1573, a human 
breast cancer cell line, MCF-7, and an adenosquamous NSCLC cell line NCI- 
H322, than adriamycin and cisplatin at similar concentrations. Au et al, 
(1998), have reported that taxol is one of the most important anticancer drugs 
developed in the past two decades as it has shown impressive activity against 
human solid tumours i.e. ovarian, head and neck, bladder, breast and lung 
cancers. Taxotere had been reported by a number of authors including 
Vanhoefer et al., (1997), and Van Ark-Otte et al, (1998), to be even more 
potent than taxol. Therefore, the taxanes appear to be the more promising 
choice of treatment for a wide range of cancer types. The implications of 
potentiating the toxicity of taxol and taxotere are very exciting for the future 
treatment of cancer.
However, to assess that the potentiation of taxol and taxotere was not specific 
to the CORL23 cell lines, the ability of indomethacin and sulindac to potentiate 
the toxicity of taxol and taxotere was assessed in a range of cancer cell lines as 
described in sections 4.6 and 4.7.
concentrations (100-400|j.M) as compared to concentrations of sulindac (<
25|j.M) used in this thesis.
4.6 Investigation  o f chem otherapeutic drug enhancem ent by 
sulindac and indom ethacin in D L K P, A 549 and M C F-7 cell 
lines.
Duffy et al., (1998) and Elliot (1997), both in our laboratories, had reported 
that the active NSAIDs were not able to potentiate the toxicity of taxol in A549 
cells. However, results from sections 3.6 and 3.8 demonstrated the ability of 
indomethacin, indomethacin analogue BRI 138/1 and sulindac to potentiate the 
toxicity of both taxol and taxotere in the CORL23 and the 2008 cell lines. 
A549 overexpresses MRP1 and combination assays carried out by Duffy et al, 
(1998), and Elliot (1997), in A549 cells, using other MRP1 substrate, 
chemotherapeutic drugs, in combination with the active NSAIDs, demonstrated 
potentiation of these drugs by the NSAIDs. To investigate the non-potentiation
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of taxol by NSAIDs in the A549 cells a range of cancer cell lines were 
investigated to determine if perhaps the effect with taxol and taxotere was cell 
line specific.
The cell lines investigated included the poorly differentiated human lung 
cancer cell line, DLKP, a breast cancer cell line, MCF7, and two A549 cell 
lines. One of the A549 cell lines was obtained from the culture collection in the 
NCTCC (originally from the ATCC) and the other was obtained from an 
external source to investigate if  different drug resistance profiles were observed 
in the same cell line from different sources. Initial toxicity assays were carried 
out on the cell lines and the IC50 values obtained for adriamycin, taxol and 
taxotere were identical for both the A549 cell lines.
Combination toxicity assays were carried out on the four cell lines with 
adriamycin, taxol or taxotere in combination with indomethacin, and taxol or 
taxotere in combination with sulindac. The results demonstrated that 
indomethacin was able to potentiate adriamycin in all four cell lines with the 
greatest potentiation observed in the DLKP cells. MRP1 mRNA expression 
was demonstrated in all four cell lines (Duffy et al., (1998); Lorraine 
O’Driscoll, personal communication, and section 3.16) and this expression 
correlated with MRP1 protein expression in these cell lines (Dr. Lisa Connolly, 
personal communication). Therefore, these results, and evidence presented in 
previous sections of this thesis, strongly support the hypothesis that the 
potentiation of adriamycin by indomethacin in these cell lines was as a result of 
an interaction with MRP1.
There was poorer potentiation of taxol and taxotere by indomethacin in the four 
cell lines as compared to the magnitude of the potentiation of adriamycin by 
indomethacin in the same cell lines. Low, but significant enhancement of taxol 
and taxotere toxicity by indomethacin was observed in the DLKP cells. Low 
enhancement of taxotere, but not of taxol toxicity was observed in the MCF7 
cell line. There was no potentiation of taxol or taxotere toxicity by 
indomethacin in either of the A549 cell lines.
In contrast there was very strong potentiation of taxol and taxotere by sulindac 
in the DLKP cell line. There was lower but significant potentiation of these two 
chemotherapeutic drugs by sulindac in the MCF7 cell line. These results 
indicate that in these cell lines sulindac was a better potentiator of taxol and
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taxotere toxicity than indomethacin. This increased potentiation by sulindac 
was also observed in the CORL23(R) cell line (section 3.6) and in the 2008 cell 
lines (section 3.10).
However, there was no potentiation of taxol or taxotere by sulindac in either 
the A549 cell lines. This supports findings by Duffy et al., (1998) and Elliot 
(1997). Therefore, it appears that the potentiation of taxol and taxotere by the 
active NSAIDs, including indomethacin and sulindac, is cell line specific. All 
cell lines had previously been shown to express MRP1. RT-PCR analysis also 
demonstrated higher levels of MRP2, MRP3, MRP4 and MRP6 in the A549 
cells as compared to the DLKP cell line (section 3.16). A549 (NCTCC) cells 
have been shown by RT-PCR (section 3.16) to express very high levels of 
MRP4 mRNA as compared to MRP4 levels expressed in DLKP cells (11-fold 
higher expression) and the 2008 cell lines (at least 4-fold higher expression). 
Expression of MRP4 protein levels in this cell line has not been determined, as 
there was no commercially available MRP4 antibody.
MRP4 has been reported to be directly linked to the efflux of nucleoside 
monophosphate analogs from mammalian cells (Schuetz et al, 1999) (see 
section 1.6.9.4). It is hypothesized that taxol and taxotere may act as GTP 
mimics due to the following facts:
i. Taxol stabilizes microtubules, and microtubule function is GTP- 
dependent (Caudron et al, 2000; Phelps et al., 2000 and Martin et al.,
2000). It is possible that taxol competes with GTP at a specific binding 
site.
ii. Taxol and taxotere have been shown to alter the phosphorylation status of 
proteins in the apoptotic pathway (e.g. bcl-2) (Wang et al, 2000 and 
Kalechman et a l, 2000) suggesting that the taxanes may interfere in the 
phosphorylation mechanisms (mainly involving ATP and GTP) in cells.
Therefore, it is possible that taxol/taxotere are ‘seen’ by the MRP binding site 
as nucleoside analogues, transported by MRP4. Perhaps when the NSAIDs are 
combined with taxol and taxotere in the A549 cells the ability of MRP1 to 
pump taxol and taxotere is reduced but this is overcome by the activity of 
MRP4. In addition, the active NSAIDs may not be effective inhibitors of 
MRP4 activity. However, it has not yet been determined if indomethacin is a
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substrate for MRP4. The complete range of substrates for MRP4 has yet to be 
elucidated (section 1.6.9.4).
Interestingly, Theodossiou et al, (1998), reported that a nucleoside-based drug, 
gemcitabine, when combined with taxol, could antagonise the effect of the 
chemotherapeutic drug. The authors reported that taxol imposed a G2/M block, 
while gemcitabine blocks entry into S-phase. Cells that were delayed during S- 
phase by gemcitabine could not proceed through the cell cycle and, therefore, 
the cytotoxic effects of taxol, which required entry into mitosis, were 
diminished. If taxol is ‘seen’ by MRP4 as a nucleoside analogue, it might be 
expected that both gemcitabine and taxol would be transported by MRP4, and 
would therefore, act as competitive substrates for this transport pump, resulting 
in synergism between both agents. However, antagonism of taxol cytotoxicity 
was observed when combined with gemcitabine. It is possible that gemcitabine 
and taxol compete for some, as yet uncharacterised, uptake mechanism.
Further investigations in to the range of substrates for MRP4 and the 
mechanism of transport is required to fully understand the contribution (if any) 
by MRP4 to taxol and taxotere resistance. Interestingly, there are higher levels 
of MRP5 mRNA expressed in the DLKP cells and the 2008 parental and 
MRP 1-transfected cell lines than in the A549 cell line (section 3.16). The best 
potentiation of taxol and taxotere by sulindac were observed in these cell lines 
(section 3.8 and 3.10). Again, the substrates for MRP5 have yet to be 
determined (section 1.6.9.5) but it is possible that there may be a connection 
between this expression of MRP5 and taxol/taxotere potentiation.
Soriano et al, (1999), reported the ability of sulindac sulfone to enhance the 
toxicity of taxotere in A549 cells. However, as stated previously in section 4.5, 
the concentrations of sulindac sulfone which were used to potentiate the 
toxicity of taxotere (100foM-400n.M) were greater than the highest non-toxic 
concentrations of sulindac used in the combination toxicity assays outlined in 
this thesis (< 23|iM).
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4.7 Investigation  o f  chem otherapeutic drug enhancem ent in 2008, 
an ovarian carcinom a cell line, transfected  w ith M R P1, -2 and  
-3.
There is much evidence to support the hypothesis that indomethacin, positive 
indomethacin analogues and other positive NSAIDs, such as sulindac, enhance 
the toxicity of a number of chemotherapeutic drugs through an interaction with 
MRP1. It is not known, however, if  these NSAIDs are capable of this 
potentiation in cell lines expressing MRP2 - 6.
The results from the experiments described in sections 4.5 and 4.6 demonstrate 
an enhancement of toxicity of taxol and taxotere in a number of MRP1- 
expressing cell lines. However, in A549 cells, where MRP1 was also expressed 
sulindac and indomethacin were unable to potentiate the toxicity of taxol and 
taxotere, even though there was strong potentiation of adriamycin by 
indomethacin in the A549 cell line. As RT-PCR analysis demonstrated that 
there was a very high expression of MRP4 in the A549 cells (section 3.16) it 
was postulated that perhaps the expression of other homologues of MRP might 
modify in some way the potentiation of the chemotherapeutic drug by the 
NSAIDs. These findings raised the question as to whether or not the 
potentiation of taxol and taxotere was due to an interaction with MRP1 only or 
if it was possible to potentiate the toxicity of these drugs in cell lines 
expressing homologues of MRP other than MRP1.
4.7.1 MRP homologues and chemotherapeutic drug resistance
To determine if  indomethacin, sulindac and indomethacin analogues could 
potentiate the toxicity of a range of anticancer drugs in cell lines which 
overexpressed MRP2 or MRP3, an ovarian carcinoma cell line, transfected 
with cDNA for MRP1, MRP2 or MRP3 and kindly donated to us by Dr. 
Marcel Kool from the Netherlands Cancer Institute, Amsterdam, was used.
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ong-term Adr. MTX Taxol Taxotere Cisplatin
2008 P 1.0 1.0 1.0 1.0 1.0
008 MRP1 5.6 1.0 0.4 1.0 0.3
008 MRP2 0.5 1.0 0.4 1.0 0.1
008 MRP3 0.9 1.0 0.4 1.0 0.2
Table 4.7.1a: Fold resistance values for chemotherapeutic drug in 2008 
transfected cell lines relative to the parental 2008 cell line in the Long-term 
toxicity assay (section 2.7.1a).
Short-term Adr. M TX Taxol T axotere
2008 P 1.0 1.0 1.0 1.0
2008 MRP1 3.0 86.8 2.0 0.1
2008 MRP2 1.6 30.1 1.0 1.0
2008 MRP3 3.0 85.4 2.0 0.5
Table 4.7.1b: Fold resistance values for chemotherapeutic drug in 2008 
transfected cell lines relative to the parental 2008 cell line in the Short-term 
toxicity assay (section 2.7.1b).
Toxicity assays and combination toxicity assays were carried out on the cells 
using a range of both NSAIDs and chemotherapeutic drugs. Initial long-term 
toxicity assays (6-day exposure to drug) on these cell lines using methotrexate 
(MTX) failed to demonstrate any difference in resistance levels between the 
parental and the MRP transfected cells. However, short-term MTX toxicity 
assays (4-hour exposure to drug) on the 2008 cells showed 2008 MRP1 and 
2008 MRP3 to be almost 100-fold more resistant to MTX than the parental cell 
line. 2008 MRP2 cells were 30-fold more resistant to MTX than the parental 
cell line. Kool et ah, (1999), and Hooijberg et ah, (1999), reported that the 
transfected 2008 MRP1, 2008 MRP2 and 2008 MRP3 cells showed a marked 
level of resistance to the polyglutamatable antifolate, methotrexate. These 
results were obtained by analysing the cells using a short-term toxicity assay as 
described in section 2.7.1b, in which the cells are exposed to the anti-cancer 
drug for 4-hours only, as opposed to a 6-day exposure in the long-term toxicity
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assay (2.7.1a). The authors suggest that the difference in toxicity of MTX 
between the two assays was due to the fact that MTX is polyglutamylated after 
entering the cell. The polyglutamylated form is an effective inhibitor of 
dihydrofolate reductase. Polyglutamylation of MTX is slow and after short­
term exposures to MTX, cells with a good MTX efflux pump can pump out the 
monoglutamate MTX. These cells will accumulate much less long-chain 
polyglutamates of MTX. In continuous exposures to MTX, a good efflux pump 
for MTX makes no difference, because these cells will eventually accumulate 
enough polyglutamylated MTX to block the dihydrofolate reductase 
efficiently, resulting in cell death.
As a result of these findings, both long-term and short-term toxicity assays 
were carried out with a number of chemotherapeutic drugs in the 2008 parental 
(2008 P) and transfected cells. These cells showed greater resistance to 
adriamycin, methotrexate, taxol and taxotere in short-term assays versus long­
term assays (table 4.11.2).
Resistance to adriamycin was greatest in the 2008 MRP1 cell line in the long­
term assay but in the short-term assay both 2008 MRP1 and MRP3 were 
equally resistant to adriamycin. MRP1 has been associated with adriamycin 
resistance (Cole et al., 1992; Cole et al., 1994; Zaman et al., 1993; Loe et al., 
1996a). Protein analysis of the 2008 cell lines indicated that although there was 
basal expression of MRP1 in all the 2008 cell lines (Dr. Lisa Connolly, 
personal communication) there was a much higher level of MRP1 protein 
expression evident in the 2008 MRP1 cell line which accounts for the higher 
resistance to adriamycin in this cell line over the other 2008 cells in the long­
term assay. Perhaps, the equal resistance to adriamycin in the short-term assay 
is due to the expression of MRP1 in both 2008 MRP1 and 2008 MRP3 cells 
which, although the expression is higher in 2008 MRP1 cells, functions at a 
similar level in both 2008 MRP1 and MRP3 cells in short-term exposure 
assays. However, the results may also indicate that MRP3 is involved in 
adriamycin resistance and MRP3 involvement in drug resistance has also been 
suggested by Young et al., (1999).
2008 MRP2 is less resistant to adriamycin than the parental 2008 cells in the 
long-term assays. RT-PCR analysis of these cells has indicated a decrease in 
MRP3 and MRP5 mRNA expression in these cells as compared to the parental 
cell line. The substrate specificities for these transporters remain uncertain but
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it is possible that MRP3 and MRP5 contribute to adriamycin resistance in the
2008 cell lines.
Adr. M TX Taxol Taxotere
2008 P 4.0 2.1 137.0 51.6
2008 MRP1 2.1 188.1 670.3 3.92
2008 MRP2 13.0 61.3 329.3 52.4
2008 MRP3 13.0 174.1 642.6 24.4
Table 4.7.2: Fold resistance values for chemotherapeutic drug in 2008 parental 
and transfected cell lines in the Short-term toxicity assay relative to resistance 
of these chemotherapeutic drugs in the parental and transfected 2008 cell lines 
in the Long-term toxicity assay (section 2.7.1a).
There was only a 4-fold increase in resistance to taxotere in the 2008 MRP1 
cells in the short term assay relative to the long-term assay and these cells were 
at least 6-fold less resistant to taxotere than the other 2008 cell lines. In 
contrast there was highest resistance to adriamycin, taxol and methotrexate in 
the 2008 MRP1 cells. Vanhoefer et al, (1997), demonstrated that both taxol 
and taxotere were substrates for MRP1 (section 4.6) in MRP 1-expressing 
HT1080/DR4 cells. The authors also reported that taxotere was not as readily 
transported by MRP1 as taxol leading to an increased therapeutic ratio in 
MRP 1-expressing tumours in vivo. They suggested that taxotere may have 
therapeutic advantages in the clinical treatment of MRP-expressing tumours. 
Therefore, the lower resistance to taxotere in the 2008 MRP1 cells may be due 
to the fact that taxotere is a poorer MRP1 substrate than taxol.
4.7.2 Problems associated with determining resistance profiles of 
transfected cell lines
Kool et al., (1999) and Borst et al., (1999), have reported a number of
problems observed when studying cells transfected with MRP. The authors
reported that it has been difficult to get MRP transfectants giving high
expression and product routed to the cell membrane. Transfected cells produce
a transporter that is trapped in an endosomal compartment and does not reach
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the plasma membrane (Borst et al, 1999). The problem was illustrated by data 
for MRP2. Some cell lines transfected with a retroviral MRP2 construct did not 
express the protein at all, or in a patchy fashion with only 10% of the cells 
positive. This 10% was maintained after cloning and was thought to reflect a 
deleterious effect of the transporter on cell viability Some of the initial 
transfection constructs produced low levels of transporter (Borst et al, 1999). 
Evers et al, (1998), reported that intra-cellular routing of MRP2 is also 
sensitive to growth conditions and in kidney cells or hepatocytes, MRP2 only 
goes to the plasma membrane if  cells are in contact with one another.
In the case of 2008 MRP3, Kool et al., (1999), reported that they were not 
successful in isolating non-polarized cells with high MRP3 levels. As a result it 
was difficult for the author to fully determine the range of compounds 
transported by MRP3. The transfection of 2008 cells with MRP1 cDNA was 
the most successful of the three transfectants (Kool et al., 1999 and Marcel 
Kool, personal communication). It is possible that the large increase in 
resistance to adriamycin, methotrexate, taxol and taxotere in the 2008 MRP2 
and MRP3 cells is due to the fact that even though there may not be high 
expression of MRP2 and MRP3 in the 2008 transfected cells, there is sufficient 
protein expressed, to effectively pump the anticancer drugs from the cell in the 
short exposure time (4hrs), in the short-term toxicity assay. Whereas in the 
long-term assays the low levels of MRP2 or MRP3 in the cells are insufficient 
to effectively efflux the chemotherapeutic drug from the cells over a long 
period of time.
In addition, most cells contain endogenous, organic anion transporters, 
resulting in background transport activity. As the endogenous transporters are 
often uncharacterised and, hence, undetectable by antibody it is difficult to find 
a solution to this problem (Borst et al, 1999). The 2008 parental cells express 
basal levels of MRP 1 protein and significant levels of MRP 1 mRNA. Although 
it is possible that the drug resistance observed in the 2008 cells may be as a 
result of the transfected MRP2 or MRP3, due to the basal levels of MRP 1 in 
the parental cells, attempts to relate the resistance profile of such cells to a 
single transporter is risky.
Borst et al, (1999), also report that cells transfected with MRP1, MRP2 or 
MRP5 cDNAs secrete GSH in to the medium, suggesting that they must be
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producing GSH at a high rate to counteract this drain. This suggests that, if the 
mechanism by which the MRP substrates are transported is through 
conjugation or in conjunction with GSH, there may not be sufficient GSH 
present in the cells to support transport of MRP substrates from the cells. 
Therefore, it may be difficult to assess the complete range of substrates for 
cells transfected with MRP1 or MRP2. Cells with high levels of MRP3 do not 
secrete GSH (Kool et al., 1999) which may limit the ability of MRP3 to 
transport non-anionic organic molecules.
4.7.3 Investigation of the potentiation of adriamycin and methotrexate 
toxicity in the 2008 cell lines.
In the combination toxicity assays, indomethacin was shown to potentiate the 
toxicity of adriamycin in all 2008 cell lines and in particular in 2008 MRP1, in 
the long-term assay. This potentiation was not so notable in the short-term 
assay with the best potentiation also observed in 2008 MRP1 cell line. Results 
obtained from HPLC experiments on DLKP cells (section 2.5) indicated that 
when indomethacin and adriamycin were removed from the medium after a 
two-hour loading period, indomethacin was effluxed from the MRP expressing 
cells very rapidly (< 2 hours). This was followed by a rapid efflux of 
adriamycin from the cells. However, when the level of indomethacin was 
maintained in the medium there was much reduced efflux of adriamycin from 
the cells. Hence, it appears that maintaining indomethacin in the cells and in 
the medium surrounding the cells was required for the enhancement of the 
toxicity of the anti-cancer drug. In the long-term combination toxicity assays 
the concentration of indomethacin in the medium and cells remained constant 
throughout the total incubation period (6 days). In the short-term combination 
toxicity assays, indomethacin was removed from the medium after four hours. 
It is possible that as there was no indomethacin in the medium to maintain the 
required levels o f indomcthacin in the cell there was an increased efflux of 
adriamycin from the cells. The positive indomethacin analogue, BRI 138/1 
was also shown to potentiate adriamycin in the 2008 cells, in the long-term 
assay at a similar rate to indomethacin, with greatest potentiation in the 2008
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Both Kool et al., (1999), and Hooijberg et al, (1999), reported that MRP1, 
MRP2 and MRP3-overexpression is associated with resistance to short-term 
exposure of polyglutamatable antifolate drugs such as MTX. Due to the 
pharmacological characteristics of methotrexate, as discussed previously, it 
was not surprising to observe very little enhancement of MTX toxicity by 
indomethacin in the 2008 cells in the long-term assays. However, there was 
potentiation of methotrexate by indomethacin in the MRP 1-transfected cell 
line. Perhaps this indicates that indomethacin is a better substrate for MRP1, 
and to a lesser extent MRP3, than MRP2 in long-term assays. In the short-term 
assays the potentiation of methotrexate was greatest in the parental 2008 cell 
line. This may be due to the fact that the IC50 of methotrexate in the parental 
cell line was only 10|a.g/ml compared to 900|j,g/ml for both 2008 MRP1 and 
MRP3 and 300(j.g/ml for 2008 MRP2. Work outlined earlier indicates that 
indomethacin enhances the toxicity of MRP substrates by acting as a 
competitive substrate for MRP, i.e. indomethacin and other such NSAIDs 
compete with the anticancer drug for preferential pumping from the cell by the 
MRP pump. In our previous combination toxicity experiments indomethacin 
was always used at much higher concentrations in the cells than the anti-cancer 
drugs (fig quantities versus ng quantities). Perhaps the potentiation effect is 
greater in the parental cell line in the short-term assay due to the lower 
concentrations of methotrexate used in these cells and the concentrations of 
indomethacin present in the parental cell line were sufficient to compete with 
methotrexate for MRP-efflux from the cell. There was very little potentiation 
of the toxicity of methotrexate in the 2008 MRP3 and no potentiation in the 
2008 MRP2 cells (Table 3.7.2b). In the transfected cell lines the concentration 
of methotrexate used in the cells was 100-fold greater than the concentration of 
indomethacin in the cells. This indicates that indomethacin was not capable of 
competing successfully for preferential pumping by MRP and as a result 
methotrexate was pumped out of the cells at a greater rate. In addition, as 
mentioned previously, a four-hour exposure of the cells to indomethacin may 
not be sufficient to sufficiently reduce the efflux of methotrexate from the 
cells. The results for 2008 MRP1, MRP2 and MRP3 cells may also suggest that
324
MRP1 cells. These results indicate that this indomethacin analogue functions
similarly to indomethacin.
indomethacin is a better substrate for MRP1 than MRP2 and MRP3 and hence 
is better capable to preferentially pump indomethacin before methotrexate.
A number of authors, including Hooijberg et al., (1999), and Bakos et al., 
(2000), have reported that methotrexate is a particularly good substrate for 
MRP2. However, Bakos et al, (2000), reported that low concentrations of 
indomethacin (< lOOpM) enhanced the efflux of N-ethylmaleimide glutathione 
(NEM-GS), an MRP1 and MRP2 substrate, in S/9 cells transfected with a 
recombinant baculoviruse containing MRP2 cDNA. Indomethacin was unable 
to potentiate the toxicity of methotrexate in the 2008 MRP2-transfected cell 
line. Therefore, as a result of the above findings by Bakos et al., (2000), it is 
possible that indomethacin was interacting with MRP2 to increase the efflux of 
methotrexate from the 2008 MRP2 cell line. These results suggest that, in the 
case of methotrexate, there are differences in transport properties for this drug 
in each of the 2008 cell lines which may indicate that the expression of MRP 1 
does not account for all of the potentiation effects observed in the 2008 cell 
lines.
Results from the combination toxicity assays in the 2008 cell lines using 
adriamycin or methotrexate in combination with sulindac, yielded similar 
results to those obtained when these anti-cancer drugs were used in 
combination with indomethacin. The best potentiation of both 
chemotherapeutic drugs was observed in the 2008 MRP1 transfected cells. 
However, there was also a small but significant potentiation of methotrexate by 
sulindac in the 2008 MRP2 cell line which indicates that sulindac does not 
behave similarly to indomethacin in this particular cell line. It appears that 
sulindac does not function to enhance the efflux of methotrexate in cells lines 
overexpressing MRP2 and that this effect is specific to indomethacin. It was 
also observed that sulindac, like indomethacin, required a longer incubation 
period in the cells than the 4hrs incubation period of the short-term assay, for 
optimum potentiation of the chemotherapeutic drugs. The results also suggest 
that MRP2 and MRP3 are poorer transporters of sulindac than MRP1.
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4.7.4 Investigation of potentiation of taxol and taxotere in the 2008 cell 
lines.
The com bination  tox ic ity  assay resu lts for taxol and taxotere in  com bination  
w ith  sulindac ind icated  that long-term  exposure to  sulindac resu lted  in  better 
po ten tia tion  o f  these  chem otherapeutic  drugs by  th is N SA ID . The strongest 
com bination  effec t w as, as before, observed  in  the M R P 1-transfected  cells. 
H ow ever, the  resu lts  obtained w ith  taxo l w ere  surprising as sulindac w as able 
to  po ten tia te  the  tox ic ity  o f  taxo l to  a  greater extent than  the o ther three 
chem otherapeutic  drugs analysed. In  addition, w hen taxotere w as com bined 
w ith  the N S A ID  piroxicam , in  the  2008 cells, no po ten tia tion  o f  this 
chem otherapeutic  drug  w as observed. D uffy  et al, (1998), had  found  that 
p iroxicam  w as n o t effective in  po ten tia ting  the tox icity  o f  chem otherapeutic  
drugs in  any o f  the cell lines analysed. T he authors postulated  th a t th is N SA ID  
w as n o t a  substra te  for M R P. H ow ever, w hen  p irox icam  w as used  in  
com bination  w ith  taxo l there w as a  statistically  significant po ten tia tion  o f  the 
an ti-cancer drug  in  the  2008 cell line. T hese results suggest the p resence o f  an 
additional m echan ism  o f  enhancem ent o f  taxo l tox icity  or th a t taxol/taxotere 
use  a  d ifferen t o r m odified  active site on  M R P. M oos et al, (1999), indicated  
th a t taxol (but n o t taxotere) increased  C O X -2 (but not CO X -1) p ro te in  and 
m R N A  expression  in  R A W  264.7  m urine m acrophages. T he authors also report 
tha t taxo l also induced  CO X -2 in  hum an  and m urine m onocytes v ia  a p38 
m itogen-associa ted  p ro te in  k inase pathw ay. Taxotere w as reported  to  induce 
C O X -2 p ro te in  expression  in  hum an  m onocytes only. A  num ber o f  studies 
have reported  th a t truncation  m utations o f  the  A P C  gene occur som atically  in  a 
large percen tage o f  colorectal cancers (Sheng et al., 1998; O shim a et al,
1996). T his m u ta tion  in  the A PC  gene has been  associated  w ith  increased 
levels o f  C O X -2 and  a decrease in  apoptosis in  a  num ber o f  cancer cell lines 
(section  1.7.9) (Sheng  et al, 1998; K argm an et al, 1995; K utchera et al, 1996 
and W atson  et al, 1997). Indom ethacin , sulindac and p iroxicam  are recognised 
as be ing  non-se lective  N SA ID s, inhibiting  bo th  COX-1 and CO X -2 (R iendeau 
et al, 1997 and  H inz  et al, 1999). It is suggested  that the inh ib ition  o f  CO X -2 
by  the  active N S A ID s, in  addition  to an  in teraction  w ith  M R P, m ay  explain  the 
increased  enhancem ent o f  taxo l tox ic ity  in  the 2008 cell lines. P iroxicam  has 
no M R P inh ib ito ry  ability so the  slight potentiation o f  taxol tox icity  by
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p irox icam  m ay  be  due to inh ib ition  o f  C O X -2, resu lting  in  an  increase in  
apoptosis in  the 2008 cell lines. The possib ility  that th is effect is cell line 
specific cannot be ru led  out as the com bination  o f  taxol/taxotere and p iroxicam  
w as on ly  analysed  in  the 2008 cell lines. It is necessary  to  carry  out th is 
com bination  in  a  num ber o f  d ifferen t cell lines to  assess i f  th is po ten tia tion  o f  
taxol tox icity  by p iroxicam  can be dem onstrated. In addition, com bination  
tox ic ity  assays using  CO X -2 specific inhibitors in  com bination  w ith  taxol and 
taxotere  w ould  a lso  be  interesting. A  recent publication  by H i da  et a l, (2000), 
reported  the ab ility  o f  a  CO X -2 inhibitor, n im esulide, to enhance the  tox icity  o f  
taxotere  in  four N S C L C  cell lines. The po ten tia tion  o f  taxo l tox icity  w as no t 
assessed. A lthough  the  results in th is thesis only dem onstrated  the  poten tia tion  
o f  taxo l by  p irox icam , th is resu lt w as observed in  one cell line only so i t  is 
possib le  th a t assessm en t o f  a range o f  cell lines m ay show  po ten tia tion  o f  bo th  
taxol and taxo tere  toxicities by  CO X -2 inhibitors. The resu lts serve to 
dem onstrate  the  p resence  o f  a  com plex m echan ism  by  w hich  taxol and taxotere 
m ay be po ten tia ted  by  N SA ID s.
4.8 Investigation o f the effect on cisplatin toxicity of indomethacin
and possible correlation between M RP2 (cM OAT) expression 
and cisplatin resistance.
A  num ber o f  au thors including C ole et al, (1992), and Loe et al, (1996), 
reported  th a t M R P1 d id  not confer resistance to  p latinum -contain ing  
com pounds such as cisp latin  and carboplatin. C isp latin  is an anticancer drug 
used  w idely  fo r the  trea tm ent o f  various cancers. H ow ever the developm ent o f  
resistance to  its cy to tox ic  effect is a m ajor problem  in  its clinical use. C isp latin  
b inds to  the N 7 position  o f  guanosine and form s in trastrand and in terstrand 
cross-links. In  add ition  to its direct b inding  to  D N A , the o ther cellu lar effects 
o f  c isp la tin  that have been  reported  include d isruption  o f  the m itochondrial 
m em brane po ten tia l, depolym erisation o f  the  m icrotubules and collapse o f  the 
in term ediate  filam en t netw ork  (Parekh et al., 1995).
cM O A T , a  190kD a m em brane glycoprotein  and a  G S-X  pum p w as first 
recogn ised  by T anaguch i et al, (1996), as a  m em ber o f  the M R P fam ily  w hich  
show s 46%  sim ilarity  to  hum an M RP1. cM O A T m ediates the A T P-dependent
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transport o f  various hydrophobic an ionic  com pounds in  liver canalicular 
m em branes and o ther tissues (K oike et al., 1997). T he spectrum  o f  hydrophilic 
anionic com pounds transported  by cM O A T resem bles that o f  M R P (R oelofsen 
et al., 1999). The function  o f  cM O A T in  drug tran spo rt and cancer is a t present 
unclear.
Tanaguchi et al., (1996), postulated tha t hum an  cM O A T  m ay  function  as a 
cellu lar c isp latin  transporter, as expression o f  hum an  cM O A T  w as enhanced in 
these c isp la tin  resis tan t cell lines w ith  decreased  cellu lar accum ulation  o f  
c isp latin  (section  1.6.8). K ool et al., (1996), also dem onstrated  a  correlation 
betw een cM O A T  transcrip t levels and sensitiv ity  to  cisplatin. H ow ever, there 
are conflicting  theories concerning the function  o f  cM O A T  in  clinical 
resistance and, in  particu lar, its relationship  w ith  cisp latin  resistance. 
T anaguchi et al., (1996) and K oike et al., (1996), acknow ledge that their 
results are no t conclusive and agree w ith  authors such  as O guri et al, (1998), 
w ho observed  no association betw een an te-m ortem  p latinum  drug  exposure 
and steady state cM O A T  m R N A , and K auffm an  et al., (1997), w ho  reported 
that the increased expression  o f  cM O A T  m R N A , after exposure to  p latinum  
drugs, m ay  be p a rt o f  the norm al stress response to xenobiotics.
4.8.1 Investigation of the potentiation of cisplatin toxicity in 2008 cells 
transfected with MRP1, -2, -3 and the HepG2 cell line which 
constitutively expresses MRP1, -2, -3.
D uffy et al., (1998), reported  that cisp latin  tox icity  w as no t po ten tia ted  in  a 
num ber o f  M R P 1 overexpressing cell lines, A 549 and  D LK P. T he resu lts from  
the  long-term  tox icity  assays in  the 2008 cell lines w ith  c isp latin  w ere 
interesting. T ransfecting M R P1, M R P2 o r M RP3 cD N z\ in  to  the 2008 parental 
cell line resu lted  in a  decrease in  resistance to c isp latin  (table 3.8.1a). The 
greatest decrease in  resistance was evident in  the 2008 M R P2 transfected  cell 
line. T he reasons for the decrease in  resistance to  c isp latin  in  the 2008 
transfected  cell lines are uncertain. R T -P C R  analysis (section 3.16) o f  the  2008 
cell lines ind icated  a decrease in  the expression  o f  M R P5 m R N A  in the 
transfec ted  cell lines rela tive to  the parental cell line. The expression  o f  M RP5 
w as increased slightly  in three cell lines selected  for c isp la tin  resistance
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(T 24/D D P10, H C T8D D P and K C P-4) (K ool et al., 1997). Therefore, M RP5 
m ay  be  involved  in  cisplatin  resistance but there is little  evidence in  the 
literature to  support th is hypothesis.
C om bination  tox icity  assays w ere carried  out in  the  2008 cell lines, w ith  
cisp latin  in  com bination  w ith  indom ethacin  and the  positive  indom ethacin 
analogue 138/1, to  assess the ab ility  o f  these com pounds to  enhance the 
tox icity  o f  c isp latin  in  cell lines expressing M R P1, -2, or -3 .  The results 
(section 3.8) dem onstrated  tha t there  w as no po ten tia tion  o f  c isp latin  in any o f  
the  2008 cell lines excep t fo r a  very  low  level o f  synerg ism  in  the  2008 M RP3 
cell line (C l =  0.930) w hen  used  in  com bination w ith  B R I 138/1. This m ay 
indicate tha t cisp latin  is a  w eak  M R P3 substrate. Y oung  et al., (1999), reported  
h ighly  significant correla tion  betw een  M RP3 and resistance to  vincristine, 
e toposide and cisplatin. H ow ever, to  date, there  have been  no other 
publications to  support these  findings and the substrate  specificities for M RP3 
rem ain  uncertain . The accurate range o f  substrates fo r each  transport protein  
cannot be e lucidated  until cell lines are generated  w h ich  express single 
transporters, w ithout background  expression  o f  other transporters as discussed 
in  section  4.7.
The hum an  hepatic  cancer cell line, H epG 2, w as found  to  express h igh  levels 
o f  cM O A T  m R N A  and  p ro te in  (N arasaki et al., 1997; K oike et al., 1997), and 
antisense transfec tion  w ork  w ith  cM O A T  in  th is cell line, resu lted  in  the  cell 
line becom ing m ore sensitive to  a range o f  drugs including  c isp latin  (section
1.6.9.1). T here w as also an  increased level o f  g lu tath ione in  the antisense 
transfectan ts ind icating  th a t the  levels o f  cM O A T w ere inversely  correlated  to 
levels o f  g lu tathione. R T -P C R  analysis carried ou t on  th is cell line (section 
3.16) dem onstrated  the  expression  o f  M R P 1, M R P2, M R P3 and M R P4 bu t not 
M R P5 m R N A . The expression  o f  M R P6 m R N A  in  th is cell line w as not 
investigated.
C om bination  tox ic ity  assays w ere carried  out on  H epG 2 cells to  assess i f  the 
po ten tia tion  o f  adriam ycin  by  indom ethacin  w as also observed in  a  cell line 
w hich  constitu tively  over-expresses M R P2. These assays w ere also carried  out 
to  investigate i f  c isp la tin  could  be poten tia ted  by  indom ethacin  in  th is cell line 
w hich  constitu tively  over-expresses M R P2 and has also been  show n by  RT- 
P C R  (section  3.16) to express M RP3 and M R P4 m R N A . In  addition to
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com bination  tox icity  assays in  the H epG 2 cell line, concurrent com bination 
tox icity  assays w ere carried  out in  D L K P cells as a  control.
Indom ethacin  significantly  enhanced the  tox icity  o f  adriam ycin  in  both  the 
H epG 2 and D L K P cell lines w hich m ay  be attributed to  the  expression  o f  
M RP1 in  these cells. H ow ever, indom ethacin  w as unab le  to  po ten tia te  cisplatin  
in  both  o f  these cell lines. In  fact, indom ethacin  appears to antagonise c isp latin  
tox icity  in  bo th  the D L K P and H epG 2 cells, i.e. the cells appeared  to becom e 
m ore resistan t to  cisp latin  w hen com bined  w ith  indom ethacin  resu lting  in  an 
increase in  cell survival. This effect w as also observed w hen cisplatin  w as 
com bined  w ith  indom ethacin  in the 2008 cell lines. S ignificant differences 
w ere observed  betw een  the com bination index  (C l) values obtained for 
cisp latin  in  com bination  w ith  indom ethacin  and the  values obtained fo r the 
com bination  w ith  the  indom ethacin  analogue B R I 138/1 in  the 2008 cell lines. 
S ignificant an tagonism  o f  the  tox icity  o f  cisplatin  w as observed w hen 
com bined  w ith  indom ethacin  in  the  2008 cells. The C l values ranged  from  
1.345 fo r 2008 M RP1 to 2.422 for the 2008 parental cell line. In  contrast the C l 
values w ere  approx im ately  1.0 for the 2008 parental, 2008 M RP1 and 2008 
M R P2 cell lines w hen  cisp latin  w as co-incubated w ith  BR I 138/1. A s discussed 
above, the  C l value for cisplatin  and B R I 138/1 in  2008 M R P3 w as 0.930, 
w hich  suggested  synergism  betw een these tw o com pounds in the 2008 M RP3 
cell line. B R I 138/1 is an N -benzyl analogue o f  indom ethacin , as described  in 
section 3.1, w ith  the  ch lorine in  the p a ra -p o s itio n  on  the benzene ring replaced 
w ith  fluorine in  the  m eta-position. These resu lts suggest tha t a lthough the 
structures o f  indom ethacin  and B R I 138/1 are sim ilar, changing the 
indom ethacin  structure to  generate BRI 138/1 also resulted  in  functional 
d ifferences betw een  the  tw o com pounds. B R I 138/1 is less toxic than  
indom ethacin  in  the  D L K P cells (section 3.1) and could  be used  in  the 2008 
cells a t h igher concentrations than  indom ethacin, 35pg/m l versus 10|j.g/ml. The 
h igher concentrations o f  B R I 138/1 in  the 2008 cells m ight partially  explain  the 
low er C l values.
It is also possib le  that the increase in  the resistance to cisplatin  is associated 
w ith  indom ethacin  alone. A part from  the  set o f  com bination tox icity  assays 
carried  ou t in  the 2008 cell lines w ith  BR I 138/1 in  com bination  w ith  cisplatin, 
com bination  tox ic ity  assays w ere only  carried  out in the 2008, H epG 2 and 
D L K PC 14 (sections 3.15 and 4.9) cell lines w ith  indom ethacin  in  com bination
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w ith  cisplatin . C isp latin  reacts read ily  w ith  com pounds contain ing  SH groups 
(P ratt et al., 1994). Thus, resistance to cisplatin  has been  found to  correlate 
w ith  increased  glutath ione conten t (B ehrens et al., 1987 and P arekh  et al., 
1995). It has been  suggested th a t quenching o f  the p latinum  com pounds by 
reaction  w ith  nucleophilic  SH  groups in  glutath ione m ay  b e  a m ajor 
determ inan t o f  tum our response to  in itial therapy. It is in teresting  that the 
an tagon ism  to c isp latin  tox icity  is observed  w ith  indom ethacin  b u t no t w ith  
B R I 138/1. R esults from  the G ST assays (section  3.2) dem onstrated  that 
indom ethacin  w as a very  good G ST inh ib ito r w hereas B R I 138/1 w as unable to 
inh ib it the  activ ity  o f  th is enzym e. H ow ever, the relevance o f  th is to  the 
observed  an tagonism  o f  cisplatin  tox icity  is unclear.
A  study w as carried  out by C osolo  et al., (1991), on  the pharm acokinetics o f
• • • • • 0 • 
c isp latin  in  five cancer patients receiving cisp la tin  (5 0 -1 0 0 m g /m ) in
com bination  w ith  indom ethacin  (12.5(j.g/ml). These patients w ere receiving
cisp latin  fo r carc inom a o f  the  ovary, testicu lar carcinom a or transitional
carcinom a o f  the bladder. The authors reported tha t there w as an  increase in
free c isp latin  in  the  p lasm a o f  these patien ts w hen co-treated  w ith
indom ethacin  at 12.5(ig/m l. The authors d id  not offer any explanations for this
in teraction. T hey d id  not investigate the expression o f  M R P in  these cancers
and d id  n o t investigate the effects o f  indom ethacin  on  cisp latin  toxicity . The
resu lts  o f  th is study suggest tha t indom ethacin  m ight be capable o f  increasing
the  efflux  o f  cisp latin  from  the cancer cells resu lting  in increased cisplatin  in
the p lasm a. I f  M R P is p resent in  these cancer types, the  results suggest that
indom ethacin  m igh t enhance the ability  o f  the M R P pum p to export cisplatin
from  the cells m ore rapidly  than  M RP alone. It rem ains to  be elucidated  i f
c isp latin  is a  substrate  for any o f  the M R P hom ologues and w hat p a rt they play
in  cisp latin  resistance. It is also possib le  that indom ethacin  inh ib its  in som e
w ay the  up take  o f  cisplatin  into the  cells.
F uture  experim ents w ill include drug efflux experim ents to  m easure  both  the 
uptake and  the  efflux  o f  c isp latin  in  a  num ber o f  cell lines, in the presence or 
absence o f  active N S A ID s such  as indom ethacin.
In addition , further experim ents are required using cisplatin  in  com bination 
w ith  a range o f  active N SA ID s such as sulindac and a num ber o f  the active 
indom ethacin  analogues (± G ST inhibitory activity), to assess i f  the  effect is
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indom ethacin  specific and also to  investigate i f  any o f  these com pounds are 
capable o f  po ten tia ting  the tox icity  o f  cisplatin.
4.8.2 Correlation between cisplatin resistance and MRP2
B oth  D L K P and H epG 2 cells  express M RP1 (section  3.16 and N arasak i et al.,
1997). The findings from  th is thesis seem  to suggest that the active N SA ID s 
m ay be only capable o f  potentiating the tox ic ity  o f  those drugs w hich  are 
substrates fo r M R P1. H ow ever, it w as no t possib le  to  determ ine from  these 
resu lts i f  indom ethacin  w as capable o f  po ten tia ting  the  tox icity  o f  adriam ycin  
by in teracting w ith  M R P2. M R P2 is reported  to  have a  sim ilar substrate 
specificity  to  M RP1 (O ude E lferink et al., 1995; K eppler et al., 1997 and 
R oelofsen et al., 1999), and  K oike et al., (1997), reported  th a t adriam ycin 
resistance is also conferred  by M RP2. Indom ethacin  is an  am phiphilic  organic 
anion so it is possib le  tha t indom ethacin  can in teract w ith  M R P2 as w ell as 
w ith  M R P1.
H ow ever, it is also possib le  that indom ethacin  m ay  n o t have an affin ity  for the 
b ind ing  site on  cM O A T  and m ay no t be able to  com pete w ith  the natural 
substrates o f  cM O A T . L T C4, the G SH  conjugate, w hich  is a  substrate for 
M R P1, is also  a  substrate  fo r cM O A T (M ayer et al., 1995; K oike et al., 1997). 
H ow ever, K epp ler et al., (1998, 1999a and 1999b) and K onig  et al., (1999), 
reported  that the L T C4 has greater affinity  for M RP1 than  cM O A T  Sim ilarities 
in  the  substrate specificity  betw een M RP1 and cM O A T (R oelofsen et al., 
1999), indicate th a t the  b inding  betw een pro tein  and substrate  in  bo th  M R P and 
cM O A T  requires sim ilar conditions. H ow ever, the sensitiv ity  o f  H epG 2 cells to 
etoposide (V P -16), w h ich  is a substrate for M R P1, w as no t increased w hen 
transfected  w ith  an tisense M R P2 cD N A  (K oike et al., 1997). In  contrast, these 
transfected  cells d isp layed  an  enhanced sensitiv ity  to cisplatin, C PT-11, ((45)- 
4,11 -d iethyl-4-hydroxy-9-[(4-p iperid inopiperid ino)carbonyloxy]d ione-hydro- 
chloride triethydrate), and SN -38, (7 -e thy l-10-hydroxycam ptothecin) w hich are 
reported  no t to  be M RP1 substrates (K oike et al., 1997). T his seem s to  indicate 
tha t there  are som e differences in  substrate specificity  betw een the  two M R P 
hom ologues. I f  the m ode o f  action o f  the active N SA ID s is v ia  com petitive
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inh ib ition  w ith  the  chem otherapeutic drugs fo r an  active site on  the M R P 
protein , th is d ifference in  substrate specificity  m ay  account for the  inability  o f  
the  active com pounds to  b ind  to  the M R P2 p ro te in  and  exert their effect.
V ersantvoort et ah, (1995), dem onstrated  th a t g lu tath ione m etabo lism  is a  
critical e lem ent in  the  drug efflux capabilities o f  M RP. It w as show n th a t 
bu th ion ine su lphoxim ine (BSO ), an inh ib itor o f  G SH  (reduced glutath ione) 
synthesis caused  an  inh ib ition  o f  the drug efflux  activ ity  o f  M R P in  M R P- 
overexpressing  cell lines. Loe et ah, (1996b) and (1998), have dem onstrated  
the ability  o f  M R P  to  co-transport v incristine w ith  G SH  in  m em brane vesicles. 
Perhaps the  active N S A ID s and analogues also requ ire  co-transport w ith  
glutath ione to  be good M R P substrates. K oike et ah, (1997), dem onstrated  tha t 
the  stable transfec tion  o f  H epG 2 cells w ith  cM O A T  antisense construct led to  a 
m arked  increase in  cellu lar GSH. N arasaki et ah, (1997), have dem onstrated , 
u sing  quan tita tive  R T -PC R , that the h ighest expression  o f  cM O A T  m R N A  is 
found in  H epG 2 cells. It appears that as a  resu lt o f  the  h igh  expression  o f  
cM O A T  in  H epG 2 cells there is a low  level o f  G SH  in  the  cells. This low  level 
o f  G SH  m ay  reduce  the  ability  o f  the active com pounds to  be  effluxed  from  the 
cell by  cM O A T  in  preference to cisplatin. H ow ever, as discussed previously , 
resistance to  c isp la tin  has also been  associated  w ith  increased GSH. T herefore, 
it appears th a t c isp la tin  resistance m ay no t be due to  the expression  o f  cM O A T  
in  the cells.
T here have  been  a  num ber o f  publications suggesting that M R P3 does not 
secrete G SH  (Z eng et ah, 1999 and B orst et ah, 1999). T herefore, the  h ig h  
G SH  content in  cells expressing M RP3 m ay  contribute to  cisplatin  resistance in  
M R P3 expressing  cell lines. C hen et ah, (1999), reported  that an  unknow n 
transporter, d istinct from  M R P1, M R P2 and Pgp, w as expressed  in  the 
cisp latin -resistan t hum an  epiderm oid carcinom a cell line, K C P-4, and w as 
involved in  c isp la tin  transport in these cells. The authors also report the ability  
o f  th is pum p to transport LT C4, w hich  is an excellen t substrate fo r M RP1 
(L eier et ah, 1994 and  Jedlitschy et ah, 1994). It is possib le  tha t a  m em ber o f  
the M R P  fam ily  o f  transporters, o ther th an  M RP1 and M R P2, contributes to 
c isp latin  resistance.
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4.9 Investigations in to the mechanisms involved in increased 
cisplatin resistance in DLKP C 14 cells
T he D L K PC  14 cell line w as developed by C leary  (1995), b y  continuous 
exposure  o f  the parental cell line D LK P in vary ing  concentrations o f  the 
p latinum  drug, carboplatin . T h is drug  selection  rendered  the cells m ore 
resis tan t to  a num ber o f  chem otherapeutic  drugs, in  particu lar, carboplatin 
(C leary, 1995) and cisplatin. The tox icity  assays carried  ou t on  the  D LK PC  14 
and  parental D L K P cells indicate th a t there w as a  sign ifican t increase in  
resistance to  cisplatin  in  the  D L K PC  14 cells (IC50 3010 ±  156.4 ng/m l) as 
com pared  to  the resistance o f  D L K P to the sam e drug (IC 50 480.0 ±  35.4 
ng/m l). There w as no  significant cross-resistance to the  chem otherapeutic 
agents adriam ycin  and v incristine. The resistan t varian t show ed  sligh t increase 
in  resistance to  5 ’fluorouracil (approx. 1.2-fold) and V P-16 (approx. 2-fold).
I t has been  postu lated  by  a  num ber o f  authors tha t c isp latin  resistance is as a 
resu lt o f  the  overexpression  o f  cM O A T  in  the cancer cells (section  1.6.9.1 and 
section  4.8 and 4.13). Im m unocytochem ical studies and  R T -P C R  analysis 
dem onstrated  that there  w as no increase in  the expression  o f  M R P 1 or Pgp in  
the  D L K P C  14 cells as com pared  to  the  parental D L K P cells (C leary, 1995). 
T hese results suggest tha t resistance to  cisplatin  in  th is particu lar cell line, 
D L K P C  14, is no t by  overexpression  o f  Pgp or M R P1. Future  R T -PC R  
experim ents w ill investigate  the  ro les o f  M R P2, M R P3, M R P 4, M RP5 and 
M R P6 in  cisplatin  and carbop latin  resistance in  th is carboplatin-selected  D LK P 
cell line.
C leary  (1995), reported  tha t the  c isp latin  resistant cells d isp lay  a unique cross­
resistance profile to  m ultip le agents including antim etabolites, such as 
5 'fluorouracil and m ethotrexate, topoisom erase inhibitors such as cam ptothecin 
and  etoposide, and D N A  polym erase inhibitors such  as azidothym idine. The 
cell lines resistan t to c isp latin  and  m entioned in  the  literature have  been show n 
to have  m ultifactorial m echanism s o f  resistance (see section  4.8). Four 
b io log ical alterations capable o f  producing cisp latin  resistance have been 
reported  and include:
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•  Decreased ce llu la r accum ulation o f  cisplatin,
•  Increased levels o f  g lu tath ione or increased glutath ione-S -transferase 
activity,
•  Increased  levels o f  in tracellu lar m etallothionein,
•  E nhanced  D N A  repair,
(C leary, 1995 and P arekh  et al., 1995).
C leary  (1995), carried  o u t a  num ber o f  experim ents to  try  to determ ine 
the m echanism  o f  resistance in  the  D L K PC  14 cells and found that:
•  G lutath ione did no t appear to  p lay  a m ajor ro le  in  m ediating  drug 
resistance in  the c isp la tin  resistan t D LK P cell lines. The addition o f  
B SO , the glutath ione b iosynthesis inhibitor, to the D L K PC  14 cells did 
no t significantly  alter the  tox ic ity  profile  o f  carboplatin  in  these cells.
•  G ST  activ ity  d id not p lay  a  m ajor ro le in  drug resistance in the D L K PC  
variants. C leary  (1995), dem onstrated  a  slight decrease in  the activity  o f  
G ST  in  the D L K PC  14 ce ll line. Furtherm ore, the  add ition  o f  ethacrynic 
acid, w hich  has been  reported  by  T ew  et al., (1988), to cause a 
reduction  in  the  levels o f  G S T  activity  and an increase in  the 
cy to toxicity  o f  a  num ber o f  alkylating agents in resistance cell lines, 
caused no significant alteration  in  the cytotoxicity  o f  carboplatin  in  the 
D LK PC  14 cells (C leary, 1995).
•  A n  overexpression  o f  m etallo th ionein  in  the D L K PC  14 cell line m ay 
be involved  in  m ediating  drug resistance in  these cells
•  T opoisom erases d id  no t seem  to  p lay  a  m ajor role in  the drug resistance 
o f  the D L K PC  variants as W estern  b lot and R T -PC R  analysis indicated 
that there w as no significant difference in  the levels o f  topoisom erase I 
and II in  the D L K PC  14 cells relative to the parental D LK P cells.
A  num ber o f  in teresting observations w ere reported  by Parekh  et al., (1995).
T he authors reported  tha t a cisplatin  resistan t hum an ovarian carcinom a cell
line, 2 0 0 8 /C l3, contained  m arkedly  low er levels (6-fold) o f  cytokeratin  18,
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w hen com pared  to  the  c isp latin  sensitive 2008 cell line. T hey  also 
dem onstrated  that the  transfection  o f  a  full length  cytokeratin  18 cD N A  in to  
the c isp latin  resistan t 2008/C  13 cell line, resu lted  in  clones w ith  increased 
levels o f  cy tokeratin  18, w hich  w as accom panied in  the m ajority  o f  the clones 
by  a m arked  increase  in  their sensitiv ity  to  cisplatin. These authors also report 
that a  decreased  expression  o f  cytokeratin  14 w as reported in c isp latin-resistan t 
varian t o f  a  hum an  lung squam ous cell carcinom a line and since in term ediate 
filam ent p ro te ins b ind  to  cisplatin-dam aged D N A  it  is possib le th a t they  m ay 
p lay  a  ro le in  the  cy to toxic action o f  cisplatin.
C om bination  tox ic ity  assays carried  out on  the D LK PC  14 cell line using a 
com bination  o f  adriam ycin  o r c isp latin  w ith  indom ethacin, gave sim ilar results 
to  those ob tained  from  com bination tox icity  assays carried out on  H epG 2 cells 
(section 3.6) and 2008 transfected  and parental cells (section 3.8). The results 
indicate th a t an  enhancem ent effect w as only observed w hen indom ethacin  w as 
com bined  w ith  adriam ycin . A n  antagonistic  effect w as observed in  D L K PC  14 
cells trea ted  w ith  c isp latin  and indom ethacin. These resu lts support the 
hypothesis that the  enhancem ent o f  the  toxicity  o f  chem otherapeutic  drugs by 
the active N S A ID s, is only observed fo r those drugs w hich are substrates for 
M R P1. A n  increase in  resistance to  cisplatin  w as also observed in  the  D L K PC  
14 cells w hen  th is chem otherapeutic  drug w as com bined w ith  indom ethacin. 
R esults p resen ted  in  th is thesis have show n that th is effect is no t cell line 
specific. T he m echan ism  o f  th is increase in  resistance is unclear (see section 
4.8) b u t da ta  p resen ted  in  th is thesis suggest an interesting in teraction  betw een 
indom ethacin  and cisplatin .
4.10 Investigation of the effect o f  pulsing HepG2 cells with  
cisplatin.
H epG 2 cells w ere pu lsed  w ith  cisp latin  for a period o f  ten  w eeks to  assess the 
effects on  chem oresistance in  H epG 2 cells due to pu lsing  w ith  th is 
chem otherapeu tic  drug. A s described in section 1.6.9.1, H epG 2 cells w ere 
found to  h igh ly  express both  M R P2 m R N A  and protein  (N arasaki et al., 1997
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and K oike  et al., 1997). There has been  a  great deal o f  conflicting evidence 
concern ing  cisp latin  as a  substrate for M RP (section 1.6.9.1 and section 4.12) 
and, as in  the  case o f  the 2008 cells (section 4.9), it  has so far been  im possible 
to  ob ta in  a  resistan t cell line w ith  resistance attribu ted  to  one single transport 
pum p to  elucidate the  substrate  specificity  o f  each  ind iv idual transporter. 
C om bination  tox icity  assays carried out in  the H epG 2 cells, w ith  cisplatin  in 
com bination  w ith  indom ethacin , dem onstrated the  inability  o f  indom ethacin  to 
enhance  the tox ic ity  o f  c isp latin  (section 3.7) and  in  fac t the cells seem ed to 
develop  greater resistance to  cisplatin  in  the p resence o f  indom ethacin  as 
described  in  section  4.8.
R T -P C R  analysis on  R N A  extracted from  the paren tal H epG 2 cell line 
dem onstrated  the  expression  o f  M R P 1, M RP2, M R P3 and M R P4 m R N A  in  the 
cells (section 3.16). N o  expression o f  M RP5 m R N A  w as detected  and M R P6 
expression  w as n o t investigated. N arasaki et al., (1997) dem onstrated  the 
p resence o f  M RP1 and a low  level o f  Pgp m R N A  expression. The results 
ob tained  to  date support the findings o f  N arasaki et ah, (1997) and K oike et ah, 
(1997). In  add ition  the resu lts  presented in  this thesis dem onstrate the presence 
o f  at least tw o m ore M R P hom ologues in the H epG 2 cell line, M RP3 and 
M R P4.
T oxic ity  assays w ere  carried  out on  the H epG 2 cells a fter pu lsing  for four 
w eeks and ten  w eeks, to  assess i f  resistance to  adriam ycin , v incristine, V P -16, 
5-FU  and cisplatin  increased  or decreased in the pu lsed  cell lines relative to  the 
paren tal H epG 2 cells. The results w ere surprising in  tha t the resistance to 
adriam ycin , v incristine  and V P -16 w as decreased approxim ately  2 .5 -fold after 
pu lsing  for ten  w eeks w ith  cisplatin. This reduction  in  resistance w as also 
ev ident, bu t no t quite  so notable, after pulsing  fo r four w eeks. H ow ever, in 
contrast, the resistance in  the  pulsed H epG 2 cells increased  10-fold  to cisplatin  
and 2.5 fold to 5-FU . D ue to  tim e constraints, R T -P C R  analysis w as no t carried 
out on  the pu lsed  H epG 2 cell lines. This analysis w ill be  carried  out in  the 
im m ediate  future to  assess i f  pulsing the H epG 2 cells w ith  c isp latin  resulted  in 
changes in  the expression  o f  any o f  the M RP hom ologues. These results w ould  
help  to  exp la in  the  changes in  resistance to the chem otherapeutic  drugs after 
pu lsing  w ith  cisplatin .
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A driam ycin , v incristine  and V P-16 are substrates for M RP1 (C ole et al, 1994, 
D uffy  et al, 1998), and  M R P2 (Koike et al, 1997 and K onig  et al, 1999). 
T hese results suggest tha t pulsing w ith cisp latin  resu lted  in  a decrease in  a  
transport m echan ism  shared by  adriam ycin, v incristine and V P -16, possib ly  
M R P1. It is possib le  tha t 5-FU  is a substrate for M R P4 (section  4.11). A s there 
is M R P4 presen t in  the  parental H epG 2 cells p rio r to  pulsing it is possib le that 
pu lsing  these cells w ith  cisplatin  resulted in  an increase in  the  expression o f  
M R P4 and hence, an  increase in  5-FU  resistance. N ish iyam a et al, (1999), 
reported  that se lecting  gastrointestinal cell lines w ith  cisp latin  (0.1 jag/ml), 
resu lted  in  an increase in  GSTtc and dihydropyrim idine dehydrogenase (D PD ) 
expression, w h ich  have been  associated w ith  5-FU  resistance (section 4.11). It 
is possib le  tha t these  genes are also being  overexpressed  in the H epG 2 cells 
after pu lsing  w ith  c isp latin  for a period o f  tim e.
It is no t clear w h a t resistance m echanism (s) caused  the  large increase in  
resistance to  c isp la tin  after pulsing the H epG 2 cells w ith  cisplatin . A gain  RT- 
P C R  analysis w ill hopefully  help  to  answ er som e o f  the questions. Possibly, 
pu lsing  w ith c isp la tin  resulted  in  an increase in  M R P2 (cM O A T) expression. I f  
th is  is the case it could  explain  the increase in  sensitiv ity  to adriam ycin, 
v incristine and V P -16. I t is postulated  tha t these anticancer drugs are 
transported  from  the cells by  M RP1 in a  G SH  dependent m anner. K oike et al,
(1997), observed reduced  levels o f  glu tath ione w hen  cM O A T w as expressed in  
the  H epG 2 cell line. I f  cM O A T  is overexpressed  in  these pulsed  cells, it is 
possib le  that the level o f  G SH  in the cells is also reduced  w h ich  m ay resu lt in  a 
reduction  o f  the G S H  dependent transport o f  adriam ycin , v incristine and V P -16 
from  the  cells. F u rther detailed  analysis o f  the pulsed  cells is required  to 
determ ine the resis tan t m echanism s present in these pulsed  cells.
4.11 Investigation o f effect o f pulsing DLKP cells with 
indomethacin.
I t has yet to  be  determ ined  which o f  the  M R P hom ologues transport 
indom ethacin . I t  is clear th a t this N S A ID  is a substrate  for M RP1 as 
determ ined  by  experim ents carried out in  th is thesis and previous w ork carried
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out by  D uffy  et a t, (1998) and  E llio t (1997). In  the 2008 transfec ted  cell lines 
the true substrates o f  M R P2 and  M RP3 could no t be determ ined  as there was 
background  expression  o f  M R P  1 m R N A  (section 3.16) and pro tein  (C onnolly, 
1999), in  these cell lines. T herefore, D LK P cells w ere pu lse  selected w ith  
indom ethacin  to  assess i f  pu lsing  w ith  this N SA ID  w ould  resu lt in  an increase 
in expression o f  M R P 1 or the  o ther M R P hom ologues.
P ulsing  D LK P cells w ith  300pg/m l indom ethacin resu lted  in  an increase in  
resistance to  all chem otherapeutic  drugs analysed (section  3.11.1 and table
4.11.1) after 4 w eeks and a g reater increase in  resistance after pulsing for 6 
w eeks. There w as also a  sm all but significant increase in  resistance to 
indom ethacin  in  the pulsed  cell lines relative to  the  parental D L K P cells (table
4.11.1). It m ust be noted, how ever, that the levels o f  indom ethacin  used in  th is 
assay  are approxim ately  100-fo ld  greater than the norm al pharm acological 
relevant concentrations (2.5fj,g/ml) used for indom ethacin.
Drug DLKP DLKP lndo6
Adriamycin 1.0 1.5
Vincristine 1.0 1.5
VP-16 1.0 2.0
5-F U 1.0 3.8
Cisplatin 1.0 2.0
Indomethacin 1.0 2.0
Table 4.11.1: Fold  resistance values for chem otherapeutic  drug and 
indom ethacin  in D L K P Indo6 cells relative to  the parental D L K P cells.
The m R N A  expression  w as analysed in  the D L K P cells after pu lsing w ith  
indom ethacin  for 4 w eeks and 10 w eeks to com pare the expression  o f  M R P 1-6 
in  these cells w ith  the  M R P expression  in the paren tal D LK P cells. The results 
ind icated  that there w as only  a  slight increase in  expression  o f  M RP1 in the 
pulsed  cells as com pared  to  the  parental cells. T here  w as also an increase in  
M R P2, M R P4 and M R P6 m R N A  expression. There w ere undetectable levels 
o f  M R P3 in the D L K P parental and the D LK P pulsed cells. Interestingly, 
pu lsing  the D L K P cells for 4-6 w eeks resulted  in  a notable decrease in M RP5
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m R N A  expression. There w as a  very low  expression  o f  Pgp in  the parental 
D L K P cells w hich w as n o t increased  or decreased  in  the  pulsed cells. 
T herefore, it is possib le  tha t indom ethacin  is a substrate  fo r M RP1, M R P2, 
M R P4 and M R P6 o r tha t these M R P hom ologues all contribute to  a  resistance 
m echanism , in  D L K P cells, to indom ethacin. It is possib le also that the 
increased  expression  o f  these M R P hom ologues are part o f  a very generalised  
response, associated  w ith  exposure to h igh  tox ic  doses o f  indom ethacin  
(300|4.g/ml) m aking  it d ifficult to  assess w h ich  (or any) o f  the M R P 
hom ologues actually  transport indom ethacin. In  the  D L K P cell line, 
indom ethacin  does n o t appear to be a  substrate  fo r M RP3 or Pgp. It is possib le  
also, that, as in  the  case o f  the  bcl and bax fam ily  o f  proteins, the upregulation 
o f  one o f  the M R P pro teins m ay resu lt in  an  upregu lation  o r dow n regulation o f  
ano ther o f  the M R P proteins. H ow ever, there  is no evidence to  support th is 
hypothesis. The increase  in  resistance to adriam ycin , v incristine, V P -16 and 
indom ethacin  m ay  be attributed to  an increase in  expression o f  M RP1 or 
M R P2, for w hich  these com pounds are know n substrates (section 1.6). 
H ow ever, the increase in  resistance to  c isp latin  and 5-FU  is m ore d ifficult to  
explain  as the m echanism s o f  resistance to  these chem otherapeutic  drugs are 
no t clear. T here has been  no  conclusive evidence to suggest that expression o f  
M R P is im portan t in  conveying resistance to  c isp latin  and 5-FU in  any 
particu lar cell line. H ow ever, a num ber o f  authors have suggested  that cisp latin  
is a  substrate  for M R P2 (cM O A T) (section 1.6.9). It is possib le  that an increase 
in  the  expression  o f  M R P2 contributed to  an  increase in  cisplatin  resistance b u t 
it is also possib le th a t pu lsing D L K P cells w ith  indom ethacin  results in  an  
increase in  o ther m echanism s o f  cisplatin  resistance and o ther transport 
proteins. N o c lear-cu t sim ple m echanism  for c isp la tin  resistance has been  
identified  as d iscussed  in  sections 4.8 - 4.10.
M echanism s o f  5-FU  resistance have also been  m uch  researched  over the last 
num ber o f  years. M R P is understood not to p lay  an im portan t role in  5-FU  
resistance (N ish iyam a et al., 1999). K irihara  e( al., (1999), also reports tha t the 
m echanism s o f  5 -FU  resistance appear to be d ifferen t from  drug resistance 
associated  w ith  the  m ultidrug  resistance phenotype related  to  Pgp and M RP. 
H ow ever, bo th  au thors have reported  an increase in  M RP1 expression in  5-FU - 
selected  gastro in testinal cell lines. They also reported  a  very h igh  increase o f  
thym idy late  synthase (TS) gene expression in  these cells as w ell as increased
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levels o f  g lu tath ione S-transferase n (GSTrc) and d ihydropyrim idine 
dehydrogenase (D PD ). It is possib le tha t the expression o f  M R P is an  effect 
due to  or associated  w ith  an  increase in  the expression o f  the  o ther 5-FU  
resistance m echan ism s b u t does no t have d irect involvem ent in  5-FU  drug 
resistance. H ow ever, there  is no evidence to  support th is hypothesis. 5-FU  can 
be m etabo lised  to  5 ’fluorodeoxyuridine m onophosphate (FdU M P), w hich  
inh ib its thym idylate  synthase and consequently  D N A  synthesis. 5 -FU  can also 
be m etabo lised  to the ribonucleoside triphosphate FU TP, and incorporated  into 
various types o f  R N A , inh ib iting  their m etabolism  and function. A  very  low  %  
o f  th is chem otherapeutic  drug can  also be converted  to  the 
deoxyribonucleoside triphosphate, FdU TP, w hich  is incorporated  n  to  D N A  
(Pratt et al., 1994). A s described  in  section 1.6.9.4, M R P4 has been  linked  w ith  
efflux o f  nucleoside m onophosphate analogues (Schuetz et al., 1999). R T -PC R  
analysis dem onstrated  an increase in  M R P4 m R N A  expression in  the pulsed 
D LK P cells as com pared  to  the parental D L K P cells. Therefore, it is possib le 
tha t 5-Fu  resistance is as a  resu lt o f  M R P4 expression  in resistant cells.
Pulsing  D L K P  cells w ith  indom ethacin  did no t dim inish  the ab ility  o f  th is 
N SA ID  to po ten tia te  the  tox icity  o f  adriam ycin  in  these cells. H ow ever, 
pu lsing  the  D L K P cells w ith  indom ethacin  resulted  in  greater resistance to  the 
an ti-cancer drugs. This could  poten tially  be a w orry ing  factor i f  indom ethacin  
is to be u sed  in  cancer chem otherapy to  overcom e resistance to a range o f  an ti­
cancer drugs. A lthough, it m ust be considered  that the concentrations used  in  
the pu lse  selection  are m ore than  100-fo ld  greater than  the  concen tration  o f  
indom ethacin  used  in  the com bination tox icity  assays (2.5p.g/ml). The p lasm a 
relevant concentrations o f  indom ethacin  are also approxim ately  2.5|j,g/m l. 
Therefore the  h igh  concentration  o f  indom ethacin , w hich  w as used  in  the  pulse 
selection, w ou ld  n o t be adm inistered to  patien ts in  a clinical setting.
4.12 Investigation o f other possible M RP substrates
Studies w ere carried  out on  a  num ber o f  T B /A ID S related drugs to  determ ine i f  
there w as a  correla tion  betw een acquisition  o f  chem otherapeutic resistance
341
m echanism s and resistance to  TB and /o r A ID S drugs. R esistance to  TB and 
A ID S related  drugs is no t generally  considered a  'cellu lar' phenom enon. 
A cquired  resistance is u sually  associated  w ith the m icroorganism  acquiring the 
resistance and n o t as a  resu lt o f  the in tracellu lar availab ility  o f  the drug to the 
m icrobe, such  as by  a  m em brane pum p extruding the d rug  from  the cell (Larder 
et al, 1991). H ow ever, there  have been  a num ber o f  publications, w hich  
consider the  possib ility  that resistance to certain  com pounds, in  particular 
resistance o f  H IV -1 to  A Z T  m ight also involve the  cellu lar expression  o f  
m ultidrug  resistance P gp  (A ntonelli et al, 1992 and  C inatl et al., 1994). In 
1994, D ianzani el al, reported  that exposure o f  the  drug  sensitive CEM  cell 
line to  continuous increasing  concentrations o f  A Z T , a  nucleoside analogue, 
resu lted  in  a  cell line resis tan t to both  the anti-proliferative and  anti-v iral action 
o f  the  drug. H ow ever, Pgp  levels, sensitivity  to chem otherapeutic  drugs and 
sensitiv ity  to  o ther anti-H IV  drugs (even w ith in  the  sam e class) rem ained 
unaltered. T he au thor suggests that there  m ay be o ther a lternative possib ilities 
to  explain  the A Z T -induced  cellu lar resistance:
i. o ther transm em brane transporter proteins cou ld  be overexpressed in  the 
C E M  resistan t cell line sim ilar to those proteins th a t are responsible for 
the expu lsion  o f  an ticancer agents
ii. the m echanism  underly ing  A Z T  resistance resides in a  defect in  
thym id ine k inase activity . This latter suggestion  is supported  by  the 
find ings o f  T urriz ianni et al, (1996).
Saw chuk et a l, (1999), investigated  the  distribution, transport and uptake o f  
an ti-H IV  drugs, including A ZT, to the central nervous system  (CN S) and 
reported  th a t the  active efflux  transport o f  A Z T  out o f  the  C N S appears to be  a  
p redom inan t m echan ism  lim iting nucleoside access to the  CNS. The authors 
have speculated  tha t th is efflux  transport is due to  the  activ ity  o f  an M R P-like 
transporter in b lood-brain  and  blood-cerebrospinal flu id  barriers. W ijnholds et 
al, (2000), has also reported  tha t M R PI helped to  lim it the  tissue d istribution 
o f  certain  drugs, including  A Z T  and contributed to  the  blood-cerebrospinal 
flu id  perm eability  barrier.
T here have been  no pub lica tions associating TB resistance to  cellu lar resistance 
m echanism s such  as transm em brane pum ps and altered  accum ulation  o f  the
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drug  in  the cell. H ow ever, T a k iff  et al. (1996) reported  the appearance o f  
F luoroqu ino lone (FQ ) resistan t strains o f  tuberculosis. T he authors selected a 
gene tha t confers low -level FQ  resistance w hen p resen t on  a  m ulticopy 
p lasm id . This gene IfrA , encodes a  putative m em brane efflux  pum p o f  the 
m ajo r facilita tor fam ily, w h ich  appears to  recognise the  hydrophilic  FQ , 
e th id ium  brom ide, acridine and som e quaternary  am m onium  com pounds. It is 
hom ologous to  qacA  from  Staphylococcus aureus.
M R P transports a  range o f  com pounds that include glutath ione-S -conjugates, 
am phiph ilic  anionic drugs, and natural product toxins. V ezm ar et al, (1998), 
dem onstrated  that the  lysosom otropic o r antim alarial drug  chloroquine w as a 
substrate  fo r M R P and tha t M R P m odulated  the transport o f  chloroquine by 
d irec t binding. H ollo  et al. (1996), has also reported  th a t the antim alarial 
com pound  quinine is also a  substrate o f  M RP. Recently , V ezm ar et al, (2000), 
reported  that a  num ber o f  quinoline drugs, chloroquine, quinine, quinidine and 
prim aquine potentiated  the tox icity  o f  adriam ycin  in a  concentration-dependent 
m anner in  tw o M R P overexpressing cell lines, H L 60 /A D R  and H69/AR. 
M oreover, the m echanism  o f  reversal appeared to  be  m edia ted  through  direct 
b ind ing  to  M RP. These findings suggest that resistance to  quinine could 
possib ly  be due to  overexpression  o f  M RP.
C ourto is et al, (1999), also reported  the ability  o f  rifam picin , the an ti­
tubercu losis drug, to  inhibit M RP. The authors dem onstrated  that rifam picin  
w as capable o f  increasing in tracellu lar accum ulation o f  calcein, a  fluorescent 
dye substrate  fo r M R P and PgP, in  M R P-overexpressing G L C 4/A D R , hum an 
lung cancer cells, th rough  inhibition  o f  its export ou t o f  cells. In  addition, 
rifam picin  also enhanced levels o f  accum ulation o f  the  anticancer drug 
v incristine , another know n substrate o f  M RP, in  G L C 4/A D R  cells. Z am an et 
a l,  (1993), dem onstrated  tha t G L C 4/A D R  cells do n o t express Pgp w hich 
ind icates that the inh ib ition  o f  efflux by  rifam picin  is th rough  an  interaction 
w ith  M R P. The exact m echanism  by  w hich  rifam picin  m odulates M RP- 
m edia ted  drug transport rem ains to be determ ined. C ourto is et al, (1999), 
hypo thesised  that rifam picin  interferes w ith  substrate-b inding  sites on M RP. 
This conclusion  is supported  by  the fact that rifam picin  and o ther rifam ycins 
m ay be considered  substrates for the M R P efflux pum p since G L C 4/A D R  cells
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w ere show n to  d isplay low , bu t sign ificant levels o f  cross-resistance to these 
com pounds w hen  com pared  to  parental drug-sensitive  G LC4 cells. H ow ever, 
both  quin ine and rifam picin  w ere used  in  experim ental procedures carried out 
by C ourtois et al., (1999) and V ezm ar et al., (2000), at quite toxic 
concentrations (20|_im and 100-200|_im respectively). So w hile they  m ay  be 
prom ising  as inhib itors/m odulators o f  M R P further studies are required  to 
develop analogues o f  these com pounds w hich  are effective against M R P at less 
toxic concentrations.
Tetracycline resistance has been  attribu ted  to  the  afflux  activities o f  secondary 
m ultidrug transporters such as the  chrom osom ally  encoded T etA  (L) pro tein  o f  
Bacillus subtilis (W ang et al., 2000), the  T etA  (K ) pro tein  o f  Staphylococcus 
aureus (G inn et al., 2000 and G ibbons et al., 2000), the T etQ  pro tein  in  
Prevotella intermedia (O kam oto et al., 2000), T et (W ) in  bacteria  from  hum an 
gut (Scott et al., 2000), EnvD  and T etA  in  E. coli, Tel (L) in  Bacillus subtilis 
and M exB  in  Pseudomonas areuginosa (N ikaido el al., 1994). H ow ever, to 
date, there is no evidence that the antib io tic tetracycline, is a  substrate for M R P 
or tha t one o f  the m echanism s by w hich  cells develop resistance to these 
com pounds is th rough  activity o f  M RP.
The results from  the com bination tox icity  assays (section 3.13) indicate that 
only rifam picin  and quinine w ere found to  po ten tia te  the  toxicity  o f  adriam ycin 
in  the  D L K P cells. The enhancem ent o f  adriam ycin  tox icity  w as slightly  better 
in  the presence o f  quinine than  rifam picin. These results support the 
experim ental find ings o f  Courtois et al., (1999), and V ezm ar et al., (2000). As 
both  quin ine and rifam picin  are reported  by these authors to  b ind directly  w ith  
M R P it is possib le tha t they are com petitive substrates for the M R P pum p, 
com peting w ith  adriam ycin  for pum ping  from  the cell by  M RP. It appears that 
these com pounds poten tiate  adriam ycin  in  a m anner sim ilar to  indom ethacin. I f  
rifam picin  and  quin ine are substrates for M RP it is also possib le that M RP m ay 
contribute to resistance to these com pounds. Further studies are required  to 
determ ine the m echanism  by w hich  rifam picin  and quinine potentiate  the 
tox icity  o f  adriam ycin  and to elucidate i f  these com pounds are substrates for 
M RP1 alone o r for o ther hom ologues o f  M R P also. Future experim ents should 
include inside-out vesicle  assays to  determ ine i f  these com pounds inhibit the 
transport o f  L T C4 by  a pure M R P preparation and w ould  provide evidence that
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these com pounds are  substrates for M RP. Future w ork  should also include G ST 
assays to  assess i f  these  com pounds inhibit G S -X  conjugation. T heir ability  to 
inh ib it the activ ity  o f  GSTy, the  rate lim iting step in the production o f  G SH , 
should  also be investiga ted  as it is possible rifam picin  and quinine potentiate 
the  toxicity  o f  ad riam ycin  by  inhibiting G SH  w hich  m ay be required  for the 
transport o f  adriam ycin  by  M R P. D rug efflux  studies w ould also aid in  
determ ining the po ten tia tion  m echanism  o f  these tw o  com pounds.
Tetracycline and A Z T  w ere unable to potentiate  the tox icity  o f  adriam ycin  in  
the D LK P cells. M R P1 is overexpressed in  D L K P cells so the results indicate 
tha t these tw o com pounds are n o t substrates fo r M R P1. H ow ever, D L K P cells 
express very  low  levels o f  M R P2 and alm ost undetectab le levels o f  M RP3 and 
M R P4 (section 3.16). I t  is possib le  that tetracycline and A ZT are substrates for 
o ther M R P hom ologues bu t th is w ould  be d ifficult to  ascertain  until cell lines, 
w ith  one single tran spo rt p ro tein  and no background expression o f  o ther 
pum ps, are generated  to e lucidate the range o f  substrates for each  transport 
protein. O f  particu lar in terest is the fact that A Z T  is a  nucleoside analogue, 3 ’- 
az ido-3’-deoxythym id ine (Saw chuck et al, 1999; B atrakova et al., 1999 and 
A rion  et al., 2000). M R P4 has been reported  by  Schuetz  et al, (1999), to  be 
involved in  nucleoside  m onophosphate analogue transport from  m am m alian  
cells (section 1.6.9) and, thus, in  resistance to  these  drugs. It is possib le tha t 
A Z T is also transported  by  M R P4. There are alm ost undetectable levels o f  
M R P4 in D L K P cells so it is possible that transport o f  A ZT w ould be evident 
in  cell lines such  as A 549  w hich  overexpresses M RP4.
4.13 Investigation of potentiation of chemotherapeutic drugs with 
reduced cardiotoxicity.
A driam ycin  is an  an thracycline antineoplastic agent used  to  treat a  w ide variety  
o f  solid  and hem atogenous tum ours and differs from  daunorubicin  by the 
p resence o f  an  add itional hydroxyl group on  the adriam ycin  structure. 
A driam ycin  and  o ther anthracyclines induce cytotoxicity  through several 
d ifferent m echanism s. A driam ycin  com plexes w ith  D N A  by in tercalating  
betw een D N A  base pairs causing the helix  to  change shape. This sim ple act o f
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changing the  conform ation  o f  D N A  can  in terfere w ith  strand elongation  by 
inh ib iting  D N A  polym erase and can  inh ib it p ro tein  synthesis due to  affects on 
R N A  polym erase. (P ratt et al., 1994).
U nfortunately , the  risk  o f  congestive cardiom yopathy increases rap id ly  once 
the to ta l cum ulative lifetim e dose o f  adriam ycin  exceeds 450-500m g/m 2 
(M inow  et al., 1977). The authors report that adriam ycin  induced  tox ic ity  can 
cause substan tia l m orb id ity  and m ay  prove fatal. M oreover, there  is a  concern 
that u se  o f  adriam ycin  as part o f  ad juven t or curative chem otherapy  m ay resu lt 
in  decreased  cardiac reserve tha t w ill lead to  the developm ent o f  congestive 
heart failu re  a t som e tim e follow ing discontinuation o f  adriam ycin  treatm ent 
(S tew art et al., 1993). C onsequently  adriam ycin  analogues have been 
developed, such  as epirubicin  (Y eung et al., 1989), and idarubicin  (G anzina el 
al., 1986), th a t in  p reclin ical studies re ta in  doxorubicin’s an tineoplastic  activity 
bu t w ith  a  lesser degree o f  cardiotoxicity.
S tew art et al., (1993), suggested that there is a gradual conversion  o f  
adriam ycin  to  adriam ycinol w ith in  cardiac tissue. A driam ycin  m ay  be 
converted  to  adriam ycinol by  the activ ity  o f  the cytoplasm ic enzym e aldo-keto 
reductase, w hich  is p resen t in  m any tissues including the heart. A driam ycinol 
appears to  b e  taken  up  in  to  the cells at a  slow er rate than  adriam ycin  but 
adriam ycinol produced  from  adriam ycin w ith in  the cell is po ten tia lly  cytotoxic 
and m ay  cause  even  m ore cardio-dam age than  adriam ycin  (F errazzi et al.,
1991). M ino tti et al., (1995), have reported tha t the card io toxicity  o f  
adriam ycin  and o ther qu inone-containing antitum our an thracyclines has been 
ten tatively  attribu ted  to  the  form ation o f  drug sem iquinones w h ich  generate 
superoxide an ion  and reduce ferritin-bound Fe(III), favouring the  release o f  
Fe(II) and  its subsequent involvem ent in  free radical reactions. This 
card io tox ic ity  has also been  reported  by  M inotti et al., (1999), to  also be as a 
resu lt o f  the  form ation  o f  a secondary alcohol m etabolite  o f  adriam ycin, 
adriam ycinol, w hich  is involved in a  non-enzym atic and superoxide anion- 
independen t redox coupling w ith Fe(III)-b inding proteins d istinct from  ferritin. 
This coup ling  resu lts in  the regeneration  o f  sto ichiom etric  am ounts o f  
adriam ycin , m obilising  a  tw o-fold excess o f  F e(ll) ions. It has prev iously  been 
postu la ted  th a t the reduced  cardiac toxicity  o f  ep irub icin  rela tive to 
doxorub ic in  could  be  due to the relatively  low  conversion o f  ep irubicin  to 
ep irub icino l (Sw eatm an et al., 1987). Epirubicin, daunorubicin  and idarubicin
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are reported  to be sign ificantly  less effective than  adriam ycin  in  m obilising 
Fe(II) (M inotti et al., 1999).
C om bination  tox ic ity  assays w ere carried out in  the  D LK P cell line using  
doxorubicin , adriam ycinol or epirubicin in  com bination  w ith  indom ethacin  to 
investigate i f  the  tox icity  o f  adriam ycinol and the less cardiotoxic analogue, 
epirubicin, can be poten tia ted  by indom ethacin  to  the sam e extent as 
adriam ycin. The results (section 3.12) indicate that to achieve 50%  cell k ill in  
the D LK P cell line, a  4-fo ld  greater concentration  o f  adriam ycinol than  
adriam ycin  w as requ ired  to  obtain  this level o f  cell kill. Indom ethacin  w as 
capable o f  po ten tia ting  the  toxicity  o f  adriam ycinol bu t the enhancem ent w as 
no t as no tab le  as the  m agnitude o f  the enhancem ent o f  adriam ycin  by 
indom ethacin . T his is o f  in terest as this m etabolite  o f  adriam ycin  causes greater 
cardiotoxicity  and i f  b o th  adriam ycin  and adriam ycinol are p resent in  the  cell 
the  tox icity  o f  adriam ycin  w ill be preferentially  poten tia ted  by  indom ethacin.
H ow ever, m ore  prom ising  results w ere obtained  from  the com bination  toxicity  
assays carried  ou t in  the A 549 cell line w ith  adriam ycin/epirubicin  in 
com bination  w ith  sulindac. G reater po ten tia tion  o f  ep irubicin  than  adriam ycin  
w as observed  w hen these  chem otherapeutic drugs w ere com bined w ith  
sulindac. In  addition, to  obtain  sim ilar cell kill to  adriam ycin, a 4-fo ld  low er 
concentration  o f  epirubicin  w as sufficient. T hese resu lts  indicate tha t epirubicin  
has greater chem otherapeutic  ability in  A 549 cells than  adriam ycin, at low er 
concentrations. E p irub icin  is also m ore effective than  adriam ycin  w hen 
com bined  w ith  sulindac in  th is cell line. This w ou ld  suggest that epirubicin  
could  effectively  rep lace adriam ycin  in vitro resu lting  in  reduced  cardiotoxicity  
w ith  greater cell kill.
A s the com bination  tox icity  assays w ith  epirubicin  w ere carried out in  one cell 
line only, w ith  one N S A ID , it is not clear i f  th is effect is cell line specific or i f  
th is chem otherapeutic  drug w ould  be m ore effective than  adriam ycin  in  a  range 
o f  cell lines. Therefore, fu ture experim ents w ill include analysis o f  epirubicin  
in  a range o f  cell lines from  different tum our types. C om bination  toxicity  
assays using  ep irub icin  in  com bination w ith a  range o f  active N S A ID s and 
indom ethacin  analogues to  assess i f  better po ten tia tion  o f  this drug can  be 
obtained. I t w ou ld  also be o f  interest to com bine epirubicin  w ith  an  active 
N SA ID , w hich  causes reduced  gastrointestinal tox icity , w hich  w ould  result in a
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com bination  o f  N S A ID  and chem otherapeutic  drug w hich is effective against 
cancer w ith  m uch  reduced tox ic  side effects.
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5.0 Conclusions
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5.1 Investigation o f SAR o f indomethacin analogues
T he results obtained from  the  in vitro com bination tox icity  assay using  an  M R P 
expressing  cell line, D L K P, indicated  that the  activity  o f  indom ethacin and 
analogues w as concentration-dependent and th a t a num ber o f  the substituents on  
the  indom ethacin  structure w ere  critical fo r the  tox icity  po ten tia ting  ability o f  the 
com pounds. E xperim ental findings are sum m arised as follows:
i. Changing indom ethacin  from  a benzoyl (indom ethacin , figure 1.10.1) to  a 
benzyl com pound (B R I 60/1, figure 1.10.3) (i.e. rem oving  the carbonyl 
oxygen, thus a llow ing potential free  ro tation) did n o t affect the 
potentiating activity  o f  the  structure. H ow ever, in  th e  benzyl and the 
benzoyl series o f  indom ethacin  analogues the  structural requirem ents for 
drug tox icity  enhancem ent differ.
ii. A lterations to  the  benzyl structure indicated th a t th e  presence o f  the 
halogen  on  the  benzene  ring  w as necessary fo r the  poten tiating  activity o f  
N -benzy l-indom ethacin  (B R I 113/1, figure 1.10.9) and could n o t be 
replaced w ith  non-halogen  substituents such  as a m ethylth io  substituent 
(B R I 124/1, figure 1.10.9).
iii. The activity o f  N -benzyl-indom ethacin  w as retained w h en  the chlorine, in  
the  />ara-position, w as replaced w ith  brom ine (B R I 114/2, figure 1.10.8) 
and fluorine (B R I 115/2, figure 1.10.8). The com pound w as inactive w hen 
chlorine w as in the  m eta-position  (B R I 106/1, figu re  1.10.8) and in  the 
or/Zzo-position (B R I 107/1, figure 1.10.8). H ow ever, w hen  fluorine w as 
m oved to  the  m eta-position  the com pound w as still active (BRI 138/1, 
figure 1.10.10). Perhaps th is is due to  the sm aller size o f  the  fluorine 
m olecule, w h ich  m ay allow  a  different type o f  in terac tion  w ith  the  active 
site.
iv. R em oval o f  the ha logen  in  N -benzoyl-indom ethacin  (BRI 88/1, figure
1.10.5) or rep lacing  the  chlorine m olecule w ith  brom ine (B R I 92/1, figure
1.10.6) indicated th a t th is substituent w as no t required  for the potentiating 
activity  o f  the  com pound. Perhaps the  lack  o f  free ro ta tion  in  the benzoyl 
com pound equates to  “locking” in to  a particular conform ation in  the 
benzyl series v ia  in teractions betw een a p a ra -h a lo g e n  and a group in the 
active site o f  M RP.
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v. F u rther investigations o f  N -benzyl-indom ethacin  com pounds determ ined 
th a t bo th  the  m ethoxy (on  the  benzene ring) and m ethyl (o n  the  indole 
ring) g roups w ere necessary  fo r the  activity  (B R I 119/1 and B R I 120/1, 
figure 1.10.11) o f  N -benzyl-indom ethacin .
vi. In  the  benzoyl series, changing  the  acetic acid side chain  to  a m ethyl ester 
(B R I 59/1, figure 1.10.4) o r a to ly l am ide (BRI 69/2, figure  1.10.4) 
reduced  the  solubility o f  the  com pound and rendered the  com pound 
inactive.
vii. R em oval o f  the  m ethoxy substituent from  the N -benzoyl-indom ethacin  
structure  did n o t render the  com pound inactive (BRI 104/2, figure  1.10.7).
F o u r com pounds w ere  produced  w ith  chem ical structures sim ilar to  know n  PL A2 
inh ib itors and o f  these, tw o  com pounds, bo th  o f  w h ich  w ere  N -benzyl-2- 
(m )ethylindole-3-acetam ides functionalised  at the  5-position  w ith  a sho rt chain 
alkoxy u n it te rm inated  by a  carboxylic  acid, w ere  capable o f  po ten tia ting  the 
tox icity  o f  adriam ycin , albeit a t h igher m olar concentrations th an  th a t required  for 
indom ethacin. T he tw o  rem aining com pounds from  th is group o f  fou r w ere  N - 
benzyl-2-(m )ethylindole-3-acetam ides w ith  a phosphonic acid residue term inating  
the  short chain  alkoxy  unit. N either o f  these com pounds had sign ifican t toxicity- 
enhancing ability. T hese resu lts suggest that the poten tiating  ability  o f  the 
N SA ID s w as n o t th ro u g h  PL A2 inhibition. H ow ever, the specific activ ity  o f  these 
com pounds and the  indom ethacin  analogues on  PLA2 activity need to  be fully 
investigated  befo re  definite conclusions re  PL A2 activity  can be draw n.
The nine analogues o f  indom ethacin  w h ich  exhibited  toxicity  enhancing ability 
w ere  all less tox ic  to  D LK P cells th an  indom ethacin  b u t only th ree  o f  these 
com pounds had sim ilar po ten tia tion  ability to  indom ethacin. The resu lts from  the 
in vitro tox icity  assays ind icate  th a t in  term s o f  po ten tia tion  ability, the  structure 
o f  indom ethacin  is the  optim um  structure  and the substituent varia tion  reported  in 
this thesis did n o t significantly  enhance the  po ten tia tion  ability o f  th is  NSAUD; 
som e o f  the  com pounds, how ever, have properties w h ich  m ay m ake them  
preferab le  to  indom ethacin  fo r in vivo use.
A  num ber o f  experim ents w ere  carried ou t to  determ ine the m echanism  by w hich  
indom ethacin  and positive  indom ethacin  analogues po ten tia te  the  tox icity  o f
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chem otherapeutic  drugs. R esults w h ich  w ere crucial in  e lucidation o f  the
m echan ism  involved  are sum m arised below:
i. A  num ber o f  the  indom ethacin  analogues, w h ich  w ere  show n to  be 
positive  in  the  com bination  toxicity  assays, did n o t inh ib it the enzym e 
G lutath ione S-transferase (G ST) w hich  is active in  the  form ation  o f  
g lu tath ione conjugates. In  particular, the N -benzyl-indom ethacin  
analogues (e.g. B R I 60/1, B R I 114/2 and B R I 115/2) w ere  poor GST 
inhib itors indicating th a t the carbonyl substituent is im portan t in  the 
inh ib ition  o f  GST. The results indicate that indom ethacin  and the active 
indom ethacin  analogues do no t potentiate the  tox ic ity  o f  the 
chem otherapeutic  drugs by inhibiting the fo rm ation  o f  glutathione 
conjugates.
ii. E xperim ents w ere  carried  out to  assess i f  these com pounds had a  direct 
effect on  the  M R P pum p. U sing  inside-out vesicles p repared  from  the 
p lasm a m em brane o f  H L 60/A D R  cells, w hich  overexpress M R P, it w as 
dem onstrated  p reviously  that the active N SA ID s, indom ethacin , sulindac 
and to lm etin , inh ib ited  up take  o f  L T C4, an M RP1 substra te  (D uffy et al,
1998). This m ethod w as used  to  assess i f  the indom ethacin  analogues had 
sim ilar ability  to  inhibit M R P-m ediated  pum ping o f  th is substrate. A ll o f  
the  active indom ethacin  analogues w ere show n to  have  the  ability to  
inh ib it the  up take  o f  L T C4 in to  the vesicles. H ow ever, one o f  the 
indom ethacin  analogues, B R I 138/1, w here the  chlorine in  the para- 
position  on  the benzene ring w as replaced w ith  a fluorine in  the m eta- 
position, w as a  very  strong potentiator in  the com bination  tox icity  assay 
but, a lthough it m odulated  the transport o f  L T C4 in  the  IO V  assay, this 
m odulation  w as rela tively  w eak as com pared to  indom ethacin  and the 
o ther active indom ethacin  analogues. Overall, how ever, the  results indicate 
tha t these com pounds are inhibiting the activity o f  the  M R P1 pum p, in  
som e w ay, and p reven ting  the pum ping o f  the M RP1 substra te  L T C 4.
iii. Indom ethacin  and the  indom ethacin  analogues w ere  assayed in  another 
M R P 1-overexpressing  lung carcinom a cell line, C O R L23(R ) to  assess that 
the po ten tia tion  effec t w as not cell line specific. T he results show ed that 
the active indom ethacin  analogues w ere capable o f  po ten tia ting  the 
toxicity  o f  a  range o f  chem otherapeutic drugs in  the  C O R L 23(R ) cell line. 
In teresting ly  po ten tia tion  o f  these drugs by indom ethacin  and active
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analogues w as also observed to  a slightly  lesser ex ten t in  the  parental cell 
line, C O R L23(S). W estern  b lo tting  ind icated  tha t there  is a basal level o f  
expression  o f  M R P 1 in  the paren tal cell line (B orst et ah, 1997, D uffy et 
ah, 1998 and K oo l et ah, 1997), w hich  is increased after the  stepw ise 
selection  w ith  adriam ycin  used  to  generate  the C O R L23(R ) cell line. The 
com bination  index values obtained fo r bo th  o f  the  cell lines (section 3.6) 
suggest th a t th e  level o f  expression o f  M R P  does n o t appear to  strictly 
correla te  w ith  the rate  o f  po ten tia tion  o f  the anticancer drugs by the 
N SA ID s. I t  appears that even the presence o f  a sm all am ount o f  functional 
M R P can be sufficient to  render cells less sensitive to  chem otherapeutic 
drugs.
iv. Indom ethacin  and the  indom ethacin  analogues w ere capable o f  
po ten tia ting  the  toxicity  o f  adriam ycin, v incristine and V P -16 in  the 
CO RL23 cell lines. These chem otherapeutic  drugs have been  reported  to  
be M RP1 substrates (Cole et ah, 1998 and H ipfner et ah, 1999). The 
positive  indom ethacin  analogues w ere  unab le  to  enhance the  toxicity  o f  
non-M R P 1 substrates 5-FU  and cisplatin  w h ich  ind icates tha t the 
enhancem ent o f  the  toxicity  o f  chem otherapeutic  drugs in  an M R P1- 
overexpressing  cell lines is specific fo r those drugs w h ich  are M RP1 
substrates. These results further indicate an in teraction  w ith  M R P as the 
m echan ism  o f  action fo r the potentiation o f  toxicity  by  indom ethacin  and 
the  positive  analogues.
v. T he efflux  o f  adriam ycin from  D LK P cells trea ted  w ith  indom ethacin  or 
active indom ethacin  analogues w as significantly  retarded  relative to 
un trea ted  cells or cells trea ted  w ith  an inactive indom ethacin  analogue. 
T hese resu lts strongly indicate th a t the  active com pounds have direct 
inh ib ito ry  poten tia l against the activity o f  M RP. It is postu lated  that 
indom ethacin  and indom ethacin  analogues exert their positive effect either 
by  b ind ing  to  M RP and inhibiting the activity o f  the  pum p or by 
com peting  w ith  an M R P substrate, such as LTC 4  o r chem otherapeutic 
drug, fo r preferential pum ping from  the  cell by the  M R P m olecule, 
inh ib iting  the  b inding  and subsequent pum ping o f  o ther substrates. Further 
efflux  studies dem onstrated  that adriam ycin w as also capable o f  reducing 
the  efflux o f  indom ethacin  from  the  D LK P cells, suggesting that 
indom ethacin  and adriam ycin  m ay be com petitive substrates fo r M RP.
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vi. D uffy  et a l, (1998), had previously  reported  tha t the  enhancem ent effect 
w as no t due to  th e  cyclooxygenase inhibitory  activ ity  o f  N SA ID s. 
H ow ever, the indom ethacin  analogues w ere  analysed fo r COX-1 and 
C O X -2 activity to  assess i f  any o f  the active analogues w ere  capable o f  
enhancing the  tox icity  o f  the  chem otherapeutic drug w ithou t COX-1 
inhibition, and therefo re  possib ly  w ithou t causing the  gastric dam age 
custom arily  associated  w ith  N S A ID s including indom ethacin  w h ich  is 
believed to  be associated  w ith  COX-1 inhibition. A gain, the  N -benzoyl- 
indom ethacin  analogues w ere  m ost effective at inh ib iting  COX-1 and 
C O X -2, w hich  ind icates tha t the  benzoyl un it in  indom ethacin  m ay be 
critical fo r COX-1 and C O X -2 inhib ition  and rem oval o f  this un it renders 
the  analogues too  dissim ilar to  indom ethacin  to  be effective 
cyclooxygenase inhibitors. It appears tha t rem oving the  chlorine from  the 
benzene ring, changing  its position  from  para-, or rep lacing  it w ith  another 
halogen, also reduces the  ability  o f  the N -benzyl-indom ethacin  analogues 
to  inhibit COX-2.
T w o o f  the  active indom ethacin  analogues, B R I 138/1 and 153/1, w ere 
found to  have a lm ost no COX-1 inhib itory  activity and w ere w eak  
inhibitors o f  C O X -2 w h ich  renders these com pounds quite interesting in  
term s o f  h igh  chem o sensitising ability w ith  likely m inim al gastro intestinal 
toxicity. O f  g rea t in terest is the  positive indom ethacin  analogue B R I 60/1 
w h ich  is a very  po o r COX-1 inh ib ito r but, in  con trast to  B R I 138/1 and 
153/1, th is analogue is a very  good  CO X -2 inhibitor. Therefore, B R I 60/1 
w ould  potentially  be very  usefu l in  a clinical situation for its high 
chem o sensitising ability, m inim al gastro intestinal tox icity  and inhibition  
o f  tum our enhancing properties associated w ith  CO X -2 (as discussed in  
section 1.7).
5.2 E nhancem ent o f chem otherapeutic drug toxicity  by N SA ID s in cell 
lines w ith varying expression o f M RP1-6.
T o assess the  ability o f  the  N SA ID s to  potentiate the tox icity  o f  a range o f  
chem otherapeutic  drugs in cell lines w hich  overexpress hom ologues o f  M R P other 
th an  M RP1 an  ovarian  carcinom a cell line, 2008, transfected  w ith  M R P1, M R P2 
o r  M R P3, w as used  in  a  num ber o f  com bination tox icity  assays.
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5.2.1 Enhancement of adriamycin toxicity
i. Indom ethacin  and sulindac w ere  bo th  show n to  have the  ability to  
po ten tia te  the  tox ic ity  o f  the M R P 1 substrate, adriam ycin, in  the 2008 
paren tal and transfec ted  cell lines. The results ind icate  tha t although the 
tox icity  o f  the  chem otherapeutic  drug w as poten tia ted  in  all the 2008 
transfec ted  cell lines, the  effect w as greatest in  the M R P 1 transfected  cells. 
The resu lts also suggest that the  enhancem ent effect, overall, w as slightly  
b e tte r in  the 2008 M R P 3  cell line than  in  the 2008 M R P 2  cell line; 
H ow ever, M R P 1 m R N A  and p ro te in  expression w as detected  in the  2008 
paren tal and transfec ted  cell lines. Therefore, it cannot be ruled out th a t the  
enhancem ent effect observed in the 2008 cell lines is as a resu lt o f  M R P  1 
expression  in  all th ese  cell lines.
ii. A driam ycin  has also been  reported  to  be a substrate fo r M RP1 (Cole et al,
1992), M R P2 (K oike et al., 1997), and M RP3 (Y oung et al., (1999). 
H ow ever, K ool et al., (1999), have show n that transfecting  M RP3 cD N A  
in to  the  2008 cell line  did n o t confer resistance to  adriam ycin, indicating 
th a t adriam ycin  w a s  n o t a substrate for M RP3 expressed in the  2008 cell 
line. Therefore, i f  th is is the case, po ten tiation  o f  adriam ycin  in  the 2008 
M R P3 cell line is m ost likely due to  the N S A lD s in teracting w ith  M RP1. 
H ow ever, in  the  short-term  assays, sim ilar resistance to  adriam ycin w as 
dem onstrated  in  the  2008 M RP3 and 2008 M RP1 cells. There is low er 
p ro te in  expression  o f  M RP1 in the 2008 M RP3 cells th an  in  the 2008 
M RP1 cells (Dr. L isa  Connolly, personal com m unication), and the  2008 
M RP3 cells overexpress M RP3 protein, therefore, it is possible tha t 
resistance to  adriam ycin  in  the short-term  assays is due to  the  expression 
o f  b o th  M RP3 and M R P1. m R N A  and pro tein  analysis o f  the  2008 M RP3 
cell line have show n  undetectab le levels o f  M R P2 (section  3.8 and 3.16). 
F rom  the resu lts detailed  in section 3.8 it is difficult to  determ ine i f  
indom ethacin  o r sulindac potentiate  the toxicity  o f  adriam ycin  in  the 2008 
M R P2 cells. A driam ycin  is poorly poten tia ted  in  the short-term  assays by 
either sulindac o r  indom ethacin  in the 2008 M R P2 cells w h ich  suggests 
th a t either these N S A ID s are poor substrates fo r M R P2 or th a t the sm all 
observed po ten tia tion  o f  adriam ycin tox icity  is due to  the low  pro tein  
expression  o f  M R P 1 in  the  2008 M R P2 cells. N o  M R P2 pro tein  expression
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w as observed  in  any o f  the  2008 cell lines except 2008 M R P2 as expected. 
T herefore, the  po ten tia tion  o f  adriam ycin  in  the  o ther 2008 cell lines is 
m o st likely  n o t due to  the  N SA ID s in teracting w ith  M R P 2 To folly 
e lucidate  the  roles o f  the  active N SA ID s and indom ethacin  analogues in  
M R P 2 and M R P3 expressing cell lines it w ill be necessary  to  obtain cell 
lines transfec ted  w ith  M R P 1, 2 o r 3 but w ith  no basal expression  o f  M R P 1 
o r o ther M R P transporters in  the  parental cell.
5.2.2 Enhancement of methotrexate toxicity
M ethotrexate  has been  show n to  be a substrate  fo r M RP1, M R P2 (H ooijberg et 
al, 1999) and M RP3 (K ool et al., 1999). H ow ever, in  our experim ents there  w as 
po ten tia tion  o f  m ethotrexate  in  2008 P, 2008 M RP1 and 2008 M RP3 only, by 
indom ethacin , w ith  g rea test po ten tia tion  in  the parental and 2008 M RP1 cell lines 
T here w as no observed po ten tia tion  o f  m ethotrexate in  the 2008 M R P2 cell line, 
by indom ethacin , bu t there  w as som e po ten tia tion  by sulindac in  the  sam e cell 
line. Sulindac w as capable o f  po ten tia ting  m ethotrexate in  all the  2008 cell lines 
w ith  g rea test po ten tia tion  in  the  paren tal and 2008 M RP1 cell lines. A  num ber o f  
authors, includ ing  H ooijberg  et a l, (1999), and B akos et al., (2000), have reported  
th a t m etho trexate  is a particu larly  good  substrate for M RP2. H ow ever, B akos et 
al, (2000), reported  th a t low  concentrations o f  indom ethacin  (< lOOpM) 
enhanced the  efflux o f  N -ethylm aleim ide glutath ione (N E M -G S), an  M RP1 and 
M R P2 substrate, in  S/9 cells transfected  w ith  a recom binan t baculoviruses 
contain ing  M R P2 cDNA.
Indom ethacin  w as unab le  to  poten tiate  the  toxicity  o f  m etho trexate  in  the 2008 
M R P2 transfec ted  cell line. Therefore, as a result o f  the  above findings by  B akos 
et a l, (2000), it is possib le th a t indom ethacin  w as in teracting  w ith  M R P2 to  
increase the  efflux  o f  m etho trexate  from  the 2008 M R P2 cell line. These results 
suggest that, in  the case o f  m ethotrexate, there  are d ifferences in  transport 
properties fo r th is drug in each  o f  the 2008 cell lines w h ich  m ay ind icate  th a t the 
expression  o f  M R P 1 does n o t account fo r all o f  the poten tia tion  effects observed 
in  the  2008 cell lines. I t  is also possible that the  transporter, M R P2, is trapped  in 
an endosom al com partm ent w ith in  the  2008 cells and cannot reach  the  plasm a 
m em brane so the  problem s w ith  the in tracellu lar routing o f  M R P2 m ay m ake it 
d ifficult to  determ ine the exact substrate specificities fo r M RP2.
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5.2.3 Enhancement of taxol and taxotere toxicity
i. In itia l experim ents w ere carried out in  the CORL23 paren tal and resistan t 
cell lines, u sing  indom ethacin  and an indom ethacin  analogue, B R I 153/1, 
in  com bination  w ith  taxol, a poor M R P substrate (Cole et a l, 1994 and 
B reun inger el al., 1995), as a negative control. P revious experim ents by 
D uffy  et al., (1998), dem onstrated  tha t th e  toxicity  o f  taxo l w as not 
po ten tia ted  by the  active N S A ID s in  A 549 cells. H ow ever, indom ethacin  
and B R I 153/1 enhanced the  tox icity  o f  taxo l in  the  CO RL23 parental and 
resis tan t cells. The effect w as n o t specific fo r indom ethacin  as sulindac 
could  also poten tiate  the tox icity  o f  taxol in  the CO RL23 cell lines.
A no ther m em ber o f  the  taxanes, taxotere, w as also found to  be  potentiated 
by  sulindac in  th e  CO RL23 cells.
ii. B o th  these taxanes w ere analysed in  the  2008 cell lines and their toxicity  
w as potentiated  by sulindac, indom ethacin  and one o f  the indom ethacin  
analogues, B R I 138/1. The poten tia tion  effect w as m ost ev ident in  the 
M R P1 transfected  cell line suggesting  that these drugs are be tte r M RP1 
substrates. R ecen t reports have suggested  th a t bo th  taxol and taxotere  are 
substrates for M RP1 (V anhoefer et al., 1997). Therefore, it is possib le that 
the  enhancem ent o f  taxol and taxo tere  toxicity  is due to  an  in teraction 
betw een  the  N S A ID  and M R P1. I t also appears th a t the  effect is cell line 
specific as the enhancem ent o f  taxo l and taxotere  tox icity  by  indom ethacin  
o r sulindac w as evident in  D L K P cells, very  slightly in  the  M C F-7  cells, 
bu t no t in  the  A 549 cell lines (from  tw o different external sources). All 
cell lines had previously been  show n to express M RP1. A 549 cells have 
b een  show n by  R T -PC R  to express very  h igh levels o f  M R P4 m RNA . 
E xpression  o f  M R P4 protein  levels in  this cell line  h as  not been 
determ ined as there  w as no com m ercially  available M R P4 antibody. 
M R P4 has b een  reported  to  be directly linked to  the  efflux o f  nucleoside 
m onophosphate  analogs from  m am m alian  cells (Schuetz et al., 1999 and 
section 1.6.8.4). The range o f  substrates fo r M R P4 has no t been  elucidated 
yet, so it  is possib le th a t taxo l and taxotere  are substrates fo r M RP4. 
Perhaps w hen  the  N SA ID s are com bined w ith  taxol and taxo tere  in  the 
A 549 cells, the  ability o f  M R P 1 to  pum p taxo l and taxo tere  is reduced but 
th is is overcom e by the activity o f  M RP4.
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This theo ry  is also dependent on  the active N SA ID s n o t being substrates 
fo r M R P4. W e have no t been able to  determ ine th is yet. Taxol and taxotere 
tox icities w ere  potentiated  in  the  2008 cell lines, w h ich  have been  show n 
to  express M R P4, bu t the  levels are m uch low er than  th a t observed in  the 
A 549 cell line.
P irox icam  w as unable to  poten tiate  the tox icity  o f  any o f  the 
chem otherapeutic  drugs analysed in the  2008 cells, except fo r taxo l w here 
th e  com bination  index  values ind icated  a slight po ten tia tion  o f  taxol 
tox icity  by piroxicam . M oos et al, (1999), indicated th a t taxol (but no t 
taxo tere) increased CO X -2 (but no t CO X -1) protein and m R N A  
expression  in  R A W  264.7 m urine m acrophages. It is suggested  th a t the 
inh ib ition  o f  C O X -2 by the active N SA ID s, in  addition to  an  interaction 
w ith  M RP, m ay explain  the increased enhancem ent o f  taxo l tox icity  in  the 
2008 cell lines. P iroxicam  has no M R P-inhibitory  ability  so the  slight 
po ten tia tion  o f  taxo l tox icity  by  p iroxicam  m ay be due to  inh ib ition  o f  
CO X -2, resu lting  in  an  increase in  apoptosis in  the 2008 cell lines. The 
possib ility  tha t th is effect is cell line specific cannot be  ru led  ou t as the 
com bination  o f  taxol/taxotere  and p iroxicam  w as analysed only in  the 
2008 cell lines. This com bination  needs to  be tested  in  a num ber o f  
d ifferen t cell lines.
.4 Enhancement of cisplatin toxicity
T he m echanism  o f  c isp latin  resistance has proven  d ifficult to  elucidate but 
a  num ber o f  reports have linked cisplatin  resistance to  M R P2 (cM O A T) 
expression  (N arasaki et al, 1997; K oike et al, 1997; Taniguchi et al, 
1996 and K ool et a l, 1996). The toxicity  o f  cisplatin, a non-M R Pl 
substrate, could no t be potentiated  by indom ethacin  in  any o f  the  cell lines 
assayed in  th is thesis including the 2008 M R P 1-3 cell lines, H epG 2, a 
M R P2-overexpressing  cell line, and D L K PC  14, a  carboplatin  selected  cell 
line resis tan t to  cisplatin. This indicates that either c isp latin  is no t a 
substra te  fo r any o f  the  M RP hom ologues analysed in th is thesis o r that 
indom ethacin  is no t capable o f  com peting w ith  this chem otherapeutic  drug 
fo r the  cisp latin  resistance m echanism . In  fact, resistance to  cisplatin  was 
increased  in  all o f  the  above cell lines in the presence o f  indom ethacin.
Shen et a l, (2000), reported  th a t a decrease in  c isp latin  uptake m ay 
account fo r some resistance to  this chem otherapeutic  drug  in  a num ber o f  
cancer cell lines, and tha t th is reduction  o f  in flux  w as  independent o f  
M RP1 and M R P2.
H ow ever, B R I 138/1 poten tia ted  very  slightly the tox ic ity  o f  cisplatin  in  
2008 M RP3 suggesting th a t bo th  B R I 138/1 and cisplatin  are w eak  
substrates fo r M RP3. In  addition  resistance to  c isp latin  w as not increased 
in  the presence o f  B R I 138/1 in  the o ther 2008 paren tal and transfected 
cell lines w h ich  suggests th a t this enhancem ent o f  resistance to  cisplatin 
m ay be an indom ethacin  specific m echanism .
Effect of pulsing DLKP cells with indomethacin
Pulsing  D L K P cells w ith  indom ethacin  resulted  in  an  increase in  resistance 
to  adriam ycin  («  1.5-fold), v incristine («  1.5-fold), V P -16 («  2-fold), 
c isplatin  («  2-fold), 5-FU  («  4-fold) and indom ethacin  («  2.2-fold). R T - 
P C R  analysis indicated tha t pulsing D L K P cells w ith  indom ethacin 
resu lted  in  an increase in  the expression o f  M R P 1, 2, 4 and 6, no change in 
M RP3 or M D R 1 expression and a dow n-regulation  o f  M RP 5 m RNA. 
A driam ycin, v incristine  and V P -16 are reported  to  be  substrates for M RP1 
and 2 and th e  overexpression  o f  these pro teins could  account fo r the 
increase in  resistance to  these three chem otherapeutic  drugs. H ow ever, 
there  is no evidence tha t M R P4 is involved in  the transport o f  
chem otherapeutic  drugs. A lthough experim ents in  th is thesis have not 
produced  evidence tha t cisplatin is a substra te  fo r M R P2 it is possible tha t 
M R P2 is involved in  som e w ay  in a com plicated  m echanism  o f  cisplatin  
resistance. Pulsing  the D L K P cells w ith  indom ethacin  m ay also have had a 
negative effec t on  the  up take  o f  chem otherapeutic  drug in  to  the  cell.
The m echanism s o f  5-FU  resistance are know n to be different from  drug 
resistance associated  w ith  the  m ultidrug resistance phenotype related to 
Pgp and M R P (K irihara et al., 1999). H ow ever, a num ber o f  authors have 
reported  th a t although it appears tha t 5-FU  resistance is no t due to  M R P or 
Pgp, M R P w as identified as a  pred ictor o f  prim ary 5-FU resistance 
(K irihara et a l, 1999 and N ishiyam a et a l, 1999). It is possible that
pulsing the  D L K P cell line w ith  indom ethacin  resu lted  in  an increased 
activity  o f  thym idy late  synthase (TS) or dihydropyrim idine dehydrogenase 
(D PD ), a ra te  lim iting  enzym e o f  5-FU  catabolism  (F ischel et al., 1995), in  
the  cells, resu lting  in  resistance to  5-FU. Future experim ents should  
determ ine the  activ ity  o f  bo th  enzym es in  the  D L K P cells prior to  and after 
pu lsing th e  cells w ith  indom ethacin  to  determ ine i f  they  are involved in  5- 
F U  resistance in  D L K P cells. 5 -FU  can be m etabolised to  
5 ’fluorodeoxyurid ine m onophosphate, w h ich  inhibits thym idylate synthase 
and consequently  D N A  synthesis. Therefore, it is also possible th a t 5-FU  
is a substra te  fo r the  M R P4 w hich  has been  linked to  the transport o f  
nucleoside m onophosphate  analogs (Schuetz  et al., 1999).
Indom ethacin, positive  indom ethacin  analogues, sulindac and o ther active 
N SA ID s are capable o f  poten tiating  the  toxicity  o f  a class o f  chem otherapeutic 
drugs know n to  be M RP1 substrates, in  cell lines w h ich  have been show n to  
overexpress M R P1. The results indicate th a t these active N SA ID s m ay be 
substrates for M R P2 and M R P3 also bu t cell lines w ith  expression o f  these M R P 
hom ologues only, w ithou t expression o f  M R P1, are required  to  elucidate the 
activity  o f  the active N S A ID s on  M R P2 and 3 and th is has p roven  difficult. The 
poten tia tion  o f  taxo l and taxotere  by the  active N SA ID s and positive  
indom ethacin  analogues is very  in teresting as it w as believed that the taxanes 
w ere  poor M R P substrates and tha t the po ten tia tion  effect w ould  n o t be ev ident 
w ith  these drugs. H ow ever, there  also appears to  be an alternative o r additional 
m echanism  o f  enhancem ent o f  taxol toxicity  in  certain  cell lines w h ich  m ay 
invo lve the inh ib ition  o f  taxol induced C O X -2 by the  N SA ID s. The lack  o f  
po ten tia tion  o f  these taxanes in  the A 549 cells m ay  be due to  the high expression  
o f  M R P4 (o r another taxane efflux pum p) in  these cells. Further research  is 
required  in  th is  area  to  fully  elucidate the  m echanism  o f  taxo l/taxo tere  
poten tia tion  in  any o f  the  cell lines analysed.
Overall, the  results have  dem onstrated  the ability o f  indom ethacin, a num ber o f  
indom ethacin  analogues and o ther active N SA ID s, w h ich  appear to  be relatively  
selective M R P inhib itors, to  have the ability to  po ten tia te  the toxicity o f  a num ber 
o f  clin ically  im portan t chem otherapeutic drugs at non-toxic concentrations. F o r 
certain  cancers, w here  drug resistance is particularly  as a result o f  M R P over-
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expression, these active N S A ID s and analogues are prom ising  as poten tiators o f  
the  tox ic ity  o f  chem otherapeutic  d rug  in  fu ture cancer treatm ents and therefore, 
enhanced treatm ent fo r cancer patients.
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6.0 Future experiments
There are a  num ber o f  future experim ents areas th a t could  fo llow  from  w ork  in 
th is thesis:
i. The generation  and analysis o f  cell lines, w hich  express a  single M RP 
transport p ro te in  only , w ithou t background expression  o f  other M RP 
hom ologues o r Pgp, to  elucidate the  range o f  substrates for each transport 
protein . Ideally  th is w ould  involve transfection  o f  cell lines w hich  have no 
background expression  o f  any M RP fam ily  m em bers.
ii. T oxicity  assays w ill be  carried out in  the  2008 cells using  a w ider range o f 
chem otherapeutic  drugs, including V P -16 and 5-FU , to  assess the resistance 
profiles fo r a  w ider range o f  drugs in  the 2008 cells th an  those used  in  section
3.8 o f  th is  thesis.
iii. Investigations o f  the ability  o f  N SA ID s to  po ten tia te  the  toxicity  o f  anticancer 
drugs w here drug resistance is due to the  expression  o f  M R P hom ologues 
o ther th an  M R P1. A gain, cell lines expressing single transport proteins, as 
described  above, w ould  be ideal for som e experim ents.
iv. A nalysis o f  the  poten tia tion  o f  taxol and taxotere in  a  w ide range o f  cell lines, 
in  com bination  w ith  the active N SA ID s, and in  particu lar w ith  piroxicam , to 
further asses i f  the  po ten tia tion  o f  taxol and  taxo tere  is cell line-specific  and 
also to determ ine i f  the potentiation o f  taxol by  p irox icam  is observed in  cell 
lines o ther than  the  2008 cell line.
v. W estern  b lo t analysis o f  a num ber o f  cell lines, exposed  to  taxol or taxotere, 
to  assess i f  the  expression  o f  CO X -2 is increased or induced in  these  cell 
lines. T h is experim ent w ould  help  to  clarify  i f  po ten tia tion  o f  taxo l by 
p irox icam  is th rough  inhibition  o f  COX-2.
v i. Pu lse  selecting  D L K P cells w ith  indom ethacin  resu lted  in  an increase in  the 
expression  o f  M R P4. Toxicity  assays should  be carried  out in  these pulsed 
cells using  taxol and taxotere to assess i f  there is increased  resistance to  taxol 
and taxotere in  the pu lsed  cells versus th e  parental cells. A lso, com bination  
assays should  be  carried  out on the parental and pu lse  selected D L K P cell 
lines to  e lucidate  i f  taxol and taxotere are poten tia ted  in  the pulsed cell line 
w here there  is a  h igher expression o f  M R P4 as com pared  to the paren t cell
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line. T his w ork  w ould  aid in  determ ining  the role o f  M R P4 in taxol and 
taxo tere  resistance.
vii. It w ould  also be o f  in terest to  pulse select D L K P cells w ith  a  com bination o f
both  indom ethacin  and chem otherapeutic  drug to  assess the difference in
tox ic ity  profiles betw een the  cells pu lsed  w ith  indom ethacin  alone and those 
pulsed  w ith  a  com bination  i f  indom ethacin  and chem otherapeutic  drug.
viii. Pulse selecting D LK P cells (w hich  express very low  levels o f  M R P4, w ith 
taxo l o r taxo tere  to  assess i f  an  increase o f  any o f  the M R P transport proteins, 
in  particu lar M R P4, is observed.
ix. R T -P C R  analysis o f  the H epG 2 cells w hich  w ere pu lsed  w ith  cisplatin, to
assess i f  the  expression  o f  M RP1 or its hom ologues have increased or
decreased due to the pu lse  selection  o f  these cells w ith  cisplatin.
x. To assess i f  the changes in  the expression  o f  the M RP1 and M R P  hom ologues 
are also observed  at p ro te in  level as w ell as m R N A  level, in  the indom ethacin 
pulsed  D L K P cell line and the c isp la tin  pulsed H epG 2 cell line, W estern 
b lo tting  should  be carried out on bo th  cell lines to  fu rther elucidate the effects 
o f  pu lsing  these cell lines w ith  indom ethacin  or cisplatin.
xi. A s described  in  section  4.6, further drug efflux studies w ould also be 
beneficial in  defining the  effect o f  indom ethacin , indom ethacin  analogues or 
o ther active N SA ID s, such  as sulindac, on the efflux  o f  a range o f  
chem otherapeutic  drugs, especially  taxol, taxotere and cisplatin. These efflux 
studies w ould  also aid in  determ ining m echanism s o f  resistance in  cancer 
cells to  these chem otherapeutic drugs.
xii. It w ould  also be in teresting to carry out efflux studies on cells treated  w ith 
tw o active N SA ID s or tw o chem otherapeutic drugs, to assess i f  there is 
p referen tial pum ping  o f  one N SA ID  over the other, or one chem otherapeutic 
drug over another drug in  M R P expressing cell lines. Cell lines expressing 
single transport m echanism s w ould  also be useful so tha t the efflux  o f  drugs 
o r com pound can be attribu ted  to  specific transport m echanism s.
xiii. To aid in  determ ining the  m ode o f  action o f  the N S A ID s in poten tiating  the 
tox icity  o f  certain  chem otherapeutic  drugs, the ability  o f  the N SA ID s to 
inh ib it G SH  synthesis should  be exam ined. It is possib le that the active 
N S A ID s po ten tia te  the  tox icity  o f  the chem otherapeutic  drugs through 
inhib ition  o f  the synthesis o f  G SH  w hich  m ay be required  fo r their transport
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by M RP. T his experim ent w ould  also help to determ ine i f  the transport o f  the 
chem otherapeutic  drugs, w h ich  are substrates for M R P, is G SH  dependent,
xiv. It w ou ld  also be  in teresting  to  investigate further ho w  cytokeratins influence 
cisp latin  resistance in  the  H epG 2 and the D L K PC  14 cells. Possib le future 
experim ents include the transfec tion  o f  cytokeratin  18 or cytokeratin  14 in  to 
D L K PC  14 cells, to  determ ine i f  increased levels o f  e ither cy tokeratin  in  the 
cells resu lts  in  increased sensitiv ity  o f  the cells to cisplatin . Perhaps also, 
N orthern  b lo t analysis could  be  carried out to  investigate i f  D L K PC  14 cells 
express cy tokeratin  18 o r cytokeratin  14 and assess i f  the levels in  the 
D L K PC  14 cells com pare to  the levels o f  the  cytokeratins in  the parental cell 
line. A dditional fu ture experim ents to  be perform ed in  this area include RT- 
P C R  and W estern  b lo t analysis o f  the parental and resistan t cell lines to 
estab lish  i f  pu lsing  the D L K P cells w ith carboplatin  resu lted  in  an  increase in 
M R P2, -3, -4, -5, -6. T hese experim ents w ould  help  to  elucidate the 
contribu tion  ( i f  any) o f  these  transporters to  p latinum  drug resistance.
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Appendix A  PCR primers used for the detection of MDR genes.
Gene Primer
length
A+T:G+C Tm* Amplified cDNA 
length (bases)
‘MRP1 21 13:8 55 203
^MRP2 20 11:8 53 241
2MRP3 19 7:12 63 262
iMRP4 19 10:9 42 239
^MRP5 18 9:9 49 381
3MRP6 20 9:11 68 221
'm d r i 21 10:11 56 324
*Tm: Annealing temperature
1 NicAmhlaoibh, (1997);2 Kool et al, (1997);3 O’Neill el a l, (1998).
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Appendix B Abbreviations
AA Arachidonic Acid
ABC ATP Binding cassette
ADR Adriamycin
AMP Adenosine 5'-monophosphate
ATCC American Tissue Culture Centre
ATP Adenosine triphosphate
BSA Bovine serum albumin
BSO DL -Buthionine- [S ,R] -sulfoximine
cDNA Complementary deoxyribonucleic acid
CHO Chinese hamster ovary
COX Cyclooxygenasc or Prostaglandin H synthase
DEPC Diethyl Pyrocarbonate
DMEM Dulbeccos modified Eagles medium
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic Acid
dNDP Deoxynucleotide Diphosphate (where N= A,C,G,T,U)
dNMP Deoxynucleotide Monophosphate (where N= A,C,G,T,U)
dNTP Deoxynucleotide Triphosphate (where N= A,C,G,T,U)
ECACC European Collection of animal cell culture
ECL Enhanced Chemiluminescence
EDTA Ethylenediaminineetetraacetic acid
ELISA Enzyme linked immunosorbant assay
FCS Foetal calf serum
5-FU 5-fluorouracil
GSH Reduced glutathione
GST Glutathion S-transferase
HC1 Hydrochloric acid
Hepes 4-(2-hydroxyethyl)-1 -piperazine ethane sulphonic acid
HIV Human Immunodeficiency Virus
HPLC High pressure liquid chromatography
IC50 Inhibitory Concentration 50%
IL-ip Interleukin 1P
IMS Industrial Methylated Spirits
Indo Indomethacin
IOV Inside Out Vesicles
Kcl Potassium chloride
Km Substrate concentration which allows reaction to proceed 
at one half of maximum rate
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LRP Lung related-resistance protein
Lt Leukotriene
LT Long-term
MDR Multidrug resistance
Mef Mefenamic acid
MEM Minimum essential medium
MgCl2 Magnesium chloride
MMLY-RT Molomey Murine Leukemia Virus-Reverse Transcriptase
mRNA Messenger ribonucleic acid
MRP Multidrug Resistance Protein
MTX Methotrexate
NaCl Sodium chloride
NADPH Nicotine adenine dinucleotide phosphate
NaOH Sodium hydroxide
NCTCC National Cell and Tissue Culture Centre
NEAA Non-essential amino acids
NSAID Nonsteroidal antiinflammatory drugs
NSCLC Non-small cell lung carcinoma
NTP Nucleotide Triphosphate (where N=ACGTU)
OD Optical Density
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PCR Polymerase Chain Reaction
Pg Prostaglandin
PGHS Cyclooxygenase or Prostaglandin H synthase
Pgl2 Prostacycline
PgP P-glycoprotein
PKC Protein Kinase C
PMSF Phenylmethylsulphonyl fluoride
RNA Ribonucleic acid
r.p.m. Revolutions per minute
RNase Ribonuclease
RNasin Ribonuclease inhibitor
RT-PCR Reverse Transcriptase Polymerase Chain Reaction
SCLC Small cell lung carcinoma
SD Standard deviation
SDS Sodium dodedecyl sulphate
ST Short-Term
Sul Sulindac
TBS Tris buffered saline
TEMED N,N,N',N'-Tetramethyl-ethylenediamine
TGF-p Transforming growth factor p
Topo II Topoisomerase II
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Tris Tris(hydroxymethyl)aminomethane
TS Thymidylate Synthase
UV Ultraviolet
Vcr Vincristine
V max Maximum rate of reaction when substrate present at 
saturation levels
V P-16 Etoposide
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A ppendix C M olecular W eights
Compound Molccular Weight
Adriamycin 580
ATP 509
Cisplatin 300
Daunorubicin 564
5-FU 130
GSH 307
Indomethacin 358
BRI 60/1 344
BRI 88/1 322
BRI 92/1 402
BRI 104/2 328
BRI 59/1 372
BRI 69/2 447
BRI 106/1 344
BRI 107/1 344
BRI 114/2 388
BRI 115/2 327
BRI 113/1 308
BRI 124/1 391
BRI 138/1 327
BRI 119/1 314
BRI 120/1 329
BRI 153/1 384
BRI 203/1 370
BRI 205/4 406
BRI 215/1 420
Leukotriene C4 626
Methotrexate 454
Piroxicam 331
Sulindac 356
Taxol 854
Taxotere 808
Vincristine 825
VP-16 589
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Appendix D
Chemical analysis of indomethacin and indomethacin analogues
The indomethacin analogues described in this thesis were synthesised by Dr. 
Anita Maguire and Dr. Stephen Plunkett in the Department of Chemistry, 
University College Cork (UCC). To identify, characterise and assess purity of 
each of the analogues a number of analytical procedures were carried out on 
the indomethacin analogues in UCC prior to being sent to our group for 
biological analysis. These analytical procedures consisted of the following (Dr. 
Anita Maguire, personal communication):
• Nuclear Magnetic Resonance spectroscopy (NMR) was recorded on a Joel 
PMX60SI (60 MHz) spectrometer;
• Mass spectra were recorded on a Kratos Profile HV-4 double focussing 
high resolution mass spectrometer;
• IR spectra were recorded on a Perkin Elmer Paragon 1000 FT-IR 
spectrometer as liquid films, chloroform (CHCI3) solutions or potassium 
bromide (KBr) disks;
• Elemental analyses were recorded on a Perkin Elmer 240 elemental 
analyser;
• Thin layer chromatography was performed on DC-Alufoilen Kieselgel 
6OF254 0.2mm plates (Merck) and visualised under UV light with a vanillin 
stain;
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